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Abstract
Complex diseases are driven by multiple risk factors, including genetic variants,
environmental exposures and interactions between the two. The advent of GWAS
in 2005 and subsequent methodological advances have increased our knowledge of
the genetic risk factors underpinning complex diseases. In addition, some research
exploring genotype-environment interaction (G×E) effects has been conducted,
revealing that multiple environments are linked to interaction effects at a single
locus for a given trait. However, correlation between these identified environments
renders interpretation of the results difficult. This, together with the collation of
large-scale biobanks that contain a multitude of phenotypic and environmental data
(facilitating an increase in the number of G×E effects detected) has generated the
need for methods that jointly account for G×E at multiple environments. Such
methods may also increase the power to detect interaction effects by aggregating
modest or weak G×E effects across environments and in addition enable additional
phenotypic variance to be explained. Thus, the aim of this thesis is to provide
suitable methods to identify variants subject to G×E effects, jointly accounting
for multiple environmental exposures and explore these effects across a range of
phenotypes using the UK Biobank data.
In Chapter 2, I describe the structured linear mixed model (StructLMM), a novel
computationally efficient multivariate G×E framework. This model can be used to
test for interaction or association effects. The latter accounts for possible
heterogeneity in variant effects across individuals due to differences in environmental
exposures, thus enabling the detection of variant effects that might otherwise be
masked due to the presence of interaction effects. I show through the use of
simulation experiments that StructLMM is robustly calibrated and in general, better
powered than existing interaction and association tests.
In Chapter 3, I present an application of StructLMM, where I identify significant
interaction effects with 64 lifestyle-based factors for BMI using the UK Biobank data.
In addition, I show that the StructLMM association test can be used to identify loci
II
with genotype-environment contributions. Subsequently, I explore characteristics of
loci with significant interaction effects, including the fraction of the genetic variance
that is explained by G×E and the environmental profiles that increase or decrease
phenotypic risk, using methods that are implemented as part of StructLMM.
In Chapter 4, I apply the StructLMM interaction test to multiple cardiometabolic
traits using the UK Biobank data, facilitating exploration of shared G×E
architecture. Additionally, I provide preliminary estimates of the amount of
phenotypic variation that can be explained by G×E effects, relative to marginal
association effects.
Taken together, the work in this thesis demonstrates the need and advantages
of jointly modelling interaction effects at multiple environments, providing a new
computationally efficient method to achieve this. Combined with the recent and
ongoing generation of large biobanks, further research in this field has the potential
to advance our understanding of complex traits and diseases.
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Chapter 1
Introduction
1.1 Identifying the genetic basis of traits and
diseases
1.1.1 Mendelian and complex traits and diseases
The genetic basis underpinning traits and diseases was a hotly debated topic in the
early 20th century1–8, commonly referred to as the ‘Biometric-Mendelian debate’.
Opinions were divided between Gregor Mendel’s laws of inheritance9 and those
originally put forward by Francis Galton10. It is now widely accepted that both
modes of inheritance exist, such that some traits are classified as Mendelian and
others as complex.
Mendelian traits are also referred to as monogenic disorders, which as the name
suggests, are driven by mutations within a single gene. Examples of such traits
include X-linked muscular dystrophies, cystic fibrosis, Fanconi anaemia, the classic
form of Ehlers-Danlos syndrome and phenylketonuria11–18. Phenylketonuria is an
example of a monogenic disorder that only manifests under specific environmental
conditions; specifically the phenotype only occurs when there are both mutations
within the PAH gene and when an individual is exposed to phenylalanine (naturally
occurring in dietary proteins)19,20. Mendelian traits are typically rare in the general
population but often cluster in families21.
In comparison, complex traits are typically common in the general population21.
They are driven by a combination of multiple genetic risk factors across the genome
(thus they are often referred to as polygenic traits), environmental risk factors, as
1
well as interaction effects between genetic variants and environmental exposures21,22.
The combined contribution of the genetic and environmental factors, results in a
continuous range of phenotypic values; hence complex traits are sometimes referred
to as quantitative traits23. Such complex traits include height, weight and blood
pressure23. However, for some complex traits, the combination of genetic and
environmental factors can be viewed as a predisposition measure that when combined
with a suitable penetrance (defined here as the probability of having a disease given
the predisposition score) mapping function results in an observed binary outcome
(i. e. either diseased or not)24. Examples of complex traits with binary outcomes
include heart disease, type 2 diabetes, schizophrenia, asthma and cancer8,25,26.
It is now recognised that this binary classification of phenotypes as Mendelian or
complex is an oversimplification and that a continuum spanning from monogenic
to polygenic disorders exists17. Traits that bridge the two are often referred to
as oligogenic. This additional classification stemmed from the fact that not all
individuals with known Mendelian mutations presented with the expected phenotype,
termed incomplete penetrance, suggesting the presence of a few modifier genes17,27,28.
Examples include phenylketonuria, cystic fibrosis and Hirschsprung disease, traits
that were classically considered to be Mendelian17,27,28.
1.1.2 Genetic linkage studies
Early success in identifying genetic factors responsible for human trait and diseases,
was predominantly for monogenic disorders through the use of genetic linkage studies,
first proposed in 198018,29. As of 2003, about 1,200 genes were linked to Mendelian
traits18. Genetic linkage relies on a definitive phenotype repeatedly occurring within
a family that does not affect all members (segregation) and that during meiosis,
physically close genes remain in linkage whilst those that are further apart are less
likely to cosegregate due to recombination events18,30,31. This enables, with the use of
genetic markers (approximately spaced uniformly along the genome), identification
of genomic regions that are co-inherited in diseased individuals more often than is
expected by chance that are not co-inherited in non-diseased individuals32. The
allelic configuration of a set of genetic markers along a single chromosome (or a
section of a chromosome) is defined as a haplotype (Fig. 1.2b) and as result diseased
individuals will share the same haplotype at the co-inherited genetic markers25.
Typically, these analyses identify large causal genomic regions, which can be refined
in subsequent follow up studies using a denser panel of genetic markers in the
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identified region18. Nevertheless, the resolution of such analyses ranges between 1
and 10 cM corresponding to between a few and a few hundred candidate genes18.
One such example that illustrates this approach, was the identification of a 7 cM
region on chromosome 12 for Ehlers-Danlos syndrome type VIII (EDS-VIII), using
a large Swedish pedigree31,33. In this study, 400 hundred microsatellite markers
spaced approximately every 10 cM along the genome were analysed in 11 affected
individuals, identifying a putative causal region on chromosome 12. This region
was further examined using a denser panel of markers (17 markers spanning a 30
cM region) and additional family members, including eight unaffected individuals to
confirm and refine the region33 (Fig. 1.1). Meiotic recombination in individuals three
and 18 results in the identification of a 7 cM region flanked by markers ‘D12S314’
and ‘D12S1695’ as likely causal (Fig. 1.1).
Whilst there was some success in using linkage studies to identify genetic regions
involved in complex traits and diseases, including NOD2 for inflammatory bowel
disease34–38 and BRACA1 for breast and ovarian cancer38,39, the relative lack of
success implied that the genetic mechanisms responsible for complex diseases were
different to those responsible for rare disorders26. That is, complex disorders are not
driven by rare variants with large effects. This difference in architecture combined
with the use of very small sample sizes, inherently restricted by the size of the
pedigree analysed, meant that genetic linkage studies were underpowered to detect
regions with significant linkage for complex traits and diseases38. This led to
both the use of suggestive rather than significant thresholds, resulting in many
reported false positive findings and studies that focussed on detecting regions that
were not associated with the trait under study, sometimes referred to as exclusion
mapping32,38,40–42.
1.1.3 Common disease/common variant hypothesis
The observation that complex disorders are not driven by rare variants with large
effects, led to the common disease/common variant (CD/CV) hypothesis26,43, which
postulated that common traits are driven by genetic variation that is common in
the population. If true, based on the population prevalence of complex traits,
the effects of these variants would be small relative to the effects observed for
rare variants26. Consequently, to explain the estimated heritability (estimated
fraction of phenotypic variation explained by genetics44,45; see Section 4.1 for further
details) of such common traits, many genetic variants must influence complex disease
3
Fig. 1.1 Genetic linkage analysis to identify the genetic region linked to
EDS-VIII in a Swedish pedigree | Swedish pedigree of individuals, with those
affected by EDS-VIII represented by black symbols and those unaffected by white
symbols (square = male, circle = female). Haplotypes for 17 markers on a region of
chromosome 12, with black bars next to the marker alleles indicating that the disease
segregating haplotype is present in affected individuals. Meiotic recombination in
individuals three and 18, results in the identification of a putative causal region,
flanked by markers ‘D12S314’ and ‘D12S1695’. Figure as shown in Rahman et al.33.
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susceptibility26.
This hypothesis was described as early as 1996, when it was suggested that family
based linkage studies would be underpowered to detect variants with more modest
effects46. Instead it was proposed that using linkage disequilibrium (LD), the
observed departure from the expected co-occurrence of two genetic markers based
on their observed frequencies (i. e. non-zero correlation between the two genetic
markers), combined with larger population based studies would be more suitable46,47.
This latter design was termed a genomic association study (now referred to as
genome-wide association study)46.
These population based association studies can be viewed as a special case of family
based linkage studies, in which the population studied can be viewed as an extended
pedigree (due to common ancestors). A greater number of meiotic recombinations
will have occurred between the analysed distant relatives, such that LD regions are
much smaller than within pedigrees of close relatives, thus requiring a denser panel
of genetic markers to be examined48.
When proposed, implementation of genomic association studies was not possible.
This was due to the lack of information surrounding the location and density of the
genetic polymorphisms and the lack of knowledge of the LD between genetic variants
across different populations, required for such analyses. In addition, the technology
required to genotype thousands to millions of markers in a single experiment for the
larger required sample sizes was not available8,46,49.
1.1.4 Characterising the LD structure of the human genome
The International HapMap Project was set up with the goal of characterising the
LD structure of the human genome, such that genomic association studies would be
feasible. The project initially focussed on 270 samples from four different
populations50 at approximately 1.6 million single nucleotide polymorphisms (SNPs;
defined as a DNA sequence variation at a single nucleotide25,26, Fig. 1.2a) with minor
allele frequency (MAF) > 5%8 and was later expanded to consider 11 populations at
3.1 million SNPs8,26,51. The generated data enabled calculation of the LD (Pearson’s
correlation coefficient squared, r2, is commonly used) between SNPs within the
genome, effectively describing the chance that two SNPs will be inherited together26.
Subsequently, this enabled the identification of haplotypes (Fig. 1.2b) and thus a
minimal set of SNPs that capture the majority of the haplotype diversity (common
variation) within a population, known as tag SNPs (Fig. 1.2c)50. Tag SNPs are
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population specific, with approximately 500,000 variants in Europeans and up to
one million variants in non-Europeans required to capture > 80% common variation
(MAF > 5%) with LD, r2 > 0.826,49.
b
a
c
Fig. 1.2 Identification of tag SNPs | (a) Four versions of the same chromosome
region, spanning 6,000 bases of DNA, containing three SNPs (i. e. DNA sequence
variation across individuals at three single nucleotides). (b) This combination of
SNPs defines four different haplotypes, defined as a particular combination of alleles
at nearby SNPs. (c) Genotyping just three SNPs across the 6,000 bp region of DNA
is sufficient to identify these four haplotypes uniquely and thus these SNPs are
defined as tag SNPs. Figure as shown by The International HapMap Consortium,
200350.
These tag variants are used to conduct indirect association studies, where
associations are tested for only at the tag variants. As a result, any identified
significant associations can be due either to the tested tag SNP or caused by a
variant that is in high LD with the tested tag variant. Indirect association studies
are much cheaper than conducting direct association studies, where association at
each common SNP is tested for26,48. Using such tag SNPs, reduces the genetic region
associated with a trait to approximately 10−100 kb (which is often just a few genes)
from the 5− 10 Mb (which can contain tens to hundreds of genes) regions that were
identified with genetic linkage studies8.
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1.1.5 Genome-wide association analyses
The data generated by the International HapMap Project combined with
development of appropriate chip-based microarray technology, enabling simultaneous
genotyping of more than one million SNPs, led to the first wave of genome-wide
association studies (GWAS)26. Briefly, GWAS are a hypothesis free approach to
test for significant correlation between genetic variants (one by one across the entire
genome) and a trait of interest. The first successful GWAS conducted in 2005 for
age-related macular degeneration using 96 cases and 50 healthy controls, tested
for associations at ∼100,000 SNPs52. This was promptly followed by GWAS for
Crohn’s Disease53, myocardial infarction54, inflammatory bowel disease55 and type 2
diabetes56. A landmark well-designed study was conducted in 2007 by the Wellcome
Trust Case Control Consortium (WTCCC), which demonstrated that a common set
of controls for all diseases could be used instead of matching cases and controls
for each trait, making the study very cost effective; explicitly, associations using a
shared set ∼3,000 common controls and ∼2,000 cases (at the time regarded as a
large sample size) for each of seven traits were tested for, using a panel of SNPs
with good coverage across the genome8,49,57.
Whilst these early GWAS were based on the directly genotyped tag SNPs (described
in Section 1.1.4), from 2008 onwards, utilisation of methods to fill in missing genotype
data became increasingly common practice, referred to as imputation58. Imputation
is a statistical technique to infer genotypes. The general idea is to compare genotyped
samples to a reference panel of individuals of similar ancestry (Fig. 1.3a) to identify
short haplotype stretches that are shared between the genotyped and reference
samples (Fig. 1.3b). This then allows missing genotypes to be filled in (Fig. 1.3c)58.
Initially, data from the HapMap Project was used as a reference panel, with for
example the CEU panel used to impute samples of European ancestry58,59.
Imputation is now also used to explore association effects of rare variants (see
Section 1.2.1 for further details of imputation of rare variants, including examples
of current reference panels used).
Genotypes may be missing either due to poor quality calls or because they were not
directly typed due to the design of the microarray chip. Consequently, imputation
allows pooling of results across multiple studies that use different microarray chips
(both in design and content) without the need to restrict attention to the overlapping
set of SNPs that are examined in all studies, known as meta-analyses (I refer
the reader to Evangelou et al. for a review on such methods60). Meta-analyses
result in larger sample sizes and thus in theory greater power to detect associations.
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Fig. 1.3 Imputation of genotype data | (a) Comparison of samples genotyped
at a small number of genetic variants within a given region and a reference panel
of individuals that have been densely genotyped in the same region, to (b) identify
regions that are shared between the genotyped study samples and individuals on
the reference panel, such that (c) unobserved genotypes in the study samples can be
filled in based on observed genotypes in the reference panel. Figure adapted from
Li et al.58.
Furthermore, imputation combines evidence across multiple directly genotyped
SNPs, such that imputed SNPs may better tag the true causal variant than any of the
individually genotyped SNPs. Therefore, imputation can lead to the identification
of additional association signals that are not detectable using the raw genotyped
data58. For example, Kathiresan et al. identified a common variant (rs6511720 ) in
the LDLR gene that is strongly associated with low density lipoprotein cholesterol
levels. This was not identified in an initial analysis using directly genotyped
variants58,61; this is because the best proxy SNP (rs12052058 ) included on the
Affymetrix array used for genotyping was in low LD, r2 = 0.21, with rs6511720 58.
Initially, GWAS focussed on complex phenotypes with binary outcomes, using a
case control design. Quantitative traits have since become increasingly popular to
use as phenotypes. This is partly due to the fact that the onset of many diseases
is time dependent, meaning that some individuals selected as controls may later
become cases and hence the control group actually contains a mixture of cases
and controls, resulting in some loss of power26. In addition, some binary traits are
defined by thresholding a continuous variable, with the threshold somewhat arbitrary
such that an individual with a value marginally greater than the cutoff is said to
be ‘diseased’ whilst an individual just below the threshold is defined as ‘healthy’.
Examples include defining obesity based on a BMI threshold and diabetes based
on fasting glucose levels. This thresholding approach results in loss of information
regarding phenotypic similarity and as a result, using the binary outcome is likely to
be less powered than using the underlying quantitative trait. Moreover, quantitative
traits are often closer to the underlying biology, providing greater insight into the
mechanisms underpinning trait or disease development and the results from using
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continuous traits may be more directly interpretable, in that it is possible to quantify
the average difference in trait outcome per risk allele carried26.
Traditionally, the effect of an allele was either classified as dominant, when the
presence of one allele masks the effect of the second allele or recessive, in which case
two copies of an allele are required for an effect. For both binary and quantitative
trait study designs, there are multiple ways in which the genotype data can be
encoded, allowing for different assumptions regarding the variant impact on a
phenotype. This includes the ability to model dominant or recessive effects or
alternatively, that each additional copy of a non-reference allele increases (decreases)
disease risk either multiplicatively or additively26,48. The allelic additive encoding
model is often used in practice since it has good power to detect both additive and
dominant effects but it can be underpowered to detect recessive effects26,62.
Regression based models are often employed for association testing, with case control
designs based on logistic regression whilst quantitative traits are based on linear
mixed models26. These models can be cast as:
logit(yD) = Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+ ︸︷︷︸
Noise
, (1.1)
where yD is an N ×1 binary phenotype vector, capturing for example disease status
or:
y = Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+ ︸︷︷︸
Noise
, (1.2)
where y is an N × 1 quantitative phenotype vector. In both cases, N is the number
of samples used in the analysis, W is an N × a covariate design matrix and α is an
a × 1 vector of corresponding effects, x is an N × 1 genotype vector for the focal
variant (which depending on the encoding can be used to test different assumptions
of the variant effect as described above), βG is the marginal genetic effect and  is
an N × 1 noise vector, modelled as random effect following the multivariate normal
distribution:
 ∼ N (0, σ2nIN), (1.3)
where IN is the N ×N identity matrix.
An association test, tests whether βG 6= 0 and different statistical tests, for example
the likelihood-ratio test (LRT), score test or wald test, can be employed to achieve
this (I refer the reader to Rao et al.63 and Xing et al.64 for further details on these
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different statistical tests). Formally the association hypothesis test is:
H0 : βG = 0 (1.4)
vs
H1 : βG 6= 0. (1.5)
GWAS results are often visualised using Manhattan plots, with the negative log P
value plotted on the y-axis against the corresponding genomic position ordered by
chromosome and position on the x-axis (Fig. 1.4). Peaks on these plots represent
loci (multiple variants in LD) that display evidence of association with the analysed
phenotype. Variants are deemed to be significantly associated with a trait if they
exceed an appropriately chosen P value threshold. Due to LD structure, if a peak
arises from a single variant, this is usually indicative of a false positive finding.
Fig. 1.4 Example Manhattan plot | Manhattan plot for type 2 diabetes from the
Wellcome Trust Case Control Consortium Study, displaying the negative log P value
(y-axis) for each tested variant against the genomic position ordered by chromosome
and position (x-axis). Alternate chromosomes are represented by different shades of
blue and SNPs displaying evidence of association (in this example P < 1×10−5) are
highlighted in green. Adapted from the Wellcome Trust Case Control Consortium,
200757.
1.1.6 Caveats of association analyses
Population structure
It was recognised, even before the first GWAS was conducted, that there was a
possibility of identifying false positives or that true positives may be masked when
using population based association studies instead of family based linkage studies,
due to confounding effects25,48. In particular, this is because both phenotypic
prevalence and allele frequencies vary across different populations, which may result
in the identification of variants that are indirectly associated with the phenotype of
interest due to ethnicity or population substructure25,26,48,65.
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Detection of confounding is often assessed by examining the departure of test
statistics from the expected null distribution. This can be visualised through the use
of quantile-quantile (QQ) plots, with the observed test statistics (or corresponding
negative log P values) plotted on the y-axis and the expected test statistics (or
corresponding negative log P values) plotted on the x-axis8 (Fig. 1.5). Some
departure from the null distribution in the extreme tail of the test statistics (or
corresponding negative log P values) is expected when true association signals
are present (Fig. 1.5b), whilst departure from the null due to confounding effects
is expected to affect the test statistics (or corresponding negative log P values)
globally across the genome, resulting in earlier departure from the null distribution
(Fig. 1.5c). A commonly employed measure to assess the presence of confounding is
genomic control, λGC, where the median test statistic is compared to the expected
median. If λGC ≈ 1, it is deemed that confounding is not present, whilst if λGC >> 1,
the presence of confounding is likely, resulting in a high number of false positive
findings66. It should be noted that larger inflation factors may be observed in
GWAS of large sample size for complex traits such as height, due to substantial
polygenic signal67,68.
ba c
Fig. 1.5 Example quantile-quantile (QQ) plots | Examples of quantile-
quantile (QQ) plots, displaying the expected quantiles (x-axis) versus the observed
quantiles (y-axis) of the test statistics under the null (blue line) and observed (red
circles) in (a) when no associations are present, such that there is no departure from
the null distribution, (b) in the presence of genetic association, such that there is
departure from the null in the tail of the test statistics and (c) in the presence of
confounding factors, such that there is constant departure from the null distribution.
Adapted from McCarthy et al.69.
Various solutions have been proposed to correct for observed confounding effects. An
early solution was genomic control, where the test statistics at all tested variants
are adjusted based on the calculated λGC
66. However, this method works on the
assumption that the tested variants are uniformly affected by the confounding
factors, which in the majority of cases will be a gross simplification8,66,70.
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An alternative method that attempts to correct the underlying problem is
STRUCTURE, which assigns individuals to discrete populations subgroups and then
combines the evidence for association across the different subgroups71. However, this
method does not scale with sample size and is also highly sensitive to the number
of defined population clusters70.
This led to the development of a solution, that is widely used today, which does not
require defining discrete subpopulations but rather assumes a continuum. This is
achieved through the use of principal component analysis (PCA) of the genetic data,
to infer axes of variation due to population structure. The identified top principal
components (PCs) are either first regressed on the phenotype, with subsequent
association testing performed using the phenotypic residuals or the PCs are included
as covariates (i. e. in the design matrix W in Eqs. 1.1-1.2) in the linear regression
model used for association analyses70. However, the top PCs only capture the axes
that explain the greatest amounts of variation and hence do not capture more subtle
relationships such as that between closely related individuals. Therefore, when PCs
are used to correct for population structure, closely related individuals should be
removed from the association analyses, prior to PCA calculations.
An alternative, more computationally demanding strategy, that can account for
both population structure due to closely related individuals and the presence of
subpopulations, is the use of linear mixed models (LMMs)72,73. Instead of calculating
principal components, the genetic data is used to estimate an N×N kinship matrix,
R, that describes the genetic similarity between pairs of individuals (see Hayes
et al.74 for a description of a commonly used similarity measure used to generate
R). This genetic similarity is modelled through the use of an additional random
effect term in the linear model, described by Eq. 1.2 (and equivalently, for logistic
regression described in Eq. 1.1), as follows:
y = Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+ u︸︷︷︸
Confounding
+ ︸︷︷︸
Noise
, (1.6)
where u is modelled as a random effect, following the distribution:
u ∼ N (0, σ2eR). (1.7)
It can be shown that the LMM approach is theoretically equivalent to the PC
approach when all PCs are regressed or included as covariates (see Hoffman et al.75
for details), explaining why LMMs are able to account for more subtle population
structure than the PC approach. However, regressing all PCs or including all PCs
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as covariates is not feasible in practice.
The advantages of LMMs for association analyses, has resulted in research focussed
on improving the efficiency of these methods. Whilst naively the LMM scales
cubically with the number of samples, there are now methods available that scale
linearly with the number of samples, once some up front computations that scale
quadratically with the number of samples have been performed. These include
FaST-LMM76, BOLT-LMM77 and LIMIX78, the latter built using a flexible
framework such that different types of testing procedure can be easily and efficiently
implemented, e. g. multi-trait set tests79 and interaction set tests80 (see Section 1.2.3).
Testing multiple variants
Given that a much greater number of variants are tested for associations in
population based studies than family-based linkage analyses, a second caveat of
population based association testing, is the need to use appropriate multiple testing
adjustments such that the number of reported false positive findings is controlled8,26.
Adjustment for testing multiple hypotheses is required since some tests statistics will
be very extreme by chance when many hypotheses are tested81.
One way to account for multiple testing is to control the family wise error rate
(FWER) at a given level α (often α = 0.05), such that the probability of making one
or more false discoveries across all tested variants is less than α81. The Bonferroni
correction is commonly used, such that the ith variant is significantly associated
with a phenotype, only if Pi ×m < α, where m is the number of tests conducted
(Pi ×m is often referred to as the Bonferroni adjusted P value)26. This correction
method assumes that the test at each variant is independent of the tests at all
other variants. Hence, in the presence of LD, this multiple testing correction can be
conservative. Methods have been developed to calculate the ‘effective’ number of
independent tests, accounting for LD, such as eigenMT82. The ‘effective’ number of
tests is given by the number eigenvalues (from PCA) required to explain a certain
percentage of the total variation (a suggested value is 99%)82. The widely accepted
genome-wide significance threshold of 5 × 10−8 was derived using this Bonferroni
correction, after calculating the number of independent tests using the SNP data
based on individuals of European ancestry, generated by the International HapMap
Project81,83,84. Since the International HapMap Project considered only common
variants (MAF > 5%), this threshold is unlikely to be appropriate if variants with
lower MAFs are included in the association analysis, as is now common practice or
alternatively, if different population ancestries are considered due to differences in
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LD structure. For example, as described in Section 1.1.4, a much greater number of
tag SNPs are required for Africans than non-Africans, indicative of a greater number
of independent tests.
However, the FWER can be very conservative when thousands or millions of tests
are conducted85. Therefore, an alternative method to account for multiple testing
is to control the expected false discovery rate (FDR) at a given level α (often α =
0.05) and this less stringent procedure controls the expected number of ‘discoveries’
(significant results) that are false positives81,85. This approach was formally described
in 1995, with the algorithm provided known as the Benjamini-Hochberg FDR86.
Various closely linked extensions and alternatives have been since proposed including
the local FDR87. This local FDR is a slightly less stringent formulation of the widely
used Benjamini-Hochberg adjustment procedure (with equivalence under the prior
assumption that the fraction of null hypotheses is one). With this approach, the
P value of each variant is adjusted based on its rank (with increasing P values
corresponding to greater rank), such that a variant is significantly associated with a
phenotype if Pi×m
ri
< α, where m is the number of tests conducted and ri is the rank
of the ith variant (Pi×m
ri
is often referred to as the Benjamini-Hochberg adjusted P
value)87.
Replication of significant results
Where possible, a further strategy commonly employed in an attempt to reduce the
number of reported false positive results, is replication of association findings using
an independent data set8,26. Ideally, this independent data set should be obtained
from the same population as that used for the original study; this is because it is
not necessarily expected that the identified associations will be observed in other
populations due to allele frequency differences26. However, other populations can be
used to asked questions about the population specificity of the identified findings26.
Replication studies usually focus on the subset of interesting variants that were
identified in the primary analysis, testing for associations only at these variants
or proxy SNPs in high LD, if the original SNP is not available in the replication
study8,26. Since a smaller number of variants are considered in the replication
analysis, the P values are not required to be as stringent as for the primary analysis
but the variant effect should have a consistent direction of effect with the discovery
analysis8.
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1.2 Advances in association analyses
Following initial success in identifying loci associated with complex trait and disease
risk, it was recognised that the common variants identified explained only a small
fraction of the expected trait heritability, typically < 5% as of 200959,88–92. As a
result, to further increase knowledge of complex traits and diseases, various
improvements outlined in greater detail below have been implemented. This includes
methodological advances and an increase in the scope of data collection. Data
breadth, has increased in terms of the the density of genetic variants, the number
of individuals and the number of phenotypes analysed; the latter includes many
phenotypes that can be viewed as mediating traits such as gene expression data and
quantitative traits that are predictive of disease outcome.
1.2.1 Rare variants
Given the substantial unexplained heritability considering only common variants
(MAF > 5%), attention turned to the role of low frequency (1% < MAF < 5%)
and rare variants (MAF < 1%) in common disease89. Improvements in available
technology, in particular next generation sequencing (NGS)92,93 paved the way for
exploring the role of such variants in common traits and diseases. In particular, the
1000 Genomes Project employed this technology to characterise rare variants using
low coverage whole genome sequencing (WGS) and deep whole exome sequencing
(WES), initially examining 1,092 individuals from 14 ancestries and later expanding
to 2,504 genomes from 26 populations94,95.
Genotypes of less common variants for association testing can either be obtained
directly through WGS or WES or alternatively, due to the relatively high costs of
these direct sequencing methods, can be obtained through imputation (see Section
1.1.5 for details). Since, imputation accuracy decreases with MAF but increases
with the size and the use of an ethnically matched reference panel, choosing an
appropriate reference panel is particularly important for rare variant
imputation89,92,96,97. Examples of population specific WGS reference panels include
UK10K98, deCODE99, Genome of the Netherlands100, HELIC-MANOLIS101 and
SardiNIA59,102,103. There are also ongoing efforts to combine all available WGS
data to generate a single large reference panel, known as the Haplotype Reference
Consortium (HRC) panel59,104 and also to generate a reference panel for sub-Saharan
Africa, as part of The African Genome Variation Project105.
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The analysis of rare variants resulted in the need for new methods to increase the
statistical power to identify associations between these variants and phenotypes96.
These developed methods test for associations between a set of multiple rare variants
instead of testing for associations at each variant individually (see Eqs. 1.1-1.2). This
aggregation across multiple rare variants can increase the observed frequency such
that there is sufficient power to detect an association and in addition reduces the
multiple testing burden (see Section 1.1.6)106. These methods are often referred to
as set tests and can be categorised as burden, adaptive burden, variance component
or combined burden and variance component tests96.
Briefly, burden tests107–111 collapse information across multiple genetic variants,
resulting in a single combined genetic score and then test for association between
this combined genetic score and the phenotype using standard regression methods
(see Eqs. 1.1-1.2). As a result, these tests work under the assumption that all
variants contribute to the observed phenotype and act with the same direction and
magnitude of effect59,96. However, many rare variants will not confer an effect on
complex trait or disease risk. This led to the development of adaptive burden tests
which relax this assumption by incorporating information about individual variant
effects59,96,112. This can include, switching the reference and alternative allele if
there is evidence to suggest that variants have opposite directions of effect and
excluding variants that are unlikely to have an effect based on marginal genetic
association results (i. e. using a standard linear regression approach as described
in Eqs. 1.1-1.2). In addition, variants included within the set can be weighted
based on the SNP effects obtained from these single variant analyses112–117. As a
result many of these adaptive burden tests rely on a two stage procedure, where
in the first stage marginal association tests are conducted and in the second a set
test is conducted, which can be time consuming96. This is further compounded by
the fact that these tests often rely on permutations to obtain P values, which is
computationally intensive. Furthermore, these adaptive burden tests can also suffer
from unstable estimates of individual rare SNP effects96.
An alternative that does not constrain dependence in the magnitude and direction
of effect between variants within a set are variance component tests, which use a
random effects framework59,96,118–120. The Sequence Kernel Association Test
(SKAT)118 is a commonly employed rare variant method that falls within this
category.
Since variance component tests can be more powerful than burden tests if multiple
rare variants influence a phenotype with different magnitudes and direction of effect
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but burden tests can be more powerful when a number of rare variants within the set
act with similar magnitude and with the same direction of effect, tests that combine
burden and variance component tests have also been proposed59,96,121–123. The
Optimal Sequence Kernel Association Test (SKAT-O)123 falls within this category
and is commonly used for rare variant analyses.
As already alluded to, a major associated challenge of set test based approaches
is appropriate selection of the variants to include within a set; the majority of
rare variants will not be associated with a trait and inclusion of such null variants,
can hamper the power of set test approaches. For example, weaker signals were
seen when testing for associations between a set of rare variants in genes BCAM
and CD300LG with blood lipids using both burden and SKAT tests than when
individual variants were considered96,124. However, set test based approaches can
lead to substantial power gains, for example a gene based test using SKAT-O for
variants in PLD3 resulted in an association P value of 1.4× 10−11 with Alzheimers,
whilst P < 1×10−6 was not observed for any single variant96,125. Commonly, regional
or gene-based and/or functional annotations are used to select variants. There
exist a number of computational prediction tools to annotate variants within coding
regions, including but not limited to SIFT, PolyPhen2 and CADD, although there
are often differences in the predicted pathogenicity of variants between the tools,
rendering the selection of variants a difficult problem126–128. This is an even greater
issue when considering rare variants in the non-coding regions, where there exists a
greater pool of variants to start with and less functional knowledge available.
1.2.2 Increased sample sizes
Observations that heritability estimates were larger when including all common
variants instead of only those that were genome-wide statistically significant, implied
that common variants with smaller effect sizes not yet identified through GWAS,
influence complex traits and diseases89,90,129. As sample size is a critical factor
that can increase the power to detect variants with smaller effect sizes89,90,129, the
sample size for GWAS has been increasing. This has been achieved both through
the generation of larger cohorts or as mentioned in Section 1.1.5, by combining
data across multiple cohorts, often based on summary statistics using appropriate
meta-analyses methods (see Evangelou et al. for a review on such methods60). In
addition, if appropriate technology is used to capture rare variants, larger sample
sizes simply increase the probability of observing rare variants (i. e. to capture a
single individual that carries a variant with population frequency of 0.05% requires
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on average a sample size ten times as large as that required to capture an individual
that carries a variant with population frequency of 0.5%, assuming perfect detection
of rare variants) and thus increase the expected number of individuals within a
cohort that carry a rare variant at a specific chromosomal position, hence increasing
the subsequent power to detect rare variant associations (see Section 1.2.1)96.
Cohorts comprised of the order of hundreds of thousands of participants are now
being directly generated. These are largely population based cohorts, that are
collecting a multitude of phenotypic data, including electronic medical records
(EMR), biospecimens and imaging data in addition to genotypic data. Such biobanks
have been developed in a number of countries worldwide, including Iceland, Sweden,
Denmark, Latvia, Estonia, Canada, South Korea, Japan, Singapore, China, Mexico,
USA and UK130,131.
In the UK, the largest of these is UK Biobank, which is a prospective cohort
study that recruited ∼500,0000 British individuals aged between 40 and 69 years at
recruitment, between 2006 and 2010131. This study is collating a deep repository
of phenotypic and environment information, using questionnaires, links to medical
records, physical measurements (including accelerometer data), biological samples
and imaging131. An advantage of prospective cohort studies is that they collect
data prior to disease onset and this study supersedes those previously conducted by
combining a large cohort size with collection of deep meta-data131. Furthermore,
directly generating large biobanks can be better than using meta-analyses that
combine smaller cohorts since there is increased homogeneity in the definition of
the phenotypes and environmental data collated131,132.
1.2.3 Multi-trait methods
An increase in power to identify variants with small to modest effect sizes can
also be achieved through the joint analysis of multiple correlated phenotypes using
multi-trait LMMs, where smaller genetic effects are effectively aggregated across
multiple traits whilst controlling for population structure79,133,134. As well as testing
for associations between a variant and considered traits, the underlying null model
can be used to partition phenotypic correlation into shared genetic and environmental
components across the multiple traits133,135. Thus, such multi-trait methods can
also increase our understanding of the shared genetic architecture and mechanisms
underpinning complex traits and diseases133.
Korte et al.133 were the first to apply such methods on a genome-wide scale, testing
18
for associations with four blood metabolites, considering pairs of phenotypes. Multi-
trait methods included within LIMIX, GEMMA and GAMMA provide
computational efficiency improvements, enabling such analyses to be applied to tens
of traits and thousands of samples78,134–136. More recently mtSet which combines
such multi-trait tests with variant set tests was developed, compounding the
aforementioned advantages of both variant set tests (see Section 1.2.1) and multi-trait
modelling, whilst retaining computational efficiency79. Although the initial proposed
mtSet only allowed for association testing, an extension to this method, iSet can be
used to examine the shared genetic architecture80.
As well as analysing distinct correlated phenotypes, all of the aforementioned
methods can be applied to multiple phenotypes that measure the same trait under
different environmental conditions and thus can be used to identify context dependent
variation80,133. For example, iSet was used to test for stimulus-specific effects
on gene expression of primary monocytes, a white blood cell involved in immune
response, where the measured gene expression of a specific gene under four different
environmental conditions comprised the four phenotypes included in the multi-trait
test80. However, these methods are limited to categorical environments80.
1.2.4 Pleiotropy and PHEWAS
Variants can also be associated with multiple traits that are not correlated, referred
to as pleiotropy137 (although increasingly this term is used when a variant is
associated with multiple traits, regardless of their correlation138,139). Identification
of pleiotropic effects may increase our functional knowledge of complex traits and
diseases. For example, pleiotropy may occur when a locus affects a molecular
mechanisms that alters risk for multiple traits (termed direct biological pleiotropy) or
the locus may affect one trait that is a molecular intermediate for a second trait that
I henceforth refer to as the outcome trait (termed mediated pleiotropy)138–140. The
latter can often be deduced through the use of Mendelian Randomisation, a causal
inference method140,141. Explicitly, variants that are associated with the mediating
trait are used as proxy measures for this trait, such that that the analysis is robust to
reverse causation (i. e. when the outcome trait alters levels of the intermediate trait)
as genetic variants are not modifiable142. In this way, Mendelian Randomisation is
analogous to randomised control trials, where individuals are randomly placed into
different treatment groups such that there is no confounding between the treatment
and outcome143.
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Examples of pleiotropy include variants in CTLA4 and PTPN22 that are associated
with multiple autoimmune disorders144–146 and genetic variants near CDKN2A and
CDKN2B associated with type 2 diabetes and coronary heart disease suggesting
a shared mechanism or biological pathway147–151. A systematic review in 2011 of
variants listed in the GWAS catalog152, revealed that almost 5% of SNPs and almost
17% of genes or gene regions are associated with more than one distinct outcome or
trait139,151.
Whilst historically pleiotropic effects were identified through literature searches or
catalogs such as the GWAS catalog152, the generation of large biobanks with links to
EMR (see Section 1.2.2) or that have collected multiple phenotypes, for example the
PAGE study151,153 have enabled testing for pleiotropic effects within the same cohort
of individuals, referred to as phenome-wide association studies (PHEWAS). Rather
than focussing on a phenotype of interest as is the case for GWAS, PHEWAS focus
on variants of interest and test for associations with all available phenotypes.
The first PHEWAS study conducted in 2010, focussed on five variants with previous
disease associations, testing for associations with 733 phenotypes; this study
replicated four of seven known variant-disease associations and identified 19 novel
associations (P < 0.01)154. This early proof of concept study highlights how
PHEWAS can be used to identify possible pleiotropic effects and as a hypothesis
generating tool155,156. Identification of possible pleiotropic effects provides
opportunities for pharamcogenomics, including the use of already available drugs
to treat different conditions or as a predictive tool of efficacy or adverse reactions
to a drug151,155–157. More recently, these types of study have been extended to a
genome-wide scale, testing for associations between 635,525 variants and 541 traits
and 25 clinical phenotypes158.
One challenge of PHEWAS is the associated multiple testing burden (see Section
1.1.6), which increases with the number of traits analysed138,157–159. However, the
number of tests does not necessarily scale linearly with the number of traits as
in many cases there will exist some correlation between the traits included in the
analysis; thus, the tests across different traits are not independent of one another.
The effective number of independent tests can be estimated analogous to GWAS
where correlation between variants exists, using PC based methods, such as
eigenMT82 (see Section 1.1.6). Nevertheless, the significance threshold is likely to
be stringent in many cases, as the sample size per trait and for binary traits the
number of affected individuals, can be highly variable157,158.
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1.3 What about the other components of complex
traits and diseases?
1.3.1 Other contributing factors
Whilst the advent of GWAS and the subsequent advances have increased our
understanding of the genetic factors underpinning complex traits and diseases, such
that as of May 2018, 69,000 significant SNP-trait associations were listed in the
GWAS catalog152, the majority of these studies assume that phenotypes are the
result of additive variants effects.
Environmental factors can also have a direct effect on phenotypic risk; for example,
blood cadmium, lead, polychlorinated biphenyls, dietary nutrients and particulate
matter have all been associated with increases in blood pressure160–169. Linear
models, analogous to that described in Eq. 1.2, with the genotype vector (x) replaced
by an environmental exposure vector are commonly used to identify such
environmental factors. The majority of such studies analyse the impact of a single
environmental factor meaning that the results of these studies may be prone to
selection biases and false positive reporting160. To overcome such issues there
has been a recent drive to systematically evaluate the impact of environmental
exposures, referred to as environment-wide association studies160,170,171, made
possible by the in-depth collection of environmental data such as that collated by
the National Health and Nutrition Examination Survey in the USA.
As well as acting independently of one another, variants and environmental exposures
can be dependent on one another. In some cases, this may mean that the effect of
a variant on a phenotype can only be identified once the effect of another variant
or an environmental variable has been accounted for132,172–177. This dependence is
usually referred to as an interaction effect, with dependence between multiple genetic
variants termed epistasis, whilst dependence between a variant and an environmental
exposure is termed a genotype-environment interaction (G×E) effect. Interaction
effects between variants in the NAT2 gene and smoking on bladder cancer risk is an
example of a G×E effect178,179.
Whilst the concept of interaction effects has been around for more than a century, the
advent of GWAS has enabled feasible exploration of such effects on a genome-wide
scale177,180. In particular, increased interest in these studies was fostered when the
initial wave of GWAS were unable to identify variants that explained substantial
amounts of the estimated phenotypic variance181.
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The identification of additional variants involved in complex traits and diseases
through epistasis and G×E studies, may provide greater clarity as to which biological
pathways are functionally involved in trait onset and progression, as well as highlight
potentially novel biological pathways; these pathways may be of interest for drug
development132,177,182,183. As well as the identification of additional variants
associated with complex traits and the ability to explain additional phenotypic
variance, insights from interaction analyses may be clinically informative, both to
identify the environments with greatest impact and to identify particular subgroups
of the population that will most benefit from environmental changes132,177,183,184.
1.3.2 Epistasis and G×E
Epistasis was initially described in terms of Mendelian inheritance (see Section 1.1.1)
and its presence demonstrated by Bateson in 1909185. Specifically it was described as
a masking effect, where the effect of one allele, prevents a second allele from exerting
its effect (i. e. an extension of the dominance effect)172,186,187. In 1918, Fisher defined
epistasis as departure of the phenotype from a model that assumes independence of
variant effects2,172,187,188.
This is the basis of the statistical definition for both epistasis and G×E effects
that is widely used in the study of complex traits and diseases182,186. Explicitly,
whilst a variant with a significant genetic effect is determined by a mean phenotypic
difference between groups of individuals with different allele dosages (Fig. 1.6a) and
a significant environment effect is determined by a mean phenotypic shift that is
constant across different allele dosages (Fig. 1.6b), a significant statistical interaction
effect is defined when there is a significant difference in the genetic effect between
two groups of individuals with different environmental exposures (Fig. 1.6c).
Environment in the context of G×E has a broad definition, encompassing microbiota
composition, medication, gestational environment, internal mediating factors such
as biomarkers, epigenetic features and factors that have a genetically driven
component183,189.
There are challenges that are common to both epistasis and G×E studies. One
such challenge is that larger sample sizes are required to detect interaction effects
than marginal effects; it has been suggested that sample sizes four times as large are
required to detect interaction effects as marginal effects132,177,182,189,190. One reason
for this is that successful GWAS depends on high LD between the causal variant and
the observed tagging variant since the additive variance of the tagging variant will
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Fig. 1.6 Different relationships between allele dosages, environmental
exposures and phenotypes | The relationship between allele dosage and the
mean phenotypic value when (a) a significant genetic effect is present, with the
variant effect given by the line gradient, (b) in the presence of a direct environment
effect where the red and blue lines represent two groups of individuals that are
stratified based on environmental exposure levels (either lowly and highly exposed
or homozygous reference or homozygous alternative at a second allele that is
independently associated with the phenotype) such that the allelic effect of each
population subgroup is the same (line gradients are equal) but there is a shift in
the mean phenotype that is independent of the focal allele dosage and (c) in the
presence of an interaction effect where the red and blue lines represent two subgroups
of individuals that are stratified based on environmental exposure levels (either lowly
and highly exposed or homozygous reference or homozygous alternative at a second
allele) such that the genetic effect in the two groups are different (difference in line
gradients).
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decrease linearly with LD, r2 180. It follows that the variance explained by pairwise
epistasis effects decreases on average with LD r4 180. Similarly, for G×E, the observed
environment may be tagging the causal interaction environment, which similarly
reduces the power to detect interaction effects. Whilst not directly alleviating this
problem, the generation of cohorts with increasing sample size, in particular large
scale cohorts such as UK Biobank (Section 1.2.2) should enable the detection of
more modest interaction effects.
However, since these large cohorts are also starting to collect multiple environmental
variables, if interaction effects with different environmental factors are tested for,
there will be an increased multiple testing burden (see Section 1.1.6) for G×E studies
that may counteract the gain in power obtained from using larger sample sizes.
This multiple testing burden is an even greater problem for epistasis studies177,186.
Whilst there will be V (V−1)
2
tests, where V is the number of genotyped (and imputed)
variants, when considering all possible pairwise interactions, there is a much greater
number of tests when considering higher order interactions189. The multiple testing
burden associated with exhaustive testing of higher order epistasis effects is likely
to outweigh the benefit of considering more complex models180. In comparison,
typical G×E scans that consider a single environmental variable conduct V tests,
the same number as the corresponding GWAS. Even when multiple environmental
variables are considered, typically L << V (where L is the number of environmental
variables) such that the total number of interaction tests (V L) is still much smaller
than for exhaustive pairwise epistasis scans. As a result, G×E analyses are more
tractable than epistasis studies.
Challenges that are specific to G×E tests largely arise due to the fact that measuring
environmental exposures is less straightforward than genotyping. In particular,
global standards for measuring environmental exposures are generally not defined,
such that G×E meta-analyses are likely underpowered and the replication of
identified interactions is difficult182,183. Even within a cohort environmental
measures are more prone to error, in particular when self reporting questionnaires
are used or due to changes in behaviour when people know that they are being
observed, known as the Hawthorne effect177,179. In addition, not knowing which
exposures and at what time points (e. g. during in-utero development, childhood
development or accumulation over time) these environments matter, with exposures
changing over time, makes it difficult to both collect the required data and capture
or describe an environmental exposure through the use of single variable generally
required for modelling purposes132,182,183.
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A further difficultly in replicating G×E effects arises because environmental
exposures can vary substantially with geographical location, meaning that finding
an appropriate replication cohort may not be that easy179,182. This is compounded
by the fact that the identified environmental exposures may be tagging the causal
interaction environment and this tagging may vary across different populations (can
be viewed similarly to different LD tagging across different populations).
Interpretation of G×E is not as straightforward as for epistasis studies. In particular,
it is possible that environmental variables can themselves have a genetic component
and it might be this genetic component that is driving the observed interaction
effect such that the identified G×E effect is actually an epistatic effect. If it is the
non-genetic component of the environment driving the interaction effect, then the
G×E effect may be more apparent in subjects of a given age range, which again
can make replication difficult189. In addition, as greater numbers of environmental
variables are tested for interaction effects, it is becoming apparent that the identified
environment may not be the driving environment but instead tag an unobserved or
compound environmental measure. Given that the environmental search space is
not a well defined domain, identification of the causal environment may prove to be
very difficult.
Whilst there are some differences in the challenges for identifying epistasis and G×E
effects, the majority of methods used to detect interaction effects can be applied both
to epistasis and to G×E, since the statistical definition is the same for both177. As
G×E is the application focus throughout this thesis, for simplicity I will describe
commonly used interaction methods in Section 2.1 in terms of G×E, noting that for
epistasis the environmental variable can simply be replaced by a genetic factor.
Due to the aforementioned shortcomings, there has been limited success in robustly
identifying both genotype-environment and epistatic interaction effects. However,
some G×E effects for human disease risk191,192 and molecular traits193,194 have
already been identified and there are concerted efforts underway to increase sample
sizes and improve the quality of environmental data collected. In particular, this is
through the generation of large scale biobanks that collate a multitude of phenotypic
and environmental data, such as UK Biobank131 (see Section 1.2.2), which in theory
enables a more comprehensive analysis of genotype-environment interactions.
These large scale datasets with multiple environmental measures available, bring to
the forefront a new problem; as a greater number of interaction effects are identified
due to the increased power, there is a growing body of evidence to suggest that
multiple environments are linked to interaction effects at the same genetic loci for a
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given trait. For example, there is evidence of G×E effects due to different lifestyle
factors, including diet and physical activity at FTO on BMI195–206.
These environments are often correlated with one another, making it difficult to
interpret whether the identified environments are acting independently of on another
or tagging the same either observed or an unmeasured environment179,195. The
latter would invalidate the claims of early studies, which often stated that the
tested environment is the driving interaction environment and that public health
policies should be based on these findings207. Furthermore, testing for interactions
at individual environments makes it difficult to determine which environmental
components have the greatest impact on the observed interaction effect179,195,208–211.
This has fostered interest to jointly test for interaction effects at multiple
environments but established computationally efficient robust methods with
available software, prior to this work were not available (see Section 2.2.7 for further
details). Many of the advantages of doing so are similar to those of set tests that
aggregate over variants (see Section 1.2.1). Namely, set tests that aggregate over
environments may increase the ability to detect interaction effects with modest or
weak effects at individual environments or alternatively a set of environments may
better tag the true driving environment. In addition, if the original analysis plan was
to test for interaction effects using different environments (one by one), environment
set test based approaches will reduce the multiple testing burden. Furthermore,
methods that account for other correlated environments can increase the ability
to identify the relative importance of different environmental components for an
observed interaction effect.
These benefits, together with the growing availability of large scale biobanks that are
collecting deep environmental data, necessitate the need for method development in
this direction.
1.4 Thesis overview
The overall aim of this thesis is to provide suitable methods to identify multivariate
G×E and explore these effects across a range of phenotypes using the UK Biobank
data.
Specifically, in Chapter 2, I describe the structured linear mixed model (StructLMM),
a novel computationally efficient multivariate G×E framework that can be used to
test for interaction effects. In addition, the same framework, similarly to existing
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interaction methods can be used to test for joint association effects, i. e. test for
associations whilst accounting for possible heterogeneity in variant effects across
individuals due to differences in environmental exposures. I show through the use
of simulation experiments that StructLMM is robustly calibrated and in general,
better powered than existing interaction and association tests.
In Chapter 3, I present an application of StructLMM, where I identify significant
interaction effects with 64 lifestyle-based factors for BMI using the UK Biobank data.
In addition, I show that the StructLMM association test can be used to identify loci
with genotype-environment contributions. Subsequently, I explore characteristics
of significant interaction loci, including the fraction of the genetic variance that is
explained by G×E and the environmental profiles that increase or decrease
phenotypic risk, using methods that are implemented as part of StructLMM.
Finally, in Chapter 4, I apply the StructLMM interaction test to multiple
cardiometabolic traits using the UK Biobank data, facilitating exploration of the
shared G×E architecture. Additionally, I provide preliminary estimates of the
amount of phenotypic variation that can be explained by G×E effects, relative to
marginal association effects.
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Chapter 2
StructLMM: a linear mixed model
approach to study multivariate
genotype-environment
interactions
2.1 Introduction
As outlined in Section 1.4, there is evidence that a single genetic locus may interact
with multiple environments to influence the outcome of a given phenotype. For
example, it has been shown that FTO interacts with physical activity195–197,212,213,
diet195,196,206,214 and smoking196 to impact BMI. Difficulties in interpreting results
due to correlation between these environmental factors combined with the increasing
availability of large datasets, such as UK Biobank215, that collect deep phenotype,
environment as well as genotype data, necessitates a need for multi-environment
G×E methods.
A current way to detect interaction effects, is to stratify samples into discrete
subpopulations based on their environmental exposure. Then linear regression
(Eqs. 1.1-1.2, see Section 1.1.5) is applied to each strata and subsequently the
marginal variant effects are compared to assess whether there is a significant
difference in these effects across the different subgroups (in the remainder of this
introduction section, I will refer to this method as the ‘stratification interaction
test’)212,216,217. However, as more detailed environmental data is collected, allowing
for finer stratification of the population, these methods are no longer optimal as
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the subpopulations become too small to obtain stable estimates of the variant
effects216.
A second commonly used method to test for interaction effects relies on a simple
extension to the linear regression models used for GWAS (described by Eqs. 1.1-1.2,
see Section 1.1.5), via the addition of two additional fixed effect terms (G×E and
E), which can be cast as:
logit(yD) = Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+x eβG×E︸ ︷︷ ︸
G×E
+ eβE︸︷︷︸
E
+ ︸︷︷︸
Noise
, (2.1)
where yD is an N × 1 binary phenotype vector, capturing for example disease
status179,218 or:
y = Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+x eβG×E︸ ︷︷ ︸
G×E
+ eβE︸︷︷︸
E
+ ︸︷︷︸
Noise
, (2.2)
where y is an N × 1 quantitative phenotype vector (in the remainder of this
introduction section, I will refer to this method as the ‘linear interaction test’)179.
In both cases, N is the number of samples used in the analysis, W is an N × a
covariate design matrix and α is an a × 1 vector of corresponding effects, x is an
N × 1 genotype vector for the focal variant,  denotes element wise multiplication
(Hadamard product), e is an N × 1 environmental exposure vector, and βG, βG×E
and βE are the marginal genetic, interaction and environment effects, respectively.
 is an N × 1 noise vector, modelled as random effect following the multivariate
normal distribution:
 ∼ N (0, σ2nIN), (2.3)
where IN is the N ×N identity matrix179.
The interaction test, assesses whether βG×E 6= 0. Formally the interaction hypothesis
test is:
H0 : βG×E = 0 (2.4)
vs
H1 : βG×E 6= 0. (2.5)
Since researchers are often interested in identifying variants associated with a
phenotype, whether that be due to marginal or interaction effects and the presence
of interaction effects may mask or reduce the observed marginal effect of a
variant177,179,188,218, it has been proposed that the same model framework can be
used to test for association effects whilst allowing for the presence of interaction
29
effects. This may enable the identification of variants associated with traits that
are not be detected through the use of a conventional LM. This is often referred to
as a ‘joint association’ test, which tests whether at least one of two variables has a
non-zero effect, i. e. [βG, βG×E] 6= 0179,218. Due to the second degree of freedom that
is introduced, these joint tests can be slightly less powered than marginal association
tests when there is no dependence on the environment188.
Similarly to the marginal association model (see Section 1.1.5), different data
encodings can be used to make different assumptions regarding the dependence
between the genetic variant and environment including dominance, recessiveness and
multiplicative effects188. However, similarly to considering higher order interactions
(see Section 1.3.2) the benefits of considering these alternative models is likely
outweighed by the increase in the degrees of freedom of the test or an increased
multiple testing burden180.
Using these two aforementioned methods, there has been limited success in robustly
identifying interaction effects, namely due to the many shortcomings of interaction
tests outlined in Section 1.3.2. As well as concerted efforts to increase sample sizes
and improve the quality of environmental data collected in an attempt to improve
detection of interaction effects, there have been methodological developments in two
main directions.
The first are methods that test a subset of the SNPs based on their marginal
genetic effects or variance heterogeneity (and in some cases select a subset of the
environments based on marginal effects from environment-wide association studies),
thereby reducing the multiple testing burden180. These marginal effects can be
determined based on a previous association study, literature mining or two step
procedures that test all variants for marginal effects in the first step, selecting
variants to test for interaction effects at the second step; the latter is valid as long
as the marginal test and interaction test are independent of one
another175,177,180,193,219–231.
A key disadvantage of this approach is that interaction effects may be missed when
variants or environments have no or weak marginal effects and evidence does exist
to demonstrate that interaction effects can occur for variants with no marginal
effects186,188,226,232,233. In addition, there will be a bias towards increasing knowledge
at loci for which information is already available188,226,232,233.
Combining interaction tests based on linear models with variant set test based
approaches that were originally developed for marginal association tests (see Section
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1.2.1), is a second direction of method development. Analogous to the advantages
for marginal association tests, these set test based approaches can increase power
to detect interactions by aggregating modest and weak interaction effects across
variants. In addition, a regional set of genetic markers can better tag an unmeasured
causal variant than individual genetic markers, thereby boosting the power to detect
interaction effects (see Section 1.3.2 for a description of how variance explained
depends on the tagging strength)234. Additionally, similarly to the benefit of filtering
approaches, these set tests reduce the multiple testing burden. There are a number
of set test based approaches for interaction testing, which as for marginal association
set tests, can be broadly categorised as burden207,212,213,235–239, adaptive burden
240–242, variance component243 and combined burden and variance component
approaches (see Section 1.2.1)244. Further more specific details of interaction set
test approaches are provided in Section 2.2.7.
Method development to test for G×E effects jointly at multiple environmental
variables has largely been ignored. The exception is a study published in 2016
by Young et al.195, where the authors test for interaction effects with multiple
lifestyle-based environment factors on BMI, focussing on a single variant (rs1421085 )
within the FTO gene. This analysis is based on a two step procedure, where in the
first step they identify environments that display evidence of marginal effects on BMI
whilst accounting for the effect of the other considered environments and then in the
second step test for interactions using an extended version of the linear interaction
test described above.
Briefly the linear interaction test can be modified to test for multi-environment
G×E through the inclusion of additional interaction and environment terms (see
Section 2.3.2 for full details). However, as I will show in Section 2.4.4, these methods
are not always calibrated, in particular when the number of environments is large
compared to the sample size. In theory, the stratification interaction test can also
be modified such that multiple environments are used to stratify the samples into a
greater number of subgroups. However, discretisation of continuous environmental
variables results in loss of information and in addition, subgrouping of samples
reduces the sample size for fitting each LM, both of which result in a loss of potential
power to identify G×E effects.
Therefore, in this chapter, I will present a multi-environment G×E test, the
structured linear mixed model (StructLMM), that generalises and overcomes the
problems of existing interaction tests. Whilst primarily designed to identify
interaction effects, I will show that the framework can also be used to test for joint
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associations, in a similar vein to Kraft et al.218 and can be used for downstream
interpretation (see Chapter 3). The method has been implemented such that it
is computationally efficient, enabling analysis of cohorts containing hundreds of
thousands of individuals and hundreds of environments. StructLMM is flexible,
such that included environments can be continuous and/or binary, external (e. g.
lifestyle factors) or intrinsic (e. g. tissue or cell type) in nature, or be genetic variants
themselves (i. e. testing for epistatic interactions). StructLMM is freely available
from https://github.com/limix/struct-lmm and is supported within the LIMIX
framework78 at https://github.com/limix/limix. For tutorials and illustrations
on how to use the model, see http://struct-lmm.readthedocs.io.
In Section 2.2, I describe the StructLMM model, in Section 2.3, I provide details of
other models that are used to benchmark StructLMM and in Section 2.4, I present
results from simulation experiments.
Some of the material presented in this chapter is joint work with Francesco Paolo
Casale. Specifically, whilst I derived the first version of the mathematics
underpinning the method described in Section 2.2.5, suggestions from Francesco
Paolo Casale to improve the elegance of the proof, were incorporated. In addition,
Francesco Paolo Casale suggested possible ways in which StructLMM may be made
more computationally efficient that I subsequently incorporated (see Section 2.2.6).
Finally, the design of the simulation experiments and production of simulation
results described in Section 2.4 was joint work. This work has been published by
Nature Genetics245. A copy of this publication can be found in Appendix A (apart
from the Supplementary Tables which are available at https://www.nature.com/
articles/s41588-018-0271-0).
2.2 StructLMM
In this section, I introduce the StructLMM model and provide an overview of
the available interaction and joint association tests, followed by assumptions that
are made throughout this work. I then provide details of the testing procedures,
including the generation of the environment covariance matrix and the mathematics
underpinning the statistical tests before describing specific implementation details
and the corresponding computational complexities. Finally, I place StructLMM
in context to existing interaction and joint association tests, describing technical
similarities.
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2.2.1 The model
LMM As described in Section 1.1.6 (Eq. 1.6), a conventional LMM used to test
for associations between a N × 1 phenotype vector, y (where N is the sample size
of the analysis), and a N × 1 genotype vector of a focal variant, x can be written
as:
y = Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+ u︸︷︷︸
Confounding
+ ︸︷︷︸
Noise
, (2.6)
where the scalar βG is the focal variant effect, W is an N × a design matrix of a
covariates and α is an a×1 vector of the corresponding effects, u is an N ×1 vector
that can account for population structure, other confounding factors (between y and
x) or additive environment effects, and  is anN×1 noise vector. The final two terms
are modelled as random effects following multivariate normal distributions:
u ∼ N (0, σ2eR), (2.7)
 ∼ N (0, σ2nIN), (2.8)
where R is an N ×N matrix and IN is the N ×N identity matrix.
An association is present when βG 6= 0 (formal definitions of this hypothesis test, are
provided in Section 1.1.5). This association test is performed under the assumption
that the effect of a variant is the same across all N samples (referred to as a persistent
genetic effect), whilst in reality the effect of the variant may vary from one individual
to the next due to differences in their environmental exposures (G×E).
StructLMM The StructLMM model builds on the conventional LMM (Eq. 2.6),
allowing for heterogeneity in variant effect sizes across the N individuals due to G×E
through the inclusion of an additional term, x  βG×E, resulting in the following
model:
y = Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+x βG×E︸ ︷︷ ︸
G×E
+ u︸︷︷︸
E
+ ︸︷︷︸
Noise
, (2.9)
where  denotes element wise multiplication (Hadamard product), such that x 
βG×E is an N×1 vector, and is equivalent to diag(x)βG×E where diag(x) is an N×N
matrix which has non-zero values only on the diagonal. βG×E is an N × 1 vector,
modelled as a random effect, following the multivariate normal distribution:
βG×E ∼ N (0, σ2G×EΣ), (2.10)
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where Σ is N × N symmetric matrix that encodes the environmental similarity
between pairs of individuals (see Section 2.2.4 for details). In the special case, where
βG×E = 0 or alternatively, σ2G×E = 0, Eq. 2.9 is identical to the conventional LMM
described in Eq. 2.6. This form of the model is used to obtain the marginal model
(see Section 2.2.5) of the StructLMM interaction test and downstream interpretation
tools described in Chapter 3 (see Section 2.2.5). I will refer to this marginal form
of the model as the ‘interaction test marginal distribution’.
If I also model, the persistent genetic effect, βG, as a random effect, following the
normal distribution:
βG ∼ N (0, σ2G), (2.11)
it is possible to rewrite Eq. 2.9†, such that the persistent, βG, and heterogeneous,
βG×E, genetic effect terms are captured by a single term, β as follows:
y = Wα︸︷︷︸
Covariates
+ x β︸ ︷︷ ︸
G+G×E
+ u︸︷︷︸
E
+ ︸︷︷︸
Noise
, (2.12)
where β is an N × 1 vector, modelled as a random effect, following the multivariate
distribution:
β ∼ N (0, σ2G1N1TN + σ2G×EΣ), (2.13)
where 1N is an N × 1 vector of ones such that 1N1TN is an N × N matrix of
ones. The first covariance term models full correlation of the SNP effect across
individuals, thereby capturing the component of the SNP effect that is persistent
across all individuals and the second covariance term is identical to that described in
Eq. 2.10, and thus allows the SNP effect to vary across individuals due to differences
in environmental exposures. This form of the model is used to obtain the marginal
model of the StructLMM joint association test (see Section 2.2.5). I will refer to this
marginal form of the model as the ‘association test marginal distribution’.
With these random effect designs that capture G×E through a single covariance
term, σ2G×EΣ (see Eqs. 2.10 and 2.13), both forms of the StructLMM model
(described in Eqs. 2.9 and 2.12) can be used to model different possible G×E
scenarios, thereby generalising previous approaches. In the simplest case, to assess
G×E driven by two subgroups of individuals (Fig. 2.1a), for example gender specific
effects or by stratifying the individuals based on their environmental exposure (e. g.
highly and lowly exposed), a block diagonal covariance matrix, Σ, can capture
this (Fig. 2.1d). If the number of subgroups considered is increased, either by
†noting that xβG = x βG, where βG and βG are modelled as a random effects following the
distributions βG ∼ N (0, σ2G) and βG ∼ N (0, σ2g1N1TN ), respectively.
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increasing the number of environmental variables that are used for stratification, for
example, four subgroups could be defined by combining the aforementioned gender
and environmental exposure levels or by stratifying the data into a greater number
of subgroups when non-binary environmental variables are available (Fig. 2.1b), a
block diagonal covariance matrix, Σ, with greater rank can be used. In many cases,
it will be possible to define a hierarchy over these different environmental subgroups,
which can be captured by off diagonal terms in the covariance matrix, Σ (Fig. 2.1e).
In the limiting case, where many environments or a continuous exposure variable
are assessed, each individual is its own subgroup, resulting in per-individuals effect
sizes (Fig. 2.1c, f).
2.2.2 StructLMM interaction and association tests
The StructLMM framework allows for performing two different tests:
1. The first is an interaction test, that tests whether the effect of a variant is
significantly different under different environmental exposures, whilst
accounting for persistent genetic effects under the null. This is equivalent to
testing whether σ2G×E 6= 0 for both forms of the model given by Eqs. 2.9-2.13.
As outlined in Section 1.1.5, there are slightly different statistical testing
procedures that can be used to perform this interaction test. Since the score
test is both computationally efficient and the framework readily adapted for
the joint association test (where the score test yields even greater efficiency
advantages), I employ a score-based test.
The formal interaction hypothesis test is:
H0 : σ
2
G×E = 0 (2.14)
vs
H1 : σ
2
G×E > 0, (2.15)
noting that σ2G×E is a variance parameter and hence can only take positive
values.
As a result, the tested parameter is on the boundary of the parameter space
under the null model246–249, such that the score test statistic does not follow
the usual χ21 but instead a mixture of χ
2 distributions. Since, in general, Σ
is not an identity matrix or block diagonal, the score test statistic will not
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Fig. 2.1 Different G×E scenarios that can be tested using StructLMM
and corresponding examples of environment covariance structures, Σ |
(a) Basic G×E with two subgroups (one subgroup represented by the blue line and
the other by the red line) of individuals stratified based on their environmental
exposures. Deviation in the difference of the average phenotypic value between the
two subgroup across the two genotype dosages signifies G×E effects are present. (b)
G×E with multiple (three in this illustrative example) subgroups present due to the
availability of multiple environmental exposure variables or due to stratification of
the environmental data into a greater number of subgroups. Subgroup hierarchy
based on environmental exposure levels may be present. (c) G×E in the limiting
case where effect sizes are defined per-individual, which can be driven both by a large
number of environmental variables and through the use of continuous measures of
environmental exposure. (d-f) Examples of environment covariance structures, Σ for
different settings, (d) when there exist two subgroups, (e) when there exist multiple
(three in this illustrative example) subgroups, in the presence of subgroup hierarchy
and (f) when there exist many binary and continuous environmental exposures.
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follow the conventional 50:50 mixture of χ20 and χ
2
1
250–252 but instead has been
shown to follow a mixture of χ21 variables, weighted based on the structure
of Σ118,123,251,253 (see Section 2.2.5 for details). Full details of the interaction
testing procedure are described in Section 2.2.5.
2. Whilst primarily designed for interaction testing, the framework can also
be used for joint association testing, similar to Kraft et al.218, testing for
associations between a variant and a phenotype, accounting for possible
heterogeneity in the variant effect due to G×E. More explicitly, this
corresponds to testing whether [βG, σ
2
G×E] 6= 0 in Eqs. 2.9-2.10, or alternatively,
[σ2G, σ
2
G×E] 6= 0 in the form of the model described by Eqs. 2.12-2.13. In the
latter case, the formal joint association hypothesis test is:
H0 : [σ
2
G, σ
2
G×E] = 0 (2.16)
vs
H1 : [σ
2
G, σ
2
G×E] > 0, (2.17)
again noting that σ2G and σ
2
G×E are variance parameters and hence can only
take positive values.
Again, for computational efficiency a score-based test is used; for the joint
association test, it can be seen that the score-based implementation yields
even greater efficiency gains compared to the LRT and Wald test than for
the interaction test, since a single null model needs to be fit to perform a
genome-wide scan.
Again, the tested parameters lie on the boundary of the parameter space
and deriving the appropriate mixture of χ2 variables is substantially more
difficult in this setting249, where two variance components are tested, than
in the interaction test setting. To avoid computationally inefficient Monte
Carlo based254,255 and permutation based solutions249, StructLMM follows the
approach taken in SKAT-O123, where the variance component test of two
free parameters is reduced to a variance component test with a single free
parameter. This is achieved via the introduction of the parameter ρ, which I
grid search over (i. e. a test for each value of ρ is conducted, which is followed
by an adjustment to account for this ‘multiple testing’, resulting in a single
final P value per variant; see Section 2.2.5 for details) such that Eq. 2.13 can
be rewritten as:
β ∼ N (0, σ2tot[(1− ρ)1N1TN + ρΣ]). (2.18)
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By comparison with Eq. 2.13, it can be seen that σ2tot(1−ρ) ≡ σ2G and σ2totρ ≡
σ2G×E, from which it follows that σ
2
tot ≡ σ2G + σ2G×E†. σ2tot denotes the total
variance of the genetic effect (encompassing both the persistent and G×E
components), after appropriate adjustment for the matrix variance of Σ (see
Section 3.2.1 for full details), whilst the parameter ρ corresponds to the fraction
of the total genetic variance that can be explained by G×E:
ρ =
σ2G×E
(σ2G + σ
2
G×E)
=
σ2G×E
σ2tot
(2.19)
The formal hypothesis test is now:
H0 : σ
2
tot = 0 (2.20)
vs
H1 : σ
2
tot > 0 (2.21)
Full details of the joint association test are described in Section 2.2.5.
2.2.3 Simplifying assumptions
I now make three simplifying assumptions that hold throughout the rest of this
thesis.
1. The individuals included in the analysis are unrelated. In theory,
StructLMM can account for confounding due to population structure using a
random effect term (as described in Eqs. 2.6 and 2.7), where R is defined as
the genetic relatedness matrix (see Section 1.1.6), such that related individuals
can be included in the analysis. However, the genetic relatedness matrix, R,
is typically full rank and hence StructLMM would not scale linearly with the
number of samples. To retain computational efficiency, such that the method
can be applied to large cohorts, I account for population structure using
principal components, which will be included as covariates (see Section 1.1.6).
2. The covariance matrix used to account for additive environment
effects is identical to the covariance matrix used to model G×E.
Whilst in general, different covariance structures can be used to model the
additive environment effects (which accounts for direct correlation between the
†Substituting σ2totρ ≡ σ2G×E into σ2tot(1 − ρ) ≡ σ2G, gives σ2tot − σ2G×E ≡ σ2G, which once
rearranged gives, σ2tot ≡ σ2G + σ2G×E
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environments and the phenotype) and the interaction effects, for simplicity, I
assume they are the identical. Explicitly, the additive environment effect is
modelled through the random effect term, u, with R = Σ (Eqs. 2.7 and 2.9).
3. The linear covariance function is used to build the environment
covariance, Σ. Whilst in principle, any valid covariance function256 can be
used to define the environmental similarity matrix Σ, in this thesis I consider
only the linear covariance function, defined as:
Σ = EET , (2.22)
where E is an N × L matrix, where L is the number of tested environments
(which may be continuous and/or discrete) and
E = f(Eraw), (2.23)
where f represent any functional mapping (equivalent to using basis functions
in linear regression) from the raw observed environment covariates, Eraw, to
the environment covariates, E, used to build the covariance matrix, Σ (see
Section 2.2.4 for descriptions of commonly used functional mappings).
The use of a linear covariance function was motivated by two appealing
properties. The first is that in general the number of environments, L, will
be much smaller than the number of individuals, N (L << N), meaning
that the linear covariance function will be low rank. This enables algebraic
reformulation, which in turn results in computational complexity that scales
linearly with the number of samples, N , i. e.O(N) complexity (see Section 2.2.6
for details). The second is that a linear covariance is directly interpretable
as there is a one-to-one correspondence between StructLMM and multivariate
linear regression using L covariates to capture the interaction term (see Section
2.2.4).
2.2.4 Environment covariance, Σ
As already outlined in the previous section, in this work, I use the linear covariance
function to build an environmental similarity matrix, Σ. In this section, I will
describe commonly employed functional mappings (see Eq. 2.23) and the broad
range of settings, including non-linear relationships that a linear covariance function
can capture. Finally, I will provide details of the one-to-one correspondence between
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multivariate linear regression and StructLMM, when a linear covariance function is
used to capture environmental similarity.
Common functional mappings
A commonly employed functional mapping, is to normalise the L environmental
variables such that each exposure has mean 0 and standard deviation 1. A standard
strategy is to then rescale these normalised features by a factor of 1√
L
such that the
resulting covariance matrix, Σ has sample mean 0 and sample variance 1257. Other
valid strategies, include row standardisation such that either the resulting covariance
matrix, Σ has per-individual variance 1 or is a correlation matrix256. These different
standardisation procedures make slightly different assumptions regarding the
variance explained by different environments within the interaction and additive
environment terms, similar to building linear covariances using genetic factors74.
Settings captured by linear covariance function
The linear covariance function is able to capture different interaction settings. This
includes group specific effects through the use of L binary environmental variables,
where L is the number of defined subgroups, resulting in a block diagonal matrix
(Fig. 2.1d) or if some of these L environmental variables are ordinal then a natural
hierarchy amongst the different subgroups can be captured resulting in off-diagonal
non-zero values (Fig. 2.1e) and finally if some of the L exposures are continuous then
per-individual variant effects can be modelled (Fig. 2.1f). Despite the name, a linear
covariance function can also capture non-linear relationships between the observed
environments, through the introduction of additional transformed environmental
variables, similar to using basis functions for non-linear regression256. This may
include exponentiation of the observed environments or combining several variables.
For example, the L environmental variables, {e1, e2, ..eL} can be combined with a
categorical variable, c ∈ {0, 1}N×1, such as gender, to define E = [ce1, ce2, ...c
eL, (1−c)e1, (1−c)e2, ..., (1−c)eL], an N×2L matrix. This is the approach
taken to define gender and age adjusted environmental variables (Section 2.4.1 and
Chapters 3 and 4).
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Derivation as marginalised linear G×E interaction model
Using the linear covariance function to define the environmental similarity matrix, Σ,
facilitates direct interpretation, since StructLMM can be derived from a multivariate
linear interaction model, analogous to the well-known relationship between
multivariate Bayesian linear regression and LMMs (as outlined in Section 2.2.3,
simplifying assumption 3)75. Denoting theN×1, L environment vectors as e1, . . . , eL,
a multivariate linear interaction model can be cast as:
y = Wα︸︷︷︸
covariates
+xβG︸︷︷︸
G
+
L∑
l=1
(x el)βG×El︸ ︷︷ ︸
G×E
+
L∑
l=1
elβEl︸ ︷︷ ︸
E
+ ︸︷︷︸
noise
. (2.24)
By defining the following priors on the variance of βG×El and βEl :
βG×El ∼ N (0, σ2G×E), (2.25)
βEl ∼ N (0, σ2e) (2.26)
and marginalising over βG×El and βEl , it can be seen that this multi-environment
linear interaction model is equivalent to the form of StructLMM described by Eqs. 2.7-
2.10. The multivariate linear interaction model described here, is one of the
comparison partners (Section 2.3) used in simulation experiments (Section 2.4) and
in application to real data (Chapter 3).
2.2.5 Statistical testing
In this section, I will describe in detail the statistical testing procedures and the
underpinning mathematics for both the interaction and joint association StructLMM
tests (outlined in Section 2.2.2). I will first describe the marginal models used
for parameter inference, followed by the different steps required for the statistical
tests.
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Marginal models
A marginalised form of Eq. 2.9 can be obtained by integrating over βG×E† (Eq. 2.10)
and u (Eq. 2.7), such that:
y ∼ N (Wα+ xβG, σ2G×Ediag(x)Σdiag(x) + σ2eΣ + σ2nIN). (2.27)
This marginalised form of the model is used for the interaction test and for the
downstream analysis described in Chapter 3 and is referred to as the ‘interaction
test marginal distribution’.
A fully marginalised form of the model can be obtained by additionally integrating
over the persistent genetic effect. This is equivalent to integrating over β (Eq. 2.18)
and u (Eq. 2.7) using the form of the model described in Eq. 2.12, such that:
y ∼ N (Wα, σ2totKρ + σ2eΣ + σ2nIN), (2.28)
where:
Kρ = (1− ρ)diag(x)1N1TNdiag(x) + ρdiag(x)Σdiag(x). (2.29)
Noting that diag(x)1N ≡ x, Kρ can be simplified to:
Kρ = (1− ρ)xxT + ρdiag(x)Σdiag(x). (2.30)
This marginalised form of the model is used for the joint association test and is
referred to as the ‘association test marginal distribution’.
Fitting the models under the null
The score test requires fitting the models under the null hypothesis. For the
StructLMM interaction test, the null model is:
y = Wα+ xβG + u+ , (2.31)
where the interaction test marginal distribution (based on Eq. 2.27):
y ∼ N (Wα+ xβG, σ2eΣ + σ2nIN), (2.32)
is used for parameter inference.
†using x βG×E ≡ diag(x)βG×E
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For the StructLMM joint association test, the null model is:
y = Wα+ u+ , (2.33)
where the association test marginal distribution (based on Eq. 2.28):
y ∼ N (Wα, σ2eΣ + σ2nIN), (2.34)
is used for parameter inference.
Parameter inference is performed using a previously implemented REML-based
framework, LIMIX78, to identify the optimal parameters αˆ, σˆ2e and σˆ
2
n and in
addition βˆG for the interaction test.
Subsequently the covariance under the null, K0, for both the interaction and joint
association test is:
K0 = σˆ
2
eΣ + σˆ
2
nIN (2.35)
Score-based test statistic
As described in Lippert et al.253, the score-based test statistic, Q, is given by:
Q =
1
2
yTP0
∂K
∂θ
P0y (2.36)
where K is the covariance of the marginal likelihood (see Eq. 2.27 and Eq. 2.28 for
the interaction and joint association tests, respectively), θ is the focal parameter of
the hypothesis test (σ2G×E, Eqs. 2.14-2.15 and σ
2
tot, Eqs. 2.20-2.21 for the interaction
and joint association tests, respectively) and:
P0 = K
−1
0 −K−10 X(XTK−10 X)−1XTK−10 , (2.37)
where K0 is the covariance of the marginal likelihood under the null hypothesis
(defined in Eq. 2.35) and X is the combined design matrix of all fixed effects in the
marginal likelihood, such that X = [W ,x] and X = W for the interaction and
joint association test, respectively.
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Derivative of the covariance, K, w. r. t. the parameter of interest, θ:
∂K
∂θ
For the interaction test, using the marginal likelihood described by Eq. 2.27, where
K = σ2G×Ediag(x)Σdiag(x) + σ
2
eΣ + σ
2
nIN and θ = σ
2
G×E,
∂K
∂σ2G×E
= diag(x)Σdiag(x). (2.38)
For the joint association test, using the marginal likelihood described by Eq. 2.28,
where K = σ2totKρ + σ
2
eΣ + σ
2
nIN and θ = σ
2
tot,
∂K
∂σ2tot
= Kρ, (2.39)
where Kρ = (1− ρ)xxT + ρdiag(x)Σdiag(x) as defined in Eq. 2.30.
It can be seen that the derivative for the interaction test, is the special case of the
derivative of the association test when ρ = 1, i. e. K1 = diag(x)Σdiag(x) (I use
the notation K1 throughout the rest of this chapter to denote this interaction test
derivative).
Score-based test statistic for interaction test
The score-based test statistic for the interaction test is thus:
Qint =
1
2
yTP0K1P0y, (2.40)
where K1 is as defined above.
Evaluating the significance of the score-based interaction test statistic
It can be shown that under the null, the score-based test statistic, Q, follows a
weighted sum of χ21 variables
253:
Q ∼
∑
k
λkχ
2
1, (2.41)
where λk are the non-zero eigenvalues of
1
2
P
T
2
0
∂K
∂θ
P
1
2
0 .
There are a number of methods that can be used to evaluate the significance of
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the score-based test statistic, Qint, given the null distribution (I refer the reader to
Duchesne et al.258 and Wu et al.259 for further details). For the interaction test, I
follow the approach taken in SKAT118, where P values are calculated using Davies
method258,260, an exact characteristic inversion method, switching to the modified
moment matching approximation method123,258,261† when this fails to converge.
Test statistic for the joint association test
The score-based test statistic for the joint association test is:
Qρ =
1
2
yTP0KρP0y, (2.42)
where Kρ is as defined in Eq. 2.30.
However, this requires setting ρ to a given value but in general this parameter is
unknown. I therefore follow a similar approach to that taken in SKAT-O123, which
performs a grid search over ρ. Explicitly, this involves:
1. Define a set, r = 1, ..., R, of values for ρ to grid search over, 0 = ρ1 < ρ2 <
... < ρR = 1 (In all analyses, I use [0.0, 0.5, 0.75, 0.84, 0.91, 0.96, 0.99, 1.0] by
default).
2. Calculate the score-based test statistic, Qρr for each ρr (using Eq. 2.42). For
each of these test statistics a P value, Pρr , is calculated; this is achieved
following the same process as was used to obtain the interaction test P value,
namely that these score-based test statistics follow a weighted sum of χ21
variables under the null (Eq. 2.41). In this step the modified moment matching
approximation method123,258,261 is used since it is computationally more efficient
than the exact Davies method258,259 and as will become clear in the following
steps these P values are not the final ones reported.
3. Calculate the test statistic T = min{Pρ1 ,Pρ2 , ...,PρR}.
4. Compute the P value of the test statistic, T . Details on how this is done are
provided below.
†The moment-matching method is an approximation method that is based on matching the
first three moments (mean, variance and skewness) but can lead to inflated Type 1 error rates,
in particular for small P values259. A modified version of this moment-matching method was
implemented in SKAT, which matches the kurtosis instead of skewness, to improve the tail
probability approximation123,258,261 but can still lead to inflated Type 1 error rates, in particular
for small P values.
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Evaluating the significance of the test statistic T
I now describe how the P value of the test statistic, T is calculated. The obtained
P value describes the significance of the StructLMM association test. The following
derivation generalises that required for SKAT-O123, where Kρ is the sum of a 11
T
(matrix of ones) and I (an identity matrix) matrix. The derivation provided here
facilitates the use of a non-identity matrix as the second term in Kρ (Eq. 2.30, see
Section 2.2.7 for a comparison to SKAT-O). To the best of my knowledge, this is
the first time that explicit derivations have been presented (i. e. explicit derivations
are not presented in previous SKAT-O publications).
By definition the P value, is the probability under the null hypothesis of obtaining
a test statistic, t, at least as extreme as the one observed, T :
P = Pr(t < T )
= Pr(min{pρ1 , pρ2 , ..., pρR} < T )
= 1− Pr(pρ1 ≥ T, pρ2 ≥ T, ..., pρR ≥ T ), (2.43)
where pρr is defined as the r
th P value obtained under the null hypothesis. Again, by
definition, the P value, pρr is the probability under the null hypothesis of obtaining
a value, qρr , at least as extreme as the score-based test statistics Qρr :
pρr = Pr(Qρr < qρr). (2.44)
Substituting, Eq. 2.44 into Eq. 2.43, gives:
P = 1− Pr(Pr(Qρ1 < qρ1) ≥ T,Pr(Qρ2 < qρ2) ≥ T, ...,Pr(QρR < qρR) ≥ T ). (2.45)
Eq. 2.45 can be rewritten as†:
P = 1−Pr(1−Pr(Qρ1 ≥ qρ1) ≥ T, 1−Pr(Qρ2 ≥ qρ2) ≥ T, ..., 1−Pr(QρR ≥ qρR) ≥ T ),
(2.46)
which rearranging gives:
P = 1−Pr(Pr(Qρ1 ≥ qρ1) ≤ 1−T,Pr(Qρ2 ≥ qρ2) ≤ 1−T, ...,Pr(QρR ≥ qρR) ≤ 1−T ).
(2.47)
Either by quantile function definitions or through visualisation of the probability
†using Pr(Qρr < qρr ) = 1− Pr(Qρr ≥ qρr )
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density function (Fig. 2.2), this is equivalent to:
P = 1− Pr(Qρ1 ≤ qmin(ρ1), Qρ2 ≤ qmin(ρ2), ..., QρR ≤ qmin(ρR)), (2.48)
where qmin(ρr) is the 1 − T th percentile of the distribution of qρr , corresponding to
the test statistic Qρr .
Qqρr
ρr qmin(ρr)Qqρr
ρr
ba
Fig. 2.2 Visualisation of equivalence of Eq. 2.47 and Eq. 2.48 using
the probability density function of qρr | Probability density function of the
distribution of qρr (density (y-axis) as a function of qρr (x-axis)) highlighting the
Pr(Qρr ≥ qρr) which is the area under the probability density function curve to
the left of Qρr in red (a) and additionally the greater area (as defined in Eq. 2.47)
of 1 − T in blue (b). The area of 1 − T is bounded by qρr = qmin(ρr), where by
definition qmin(ρr) is the (1−T )th percentile of the distribution of qρr corresponding
to the test statistic Qρr . It can be seen that if, Pr(Qρr ≥ qρr) ≤ 1−T it follows that
Qρr ≤ qmin(ρr).
I will now show that under the null, Qρ, can be written as the sum of S + 1
independent random variables in the form 1
2
τρη0 +
1
2
ρκ, where:
τρ = (1− ρ)m+ ρ1
TZTZΣZTZ1T
m
, (2.49)
Z = P
T
2
0 diag(x), (2.50)
m = 1TZTZ1, (2.51)
κ = φ+ ξ, (2.52)
φ =
S∑
s=1
λsηs, (2.53)
ξ = 2vT (I −M )ZΣZTMv, (2.54)
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M =
1
m
Z11TZT , (2.55)
v = P
T
2
0 y, (2.56)
λs are the S non-zero eigenvalues of E
TZT (I −M )ZE, and ηs are i.i.d. χ21 for
s = 0, 1, ..., S.
Proof Starting from Qρ (defined in Eq. 2.42):
Qρ =
1
2
yTP0KρP0y, (2.57)
substitute Kρ (as defined in Eq. 2.29) and write P0 as a product of its matrix square
roots to give:
Qρ =
1
2
yTP
1
2
0 P
T
2
0 [(1− ρ)diag(x)11Tdiag(x) + ρdiag(x)Σdiag(x)]P
1
2
0 P
T
2
0 y. (2.58)
Let v = P
T
2
0 y, to give:
Qρ =
1
2
(1− ρ)vTP
T
2
0 diag(x)11
Tdiag(x)P
1
2
0 v +
1
2
ρvTP
T
2
0 diag(x)Σdiag(x)P
1
2
0 v
(2.59)
and Z = P
T
2
0 diag(x), such that:
Qρ =
1
2
(1− ρ)vTZ11TZTv + 1
2
ρvTZΣZTv (2.60)
and finally, let M = 1
m
Z11TZT , resulting in:
Qρ =
1
2
m(1− ρ)vTMv + 1
2
ρvTZΣZTv. (2.61)
This is equivalent to:
Qρ =
1
2
m(1− ρ)vTMv︸ ︷︷ ︸
Term 1
+
1
2
ρvTZΣZTv︸ ︷︷ ︸
Term 2
+
1
2
ρvTZΣZTMv︸ ︷︷ ︸
Term 3
−1
2
ρvTMZΣZTv︸ ︷︷ ︸
Term 4
− 1
2
ρvTMZΣZTMv︸ ︷︷ ︸
Term 5
+
1
2
ρ
vTMv
m
× 1TZTZΣZTZ1︸ ︷︷ ︸
Term 6
, (2.62)
since Terms 3 and 4 and Terms 5 and 6 cancel out. This can be explicitly shown
using the definition of M (Eq. 2.55) and noting that a, b and c are scalars as
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follows:
Term 3 =
ρ
m
vTZΣZTZ1︸ ︷︷ ︸
a
1TZTv︸ ︷︷ ︸
b
=
ρ
m
vTZ1︸ ︷︷ ︸
b
1TZTZΣZTv︸ ︷︷ ︸
a
= Term 4, (2.63)
Term 5 =
ρ
m2
vTZ1︸ ︷︷ ︸
b
1TZTZΣZTZ1︸ ︷︷ ︸
c
1TZTv︸ ︷︷ ︸
b
=
ρ
m2
vTZ1︸ ︷︷ ︸
b
1TZTv︸ ︷︷ ︸
b
1TZTZΣZTZ1︸ ︷︷ ︸
c
= Term 6. (2.64)
Eq. 2.62 can be rewritten as:
Qρ =
1
2
m(1− ρ)vTMv + 1
2
ρvTZΣZTv − 1
2
ρvTZΣZTMv + ρvTZΣZTMv
− 1
2
ρvTMZΣZTv +
1
2
ρvTMZΣZTMv − ρvTMZΣZTMv
+
1
2
ρ
vTMv
m
× 1TZTZΣZTZ1, (2.65)
which can be factorised as follows:
Qρ =
1
2
[m(1− ρ) + ρ
m
1TZTZΣZTZ1]vTMv
+
1
2
ρvT (I −M)ZΣZT (I −M )v + ρvT (I −M )ZΣZTMv. (2.66)
Let τρ = (1− ρ)m+ ρ1TZTZΣTZTZ1Tm and ξ = 2vT (I −M )ZΣZTMv, then:
Qρ =
1
2
τρ v
TMv︸ ︷︷ ︸
Term 1
+
1
2
ρ(vT (I −M )ZΣZT (I −M )v︸ ︷︷ ︸
Term 2
+ ξ︸︷︷︸
Term 3
). (2.67)
I will now show that the three terms (noting that τρ and ρ are scalars) are independent
of one another, such that Qρ can be expressed as a mixture of independent random
variables.
Throughout these derivations, I will use the fact that v is normally distributed (see
Lippert et al.253 for the proof):
v = P
T
2
0 y ∼ N (0, I), (2.68)
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and let m = 1TZTZ1, such that M is a projection matrix (with the column space
of M spanned by Z1).
To demonstrate the independence of the three terms, I will show that the covariance
between each pair of terms is 0. Let v be normally distributed (as defined in Eq. 2.68)
and A and B be two general matrices, then using results in section 8.2 of the matrix
cookbook262:
Cov(vTAv,vTBv) = E(vTAvvTBv)− E(vTAv)E(vTBv)
= tr(A(B +BT )) + tr(A)tr(B)− tr(A)tr(B)
= tr(A(B +BT )) (2.69)
Using Eq. 2.69 and noting that M (I −M) = 0, (I −M ) = (I −M )T and
MM = M when M is a projection matrix and tr(AB) = tr(BA):
Cov(Term 1,Term 2) = Cov(vTMv,vT (I −M )ZΣZT (I −M )v)
= tr(M [(I −M )ZΣZT (I −M )
+ (I −M )ZΣZT (I −M)])
= 2tr(M (I −M )ZΣZT (I −M))
= 0, (2.70)
Cov(Term 1,Term 3) = Cov(vTMv, 2vT (I −M)ZΣZTMv)
= 2tr(M [(I −M)ZΣZTM + ((I −M )ZΣZTM )T ])
= 2tr(0 +MMZΣZT (I −M ))
= 2tr(MZΣZT︸ ︷︷ ︸
A
(I −M)︸ ︷︷ ︸
B
)
= 2tr((I −M )︸ ︷︷ ︸
B
MZΣZT︸ ︷︷ ︸
A
)
= 0 (2.71)
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and
Cov(Term 2,Term 3)
= Cov(vT (I −M )ZΣZT (I −M )v, 2vT (I −M )ZΣZTMv)
= 2tr((I −M)ZΣZT (I −M )[(I −M )ZΣZTM + ((I −M )ZΣZTM )T ])
= 2tr((I −M)ZΣZT (I −M )ZΣZTM
+ (I −M )ZΣZT (I −M)MZΣZT (I −M))
= 2tr((I −M)ZΣZT (I −M )ZΣZT︸ ︷︷ ︸
A
M︸︷︷︸
B
+0)
= 2tr( M︸︷︷︸
B
(I −M )ZΣZT (I −M )ZΣZT︸ ︷︷ ︸
A
)
= 0. (2.72)
Using that when A is a symmetric matrix then:
vTAv ∼
∑
k
λkχ
2
1, (2.73)
where λk are the eigenvalues of matrix A (see Lippert et al.
253 for the proof), I now
show show that the first two terms of Eq. 2.67 follow mixtures of χ21 variables.
Since the only eigenvalues of a projection matrix M are 0 and 1, then Term 1,
vTMv, has the following distribution:
vTMv ∼ χ21, (2.74)
Term 2, vT (I −M )ZΣZT (I −M )v, follows the distribution:
vT (I −M )ZΣZT (I −M )v ∼
∑
k
λkχ
2
1, (2.75)
where λk are the eigenvalues of E
TZT (I −M )ZE, where I have used that
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eigenvalues(AAT ) = eigenvalues(ATA)†, such that:
eigenvalues((I −M )ZΣZT (I −M))
= eigenvalues((I −M )ZE︸ ︷︷ ︸
A
ETZT (I −M)︸ ︷︷ ︸
AT
)
= eigenvalues(ETZT (I −M )︸ ︷︷ ︸
AT
(I −M )ZE︸ ︷︷ ︸
A
)
= eigenvalues(ETZT (I −M )ZE). (2.76)
Therefore, I can write Eq. 2.67 as:
Qρ =
1
2
τρη0 +
1
2
ρκ, (2.77)
where κ = φ+ξ and φ =
S∑
s=1
λsηs, where λs are the non-zero eigenvalues ofE
TZT (I−
M )ZE, and ηs are i.i.d. χ
2
1 for s = 0, 1, ..., S.
Having proved that Qρ =
1
2
τρη0+
1
2
ρκ, I now substitute this form for Qρ into Eq. 2.48,
to give:
P = 1− Pr((1
2
τρ1η0 +
1
2
ρ1κ) ≤ qmin(ρ1), ..., (1
2
τρRη0 +
1
2
ρRκ) ≤ qmin(ρR)), (2.78)
which can be rewritten in terms of κ, as:
P = 1− E[Pr(κ ≤ (2qmin(ρ1)− τρ1η0)
ρ1
, ..., κ ≤ (2qmin(ρR)− τρRη0)
ρR
)|η0]
= 1− E[Pr(κ ≤ minRr=1{
(2qmin(ρr)− τρrη0)
ρr
})|η0] (2.79)
Again using results from section 8.2 of the matrix cookbook262, tr(AB) = tr(BA),
M (I −M) = 0 and (I −M )(I −M ) = (I −M ) (M is a projection matrix), it
can be shown that:
E(ξ) = E(2vT (I −M)ZΣZTMv) = 2tr((I −M)ZΣZTM) = 0 (2.80)
†and noting that Σ = EET
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and
Var(ξ) = Var(2vT (I −M )ZΣZTMv)
= 4tr([(I −M )ZΣZTM ][(I −M)ZΣZTM + ((I −M)ZΣZTM )T ]
= 4tr((I −M)ZΣZTM(I −M)ZΣZTM
+ (I −M )ZΣZTMMTZΣZT (I −M )T )
= 4tr(0 + (I −M )ZΣZTMZΣZT (I −M ))
= 4tr((I −M )ZΣZTMZΣZT (I −M ))
= 4tr((I −M )ZΣZTMZΣZT )
= 4tr((I −M )ZEETZTMZEETZT )
= 4tr(ETZT (I −M )ZEETZTMZE) (2.81)
It therefore follows that the P value (as defined by Eq. 2.79) can be calculated
using one-dimensional numerical integration, approximating the distribution of κ
using Davies exact characteristic inversion method123,260 after adjusting for the extra
variance term of ξ, switching to the modified Liu method123,258 when Davies method
fails to converge.
2.2.6 Computational complexities
As described in Section 2.2.5, the StructLMM interaction and joint association
tests require fitting null models, calculating test statistics and then computing the
corresponding P values. These operations are implemented in a computationally
efficient manner, such that the tests scale linearly with the number of samples
(assuming that N >> L > a where N is the number of samples, L the number
of environments and a the number of covariates) instead of cubically as would be
the case if implemented naively.
In this section, I will first describe the steps and computational efficiency of general
operations that are used repeatedly, followed by computational details for each of
the tasks required for the StructLMM tests. I then provide a table summarising the
computational complexity of the main steps involved.
Computational complexity of general operations
I will first describe how P0A is computed efficiently, where P0 is as defined in
Eq. 2.37 and A is a general N ×M matrix (or an N × 1 vector, corresponding to
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the special case that M = 1), under the assumption that M << N .
Explicitly,
P0A = K
−1
0 A︸ ︷︷ ︸
Term 1
−K−10 X(XTK−10 X)−1XTK−10 A︸ ︷︷ ︸
Term 2
. (2.82)
I will start with the calculation of Term 1. Whilst naive calculation of K−10 A is
cubic in the number of samples, N , sinceK0 (defined in Eq. 2.35) is the combination
of a low rank matrix (rank L) and an identity matrix, the computational complexity
of this operation can be reduced76,78,253, by writing K0 as follows:
Let δ = σˆ
2
e
σˆ2n
. Then:
K−10 = (σˆ
2
n(δEE
T + IN))
−1. (2.83)
Let the spectral decomposition ofEET = USUT , noting thatUUT = IN , then:
K−10 = (σˆ
2
nU (δS + IN)U
T )−1. (2.84)
Using (AB)−1 = B−1A−1, U−1 = UT and U−T = U :
K−10 =
1
σˆ2n
U(δS + IN)
−1UT . (2.85)
Since EET is a low rank matrix, with rank L:
U(δS + IN)
−1UT = [U1,U2]
[
δS + IL 0
0 IN−L
]−1
[U1,U2]
T , (2.86)
where U1 is an N × L matrix and U2 is an N × (N − L) matrix. As the inversion
operation is of a diagonal matrix, this can be rewritten as:
U1(δS + IL)
−1UT1 +U2IN−LU
T
2 = U1(δS + IL)
−1UT1 +U2U
T
2 . (2.87)
Additionally as UUT = IN , this implies that:
UUT = [U1,U2][U1,U2]
T = U1U
T
1 +U2U
T
2 = IN (2.88)
and therefore:
U2U
T
2 = IN −U1UT1 , (2.89)
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resulting in:
K−10 =
1
σˆ2n
[U1(δS + IL)
−1UT1 + (IN −U1UT1 )(IN −U1UT1 )T ]
=
1
σˆ2n
[U1(δS + IL)
−1UT1 + (IN −U1UT1 )(IN −U1UT1 )]. (2.90)
Using the form of K−10 given by Eq. 2.90, calculation of Term 1, K
−1
0 A, can be
written as:
K−10 A =
1
σˆ2n
[U1(δS + IL)
−1UT1 + (IN −U1UT1 )(IN −U1UT1 )]A
=
1
σˆ2n
[U1(δS + IL)
−1UT1 A+ (IN −U1UT1 )(IN −U1UT1 )A]
=
1
σˆ2n
[U1(δS + IL)
−1UT1 A︸ ︷︷ ︸
Term a
+ (IN −U1UT1 )(A−U1UT1 A)︸ ︷︷ ︸
Term b
]. (2.91)
Spectral decomposition of the low rank matrix EET to find the eigenvectors U1 and
eigenvalues S is O(NL2)263 and inversion of the L × L matrix, (δS + IL) is O(L).
Calculation of UT1 A and U1(δS+IL)
−1 are O(NLM) and O(NL2), respectively and
then matrix multiplication of the two aforementioned terms gives, Term a, U1(δS+
IL)
−1UT1 A with O(NLM). Having already calculated, U
T
1 A, matrix multiplication
with U1 to give U1U
T
1 A is O(NLM). This is followed by matrix subtraction of
O(NM) such that (A − U1UT1 A) is a N ×M matrix and thus the complexity of
calculating Term b, (IN−U1UT1 )(A−U1UT1 A) (once the second bracketed term has
been computed) is the same as the complexity of computing (IN −U1UT1 )A, which
has identical form to the expression in the second bracket of Term b, for which I have
already described the computational complexity. The final operation to calculate
K−10 A is the addition of two N ×M matrices which has O(NM). Therefore the
complexity of calculating K−10 A has O(NL
2 +NLM).
I will describe the computational complexity to calculate Term 2 in Eq. 2.82. First,
recall that X is the design matrix of the covariates which is N × (a + 1) for the
interaction test (X = [W ,x] as described in Section 2.2.5) and N × a for the
joint association test (X = W as described in Section 2.2.5). For simplicity, the
complexity of any operations involving X, will be described on the basis that X is
an N × a matrix. I will now split Term 2 as follows:
Term 2 = K−10 X︸ ︷︷ ︸
Term a
Term c︷ ︸︸ ︷
(XT K−10 X︸ ︷︷ ︸
Term a
)−1
Term d︷ ︸︸ ︷
XT K−10 A︸ ︷︷ ︸
Term b
. (2.92)
55
Terms a and b, have the same form as Term 1 (previously described) and hence
have computational complexity O(NL2 +NLa) and O(NL2 +NLM), respectively.
Calculation of Term c, requires matrix multiplication of XT with Term a which
is O(Na2) followed by inversion of an a × a matrix which is O(a3). Calculation
of Term d, requires matrix multiplication of XT with Term b which is O(NMa).
Matrix multiplication of Term a and Term c is O(Na2) and then further matrix
multiplication with Term d is O(NMa). Thus calculation of Term 2 is O(NL2 +
NLM +NLa+NMa+Na2 + a3).
Therefore calculation of P0A, whereA is a general N×M matrix has computational
complexity O(NL2 +NLM +NLa+NMa+Na2 + a3).
From this it follows that calculation of BP0A, where again P0 is as defined in
Eq. 2.37 and A is a general N ×M matrix and B is another general P ×N matrix
(also assuming that P << N), involves a further matrix multiplication operation
of O(NMP ) such that the total computational complexity to compute BP0A is
O(NL2 +NLM +NLa+NMa+Na2 + a3 +NMP ).
Computational complexity of fitting the null model
The StructLMM interaction test and joint association test null models (Eq. 2.32
and Eq. 2.34, respectively) are fitted using LIMIX (using REML-based inference)78,
which is implemented efficiently. In particular the linear covariance structure of
Σ, such that the covariance of the null distribution for both the interaction and
joint association test can be written as σ2eEE
T + σ2nIN (see Eqs. 2.32 and 2.34),
is exploited enabling fitting of these null models with computational complexity
O(NL2 + L3) (I refer the reader to Lippert et al.253 and Casale et al.79 for full
details).
I note that for the interaction test, a null model per variant needs to be fitted
(see Eq. 2.32), whilst for the association test only one null model for all considered
variants is required.
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Computational complexity of calculating Qρ
The score-based test statistic Qρ (Eq. 2.42), with the form of Kρ described by
Eq. 2.30 explicitly substituted gives:
Qρ =
1
2
yTP0[(1− ρ)xxT + ρdiag(x)Σdiag(x)]P0y
= (
1√
2
yTP0D)(
1√
2
yTP0D)
T , (2.93)
where D = [
√
1− ρx,√ρdiag(x)E], noting that the interaction test statistics has
the same form with Kρ = K1, such that D is an N × L matrix for the interaction
test and N×(L+1) for the association test. For simplicity, I will use the dimensions
of the former when stating the computational complexities.
Using diag(x)E = xE, this operation has complexity O(NL). Then noting that
yTP0D has the same form as BP0A (general computation described above) with
P = 1 and M = L, this can be calculated in O(NL2 + NLa + Na2 + a3). Then
matrix multiplication of BP0A with its transpose is O(L
2).
Thus computation of this score-based test statistic has complexity O(NL2 +NLa+
Na2 + a3).
Computational complexity of evaluating the significance of the score-based
test statistics
The eigenvalues of 1
2
P
T
2
0 DD
TP
1
2
0 are required to calculate the P values of the
score-based test statistics (see Section 2.2.5). Naively, this requires eigenvalue
decomposition of anN×N matrix which has computational complexity ofO(N3).
However, using the fact that eigenvalues(AAT ) = eigenvalues(ATA)262, I instead
calculate the eigenvalues of, 1
2
DTP
1
2
0 P
T
2
0 D =
1
2
DTP0D. Noting that D
TP0D has
the same form as BP0A (general computation described above) with P = M = L,
this can be calculated as O(NL2 +NLa+Na2 + a3) and eigenvalue decomposition
of the resulting L× L matrix has computational complexity O(L3)
Calculation of P values using the exact Davies260 or the modified moment
approximation method123 are independent of the sample size, N .
Therefore this operation is O(NL2 +NLa+Na2 + L3 + a3).
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Computational complexity of the interaction test
To summarise the computational complexity of the interaction test is O(NL2 +
NLa+Na2+L3+a3) and thus scales linearly with the number of samples, N .
Computational complexity of the association test
A number of operations involved in calculating, Qρ and the corresponding P value,
Pρ, will need to be calculated R times (once for each of the R values for ρ). Thus
these initial steps are computed with complexity O(NL2R+NLaR+Na2R+a3R),
noting that R << N (and in many cases R << L).
To calculate the final P value for the association test, corresponding to the test
statistic, T , τρ and the quantities defining κ need to be computed.
I will first consider τρ = (1 − ρ)m + ρ1TZTZΣZTZ1Tm , where m = 1TZTZ1 and
Z = P
T
2
0 diag(x).
m, can be written as follows:
m = 1TZTZ1 = 1Tdiag(x)P
1
2
0 P
T
2
0 diag(x)1 = x
TP0x. (2.94)
Noting that xTP0x has the same form as BP0A (general computation described
above) with P = M = 1, this can be calculated in O(NL2 +NLa+Na2 +a3).
Now consider, the numerator of the second term of τρ, 1
TZTZΣZTZ1T , which can
be written as follows:
1TZTZΣZTZ1T = 1Tdiag(x)P
1
2
0 P
T
2
0 diag(x)EE
Tdiag(x)P
1
2
0 P
T
2
0 diag(x)1
= (xTP0(xE))(xTP0(xE))T . (2.95)
I have already calculated x  E (in order to calculate Qρ) which gives a N × L
matrix and calculation of xTP0(xE) is analogous to calculation ofBP0A (general
computation described above) with P = 1 and M = L, which can be computed with
complexity O(NL2 +NLa+Na2 +a3). Matrix multiplication of (xE)TP0x with
its transpose is O(L2).
Therefore τρ is computed with complexity O(NL
2 +NLa+Na2 + a3).
κ is defined as κ = φ + ξ. I need to calculate the eigenvalues corresponding to the
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variable φ:
ETZT (I −M )ZE
= ETdiag(x)P
1
2
0 (I −M)P
T
2
0 diag(x)E
= (xE)TP
1
2
0 P
T
2
0 (xE)− (xE)TP
1
2
0 MP
T
2
0 (xE)
= (xE)TP0(xE)− 1
m
(xE)TP
1
2
0 P
T
2
0 diag(x)11
Tdiag(x)P
1
2
0 P
T
2
0 (xE)
= (xE)TP0(xE)− 1
m
(xE)TP0xxTP0(xE)
= (xE)TP0(xE)− 1
m
((xE)TP0x)((xE)TP0x)T , (2.96)
using M as defined in Eq. 2.55. (xE)TP0(xE) has the same form as BP0A
(general computation described above) with P = M = L, which can be computed
with complexity O(NL2 +NLa+Na2 +a3) and (xE)TP0x)((xE)TP0x)T has
already been computed (in order to calculate τρ). Eigenvalue decomposition of the
resulting L× L matrix is O(L3).
I also need to calculate:
Var(ξ) = 4tr(ETZT (I −M )ZE︸ ︷︷ ︸
Term 1
ETZTMZE︸ ︷︷ ︸
Term 2
), (2.97)
which requires matrix multiplication of Term 1, which is the term just computed
to calculate the eigenvalues of φ and Term 2 which is one of the two terms used to
calculate the eigenvalues of φ (the second term above) and therefore has complexity
O(L3). Finally calculation of the trace is O(L).
Therefore calculation of the terms needed to define the variable κ is O(NL2+NLa+
Na2 + L3 + a3).
Calculation of P values using the exact Davies260 or the modified moment
approximation method123 whilst adjusting for the extra variance of ξ is independent
of the sample size, N .
To summarise the computational complexity of the StructLMM joint association
method is O(NL2R + NLaR + Na2R + L3R + a3R) and thus scales linearly with
the number of samples, N .
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Summary of the computational complexity of the StructLMM interaction
and association test
Table 2.1 summarises the computational complexity of different operations required
for the StructLMM interaction and association tests, based on N individuals, L
environments, a covariates and for the association test, R values of ρ to be grid
searched over, assuming that N >> L > a (also assuming that N >> R but
making no assumptions on the relationship between R, L and a).
Operation Computational complexity Interaction test Association test
Fitting null model O(NL2+L3) Once per variant Once for all variants genome-wide
Calculation of score-based test 
statistic, Q휌 O(NL
2+NLa+Na2+a3) Once per variant R times per variant
Evaluating the significance of the 
score-based test statistic
O(NL2+NLa+Na2+L3+a3) Once per variant R times per variant
Calculation of 휏휌 O(NL2+NLa+Na2+a3) N/A R times per variant
Calculation of 휅 O(NL2+NLa+Na2+L3+a3) N/A Once per variant
Total complexity of StructLMM 
interaction test
O(NL2+NLa+Na2+L3+a3) Per variant N/A
Total complexity of StructLMM 
association test
O(NL2R+NLaR+Na2R+L3R+a3R) N/A Per variant
Table 2.1 Computational complexity of different operations required
for the StructLMM interaction and association tests | Summary of the
computational complexity of different operations required for the StructLMM
interaction and association tests, showing the operation (column 1), the order of
computational complexity (column 2) and the number of times an operation needs
to be repeated for the interaction test (column 3) and association test (column 4),
based on N individuals, L environments, a covariates and R values of ρ to be grid
searched over in the association test, assuming that N >> L > a (also assuming
that N >> R but making no assumptions on the relationship between R, L and a).
2.2.7 Relationship to existing methods
In this section, I will place StructLMM in context, comparing to existing interaction
(and joint association) tests and describe technical similarities, where appropriate.
Interaction tests between a single genetic variant and a single environmental variable
are already established (see Section 2.1) and the underlying model can be cast
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as:
logit(yD) = Wα+ xβG + x eβG×E + eβE + , (2.98)
where yD is an N × 1 binary phenotype vector, capturing for example disease
status179,218 or:
y = Wα+ xβG + x eβG×E + eβE + , (2.99)
where y is an N × 1 quantitative phenotype vector. In both cases, N is the number
of samples used in the analysis, W is an N × a covariate design matrix and α is
an a × 1 vector of corresponding effects, x is an N × 1 genotype vector for the
focal variant, e is an N × 1 environmental exposure vector, and βG, βG×E and βE
are the marginal genetic, interaction and environment effects, respectively.  is an
N × 1 noise vector, modelled as random effect following the multivariate normal
distribution:
 ∼ N (0, σ2nIN), (2.100)
where IN is the N ×N identity matrix179.
For both binary and quantitative phenotypes, the model can be used to perform a
1 df interaction test (i. e. βG×E 6= 0) or a 2 df joint association test [βG, βG×E] 6=
0179,218.
Method development has largely focussed on increasing power to detect G×E
through reducing the multiple testing burden and as outlined in Section 2.1 these
methods can be classed into two main categories; those that incorporate a screening
strategy, to select a subset of variants to test for interactions (between a single
genetic variant and a single environmental exposure)175,193,224–231 and those that use
a set test based approach to test for interactions between a single environmental
variable and a set of S genetic variants, {x1,x2, ...,xS}.
The underlying model for the majority of these set test based approaches can be
cast as:
y = Wα+
S∑
s=1
xsβGs +
S∑
s=1
xs  eβ(G×E)s + eβE + . (2.101)
As already discussed in Sections 1.2.1 and 2.1, not only do these set tests reduce
the multiple testing burden, but in addition aggregating over variants, in particular
sets of rare variants can increase the power to detect associations and interactions,
when the effects are driven by multiple weak signals107–111,118,123,179.
One of the first set tests for G×E analysis was a burden based approach, proposed by
Chatterjee et al.235, which assumes that the interaction effect is proportional to the
marginal genetic and environment effects, such that β(G×E)s = θβGsβE in Eq. 2.101.
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This is a 1 df test, since θ takes the same value across the set of S variants, a strong
constraint, further adding to the assumption that interactions only exist when there
are marginal genetic and environment effects. Whilst as described in the paper,
this method can in theory aggregate across both a set of variants and a set of
environments, in this setting the 1 df (θ) is even more constraining.
The set test based approach proposed by Jiao et al.240 relaxes this constraint in
a similar vein to adaptive burden tests112–117, calculating the correlation between
the variant dosages and the single environmental exposure, such that variants in
the set can be weighted (by 1, -1 or 0) based on whether they are likely to drive
an interaction effect (and the likely direction of this effect). Extensions include,
adapting the threshold that determines if a variant is likely to have an interaction
effect (i. e. determining if a variant has non-zero weight), based on the set of variants
under consideration241 and incorporating different filtering statistics, enabling
application to quantitative phenotypes242 (e. g. correlation of a genotype and
environment for binary phenotypes and Levene’s statistic264 for quantitative traits).
Another commonly employed burden test approach requires selecting variants to
include in the genetic set based on the significance of marginal association tests
(between variants and the trait of interest). It is then either assumed that all of
the selected variants have the same interaction effect, i. e. β(G×E)s = θ(G×E) (and
often the same association effect, i. e. βGs = θG) in Eq. 2.101, equivalent to first
building an unweighted genetic risk score (GRS) and using this score in place of
x in Eq. 2.99212,213,236–239; or that the selected variants have the same interaction
effect after weighting by the marginal variant effect (βmargGs ) identified in the marginal
association test, i. e. β(G×E)s = β
marg
Gs
θ(G×E) (and similarly for the association effect,
i. e. βGs = β
marg
Gs
θG) in Eq. 2.101, equivalent to first building an weighted genetic
risk score (GRS) and using this score in place of x in Eq. 2.99207.
Variance component set tests are an alternative that can be more powerful than
burden based approaches when the magnitude and direction of the interaction effects
vary across the variants included within the set. As detailed below, these variance
component based tests are technically related to StructLMM. Variance component
set tests, model β(G×E)s in Eq. 2.101 as random effects following the distribution
β(G×E)s ∼ N (0, τ 2) and score-based test statistics, Q and corresponding P values
are derived similarly to the StructLMM interaction test (Section 2.2.5), settingK1 =
TT T and T = [x1  e,x2  e, ...,xS  e]T .
GESAT243, was the first variance component test proposed for interaction testing.
To enable stable estimation of the marginal genetic effects for all S variants under
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the null (instability may arise when large numbers of variants are included in the
set, further compounded by the LD between them) ridge regression is used; by
comparison in StructLMM where there are potentially large number of environments
included in the set, a single variance component is used to estimate their marginal
effect.
Whilst GESAT was designed for interaction set testing of common variants, a
similar test by Chen et al.265 was later developed to test for interactions with
a set of rare variants. They proposed that the marginal genetic effects of rare
variants, βGs in Eq. 2.101 are modelled as random effects following the distribution
βGs ∼ N (0, τ 21 ) such that a single variance component (with the same form as the
tested genetic effect term in SKAT118) accounts for marginal genetic effects of the S
variants under the null; this is analogous to the approach taken by StructLMM
to account for marginal environment effects of L environments under the null.
This proposal also enables a joint association test to be conducted, by setting
Kρ = ρGG
T + (1− ρ)TT T , where G = [x1,x2, ...,xS]T and using a similar testing
procedure to SKAT-O123 and the StructLMM joint association test described in this
chapter.
An alternative to test for interaction effects with a set of rare variants is iSKAT244.
iSKAT fits marginal genetic effects in a similar vein to GESAT; the key difference
between the tests is that iSKAT uses MAF weighted ridge regression to fit the
marginal genetic effects of the S variants, since these may not be comparable in
magnitude across a set of rare variants in the same way that they are for common
variants. A second key difference is that β(G×E) in Eq. 2.101 follows the distribution
β(G×E) ∼ N (0, τ 2[ρ1S1TS + (1− ρ)IS]), where β(G×E) = [β(G×E)1 , ..., β(G×E)S ]T . This
change, similar to the development of SKAT-O123 from SKAT118 for association
tests, is to overcome the limitation that variance component tests may be
underpowered when the majority of interactions in a set influence the phenotype with
the same direction of effect; the iSKAT form of the random effect distribution for
β(G×E) combines burden and variance component interaction tests to overcome this
limitation. The score-based test statistics Qρ, the corresponding P values, the test
statistic T and the corresponding P value are calculated similarly to the StructLMM
joint association test, setting Kρ = TRρT
T , where Rρ = ρ1S1
T
S + (1− ρ)IS.
Whilst technically related to the StructLMM joint association test, the iSKAT244
optimal test interpolates between fully correlated (T1S1
T
ST
T ) and independent
(TIST
T ) variant effects after accounting for a single environmental exposure, where
ρ can be interpreted as the average correlation of the variant effects across the S
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variants included in the set. The optimal test proposed by Chen et al.265 interpolates
between no G×E dependent (GISGT ) and only G×E dependent (TIST T ) variant
effects, such that 1−ρ can be interpreted as the average fraction of the variant effects
explained by interactions with a single environment across the set of S considered
variants. In comparison, the StructLMM optimal test interpolates between fully
correlated (diag(x)1N1
T
Ndiag(x)) and environmentally dependent (diag(x)EILE
T
diag(x)) per-individual effects (in the special case that EET = IN , there is no
constraint on the similarity of the per-individual effects) and ρ can be interpreted
as the fraction of the genetic effects explained by G×E at a single variant when
accounting for multiple environmental exposures. Modelling of the latter required
generalising the existing optimal testing procedure (as described in Section 2.2.5).
Genetic similarity regression is another set test based approach that has been
proposed for interaction testing266–268, where trait similarity after accounting for
covariates (including the environmental exposures themselves) is regressed on genetic
similarity for a set of variants, taking into account environmental exposure. The
model can be cast as:
E(Zij) = aSij + bSij ×XiXj, i 6= j, (2.102)
where Zij is the trait covariance of individuals i and j, obtained after accounting for
covariates, i. e. Zij = (Yi − µi)(Yj − µj) where µi is the subject specific mean. Sij
is the average genetic similarity over the S variants in the genetic set and Xi is the
environmental exposure of individual i. A score test procedure, analogous to the
StructLMM interaction and GESAT test, is used to test for interactions (b 6= 0) and
a score test under the assumption that b = d is used to test for joint associations
(b = d 6= 0). This joint association test is similar to that proposed by Chen et al.265,
setting ρ = 0.5 (i. e. no grid based search for optimal ρ). Whilst not demonstrated, it
is noted that the procedure can be extended to incorporate multiple environmental
exposures by replacing Xi which describes a single environmental exposure, with
Xi, a 1 × L vector describing L environmental exposures and thus replacing XiXj
by XiX
T
j , but again under the assumption that marginal genetic and interaction
effects explain the same amount of phenotypic variance, which is unlikely to be true.
In addition, this method does not scale to large sample sizes.
Another interaction set based test that builds on existing multi-trait set tests (see
Section 1.2.3)79 is iSet80. By testing for associations between a set of genetic variants
and multiple phenotypes, where the phenotype matrix comprises of phenotype
measurements for the same trait in different environmental contexts, iSet can be
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used to test for interaction effects with different categorical contexts. In addition,
iSet can be used to distinguish whether the difference in SNP effect between the
environments is consistent across all SNPs included within the set or whether the
causal architecture differs between different contexts. This method is restricted
to the analysis of categorical environments and is not scalable to large numbers of
environmental variables or large sample sizes (it can handle at most tens of thousands
of individuals).
A further variance component based interaction test is MAPIT269, designed to
identify variants that are in epistasis with at least one other variant. Whilst
conceptually related to StructLMM, the proposed testing procedure scales
quadratically with the number of samples (StructLMM scales linearly) and thus is
restricted to the analysis of cohorts with moderate sample size. In addition, this
method is designed to test only for interactions, whilst StructLMM implements a
joint association test.
All of the previously described interaction tests, were primarily designed to test
for interactions with a single environmental exposure. The only interaction test,
explicitly designed to test for interactions with multiple environments is that
developed by Young et al.195, which focussed on a single variant (rs1421085 ) within
the FTO locus. This multi-environment interaction test relies on a two step
procedure. Briefly, in the first step they use a set of individuals to perform linear
regression between BMI and environmental variables and use cross-validation to
determine which environmental variables do not have any predictive power on BMI.
Marginal variant and environment effects as well as G×E interactions are then tested
for at environments with predictive power, using a fixed effect multi-environment
model similar to that described in Section 2.3.2, which as I will show in Section 2.4
is not as robust as StructLMM. In addition, there is no accompanying software
available.
2.3 Comparison partners
In order to assess the performance of StructLMM as an interaction and joint
association test, I compare results to a number of other approaches both in simulation
experiments described in Section 2.4 and in applications to real data described in
Chapter 3. These include single and multi environment models, as well as, linear
models for the association test. A summary of these other methods is displayed in
tabular form in Section 2.3.4.
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2.3.1 Single environment models
As already described in Section 2.2.7, 1 df interaction tests between single
environmental exposures and individual genetic variants are well established224. In
addition, the same framework can be used for the 2 df joint association test218. There
are three different single environment interaction models that I consider.
Single Environment model with Single environment additive effect
(SingleEnv-Senv) The standard single environment model is the same as that
described by Eq. 2.99:
y = Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+ (x el)βG×El︸ ︷︷ ︸
G×E
+ elβEl︸ ︷︷ ︸
E
+ ︸︷︷︸
Noise
, (2.103)
with marginal form:
y ∼ N ( Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+ (x el)βG×El︸ ︷︷ ︸
G×E
+ elβEl︸ ︷︷ ︸
E
, σ2nI︸︷︷︸
Noise
), (2.104)
where y is an N × 1 phenotype vector for N individuals, W is the N × a fixed
effect design matrix for a covariates, α is the a× 1 vector of their effect sizes, x is
an N × 1 genotype vector of the tested variant, βG the corresponding genetic effect
and  the residuals (following the multivariate normal distribution  ∼ N (0, σ2nIN)
as described in Eq. 2.8). This model can be used to assess the presence of G×E
with environment el by testing βG×El 6= 0 (1 df, SingleEnv-Senv-int) using a LRT.
A joint P value that corresponds to the alternative hypothesis that at least one
of L environments is participating in G×E effects, can then be constructed by
performing L tests followed by appropriate adjustment for multiple testing (I use
Bonferroni). Similarly, a joint association test that accounts for G×E effects due to
single environments el can be derived by testing [βG, βG×El ] 6= 0 (2 df, SingleEnv-
Senv), where again multiple environments and their corresponding tests can be
combined using Bonferroni adjustment.
Single Environment model with multi-environment additive effect as
Fixed effect (SingleEnv-Fenv) When multiple environmental exposure
measurements are available, the approach above can be extended by modelling
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additive environment effects from multiple environments:
y = Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+ (x el)βG×El︸ ︷︷ ︸
G×E
+
L∑
l=1
elβEl︸ ︷︷ ︸
E
+ ︸︷︷︸
Noise
, (2.105)
with marginal form:
y ∼ N ( Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+ (x el)βG×El︸ ︷︷ ︸
G×E
+
L∑
l=1
elβEl︸ ︷︷ ︸
E
, σ2nI︸︷︷︸
Noise
). (2.106)
This approach can improve the accuracy of the null model since additive effects
of other potentially relevant environments are included. Again, the presence of
interactions and associations can be assessed by testing βG×El 6= 0 (SingleEnv-Fenv-
int) and [βG, βG×El ] 6= 0 (SingleEnv-Fenv) for each environment respectively, where
again multiple environments can be combined using Bonferroni adjustment.
Single Environment model with multi-environment additive effect as
Random effect (SingleEnv-Renv) Alternatively, one can use a random effect
to model multivariate additive environments, which is the approach taken in
StructLMM. Since the null model of this approach is identical to that of StructLMM,
this is the default single environment method used for comparison with StructLMM.
Specifically, one can define an environmental covariance Σ based on the observed
environments as described in Section 2.2.4 and consider the model:
y = Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+ (x el)βG×El︸ ︷︷ ︸
G×E
+ u︸︷︷︸
E
+ ︸︷︷︸
Noise
, (2.107)
where u follows the multivariate normal distribution u ∼ N (0, σ2eΣ), such that the
marginal form is as follows:
y ∼ N ( Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+ (x el)βG×El︸ ︷︷ ︸
G×E
, σ2eΣ︸︷︷︸
E
+ σ2nI︸︷︷︸
Noise
), (2.108)
where again interaction (SingleEnv-Renv-int) and association tests (SingleEnv-Renv)
can be implemented as described above.
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2.3.2 Multi-environment models
An alternative strategy to model interaction effects between multiple environmental
variables and a genotype is to use multiple fixed effects to account for the interactions.
As already described in Section 2.2.4, StructLMM can be derived from this model
by marginalising over the interaction effects. This approach requires an additional
fixed effect for each additional environment that is tested for interactions such that
the df of this test scale linearly with the number of environments. In comparison,
for StructLMM the df are independent of the number of environments considered
(1 df accounts for all tested environments), which can have calibration and power
advantages as I will show in Section 2.4. Similarly, to StructLMM, the multi-
environment models described here can be used to define both an interaction and a
joint association test.
Multi-Environment model with multi-environment additive effect as
Fixed effect (MultiEnv-Fenv) Explicitly, denoting with e1, . . . , eL the N × 1
vectors for L environments, a fixed-effect based multi-environment model can be
cast as:
y = Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+
L∑
l=1
(x el)βG×El︸ ︷︷ ︸
G×E
+
L∑
l=1
elβEl︸ ︷︷ ︸
E
+ ︸︷︷︸
Noise
, (2.109)
with marginal form:
y ∼ N ( Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+
L∑
l=1
(x el)βG×El︸ ︷︷ ︸
G×E
+
L∑
l=1
elβEl︸ ︷︷ ︸
E
, σ2nI︸︷︷︸
Noise
), (2.110)
where both interactions due to L environmental variables and their additive effects
are modelled as fixed effects. Within this model, the presence of interactions and
associations can be assessed by testing [βG×E1 , . . . , βG×EL ] 6= 0 (L df test) and
[βG, βG×E1 , . . . , βG×EL ] 6= 0 (L+ 1 df test), respectively.
This test can be implemented using the LRT (named MultiEnv-Fenv-LRT-int and
MultiEnv-Fenv-LRT for the interaction and association test, respectively).
Alternatively a score-based implementation can be employed (named MultiEnv-Fenv
-Score-int and MultiEnv-Fenv-Score for the interaction and association test,
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respectively), using Rao’s score test statistic270.
Rao’s score test statistic = UT0 I
−1
0 U0, (2.111)
where U0 is the gradient and I0 the Fisher Information matrix with respect to the
tested parameters, computed using MLE under the null†. Rao’s score test statistic
has an asymptotic chi-square distribution with the number of tested parameters as
degrees of freedom.
Multi-Environment model with multi-environment additive effect as
Random effect (MultiEnv-Renv) Alternatively, as for the single environment
test, the multivariate additive environments can be modelled as a random effect
instead of fixed effects, giving the following model:
y = Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+
L∑
l=1
(x el)βG×El︸ ︷︷ ︸
G×E
+ u︸︷︷︸
E
+ ︸︷︷︸
Noise
, (2.115)
with marginal form:
y ∼ N ( Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+
L∑
l=1
(x el)βG×El︸ ︷︷ ︸
G×E
, σ2eΣ︸︷︷︸
E
+ σ2nI︸︷︷︸
noise
). (2.116)
Again as described above, both LR tests (MultiEnv-Renv-LRT-int, MultiEnv-Renv-
LRT) and score tests (MultiEnv-Renv-Score-int, MultiEnv-Renv-Score) can be
employed to test for interactions and associations respectively.
2.3.3 Linear association models
For the joint association test, standard linear models that assume constant genetic
effect sizes in a population, can be used as an additional class of comparison methods.
†Specifically, for the test β 6= 0 in the Gaussian model
y ∼ N (Wα+ Sβ,H), (2.112)
U0 = (y −Wα0)TH−10 S, (2.113)
I0 = S
TH−10 S, (2.114)
where α0 and H0 are MLE of α and H under the null model.
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Linear model (LM) The standard linear model is cast as:
y = Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+ ︸︷︷︸
Noise
, (2.117)
with marginal form:
y ∼ N ( Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
, σ2nI︸︷︷︸
Noise
). (2.118)
A 1 df LR test βG 6= 0 is used to test for association.
Linear model with multivariate additive environment effects modelled
as Fixed effect (LM-Fenv) When L environmental exposure measurements are
available, multivariate additive environment effects can be accounted for using fixed
effects as follows:
y = Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+
L∑
l=1
elβEl︸ ︷︷ ︸
E
+ ︸︷︷︸
Noise
, (2.119)
with marginal form:
y ∼ N ( Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+
L∑
l=1
elβEl︸ ︷︷ ︸
E
, σ2nI︸︷︷︸
Noise
). (2.120)
Linear model with multivariate additive environment effects modelled as
Random effect (LMM-Renv) Alternatively, similarly to the single and multi-
environment models, the multivariate additive environmental effects can be modelled
as random:
y = Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
+ u︸︷︷︸
E
+ ︸︷︷︸
Noise
, (2.121)
with marginal form:
y ∼ N ( Wα︸︷︷︸
Covariates
+xβG︸︷︷︸
G
, σ2eΣ︸︷︷︸
E
+ σ2nI︸︷︷︸
Noise
). (2.122)
Since this model is identical to StructLMM under the null, this is the default
comparison partner used.
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2.3.4 Summary of comparison partners
Table 2.2, summarises the modelling choice for the interaction and additive
environment terms, as well as the number of degrees of freedom (based on testing L
environments) for the various comparison methods described above.
Method name GxE Additive E Test type Number parameters for additive E
Number df 
Interaction test
Number df 
association test
Multi-environment tests
StructLMM Random Random Score 1 1 2
MultiEnv-Renv-LRT Fixed Random LRT 1 L  +1
MultiEnv-Fenv-LRT Fixed Fixed LRT L L  +1
MultiEnv-Renv-Score Fixed Random Score 1 L  +1
MultiEnv-Fenv-Score Fixed Fixed Score L L  +1
Single-environment tests
SingleEnv-Renv Fixed Random LRT 1 1 2
SingleEnv-Fenv Fixed Fixed LRT L 1 2
SingleEnv-Senv Fixed Fixed LRT 1 1 2
Linear association tests
LMM-Renv None Random LRT 1 NA 1
LM-Fenv None Fixed LRT L NA 1
LM None None LRT 0 NA 1
Table 2.2 Comparison methods considered | Summary of the comparison
methods used throughout this thesis, showing the method name (column 1) used
for association testing and for interaction testing ‘-int’ is appended to the listed
names, whether a random or fixed effect term is used to model G×E under the
alternative hypothesis (column 2), whether a random or fixed effect term is used
to model the additive environment (column 3), the statistical test used to assess
the alternative hypothesis (column 4), how many parameters are used to model
the additive environment (column 5), the number of additional parameters used to
model the alternative hypothesis versus the null hypothesis for the interaction and
association test (columns 6 and 7 respectively). The number of model parameters in
the final three columns are based on testing L environments for interaction effects.
The tests are grouped into multi-environment tests, single environment tests, and
linear association tests. Methods that are used as the default comparison partners
are in bold.
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2.4 Simulation experiments
Simulation experiments were used to show that StructLMM is calibrated, and then
to demonstrate the power advantages of StructLMM compared to other methods for
the interaction and association test (Section 2.3). In this section, I will first describe
the data used for these experiments, the simulation procedure used to generate
phenotypes and the methods used to assess calibration and statistical power. I
will then show calibration and power results for some general settings, followed
by results for simulation experiments that explicitly examine the effect of certain
environmental properties.
2.4.1 Simulation data
Genotype data
For the simulation procedure, genotypes were derived based on the 372 European
individuals (from CEU, FIN, GBR, IBS and TSI ancestries) from the 1000 Genomes
Project phase 194 (1,092 individuals in total). The generation of a set of N samples
of European ancestry follows the procedure proposed by Loh et al.77, (see also79,80).
Briefly, 10 samples from the original data were selected (‘ancestors’) and then blocks
of 1,000 SNPs ‘inherited’ to create new individuals; this procedure retains LD
structure and using 10 ancestors, results in realistic population structure without
the inclusion of close relatives. Populations of size N = {1, 000, 2, 000, 5, 000} were
generated, with N = 5, 000, the default setting used for simulation experiments (see
Table 2.3). Only variants with a MAF> 2%, were used in the simulation experiments
and the variants were mean centred and standardised.
Environmental exposure data
The environmental covariates in this chapter were based on the UK Biobank interim
data release (Application 14069)215,271 to mimic realistic environmental distributions.
The interim release contained genotype data for 152,729 samples of the total
∼500,000 samples available in the full release (see Section 1.2.2 for further description
of the UK Biobank cohort and further details of this interim release are available at
http://www.ukbiobank.ac.uk/wp-content/uploads/2014/04/UKBiobank_genot
yping_QC_documentation-web.pdf). Thirty-two environmental variables, 9 ordinal
dietary variables (‘Oily fish intake’, ‘Non-oily fish intake’, ‘Processed meat intake’,
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‘Poultry intake’, ‘Beef intake’, ‘Lamb/mutton intake, ‘Pork intake’, ‘Cheese intake’
and ‘Salt added to food’), three continuous dietary variables (‘Cooked vegetable
intake’, ‘Bread intake’, ‘Tea intake’), three physical activity variables (‘Number
of days/week walked 10+ minutes’, ‘Number of days/week of moderate physical
activity 10+ minutes’, ‘Number of days/week of vigorous physical activity 10+
minutes’), ‘Alcohol intake frequency’, ‘Sleep duration’, ‘Sleep duration residuals
squared’, ‘Townsend deprivation index’, ‘Smoking status’, ‘Time spent watching
television’, ‘Usual walking pace’, ‘Frequency of friend/family visits’, ‘Time spend
outdoors in summer’, ‘Time spent outdoors in winter’, ‘Time spent using computer’,
‘Nap during day’, ‘Overall health rating’ and five pollutant measures (‘Nitrogen
dioxide air pollution 2010’, ‘Nitrogen oxides air pollution 2010’, ‘Traffic intensity on
the nearest major road’, ‘Average daytime sound level of noise pollution’, ‘Average
evening sound level of noise pollution’), using data from ‘Instance 0’ were selected
(see UK Biobank Data Showcase, http://biobank.ctsu.ox.ac.uk/crystal/ for
further information). I first removed the 480 individuals that were flagged as poor
quality samples (UK Biobank field ‘22010’). Then following Young et al.195, for the
three continuous dietary and five pollutant variables, I removed values exceeding the
99th percentile. For ‘Sleep duration’, I removed the top and bottom percentiles and
for each individual, calculated the squared deviations from the mean sleep duration,
creating environmental variable, ‘Squared sleep duration res.’ (33rd environmental
variable). For the four variables (‘Time spent watching television’, ‘Time spent using
computer’, ‘Time spend outdoors in summer’, ‘Time spent outdoors in winter’), less
than 0.5 hours of was encoded as 0.5 and I excluded individuals in the upper and
lower percentile. Smoking status was converted from three categories, ‘Current’,
‘Previous’ and ‘Never’ to a binary variable, ‘Ever’ and ‘Never’. I then removed
individuals with any missing environmental data, leaving a total of 92,600 individuals.
Finally, I removed any remaining individuals that had 3rd degree or closer relative
based on UK Biobank field ‘22011’, using the field entitled ‘Recommended genomic
analysis exclusions 0.0’ and kept only individuals defined as ‘White British’ using UK
Biobank field ‘22006’ (individuals who identified as ‘White British’ and have a similar
genetic ancestry based on principal component analysis of the genotype data),
resulting in 70,282 environmental profiles available for the simulation procedures.
These 33 environmental variables were age and gender adjusted, to allow for
interaction effects that are gender specific or age dependent, as described in Section
2.2.4, and age itself added to the environmental matrix, E, resulting in a total of
100 environmental covariates. N of the 70,282 profiles were randomly selected and
assigned to the generated genotypes (described in Section 2.4.1) and L of the 100
73
environments selected at random (the default setting is L = 60, see Table 2.3).
As described in Section 2.4.5, for the simulation experiments conducted to examine
the effect of specific environmental properties, these UK Biobank environments were
used to generate environmental variables with the desired characteristics.
Each environmental variable (or the subsequently generated environmental variables
as described in Section 2.4.5) was mean centred and standardised, followed by
a rescaling by factor 1√
L
(a standard linear covariance procedure as described in
Section 2.2.4).
2.4.2 Phenotype simulation procedure
The N × 1 phenotype vector, y, was simulated as the sum of a a persistent genetic
contribution (g), a G×E contribution (i), an additive environmental contribution
(e), a population structure contribution (u) and a random noise contribution (),
such that:
y = g + i+ e+ u+ . (2.123)
Each of these terms is simulated as follows:
• Persistent genetic effect, g: A genetic variant is selected at random and
then rescaled by a factor of vg(1−ρ)
std(variant)
, such that the resulting vector has sample
variance vg(1−ρ). std(variant) is the standard deviation of the selected variant,
vg is the fraction of the phenotypic variance explained by genetics (i. e. the
combination of persistent and G×E effects) and ρ, the fraction of the total
genetic contribution explained by G×E effects. By default, vg = 0.006 and
ρ = 0.7 (see Table 2.3 for other values of these parameters used).
• G×E effect, i: First a fraction (pi) of the L environmental variables were
selected (where L is as described in Section 2.4.1). Then the same genetic
variant that was used to simulate the persistent genetic effect was multiplied
element wise by {1,−1} selected at random and further multiplied with the
selected environmental variables. That is i = EsubsetβG×E  x, where Esubset
is an environmental matrix comprised of the selected environmental variables
(i. e. it is a subset of the columns of N ×L environmental matrix, E described
in Section 2.4.1). βG×E is a vector of the G×E effects for each of the selected
environmental variables, randomly selected from {1,−1}, such that selected
environments contribute equally to the generated interaction term. i is then
renormalised such that the sample variance is vgρ. By default pi = 0.5 of the
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L environments are selected such that by default 30 environments are used
to simulate the G×E interaction effect (see Table 2.3 for other values of the
parameters used).
In addition to considering settings where the environments contributing to the
G×E effect are a random subset of those randomly selected to generate the
additive environment effect (fraction pi of the L environments; see next bullet
point), settings in which Lunobs additional environments (from the 100 total;
Lunobs defines the number of additional environments) to the L already selected
were considered to generate an environmental matrix Esuperset, which contains
columns with additional environmental variables compared to environmental
matrix E described in Section 2.4.1. This corresponds to a setting where
an environmental driver that is not observed or measured but is somewhat
correlated with the observed environmental variables, contributes to the
interaction effect, a scenario that is likely to occur in reality.
For all experiments (both when a fraction pi of the L environments are used
and when Lunobs environments in addition to the L environments are used to
simulate the G×E effect), the original L environments are used to simulate
the additive environment effect (see next bullet point). In all cases the testing
models use the L environments for both the G×E and the additive environment
term (see Section 2.4.3). This strategy results in no model mismatch of the
additive environment term.
• Additive environmental effect, e: For each of the L environmental
variables (selected as described in Section 2.4.1), an effect βEl is randomly
generated from βEl ∼ N (0, 1) and then e is calculated as e =
∑L
l=1 elβEl . e is
then renormalised to have sample variance ve, for which the default setting is
ve = 0.2 (see Table 2.3 for other values of this parameter used).
• Population structure, u: The first ten principal components from the
kinship matrix (see Section 1.1.6 for a description) of the genotype data are
used to generate population structure. The effect, βpopp , of each principal
component (PCp), was generated randomly as βpopp ∼ N (0, 1) and then u
is calculated as u =
∑10
p=1 PCpβpopp . u is then renormalised to have sample
variance vpop, which is always set to vpop = 0.4.
• Random noise, : An N×1 noise vector is generated as  ∼ N (0, IN) and
then rescaled to have sample variance 1− vg − ve − vpop.
75
General simulation parameters
- - - 1,000 2,000 5,000 - - - -
- 2 10 20 40 60 80 100 - -
- - 0.033 0.167 0.333 0.50 0.667 1 - -
- - - - - 0.006 - - - -
- 0.0 0.1 0.3 0.5 0.7 0.8 0.9 1.0 -
- - - 0 0.1 0.2 0.3 0.4 - -
- - - - - 0.4 - - - -
- - - - - 0 10 20 30 40
Skewed (Gamma-distributed) environments
- 100 5 3 2 1 0.5 0.2 0.1 -
Binary environments
- 0 0.25 0.50 0.75 1 - - - -
- 0.50 0.20 0.10 0.05 0.02 0.01 0.005 - -
Heritable environments
- 0 0.25 0.50 0.75 1 - - - -
- 0.50 0.20 0.10 0.05 0.02 0.01 0.005 - -
r2
vx
vg
⇢
ve
N
L
⇡
vpop
Lunobs
fB
⌫
Table 2.3 Parameters used for simulation experiments | Shown are the
parameter values considered in calibration and power experiments (see Sections 2.4.4
and 2.4.5). N is the population sample size, L the number of selected environmental
variables used to generate the additive environment effect, pi the fraction of the L
environmental variables selected for the generation of the interaction effect, vg the
fraction of the phenotypic variance explained by the total genetic effect (G+G×E),
ρ the fraction of the total genetic effect explained by G×E effects, ve the fraction of
the phenotypic variance explained by additive environment effects, vpop the fraction
of the phenotypic variance explained by population structure and Lunobs the number
of environments selected in addition to the L already selected. In simulation
settings that examine the effect of certain environmental properties (described in
Section 2.4.5), additional parameters are also defined. For skewed environments, the
shape parameter k of the Gamma distribution is varied; for binary environments,
both the fraction of environments fB that are binary and the event frequency v are
varied; and for heritable environments, both the LD, r2, between the variant that
is associated with the environment and that used to generate the persistent and
G×E effects and the average fraction of the environments explained by the variant
vx (heritability) are varied. Unless otherwise specified, the parameters displayed in
bold are those used by default.
2.4.3 Simulation approach
Simulation model settings
Once the phenotypes were simulated, various models (see Section 2.3 for details on
the models compared) were used to test for interactions and associations for windows
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of variants (including the variant driving the genetic effect and that associated
with the environments in the heritable setting described in Section 2.4.5). For all
models, the included covariates were a mean intercept term (vector of ones) and the
ten principal components used to generate u (as described in Section 2.4.2). The
additive environment and G×E terms use the L selected environments (as described
in Section 2.4.2 i. e. mean centred and standardised and then rescaled by a factor
1√
L
, such that Σ used in testing is a standard linear covariance matrix as described
in Section 2.2.4).
Calibration method
Calibration was assessed by splitting the 103,527 variants on chromosome 21 into 100
chunks. Phenotypes were generated (as described in Section 2.4.2) for each chunk,
either with no genetic effects (vg = 0) or with persistent genetic effects driven by
one randomly selected causal variant (vg = 0.006, ρ = 0). This was repeated 100
times such that there were a total of ∼107 P values.
All generated P values were pooled and QQ plots of the expected negative log P
values (x-axis) versus the observed negative log P values (y-axis) were generated
and inflation parameters, λGC =
log10(m)
log10(0.5)
, where m is the median P value over all
variants tested, were calculated. If λGC ≈ 1, then the method is deemed calibrated,
with λGC much greater than 1 indicative of inflation and λGC much smaller than 1
indicative of deflation.
Statistical power method
Statistical power was assessed by selecting genomic chunks from chromosome 21 of
∼2 Mb (3,000 SNPs). Phenotypes were simulated (as described in Section 2.4.2)
with each chunk containing one causal variant. This was repeated 1,000 times for
each simulation setting.
For each experiment, a score of 1 (successful identification of the causal variant) was
assigned if the simulated causal variant or a variant in LD, r2 ≥ 0.8 had P value <
0.01 after Bonferroni correction for the number of tests, corresponding to a 1%
FWER. If this was not the case, 0 (unsuccessful identification of the causal variant)
was assigned. Power is then defined as the average score over the 1,000 repeat
experiments, resulting in a value lying between 0 and 1, where 0 corresponds to the
case that the causal variant is not identified in any experiment and 1, the causal
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variant is identified in all experiments.
An alternative rank based method for assessing model performance, was used to
compare methods that were not always calibrated. P values per experiment were
ordered from most to least significant (smallest to largest) and the cumulative true
positive rate (TPR) and false positive rate (FPR) calculated, where again true
positives were defined as the simulated causal or variants in LD, r2 ≥ 0.8 and
false positive otherwise. These cumulative rates were averaged over the repeat
experiments and then the area under the curve (AUC, where the average cumulative
FPR is plotted on the x-axis and average cumulative TPR plotted on the y-axis;
see Fawcett et al.272 for further details) calculated using a FPR limit of 10%. This
value was then normalised, such that 0 corresponds to chance performance and 1 to
a perfect performance (here all variants in LD, r2 ≥ 0.8 would have smaller P values
than all variants not in LD, r2 < 0.8).
2.4.4 Simulation results
In this section, I outline the calibration and power results for some general simulation
settings.
StructLMM calibration results
The statistical calibration of the StructLMM interaction test (StructLMM-int) and
StructLMM joint association test were assessed when no causal variants were
simulated (vg = 0, Fig. 2.3a) and StructLMM-int when persistent genetic effects were
simulated (vg = 0.006, ρ = 0, Fig. 2.3b), with increasing numbers of environmental
variables contributing to the additive environmental effect (there was no simulated
G×E effect; pi = 100%) for sample sizes of 1,000, 2,000 and 5,000 individuals. In all
cases, StructLMM interaction and association tests were calibrated.
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Fig. 2.3 Calibration of StructLMM interaction and association test |
(a) QQ plots of negative log P values from the StructLMM interaction test
(StructLMM-int, green) and StructLMM association test (blue) either simulating
no genetic effects (no G, no G×E, vg = 0) or (b) simulating persistent genetic
effects (no G×E, vg = 0.006, ρ = 0; only StructLMM-int). The genomic inflation
factors λGC (denoted by λ) for the interaction and association tests are displayed
in the top left of each plot. From top to bottom: increasing sample sizes (N) of
a synthetic population based on the European population from the 1000 Genomes
project: 1,000 individuals, 2,000 individuals and 5,000 individuals. From left to
right: increasing numbers of environmental variables (L) used for simulations and
tests (pi = 100%): 10 to 100.
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Comparison to other methods
The statistical power of StructLMM interaction and association tests were compared
to other interaction and association methods (see Section 2.3 for details on the
models compared). Initially, for interaction tests, StructLMM-int and all
implementations of the single-environment 1 df interaction tests (Table 2.2) were
considered and for association tests, StructLMM, all 2 df single environment
association tests (Table 2.2) and all implementations of the linear models (Table 2.2)
were compared.
First, the proportion of the genetic effect driven by G×E (ρ) was increased from 0 to
1 (Fig. 2.4a). This resulted in increased power of the interaction tests and decreased
power of the association tests as expected, noting that the StructLMM models
increasingly outperformed other considered methods. Other default parameters
were then varied, including the percentage (pi) of the 60 tested environments that
contribute to the G×E effect (Fig. 2.4b), the number of environments (L, using
pi = 50% to simulate G×E effects and pi = 100% to simulate additive environment
effects) using L environments when testing (Fig. 2.4c), and the amount of phenotypic
variance explained by additive environment effects (ve, Fig. 2.4d). Finally, the
scenario in which environments, in addition to the 60 observed (and tested), were
used to simulate the G×E effect (Lunobs, Fig. 2.4e), corresponding to the case
where the true G×E environmental drivers are unmeasured and therefore cannot
be included when testing for interaction and association effects. In all settings
StructLMM performed better than the other baseline methods. Additionally, it
can be seen that the modelling choice for the additive environment term made little
difference to the results; thus in the remaining simulation settings and in applications
to real data (Chapter 3), a random additive environment effect term is used (see
methods highlighted in bold in Table 2.2), such that the null model is identical to
that of StructLMM tests.
As already mentioned in Section 2.2.4 and 2.3.2, StructLMM can be derived by
marginalising over the multiple G×E terms present in a fixed effect framework.
Therefore, as a further comparison, StructLMM was compared to other
implementations of multi-environment fixed effect methods (Table 2.2). These
models were not always calibrated, in particular when the number of environments,
L, relative to the number of samples, N , was large (probably due to the high number
of df), finding that the LRT was inflated whilst the score test was deflated (Fig. 2.5).
Therefore, to compare the performance of these models, a rank based AUC method
was used (see Section 2.4.3 for details), when varying the fraction of genetic effects
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StructLMM

SingleEnv-Senv

SingleEnv-Fenv

SingleEnv-Renv

LM

LM-Fenv

LMM-Renv
StructLMM-int

SingleEnv-Senv-int

SingleEnv-Fenv-int

SingleEnv-Renv-int
b c
e
Fig. 2.4 Power comparison of different methods | Power comparison of
alternative methods for detecting interactions (top panels) and associations (bottom
panels) based on simulated data, increasing (a) the fraction of the genetic variance
explained by G×E (ρ), (b) the number of environments with non-zero GxE effects
(pi), (c) the total number of environments (L, pi = 50% contributing to G×E
effects), (d) the fraction of variance explained by additive environment effects (ve)
and (e) the number of environments that contribute to G×E but are not used
(observed) for the respective tests (Lunobs). In the top panels, considered are the
StructLMM interaction test (StructLMM-int) and alternative implementations of
the single environment interaction test (Table 2.2). In the bottom panels, considered
are the StructLMM association test, alternative implementations of the 2 df fixed
effect tests that test for associations whilst accounting for possible heterogeneity in
the variant effect due to interactions with a single environment (Table 2.2), and all
implementations of linear models that test for persistent effects (Table 2.2). Models
are assessed in terms of power (FWER < 1%) for detecting simulated causal variants.
Stars denote default values of genetic parameters, which are retained when varying
other parameters (see Table 2.3).
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driven by G×E (ρ) and the percentage (pi) of the 60 tested environments that
contribute to the G×E effect, for two sample sizes (N = 2,000, 5,000). As well
as retaining calibration, StructLMM is also bettered powered than these other
multivariate implementations (Fig. 2.6).
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Number of environments Number of environments Number of environments
StructLMM-int

MultiEnv-Fenv-LRT-int

MultiEnv-Fenv-Score-int

MultiEnv-Renv-LRT-int

MultiEnv-Renv-Score-int
StructLMM-int

MultiEnv-Fenv-LRT-int

MultiEnv-Fenv-Score-int

MultiEnv-Renv-LRT-int

MultiEnv-Renv-Score-int
StructLMM

MultiEnv-Fenv-LRT

MultiEnv-Fenv-Score

MultiEnv-Renv-LRT

MultiEnv-Renv-Score
1,000 individuals 2,000 individuals 5,000 individuals
Fig. 2.5 Calibration comparison of different implementations of
multi-environment tests | Genomic inflation factor λGC of P values from
StructLMM and alternative implementations of multi-environment tests based on
fixed effects (Table 2.2), for different numbers of environmental variables (L,
pi = 100%; x-axis) and for increasing sample size (N , left to right). Shown are results
from StructLMM-int and multi-environment fixed effect interaction tests (row 1),
and equivalent association tests (row 2) when no genetic effects are simulated (no G,
no G×E, vg = 0). Row 3 depicts results from StructLMM-int and multi-environment
fixed effect interaction tests when persistent genetic effects are simulated (no G×E,
vg = 0.006, ρ = 0). Multi-environment fixed effect models using LR tests yielded
inflated test statistics (inflation factors λGC > 1) for large numbers of environmental
factors in relation to the sample size, whilst score tests yielded deflated test statistics
(inflation factors λGC < 1) for the corresponding settings, whereas StructLMM was
calibrated in all settings.
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b  5,000 individuals
StructLMM

MultiEnv-Fenv-LRT

MultiEnv-Fenv-Score

MultiEnv-Renv-LRT

MultiEnv-Renv-Score
StructLMM-int

MultiEnv-Fenv-LRT-int
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MultiEnv-Renv-Score-int
a  2,000 individuals
Fig. 2.6 Power comparison of different implementations of
multi-environment tests | Assessment of performance of alternative methods
for detecting interactions (top panels) and associations (bottom panels) based on
simulated data, for the same simulation settings as considered in Fig. 2.4a, b for
two sample sizes: N = 2,000 (a) and N = 5,000 (b). Compared are StructLMM-int
and all other implementations of multi-environment interaction tests (Table 2.2,
top panels) and StructLMM and all other implementations of multi-environment
association tests (Table 2.2, bottom panels). As the fixed effect tests are not always
calibrated (see Fig. 2.5), shown are model performance values as assessed by the
area under the curve (AUC, in the range 0 < FPR < 0.10, normalised such that 0
corresponds to chance performance and 1 to an ideal model).
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2.4.5 Simulation results examining the effect of specific
environmental properties
In this section, I outline the calibration and power results for simulation settings, in
which the environmental variables are generated to have specific properties. I will
first describe the general method used to simulate these synthetic environments and
then explore settings when the environments are skewed and/or binary and settings
when then environmental variables are themselves heritable.
Generating synthetic environments
For the remaining simulation settings, a matrix normal distribution (see Gupta
et al.273 for details) was used to generate the environment matrix, based on the
sample and environment covariances for the selected UK Biobank environments (as
described in Section 2.4.1). Explicitly:
EL ∼MNN×L(0,R,C) (2.124)
where the N × L environment matrix EL is generated from the matrix normal
distribution, with R the N ×N sample covariance matrix describing the covariance
between pairs of individuals across the L environments and C the L× L
environmental covariance matrix describing the covariance between pairs of
environments across the N individuals.
Skewed and binary environments
For the skewed and binary environment simulation experiments C and R were
calculated directly from the randomly selected UK Biobank environment data to
generate new continuous environments with realistic correlation structure. To assess
the impact of using non-gaussian environments, all environments were rank-inverse
transformed to a Gamma distribution with scale 1 and shape k, which was varied
(see Table 2.3 for other values of this parameter used). To assess the impact of
using binary (instead of continuous environments), a fraction fB of the generated
environments were binarised. Binarisation was achieved by converting the t most
extreme continuous environmental values to ‘1’ and the remainder to ‘0’ where t
was selected to give an event frequency v. fB and v were varied whilst fixing the
other parameter, using default settings fB = 1 and v = 0.02 (see Table 2.3 for other
values of the parameters used).
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Further calibration experiments were conducted for these simulation settings, using
5,000 individuals and 60 environmental variables, considering the extreme cases
where all environments were very skewed (k = 0.1, Fig. 2.7a, b) and all environments
(fB = 1) were binary with rare event frequency (v = 0.005, Fig. 2.7c, d). In these
settings, both the StructLMM association and interaction tests were assessed when
no causal variants were simulated (vg = 0, Fig. 2.7a, c) and StructLMM-int when
persistent genetic effects were simulated (vg = 0.006, ρ = 0, Fig. 2.7b, d).
fB = 1
⌫ = 0.005
fB = 1
⌫ = 0.005
b
c
d
No genetic effect
Persistent effect (no GxE)
StructLMM-int StructLMM
StructLMM-int
a
Fig. 2.7 Calibration of StructLMM interaction and association tests
when environments are simulated to be skewed or binary with rare
event frequency | QQ plots of negative log P values when all environments
used to simulate the additive environmental effect (no simulated G×E effects) are
(a-b) highly skewed (shape parameter k = 0.1), (c-d) are binary with rare event
frequency (v = 0.005). In panels a and c, QQ plots of negative log P values from
StructLMM-int (green) and StructLMM (blue) when no genetic effects are simulated
(no G, no G×E, vg = 0) and in panels b and d analogous QQ plots to assess
the calibration of StructLMM-int when persistent genetic effects are simulated (no
G×E, vg = 0.006, ρ = 0). The genomic inflation factors λGC (denoted by λ) for the
interaction and association tests are displayed in the top left of each plot.
I then examined the effect of the environmental skew on the power of StructLMM
compared to other methods. First the skew of the environmental variables was
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increased by decreasing the shape parameter (k, whilst setting the scale parameter to
1) of the Gamma distribution from 100 (environment distribution is approximately
Gaussian) to 0.1 (environments are highly skewed, Fig. 2.8a), noting that StructLMM
increasingly outperforms other baseline methods that account for interaction effects
as the environmental skew increases. Next, the fraction of environments that were
binary (fB) was increased from 0 to 1 (Fig. 2.8b), which as expected, results in some
loss of power due to loss of information but noting that StructLMM increasingly
outperforms other methods that account for interaction effects, likely due to the
fact that combining information from multiple environments retains more structure
and thus information than assessing binary environments individually. The event
frequency (v) of these binary events was also decreased from 0.5 to 0.005 (Fig. 2.8c),
which as expected gave similar results to increasing the skew of continuous
environments.
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Fig. 2.8 Power comparison of different methods examining the effect of
using skewed and binary environments | Power comparison of alternative
methods for detecting interactions (top panels) and associations (bottom panels)
based on simulated data. (a) Power comparison when varying the shape, k, of the
Gamma distribution (lower shape values correspond to more skewed environments,
shape 100 corresponds to approximately Gaussian environments). (b-c) Power
comparison when simulating binary environments. (b) Power comparison varying
the fraction of environments that are binary, fB (with constant event frequency
v = 0.02). (c) Power comparison varying the event frequency of the binary event, v
(when all environments are binary, i. e. fB = 1). In the top panels, considered are
the StructLMM interaction test (StructLMM-int) and the default implementation
of the single-environment interaction tests (SingleEnv-Renv-int, Table 2.2). In the
bottom panels, considered are the StructLMM association test, the default 2 df fixed
effect test that tests for associations whilst accounting for possible heterogeneity in
the variant effect due to interactions with a single environment (SingleEnv-Renv,
Table 2.2), and linear models that test for persistent effects (LM and LMM-Renv,
Table 2.2). Models are assessed in terms of power (FWER < 1%) for detecting
simulated causal variants. Stars denote default values of genetic parameters, which
are retained when varying other parameters (see Table 2.3).
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Gene-environment correlations
To generate heritable environments, C was calculated directly from the randomly
selected UK Biobank environment data, whilst R was calculated as R = vxxex
T
e +
(1−vx)Rˆ, where vx is the fraction of the environmental variance driven by genetics,
xe is the selected variant associated with the environments and Rˆ the sample
covariance calculated directly from the UK Biobank environmental data. vx and
the LD, r2, between xe and the selected variant x used to simulate the g and i
components of the phenotype (see Section 2.4.2) were varied whilst fixing the other
parameter, using default settings vx = 0.2 and r
2 = 1 (see Table 2.3 for other values
of the parameters used).
Again calibration experiments were conducted, using 5,000 individuals and 60
environmental variables, considering the extreme case when all environments were
heritable (vx = 0.2). In the setting where persistent genetic effects were simulated,
the variant associated with the environments was the same variant that drives
the persistent effect (r2 = 1, Fig. 2.9b). Both the StructLMM association and
interaction tests were assessed when no causal variants were simulated (vg = 0,
Fig. 2.9a) and StructLMM-int when persistent genetic effects were simulated (vg =
0.006, ρ = 0, Fig. 2.9b). Both tests were always calibrated, demonstrating that
StructLMM can be robustly applied to different settings.
The effect on power of heritable environments was then examined. First, the LD
(r2) between the variant associated with the environments and the variant used to
simulate the genetic effect (g and i, see Section 2.4.2) was increased, considering
LD bins and the setting where this was the same variant (Fig. 2.10a). Second,
the average heritability (vx) of the environments was varied between 0.0 and 0.2
(Fig. 2.10b). Whilst the power of the interaction tests are largely unaffected by
the degree of heritability and LD between variants, all association tests (with the
exception of the LM) lose power as the heritability and LD increases. This is because
it is not possible to distinguish between the two causal mechanisms, (i) direct effect of
the variant on the phenotype and (ii) indirect effect of the variant on the phenotype
where the environments act as an intermediate. Hence, when additive environment
effects are not accounted for (as in the LM), there is no loss in power. This highlights
that for association testing, the choice of null model can have a large impact on the
power to discover associations.
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a  No genetic effect
vx = 0.2
b  Persistent effect (no GxE)
StructLMM-int StructLMM StructLMM-int
r2 = 1
vx = 0.2
Fig. 2.9 Calibration of StructLMM in the presence of heritable
environments | QQ plots of negative log P values when all environments used to
simulate the additive environmental effect (no simulated G×E effects) are heritable
(vx = 0.2). In panel a, QQ plots of negative log P values from StructLMM-int
(green) and StructLMM (blue) when no genetic effects are simulated (no G, no
G×E, vg = 0) and in panel b, analogous QQ plots to assess the calibration of
StructLMM-int when persistent genetic effects are simulated (no G×E, vg = 0.006,
ρ = 0), where the same variant is used to simulate the heritable environment and
the persistent genetic effect (r2 = 1). The genomic inflation factors λGC (denoted
by λ) for the interaction and association tests are displayed in the top left of each
plot.
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Fig. 2.10 Power comparison of different methods in the presence of
heritable environments | Power comparison of alternative methods for detecting
interactions (top panels) and associations (bottom panels) based on simulated data,
increasing (a) the LD (r2) between the variant associated with the environments
and the variant driving the G and G×E components of the phenotype and (b)
the average fraction of the environments variance explained by genetic effects
(vx, heritability). In the top panels, considered are the StructLMM interaction
test (StructLMM-int) and the default implementation of the single-environment
interaction test (SingleEnv-Renv-int, Table 2.2). In the bottom panels, considered
are the StructLMM association test, the default 2 df fixed effect test that tests for
associations whilst accounting for possible heterogeneity in the variant effect due
to interactions with a single environment (SingleEnv-Renv, Table 2.2), and linear
models that test for persistent effects (LM and LMM-Renv, Table 2.2). Models are
assessed in terms of power (FWER < 1%) for detecting simulated causal variants.
Stars denote default values of genetic parameters, which are retained when varying
other parameters (see Table 2.3).
Together, the results for general simulation settings (described in Section 2.4.4) and
settings in which environmental variables with specific properties are used (described
in this section), demonstrate that StructLMM is robust. It retains calibration across
all considered scenarios, notably including the scenario in which the environments
themselves are driven by the same variant as that driving the persistent and G×E
effect. In comparison, other implementations of multi-environment interaction and
association tests are not always calibrated, highlighting the benefit of using a random
effect term to aggregate across environments, such that the number of degrees of
freedom of StructLMM is independent of the number of considered environments.
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In addition, StructLMM offers power advantages over other baseline methods, in
particular when the number of environments contributing to the G×E effect is large,
when the environments are non-Gaussian and the fraction of the genetic variance
driven by interaction effects (ρ) is moderate to high, whilst maintaining similar
power to linear models when no G×E effects are present. StructLMM will have
marginally less power than linear models when no G×E effects are present, since it
is penalised for grid searching over different values of ρ. As a result it is not designed
to be a replacement for linear models but an alternative to identify additional loci,
in particular those with moderate to strong G×E effects.
2.5 Summary and discussion
In this chapter, I have shown that a random effect design can be used to test for
G×E effects jointly at multiple environmental variables using a single covariance
term (i. e. only 1 df is required to account for G×E at multiple environmental
variables). This framework can be used to perform both an interaction test and
an association test that accounts for possible heterogeneity in variant effects due
to differences in environmental exposures, both of which rely on a score-based
testing procedure. The association test is a new statistical test, differing from
existing set tests, for which I explicitly derive the mathematics that can be used
to evaluate the significance of the test statistics and thus obtain P values (see
Section 2.2.5). I note that SKAT-O123 is a special case of the new statistical test
derived in this chapter when the symmetric matrix, Σ, is replaced by the identity
matrix I. As described in Section 2.2.6, this methods has been implemented in
a computationally efficient manner such that it scales linearly with the number of
samples, rather than cubically as would be the case if implemented naively. The
method is broadly applicable, allowing for both interaction testing with hundreds
of environments and the identification of epistatic interaction effects, using cohorts
containing hundreds of thousands of samples. These methods are freely available at
https://github.com/limix/struct-lmm with tutorials and illustrations on how
to use the model available at http://struct-lmm.readthedocs.io.
Through the use of extensive simulation studies, I have shown that StructLMM
is calibrated across all settings considered and enjoys power gains across a broad
range of settings. It should be noted that this association test will be marginally
less powered than linear models when no G×E effects exist, since there is some
penalisation for grid searching over different values of ρ and as a result StructLMM
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is not designed to replace the linear model but rather to act as an alternative
tool to identify additional loci, in particular those with moderate to strong G×E
effects.
Currently, StructLMM is applicable to quantitative traits but the test can be readily
adapted for application to binary traits. In fact the SKAT-O method123 was
originally formulated based on application to binary traits. A potential limitation
is the speed of the method as generalised linear mixed model parameter inference is
slower than LMM parameter inference and whilst StructLMM is implemented in a
computationally efficient manner it is already slower than a standard LMM.
Throughout this work, only linear covariance functions were considered but in
principle any covariance function can be considered (see Rasmussen et al.256 for
descriptions of other covariance functions) and this may be particularly pertinent
as sample sizes increase such that there is sufficient power to detect non-linear
interactions.
Another limitation that is harder to address, is that currently the method can only
handle a single low rank random effect term, which is used to account for the additive
environment due to correlations between the environments and the phenotypes. In
theory, the method could be extended to handle a second random effect term that
can account for confounding due to population structure, thus allowing the inclusion
of related individuals. However, the kinship matrix is in general full rank; thus
in order to retain computational efficiency, particularly important for application
to cohorts of large sample size, this matrix would need to be built using suitable
low-rank approximations (e. g. as descibed by Listgarten et al.274).
Application of the StructLMM method, proposed in this chapter, to a real dataset
will be the focus of the next chapter.
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Chapter 3
Application of StructLMM to
identify genotype-environment
interaction effects that influence
body mass index in UK Biobank
3.1 Introduction
Body mass index (BMI), defined as Weight (kg)
(Height (m))2
, is a surrogate measure of adiposity
or overall obesity275, with guidelines available from the World Health Organisation
(WHO) for classifying individuals as underweight, healthy, overweight or obese
(which can be further subcategorised)276. Other commonly used measures to assess
adiposity and in particular, body fat distribution include waist circumference (WC)
and waist-to-hip ratio (WHR), both of which can be adjusted for BMI. Alternatively,
body composition can be assessed through the use of a dual energy X-ray
absorptionmetry (DEXA) scan276–278.
Obesity (characterised by an excess of adipose tissue) and overweight prevalence has
more than doubled since 1970 and if the rate of increase (as of 2005) continues, it is
estimated that by 2030, 38% of the world’s adult population will be overweight and
an additional 20% obese279–284. Consequently, due to the associated increase in risk
of other diseases, it is one of the largest global health burdens277. Comorbidities,
include type 2 diabetes, cardiovascular disease, stroke, some types of
cancer275,281,285–291 and in addition, maternal obesity can lead to congenital
abnormalities292. There are also less severe associated health outcomes, including
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osteoarthritis, infertility, asthma and sleep apnoea285,293,294. Thus a good
understanding of the factors governing BMI is important.
Whilst it is widely accepted that changes in the global food system, resulting in
increased availability and a shift to convenience based diets, coupled with an increase
in sedentary lifestyles are major contributors to this global epidemic277,295–300, there
is also a strong genetic contribution to BMI risk. Heritability estimates range from
30− 70%49,301–304.
Early genetic studies focussed on monogenic forms of obesity, where mutations in
a single gene, for example, LEP, LEPR, POMC and MC4R, drive the observed
phenotype305–312. However, for the majority of individuals, BMI is a complex trait
and the advent of GWAS, in 2005, enabled exploration of the polygenic factors
responsible295.
The first locus identified through this approach in 2007, that was later replicated
in an independent study, lies within the FTO gene277,313. To date, this is the locus
known to have the largest effect on BMI in Europeans (considering only common
variants)314, although it is estimated to explain only ≈ 0.34% of BMI variance277,297.
This was followed a year later by the identification of a signal 188 kb downstream
of MC4R 277,315, a gene already associated with monogenic forms of obesity. A
number of further loci have since been identified, with the GIANT consortium being
a major driver of these discoveries296,297,316; the 2015 meta-analysis, based on 339,224
individuals identified 97 loci, 56 of which were novel316. Despite the large number
of loci identified, these were estimated to explain only ≈ 2.7% of BMI variation.
In an attempt to identify more loci associated with BMI risk, a very large cohort
of 681,275 European individuals was recently analysed, obtained by combining the
samples collated by the GIANT consortium and UK Biobank271. This resulted in
the identification of 536 loci of which 484 had not been previously detected317.
The rapid change in lifestyles over the past few decades, during which time the
genetic pool has stayed relatively constant, has coincided with a substantial density
shift towards the upper end of the BMI population distribution298,312. This has
fostered an interest in studying G×E effects on BMI298,312. Several studies provide
evidence to suggest that genetically predisposed individuals are at a greater risk of
BMI increase in obesogenic environments318,319. The first examined 907 non-Hispanic
White adults from the Fels Longitudinal Study, with individuals binned into five
groups of approximately equal size according to year of birth (1939 or earlier, 1940−
1949, 1950−1959, 1960−1969 and 1970 or later)318. Year of birth was subsequently
used as a proxy for an individuals environmental exposure. A significant interaction
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effect (P < 0.001) on BMI between year of birth and an unweighted GRS (built
using the 32 SNPs associated with BMI reported by Speliotes et al.297 and noting
that there was no mean difference in GRS according to year of birth), whilst
appropriately accounting for other factors such as age and sex was identified318.
Similarly, the second study which uses longitudinal data from the Offspring Cohort
of the Framingham Heart Study partitioned individuals based on year of birth into
those born pre and post 1942. A significant interaction effect (P < 0.05) between
year of birth and a variant in the FTO gene (rs9939609 ) on BMI was identified,
again accounting for appropriate factors as covariates319.
Genotype-environment interaction studies have resulted in the identification of
significant G×E effects on BMI with a range of environments, including physical
activity196–199,206,212,213,320–324, dietary components196,200–205,214,325,
alcohol consumption320, smoking status196,320, socioeconomic status (often defined
by the Townsend deprivation index (TDI) in the UK)320,326, mental health320, sleep
patterns320, gender327–329 and age330,331. Genotype-age interaction effects can be
difficult to interpret as they can reflect either an accumulation of non-specific
environmental exposures or that biological mechanisms alter with age312,330. Some
of these studies have tested for G×E effects between individual environments and
single genetic variants, repeatedly finding significant interaction effects at the FTO
locus (see Section 2.2.7 for method details)197–206. Other studies have used a set test
based approach, with as many as 94 variants, building unweighted206,212,213,321,322,330
or weighted GRS, testing for interaction effects between this score and individual
environmental variables214,320,323,325,326 (see Section 2.2.7 for method details).
However, many of these environments are correlated and as a result, some of these
G×E effects may not be independent of one another but instead tag the same
environmental driving factor, which is potentially unobserved and/or directly
unmeasurable. Hence, claims that the single environmental exposure examined in an
interaction study, is the one responsible for the observed interaction effect and should
be the focus of public health policies, are likely overstated197,207,214. A recent study
by Young et al.195, largely overcame these issues by jointly testing for interaction
effects with multiple environments (see Section 2.2.7 for further details). Similarly,
the developed StructLMM method, described in Chapter 2, also mitigates these
issues by testing for interaction effects with multiple environments. In addition,
subsequent exploration of the putative driving environments using StructLMM is
based on a backward elimination procedure, thereby negating the issue of correlated
environments (see Section 3.2.2). Furthermore, I demonstrate that StructLMM
can be used to identify individuals within the population that are at increased (or
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decreased) trait and disease risk based on their aggregate environmental profiles
(and genotypes), which is perhaps more pertinent than trying to identify specific
environmental drivers.
The previous study195 that accounts for multiple environments when testing for G×E
effects on BMI, uses the UK Biobank cohort271. UK Biobank is a large prospective
cohort study, comprising of ∼500,000 British individuals, aged between 40 and 69
years at recruitment. In-depth phenotype and environment data is available for
these individuals, making this an ideal cohort for multi-environment interaction
studies (I refer the reader to Sudlow et al.271 and Bycroft et al.215 and http://www.
ukbiobank.ac.uk for further details).
Given the evidence for G×E effects to alter BMI risk, potentially due to multiple
environments that are not independent of another and the availability of such
environments in a single cohort of individuals (UK Biobank), this is a good setting
to demonstrate the practical utility of StructLMM.
In this chapter, I will use 64 lifestyle based factors derived from the available UK
Biobank data to test for interactions and associations and then further explore
some of the findings. Specifically, in Section 3.2, I will provide details of methods
implemented as part of StructLMM that can be used for exploring significant findings.
In Section 3.3, I will describe general methods that are used throughout this chapter,
including data pre-processing steps and in Section 3.4, I will outline the results of
this application.
The material presented in this chapter has been published by Nature Genetics245. A
copy of this publication can be found in Appendix A (apart from the Supplementary
Tables which are available at https://www.nature.com/articles/s41588-018-02
71-0). The implementation of methods used to explore identified loci (described in
Section 3.2) was joint work with Francesco Paolo Casale.
3.2 Methods to explore identified loci
In this section, I will describe the methods that have been implemented as part
of StructLMM, that can be used to explore significant interaction or association
variants. This includes, estimating the fraction of the genetic variance that is
driven by G×E, exploration of the environments that drive the interaction effects
and identification of environmental profiles and thus individuals (if they carry a risk
increasing allele) that are at increased or decreased disease or trait risk. Finally, the
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computational complexity of these downstream interpretation methods is discussed.
3.2.1 Estimating the fraction of the genetic variance driven
by G×E
StructLMM can be used to estimate the fraction of phenotypic variance driven
by marginal genetic effects (G), interaction effects (G×E) and if desired marginal
environment effects (E), denoted by var(G), var(G×E) and var(E), respectively. This
is achieved using the interaction test marginal distribution (described by Eq. 2.27,
Chapter 2) for parameter inference, obtaining the MLE αˆ, βˆG, σˆ
2
G×E, σˆ
2
e and σˆ
2
n.
The variance explained by the different components is then estimated as:
var(G) = vars(xβˆG)
= βˆ2Gvars(x), (3.1)
var(G×E) = E[vars(x βG×E)]
= varM(σˆ
2
G×Ediag(x)Σdiag(x))
= varM(σˆ
2
G×E(xE)(xE)T ), (3.2)
var(E) = E[vars(u)]
= varM(σˆ
2
eΣ)
= varM(σˆ
2
eEE
T ), (3.3)
where vars denotes the sample variance and varM(K) denotes the expected sample
variance of z, an N × 1 vector following z ∼ N (0,K), where K is an N × N
matrix.
Using varM(K) =
1
N−1tr(PK), where P = IN− 1N 1N1TN 257,332, it follows that:
var(G×E) =
σˆ2G×E
N − 1tr(P (xE)(xE)
T ), (3.4)
var(E) =
σˆ2e
N − 1tr(PEE
T ). (3.5)
Noting that 1
N
1N1
T
N is a projection matrix (spanning the space 1N), such that
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PP = P and P = P T and tr(AB) = tr(BA), then:
var(G×E) =
σˆ2G×E
N − 1tr(P (xE)(xE)
T )
=
σˆ2G×E
N − 1tr(PP (xE)(xE)
T )
=
σˆ2G×E
N − 1tr(P (xE)(xE)
TP )
=
σˆ2G×E
N − 1tr([P (xE)][P (xE)]
T )
=
σˆ2G×E
N − 1 ||P (xE)||
2
F, (3.6)
where ||.||F is the Frobenius norm. Similarly,
var(E) =
σˆ2e
N − 1tr(PEE
T )
=
σˆ2e
N − 1 ||PE||
2
F. (3.7)
Therefore the estimated fraction of genetic variance explained by G×E effects, ρ,
is:
ρ =
var(G×E)
var(G×E) + var(G)
. (3.8)
Whilst it can be seen that the parameter ρ described here takes a similar form
to the grid search parameter ρ used in the StructLMM joint association test (see
Section 2.2.2), this estimate is based on the MLE and thus is not constrained to a
grid of predefined values. As I have already explained in Section 2.2.2, performing a
joint association test in the same vein as described here (i. e. a 2 df joint association
test), is not possible as there is no closed form solution for obtaining P values when
jointly testing two variance component parameters that lie on the boundary of the
parameter space under the null. Using the estimate of ρ obtained here to calculate
Qρ and the corresponding P value (see Section 2.2.5) is also not valid since the tests
are not independent.
3.2.2 Exploration of the environments that drive the G×E
effects
StructLMM can be used to explore the environments that drive the observed G×E
effects, through the use of Bayes factors, which quantify the support for different
compared models. Specifically, this is achieved by subtracting the log marginal
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likelihood of a model with environments excluded from that of a model containing
all environments to give a log(Bayes factor). By calculating the effect of excluding
environments, rather than including them, I account for other correlated
environments and thus gain a clearer understanding of the environments have the
most bearing on the observed interaction effects.
Explicitly, denoting the full set of L environments, ε = {e1, e2, ...eL}, the evidence
for a subset of these environments, εi = {e1, e2, ...eLi} (where εi ⊆ ε with |εi| = Li),
driving the observed G×E effect at a given variant is given by:
log(Bayes factor)(εi) = LML(Mε)− LML(Mε\εi). (3.9)
\ denotes the set difference, such that the LML(Mε) and LML(Mε\εi) denote the log
marginal likelihoods of the models containing all L environments or the reduced
set of environments in the G×E term of the model described by Eq. 2.27 (see
Chapter 2), respectively. Note that for both models, all L environments are included
in the additive environment term (E), such that the only difference between the two
considered models is in the G×E term.
I consider removing each of the L environments individually, providing putative
evidence of whether each environment is likely or unlikely to contribute to the G×E
effect, where a log(Bayes factor) > 0 and log(Bayes factor) < 0 are evidence of
contribution and no contribution, respectively. The strength of this evidence can be
further classified based on the log Kass Rafferty scale333, where |log(Bayes factor)| ≤
1 is ‘not worth more than a bare mention’, 1 < |log(Bayes factor)| ≤ 3 is ‘positive’
and |log(Bayes factor)| > 3 is ‘strong’.
In addition, I can identify a putative causal set of driving environments using a
greedy backward elimination procedure. Specifically, I initially identify the
environment with the most evidence for driving the observed G×E effect, based on
the results from removing each environment individually in turn. This environment
is then always removed from the model (i. e. always included in εi) and then a
Bayes factor, excluding in addition each of the L − 1 remaining environments one
by one (i. e. Li = 2) is calculated. I then assess which of these additional L − 1
environments provides the most evidence for driving the observed G×E effect and
this environment is then permanently removed from the model (i. e. also included
in εi). This process is iteratively repeated, stopping when there is positive evidence
based on the log Kass Rafferty scale333 that I have selected a full set of environments
that can explain the observed G×E effect. Explicitly, this occurs at the first time
when LML(Mε\εi) − LML(M0) < 1, where M0 is the model described by Eq. 2.27
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(see Chapter 2) with no modelled G×E term. I also examine the set of environments
required to obtain strong evidence333 that I have selected a set of environments that
explain the observed G×E effect (i. e. the first time when LML(Mε\εi)−LML(M0) <
3).
3.2.3 Estimation of per-individual allelic effect sizes due to
G×E
StructLMM can be used to estimate per-individual allelic effect sizes based on
the environmental profiles present in a population, thus enabling identification of
individuals at increased or decreased trait risk if they carry the alternative allele.
This is achieved by making out-of-sample predictions for the total genetic component
(G + G× E) of the phenotype using best linear unbiased predictors (BLUP)334–336.
I note that the BLUP is equivalent to the mean of the conditional (conditioning on
the observed phenotypes y) multivariate Gaussian distribution337.
Starting from the interaction test marginal distribution described by Eq. 2.27 (see
Chapter 2)† to obtain MLE αˆ, βˆG, σˆ2G×E, σˆ
2
e and σˆ
2
n, it follows that the MLE of the
covariance (as described in Eq. 2.27), Kˆ can be written as:
Kˆ = σˆ2G×E(xE)(xE)T + σˆ2eΣ + σˆ2nIN . (3.10)
Denoting the total predicted genetic component of the phenotype as y?, which is an
N?×1 vector, where N? is the number of individuals for which predictions are to be
made and letting x? be the N?×1 genotype dosage vector for the N? individuals and
E? be the N? × L environmental matrix describing the L environmental variables
for the N? individuals, then:
E[y?|y] = x?βˆG︸ ︷︷ ︸
G?
+ σˆ2G×E(x? E?)(xE)TKˆ−1(y −Wαˆ− xβˆG)︸ ︷︷ ︸
(G×E)?
. (3.11)
I can use the same set of N? individuals to:
1. Predict the genetic component of the phenotype using the reference allele, x(r),
such that the N?×1 genotype dosage vector is x(r)? = [x(r), x(r), ..., x(r)]T , then:
y(r)? = x
(r)
? βˆG + σˆ
2
G×E(x
(r)
? E?)(xE)TKˆ−1(y −Wαˆ− xβˆG). (3.12)
†using that diag(x)Σdiag(x) = (xE)(xE)T
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2. Predict the genetic component of the phenotype using the alternate allele, x(a),
such that the N?×1 genotype dosage vector is x(a)? = [x(a), x(a), ..., x(a)]T , then:
y(a)? = x
(a)
? βˆG + σˆ
2
G×E(x
(a)
? E?)(xE)TKˆ−1(y −Wαˆ− xβˆG). (3.13)
Consequently, the predicted allelic effect, β? = y
(a)
? −y(r)? , that accounts for both G
(persistent) and G×E (interaction) effects can be written as:
β? = (x
(a)
? −x(r)? )βˆG+ σˆ2G×E(x(a)? −x(r)? )E?(xE)TKˆ−1(y−Wαˆ−xβˆG). (3.14)
If the genotype dosages are encoded as 0, 1, 2, where 0 is homozygous reference, 1 is
heterozygous and 2 homozygous alternative then, (x
(a)
? −x(r)? ) = 1 and the predicted
allelic effect given by Eq. 3.14 is simply:
β? = βˆG + σˆ
2
G×EE?(xE)TKˆ−1(y −Wαˆ− xβˆG). (3.15)
If the genotype dosages are mean centred and standardised, such that x(r) = −2p√
2p(1−p)
and x(a) = 1−2p√
2p(1−p) , where p is the observed frequency of the minor allele, then
(x
(a)
? − x(r)? ) = 1√
2p(1−p) and the allelic effect is given by:
β? =
1√
2p(1− p) βˆG +
1√
2p(1− p) σˆ
2
G×EE?(xE)TKˆ−1(y−Wαˆ−xβˆG). (3.16)
By setting E? = E, I can perform in-sample estimation of the allelic effects.
Alternatively, if I randomly select a set of individuals from the original N to obtain
the MLE and then set E? = Eremaining, where Eremaining is the environment matrix
of the remaining individuals, I can make out-of-sample predictions of the allelic
effects.
3.2.4 Estimation of the aggregate environment driving the
G×E effect at a variant
StructLMM can also be used to estimate the aggregate environment driving the
G×E effect at a variant. As already noted in Sections 2.2.4 and 2.3.2, StructLMM
can be derived from a multivariate model, in which as many fixed effects as there
are environments are used to define the model. This model, described in Eq. 2.24,
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can be rewritten as:
y = Wα︸︷︷︸
covariates
+xβG︸︷︷︸
G
+
L∑
l=1
(x el)βG×El︸ ︷︷ ︸
G×E
+
L∑
l=1
elβEl︸ ︷︷ ︸
E
+ ︸︷︷︸
noise
= Wα︸︷︷︸
covariates
+xβG︸︷︷︸
G
+x
L∑
l=1
elβG×El︸ ︷︷ ︸
G×E
+
L∑
l=1
elβEl︸ ︷︷ ︸
E
+ ︸︷︷︸
noise
= Wα︸︷︷︸
covariates
+xβG︸︷︷︸
G
+x
Aggregate environment︷ ︸︸ ︷
(Eβ
′
G×E)︸ ︷︷ ︸
G×E
+
L∑
l=1
elβEl︸ ︷︷ ︸
E
+ ︸︷︷︸
noise
, (3.17)
where β
′
G×E = [βG×E1 , βG×E2 , ..., βG×EL ]
T , E is the usual N ×L environment matrix
and Eβ
′
G×E is the aggregate environment.
Comparison of the total genetic component in Eq. 3.17 with the in-sample estimate
of the total genetic component (G+G×E) given by Eq. 3.11 (i. e. setting x? = x and
E? = E), shows that a maximum a posteriori estimate of β
′
G×E is given by:
β
′
G×E = σˆ
2
G×E(xE)TKˆ−1(y −Wαˆ− xβˆG) (3.18)
and thus the maximum a posteriori estimate of the aggregate environment driving
the G×E effect at a variant is given by:
Eβ
′
G×E = σˆ
2
G×EE(xE)TKˆ−1(y −Wαˆ− xβˆG). (3.19)
It can be seen that this estimated aggregate environment is equivalent to the G×E
component of the estimated allelic effect described by Eq. 3.15.
3.2.5 Computational complexities of methods used to
explore loci
All of the methods described in this section, used to explore identified loci, are based
on fitting the interaction test marginal model described by Eq. 2.27 (see Chapter 2).
Noting that this model can be written as:
y ∼ N (Wα+ xβG, [σG×Ediag(x)E, σeE][σG×Ediag(x)E, σeE]T + σ2nIN), (3.20)
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the same efficient inference scheme as was used to fit the null model for the
StructLMM interaction and joint association tests79,253 (see Section 2.2.6) can be
employed; the rank of the first covariance component is now 2L in place of L, such
that the computational complexity of fitting this model is O(4NL2 + 8L3).
Whilst the parameter inference of this model still scales linearly in the number
of samples, inclusion of the additional random effect component that models G×E,
results in slower inference than when fitting the null model, described in Section 2.2.5.
As a result, it is recommended that these analyses are only performed on loci with
significant interaction or joint association effects.
3.3 Methods
In this section, I will describe methods that I use throughout this chapter which are
not specific to StructLMM. I will start by describing the data pre-processing steps
that were applied to the UK Biobank data, followed by details of the calibration
assessment and finally, the method used to identify independent and exclusive
loci.
3.3.1 UK Biobank data processing
The analyses in this chapter have been conducted using the full release of UK
Biobank (Application 14069)215,271.
Phenotype and environment pre-processing
BMI phenotype data is ‘Instance 0’ of the UK Biobank field ‘21001’ (see http:
//biobank.ctsu.ox.ac.uk/crystal/ for details). Any individuals with missing
BMI data were discarded from the analysis and the remaining BMI values were log
transformed195,338.
Following Young et al.195, 20 environmental variables: 9 ordinal dietary variables
(‘Oily fish intake’, ‘Non-oily fish intake’, ‘Processed meat intake’, ‘Poultry intake’,
‘Beef intake’, ‘Lamb/mutton intake, ‘Pork intake’, ‘Cheese intake’ and ‘Salt added
to food’), three continuous dietary variables (‘Cooked vegetable intake’, ‘Bread
intake’, ‘Tea intake’), three physical activity variables (‘Number of days/week walked
10+ minutes’, ‘Number of days/week of moderate physical activity 10+ minutes’,
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‘Number of days/week of vigorous physical activity 10+ minutes’), ‘Alcohol intake
frequency’, ‘Sleep duration’, ‘Townsend deprivation index’, ‘Smoking status’ and
‘Time spent watching television’, using the data from ‘Instance 0’ (see http://
biobank.ctsu.ox.ac.uk/crystal/ for details), were selected. Again, following
Young et al.195, for the three continuous dietary variables, I removed values exceeding
the 99th percentile. For ‘Sleep duration’, I removed the top and bottom percentiles
and for each individual calculated the squared deviations from the mean sleep
duration, creating an additional environmental variable, ‘Squared sleep duration
res.’ (21st environmental variable). For ‘Time spent watching television’ , less than
0.5 hours of was encoded as 0.5 and I excluded individuals in the upper and lower
percentile. I then removed individuals with any missing environmental data.
I further removed any remaining poor quality samples flagged by UK Biobank
using the field ‘het.missing.outliers’ (based on heterozygosity and the amount of
missing data) and individuals with more than ten 3rd degree relatives using the field
‘excess.relatives’ in the released ‘Sample-QC’ file. I then kept only those individuals
that were genetically ‘White British’ based on the field ‘in.white.British.ancestry.
subset’ and finally removed any remaining individuals that were listed in field ‘ID1’
using the released ‘Relatedness’ file such that there were no relatives (3rd degree or
closer) included in the analysis. This left a total of 252,188 individuals.
Generation of principle components
Genetic principle components (PCs) were generated using FlashPCA version 2.0339,
based on the set of 147,604 SNPs flagged by the field ‘used.in.pca.calculation’ in the
released ‘Sample-QC’ file and the 252,188 individuals that passed all QC procedures
(described above). Ten PCs were used to control for population structure.
Imputed genotype QC
Testing was performed using the released imputed genotype data, considering only
SNPs that were imputed based on the HRC panel, http://www.haplotype-
reference-consortium.org/site (there were mapping issues with variants that
were imputed using UK10K+1000 Genomes panel array when this analysis was
conducted).
A fast bgen reader (https://github.com/limix/bgen-reader-py), was used to
load in the genotypes and genotype QC procedures were incorporated into the
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StructLMM interaction and association testing procedures, such that data after
intermediate QC steps was not stored. Specifically, I first replaced any genotype-
sample probabilities with missing values if the maximum probability across the
genotypes (the bgen format provides probabilities of the genotype being homozygous
reference, heterozygous or homozygous alternative) was below 0.5. I then calculated
the dosages for non-missing sites and removed SNPs if > 5% samples had missing
dosages, MAF < 1%, HWE < 1 × 10−6 and INFO score r2 < 0.4 (using the INFO
score provided in the released ‘Imputation MAF+info’ file). 7,515,856 SNPs passed
these filters. For all remaining variants that had a maximum genotype-sample dosage
probability below 0.5, I calculated a dosage from the provided probabilities as I
deemed this to be better than mean imputation. Any remaining dosage-sample
pairs with missing data were mean imputed. Genotype dosages were mean centred
and standardised.
Environment covariance, Σ, and model covariates
The 21 processed environments (described above) were age and gender adjusted,
as described in Section 2.2.4, and age itself added to the environmental matrix,
E, resulting in a total of 64 environments. Each environmental variable was then
mean centred (taking care to mean adjust only environmental values i. e. excluding
those set to 0 by gender adjustment) and standardised, followed by a rescaling
such that the per-individual variance was 1 (see Section 2.2.4). Fig. 3.1 shows an
example of the subsequently generated environment covariance, Σ, based on 5,000
randomly selected individuals and Fig. 3.2 the correlation of the 64 environments
across the 252,188 individuals. For downstream analyses (see Section 3.4.4), I did not
perform per-individual rescaling to enable direct interpretation (see Section 2.2.4).
All models used for testing and downstream analysis include a mean vector, genotype
chip (two different chips were used to collect the UK Biobank genotype information),
gender, age2, age3, gender×age, gender×age2, gender×age3 and 10 PCs (generated
as described above) to account for population structure.
3.3.2 Calibration
Calibration was assessed by permuting the 173,297 variants (over the 252,188
individuals) on chromosome 20 such that any true association and interaction signals
should be destroyed. The resulting 173,297 P values from interaction or association
testing were used to generate QQ plots of the expected negative log P values
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Covariance
Fig. 3.1 Covariance structure, Σ, of UK Biobank individuals based on
64 environmental variables | Sample covariance matrix for 5,000 randomly
selected individuals, calculated using the 64 environmental variables considered
for the analyses presented in this chapter: 12 diet-related factors, three physical
activity factors and six lifestyle factors, modelled as gender and age adjusted and age
itself. Dark red denotes pairs of individuals with stronger environmental similarity,
whilst blue corresponds to negative covariance of environmental similarity (anti
correlation). Individuals are ordered using hierarchical clustering.
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Pearson’s correlation
Fig. 3.2 Correlation of the 64 environments based on 252,188 UK Biobank
individuals | Shown are correlation coefficients between pairs of environmental
variables, considering 12 diet-related factors, three physical activity factors and six
lifestyle factors, modelled as gender and age adjusted and age itself. Environments
are ordered using hierarchical clustering.
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(x-axis) versus the observed negative log P values (y-axis) and inflation parameters,
λGC =
log10(m)
log10(0.5)
, where m is the median P value of the 173,297 variants tested, were
calculated.
3.3.3 Defining independent and exclusive loci
To define independent loci from the significantly identified variants (Benjamini-
Hochberg FDR86 adjusted P < 0.05 and P < 5×10−8 for interaction and association
tests, respectively), I iteratively (i) selected the most significant variant (using the
Benjamini-Hochberg FDR adjusted P values for interaction tests) and (ii) clumped
all variants in LD, r2 ≥ 0.1 (calculating LD using the 252,188 UK Biobank
individuals that passed sample QC) within +/ − 500 kb, until no variant was left.
This was done separately for each method considered.
To identify loci that are found exclusively by one of two methods, I (i) for all variants
in a clump, identified any variants within +/− 500 kb that were significant for the
second method, (ii) calculated LD, r2 between variants in the selected clump and
the significant variants for the second method (if any exist) and (iii) declared the
selected clump as exclusively identified if the maximum LD, r2 < 0.1.
3.4 Results
In this section, I first describe the calibration of different interaction and association
methods that are used in this chapter. I then outline the key findings when testing
for interaction effects between the 64 lifestyle factors and (i) the 97 variants identified
by Locke et al.316 and (ii) the variants associated with BMI, identified through a
genome-wide scan on the UK Biobank data. This is followed, by the results from a
genome-wide joint association test that accounts for possible heterogeneity in variant
effects due to G×E. Finally, I explore some of the identified interaction loci in further
detail using the methods described in Section 3.2.
3.4.1 Calibration assessment
To check that the data was pre-processed appropriately, I assessed the empirical
calibration of different models used in this chapter (see Section 3.3.2 for details).
The StructLMM interaction (StructLMM-int) and association tests, as well as, the
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linear models, LMM-Renv and LM (see Section 2.3 for model details) were calibrated
(Fig. 3.3a). In addition, the multi-environment interaction (MultiEnv-Renv-LRT-int)
and association (MultiEnv-Renv-LRT) methods based on fixed effects (see Section 2.3
for model details) were calibrated in this setting, since the sample size is sufficiently
large (Fig. 3.3b; see Section 2.4.4 for a discussion on the settings in which these
methods are calibrated). However, I do note that the single environment interaction
tests, SingleEnv-Renv-int (see Section 2.3 for model details) show variable levels
of statistical calibration (Fig. 3.3c). This has been noted in previous interaction
studies340–344 and may not be symptomatic of uncontrolled confounding factors
but instead occur due to minor misspecification of the null model (possibly due
to heteroskedasticity in the noise term). These minor misspecifications do not cause
a lack of observed calibration for marginal effect scans due to independence of the
test statistics across the variants. However, the interaction term is a product of
el and x, with the former repeatedly used throughout the empirical calibration
experiment, such that the test statistics across the variants are not independent
(I refer the reader to Rao et al.344 for further details). Since all other methods,
in particular StructLMM-int and MultiEnv-LRT-int that fit identical null models,
were calibrated, it is unlikely that the observed inflation and deflation is due to
uncorrected confounding. I did not attempt to correct this mis-calibration, as the
SingleEnv-Renv-int tests are not the focus of the work presented in this chapter
and adjustment is not straight forward or without further potential problems344.
These results again highlight that StructLMM is more robust than other interaction
methods.
ca b
Fig. 3.3 Calibration of interaction and association tests for BMI on UK
Biobank data | QQ plots of negative log P values from different interaction
and association tests applied to UK Biobank BMI phenotype data based on
permuted genetic variants (chromosome 20). (a) QQ plots for StructLMM-int
(green), StructLMM (blue), LM (grey) and LMM-Renv (yellow). (b) QQ plots
for MultiEnv-Renv-LRT-int (salmon) and MultiEnv-Renv-LRT (red). (c) QQ plots
for SingleEnv-Renv-int, for each of 64 considered environmental variables.
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3.4.2 Interaction test results
Interaction test results at the 97 GIANT variants
The majority of previous interaction studies for BMI, have focussed on variants
(or subsets of variants) that were significantly associated with BMI in marginal
association studies. At the time of conducting these analyses, the largest study
for which associations with BMI had been tested, was the meta-analysis performed
by the GIANT consortium316 that identified 97 loci associated with BMI (P <
5× 10−8). Thus, I initially tested for G×E with the 64 lifestyle based environments
(as described in Section 3.3.1) at these 97 loci (all of which passed the imputed
genotype QC thresholds described in Section 3.3.1), using the 252,188 individuals
that passed sample QC (see Section 3.3.1).
StructLMM-int identified 4 significant interactions at a FWER 5%. One of these
was at the FTO locus (rs1558902, P = 4.23×10−16, ρ = 0.138, Fig. 3.4a), previously
reported to interact with physical activity195–199,206,213,324, diet195,196,200–205,214,
alcohol consumption195, squared residuals of sleep duration195, and smoking for men
aged 40 − 60196. A second, was at the MC4R locus (rs6567160, P = 9.78 × 10−8,
ρ = 0.156, Fig. 3.4b), for which one previous study has reported an interaction effect
with physical activity for women aged 20 − 40196. Another, was at the SEC16B
locus (rs543874, P = 1.15×10−4, ρ = 0.133, Fig. 3.4c), for which there is suggestive
evidence of an interaction with physical activity in Europeans213 and Hispanics324
and also diet214 (P = 0.025, P = 0.003 and P = 0.02 prior to multiple testing
corrections for 12, 37 and 32 variants, respectively). The final interaction was at the
PARK2 locus (rs13191362, P = 4.69× 10−4, ρ = 0.736, Fig. 3.4d), which has been
linked to BMI change in a ten year follow up study331.
For comparison, only two of these four loci, FTO and SEC16B were significant when
testing for interactions with a single environment, using a Bonferroni correction to
account for testing 64 environments per variant (P-adj; SingleEnv-Renv-int, see
Section 2.3 for model details). In addition, these interactions were more significant
with StructLMM-int (P = 4.23× 10−16 and P = 1.15× 10−4 at FTO and SEC16B,
respectively) than with SingleEnv-Renv-int (P-adj = 6.76 × 10−6 and P-adj =
4.80 × 10−4 at FTO and SEC16B, respectively; Fig. 3.5a, Fig. 3.4a, b). Similarly,
when testing for interactions using a multi-environment model based on fixed effects
(MultiEnv-Renv-LRT-int, see Section 2.3 for model details), only two of these four
loci, FTO and MC4R were identified (Fig. 3.5b).
I also examined the results when using the more relaxed 5% FDR (Benjamini-Hochberg
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Fig. 3.4 Local Manhattan plots for the four interaction loci identified
by StructLMM-int | Local Manhattan plots of interactions identified by
StructLMM-int (5% FWER) at (a) FTO, (b) MC4R, (c) SEC16B and (d) PARK2
respectively. From top to bottom: LMM-Renv association test, StructLMM
interaction test, SingleEnv-Renv interaction test for the environment with the
most significant G×E effect at the respective GIANT variant (P values Bonferroni
adjusted to account for the number of tested environments, P-adj) and local gene
models. The red vertical line and diamond symbol indicates the position of the
GIANT variant as annotated by Locke et al.316.
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Fig. 3.5 Comparison of interaction results at the 97 GIANT loci |
Scatter plot of negative log P values from G×E interaction tests at 97 GIANT
variants, considering (a) single environment fixed effect G×E tests, plotting the
result for the environment with the most significant G×E effect at a given
variant (SingleEnv-Renv-int, x-axis; P values Bonferroni adjusted for the number
of tested environments, P-adj) and (b) multi-environment fixed effect G×E
tests (MultiEnv-Renv-LRT-int, x-axis) versus the StructLMM interaction test
(StructLMM-int, y-axis). Dashed lines correspond to α < 0.05, Bonferroni adjusted
for the number of tested variants. Colour denotes the estimated fraction of the total
genetic variance due to G×E (ρ, see Section 3.2.1 for details), where yellow/red
corresponds to variants with low/high G×E components.
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adjustment86) threshold. This results in a greater difference in the number of loci
identified by each method, where StructLMM-int identifies an additional seven
loci (11 in total), LMX1B, TOMM40, MTCH2, TLR4, UBE2E3, ADCY3 and
MIR548X2, to the four already mentioned, whilst SingleEnv-Renv-int identifies an
additional three loci (including MC4R and PARK2 ; six in total) and MultiEnv-Renv-
LRT-int identifies no additional loci (two in total).
I refer the reader to Supplementary Table 3 in Moore et al.245 for a tabular version
of results for all GIANT variants.
Interaction test results based on marginal association results in UK Biobank
As an alternative filtering strategy, I performed a genome-wide association scan,
using LMM-Renv (see Section 2.3 for model details) with the set of 252,188 UK
Biobank individuals and 7,515,856 SNPs that pass sample and genotype QC (see
Section 3.3.1), selecting 17,606 significantly associated variants (P < 5 × 10−8). I
subsequently tested for G×E at these variants with StructLMM-int, SingleEnv-Renv-
int and MultiEnv-Renv-LRT-int†, using a 5% FDR (Benjamini-Hochberg
adjustment86) to identify significantly interacting variants. StructLMM-int,
SingleEnv-Renv-int and MultiEnv-Renv-LRT-int identified 451, 309 and 273
significant variants (Fig. 3.6), corresponding to 23, 11 and 9 significant loci,
respectively (+/ − 500 kb, LD r2 < 0.1, see Section 3.3.3). As well as identifying
previously associated GIANT loci, including FTO, MC4R and SEC16B, StructLMM-
int also identified interactions at nine loci that were > 500 kb from the 97 reported
GIANT loci316 (see Supplementary Table 3 in Moore et al.245 for a tabular version
of results). This includes a locus (lead variant rs13264668 ), only identified by
StructLMM-int (P = 1.10 × 10−3, ρ = 0.443), that is upstream of the MSRA gene
and is ≈ 25 kb from a variant associated with waist circumference345,346, early
onset obesity347 and in addition was found to be significantly associated with BMI
trajectories in female children348.
†noting that the marginal association and interaction tests are independent, see229 for full
details
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Fig. 3.6 Comparison of interaction results at genome-wide significant
variants in UK Biobank | Scatter plot of negative log Benjamini-Hochberg
adjusted P values (P-adj) from G×E interaction tests at 17,606 variants that
were significantly associated with BMI using LMM-Renv (P < 5 × 10−8) in
UK Biobank, considering (a) single environment fixed effect G×E tests, plotting
the result for the environment with the most significant G×E effect at a
given variant (SingleEnv-Renv-int, x-axis; P values Bonferroni adjusted for the
number of tested environments) and (b) multi-environment fixed effect G×E
tests (MultiEnv-Renv-LRT-int, x-axis) versus the StructLMM interaction test
(StructLMM-int, y-axis). Dashed lines correspond to P-adj < 0.05 and variants
that exceed this threshold are coloured by the estimated fraction of the total genetic
variance due to G×E (ρ, see Section 3.2.1 for details), where yellow/red corresponds
to variants with low/high G×E components.
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3.4.3 Genome-wide association results
As already outlined in Chapter 2, the StructLMM framework can also be used
to perform a joint association test, i. e. test for associations whilst accounting for
possible heterogeneity in the variant effect across individuals due to G×E. Using
the same set of 64 lifestyle factors and 252,188 individuals as for the interaction
analyses, I tested for associations at the 7,515,856 low frequency and common SNPs
that pass QC (MAF > 1%; see Section 3.3.1 for data pre-processing details).
For comparison, I also performed a genome-wide association scan using linear models,
LMM-Renv and LM. The former accounts for additive environment effects using a
random effect term such that the null model is identical to that of StructLMM
(see Section 2.3 for model details) facilitating direct assessment of the impact of
modelling G×E effects.
I first note that the linear models LMM-Renv and LM identify slightly different
sets of associated loci (+/ − 500 kb, LD r2 < 0.1, see Section 3.3.3; Fig. 3.7).
LMM-Renv, identified 327 loci of which 14.37% were not detected by the LM and
the LM, identified 379 loci, of which 25.59% were not detected by LMM-Renv (see
Supplementary Table 4 in Moore et al.245 for a tabular version of all significantly
associated loci). These results agree with those seen in the simulation experiments
(Section 2.4.5), where LMM-Renv was better powered than the LM when
environments were correlated with the phenotypic outcome (Fig. 2.4) but the LM
can outperform LMM-Renv when the environments were heritable (Fig. 2.10).
Despite this, there were 23 loci found exclusively by StructLMM (351 loci in total,
+/− 500 kb, LD r2 < 0.1, see Section 3.3.3; see Supplementary Table 4 in Moore et
al.245 for a tabular version of all significantly associated loci). One such locus lies
in the ADAMTSL3 gene (lead variant rs4842838, P StructLMM = 9.35 × 10−10,
P LMM = 3.83 × 10−7, P LM = 2.37 × 10−5, ρ = 0.576; Fig. 3.8a) and codes for
a glycoprotein349. Other variants within this gene have been linked to BMI-related
traits, including lean body mass350, WC351 and hip circumference adjusted for
BMI352. A second interesting locus, lies in the PEPD gene (lead variant rs11880064,
P StructLMM = 5.23×10−9, P LMM = 1.22×10−7, P LM = 8.46×10−8, ρ = 0.525;
Fig. 3.8b) and codes for a protein involved in the final stage of degradation of
endogenous and dietary proteins. Several additional PEPD genetic variants have
been associated with adiponectin353,354, fasting insulin adjusted for BMI355, HDL
cholesterol356, triglycerides356,357, type 2 diabetes358, WC adjusted for body mass352
and WHR352. A final example, lies upstream of ONECUT1 and downstream of
WDR72 (lead variant rs473428, P StructLMM = 1.95 × 10−9, P LMM = 1.01 ×
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Fig. 3.7 Comparison of LMM-Renv and LM results on UK Biobank data
| Scatter plot of genome-wide negative log P values from the LM association test,
without accounting for additive environmental effects (x-axis), versus an LMM
association test that accounts for additive environmental effects using the same
random effect component as used in StructLMM (LMM-Renv, y-axis). Dashed lines
indicate genome-wide significance at P < 5× 10−8.
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10−7, P LM = 1.26 × 10−7, ρ = 0.415; Fig. 3.8c). ONECUT1 stimulates the
production of liver expressed genes and can inhibit glucocorticoid-stimulated gene
transcription358 and genetic associations with BMI359, HDL cholesterol357, lipids357
and triglycerides357 were reported in early GWAS but have not reached genome-wide
significance in more recent studies. This could be due to G×E effects varying across
different aggregated cohorts or due to differences in trait transformation.
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Fig. 3.8 Local Manhattan plots for three association loci exclusively
identified by StructLMM in UK Biobank | Shown are three associations
exclusively identified by the StructLMM association test, with the red vertical
line indicating the position of the StructLMM lead variant. From top to bottom:
Manhattan plot of negative log P values from StructLMM, LMM-Renv and the local
gene models, for (a) ADAMTSL3, (b) PEPD and (c) ONECUT1.
Comparison of ρ (see Section 3.2.1 for details) at variants (Fig. 3.9) and loci (+/−500
kb, LD r2 < 0.1; see Section 3.3.3 for details) identified by StructLMM (351 in total,
32 not identified by LMM-Renv) and LMM-Renv (327 in total, 16 not identified by
StructLMM; Fig. 3.10), reveals that as expected (and in agreement with simulation
experiments, Section 2.4, Fig. 2.4a), StructLMM tends to identify loci with a greater
extent of G×E (larger values of ρ), whereas LMM-Renv specific loci tend to have
no or little evidence for effect size heterogeneity due to G×E. As already mentioned
in Chapter 2, the latter can be explained by the fact that StructLMM will be
slightly less powered than LMM-Renv when no or very little G×E is present since
StructLMM is penalised for testing multiple values ρ. These results indicate that
the StructLMM joint association test can be used to identify additional loci, with a
G×E component.
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Fig. 3.9 Comparison of StructLMM and LMM-Renv association tests
on UK Biobank data at all 7,515,856 tested variants | Scatter plot of
genome-wide negative log P values from LMM association test (LMM-Renv, x-axis)
versus the StructLMM association test (y-axis). Dashed lines indicate genome-wide
significance at P < 5×10−8 and colour denotes the estimated extent of heterogeneity
(ρ), where yellow/red corresponds to variants with low/high G×E components. The
inset displays a zoom-in view of variants close to genome-wide significance.
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Fig. 3.10 Distribution of the estimated extent of G×E for significant loci
identified by the StructLMM association test and LMM-Renv on UK
Biobank data | Cumulative number of significant associations (P < 5 × 10−8,
+/ − 500 kb, LD r2 < 0.1) identified by LMM-Renv (yellow, N=327 loci) and
StructLMM (blue, N=351 loci) in decreasing (a) and increasing (b) order of the
estimated extent of G×E (ρ). (c) Distribution of the fraction of genetic variance
due to GxE (ρ) for loci identified by LMM-Renv (yellow) and StructLMM (blue).
(d) Histogram of the fraction of genetic variance due to G×E (ρ), considering the
subset of loci exclusively identified by either approach: LMM-Renv (yellow, total
16), StructLMM (blue, total 32).
Finally, I compared StructLMM to the multi-environment fixed effect based test,
MultiEnv-Renv-LRT (see Section 2.3 for details), which demonstrated that
StructLMM was able to identify a much greater number of significantly associated
variants (17,630 versus 2,037, Fig. 3.11). The difference in association P values
between StructLMM and MultiEnv-Renv-LRT (Fig. 3.11) is related to the estimated
value of ρ. Again, these results are in agreement, with the simulation experiments
(Section 2.4), where power differences between StructLMM and MultiEnv-Renv-LRT
become smaller, as the simulated value of ρ increases (see Fig. 2.6).
118
a b
Fig. 3.11 Comparison of multi-environment association tests on
UK Biobank data | (a) Scatter plot of negative log P values from the
MultiEnv-Renv-LRT association test (x-axis) versus the StructLMM association test
(y-axis). Dashed lines indicate genome-wide significance at P < 5×10−8 and colour
denotes the estimated fraction of genetic variance due to G×E (ρ, see Section 3.2.1
for details), with (b) displaying a zoom-in view of variants close to genome-wide
significance.
3.4.4 Exploration of significant loci
As well as the identification of variants, one of the principle objectives for conducting
G×E analyses, is to improve the understanding of functional mechanisms that result
in increased (or decreased) trait and disease risk.
Exploration of environments driving observed G×E effects
I first explore the environments driving the identified G×E effect at the four GIANT
loci (FWER 5%) using Bayes factors (see Section 3.2.2 for details). Initially, I
examine the evidence for each environment contributing to the observed G×E effect,
noting that at these four loci no environment displays strong evidence (Bayes factor
> 3 based on the log Kass Rafferty scale333) of driving the observed interaction
effect. However, multiple environments show positive (Bayes factor > 1, based on
the log Kass Rafferty scale333) and putative evidence (Bayes factor > 0), with the
number of such putative environments ranging from 20 to 25, indicative of multi
environment G×E effects (Fig. 3.12).
Since the environments are not independent of one another, I used a greedy backward
elimination procedure (see Section 3.2.2 for details) to identify a potential set of the
driving environments at the four loci. This analysis again revealed that multiple
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Fig. 3.12 Evidence for each environment contributing to the identified
G×E interaction effects using Bayes factors | Relevance of individual
environmental variable for G×E effects at four loci, showing Bayes factors between
models containing all 64 environments and models with a single environmental
variable removed. Shown are results for (a) FTO, (b) MC4R, (c) SEC16B and (d)
PARK2, ordered by Bayes factor, with environments for which there was evidence
of contribution to the G×E effect left of the black dashed lines whilst those that
showed no evidence of contribution to the right and environments with positive
evidence based on the log Kass Rafferty scale333 left of the blue lines.
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environments contribute to the observed interaction effect with the number of
environments required to explain the G×E effects (strong evidence based on the
log Kass Rafferty scale333, Section 3.2.2) ranging from 2 at PARK2 to 25 at FTO
(Fig. 3.13). The environments selected also varied across the loci, with PARK2
interacting with ‘tea intake’, an environment that is not selected at any other loci.
Interestingly, at MC4R, I identified gender specific (women only) and age dependent
interaction effects with physical activity (Fig. 3.13b), in agreement with the only
previous study that found an interaction effect at this locus196. However, this and
the aforementioned analysis that removed individual environments, suggests that
other environmental factors may be of greater importance, thus underlining the
benefits of multi-environment interaction tests.
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Fig. 3.13 Exploration of the environments contributing to the identified
G×E interaction effects using Bayes factors | Cumulative evidence of
environmental variables contributing to G×E at (a) FTO, (b) MC4R, (c) SEC16B
and (d) PARK2 showing Bayes factors between the full model and models with
increasing numbers of environmental variables removed using (greedy) backward
elimination. For comparison, shown is the total evidence of all environmental
variables. The additional environment that is removed at each elimination step
is labelled on the x-axis with the total number of environmental variables removed
in the considered models shown in brackets. I stopped selecting environments when
there was positive evidence based on the log Kass Rafferty scale333 that I had selected
a full set of environments that can drive the observed G×E effect and this set of
environments are those displayed left of the blue line. Sets of environments required
for strong evidence, again based on the log Kass Rafferty scale333 are shown left of
the red line.
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Identification of individuals at increased and decreased disease risk
Instead of identifying specific environments that drive the observed G×E effects,
it is perhaps more pertinent (due to the correlation between environments) to
explore the aggregate effect of all environments, thereby identifying environmental
states (and equivalently individuals if they carry the risk increasing allele) that are
potentially at the extremes of the trait or disease risk spectrum. To demonstrate
this, I first estimated in-sample per-individual allelic effects at the four GIANT loci
with significant G×E effects (FWER 5%, Fig. 3.14; see Section 3.2.3 for details).
I then selected the 5% of individuals (12,610 individuals) at the extremes of the
estimated spectrum† and subsequently obtained estimates of the variant effects in
these extreme strata using LMM-Renv (Fig. 3.14). For comparison, I also estimated
the population variant effect (using all 252,188 UK Biobank individuals), again using
LMM-Renv (Fig. 3.14). These results indicate that whilst for FTO, MC4R and
SEC16B the aggregate environment only acts to exacerbate the genotype effect,
at PARK2 there is suggestive evidence that different environmental profiles can
interact with the genotype with opposite directions of effect on BMI.
To assess the validity of identifying individuals within the population at increased
and decreased trait risk, using the per-individual allelic effect in-sample estimates,
I performed a hold-out validation experiment. For this, I used the 11 GIANT loci
with significant G×E effects (FDR 5%, Benjamini-Hochberg adjusted86), randomly
splitting the population into two groups of equal size (126,094 individuals), a training
and a testing set. I estimated per-individual allelic effects for the training set in an
identical manner to those generated for the full set of individuals (see Fig. 3.14),
again identifying the 5% of individuals (6,305 individuals) with the highest and
lowest estimated allelic effects and tested for associations in these extreme strata
using LMM-Renv, thus identifying strata that were nominally significant (P < 0.05;
Fig. 3.15a). I then made out-of-sample predictions for the test set of individuals
(which required using only their environmental information, see Section 3.2.3 for
details; Fig. 3.15b). To assess the validity of the predictions, I compared the
predicted mean allelic effects (yellow crosses, Fig. 3.15b; x-axis, Fig. 3.15c) with
the in-sample estimates of the allelic effects obtained using LMM-Renv (at this
stage using the genotype and phenotype information of the test individuals; y-axis,
Fig. 3.15c), for the nominally significant strata identified based on the training set
of individuals. To ensure that the persistent genetic effect was not dominating these
†noting that these per-individual allelic effects are the sum of the estimated persistent effect
and the estimated aggregate environment effect, this is equivalent to selecting individuals with the
most extreme estimated aggregate environment effects
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Fig. 3.14 Exploration of the aggregate environment effect at identified
G×E loci | Violin plot (centre) showing the distributions of the in-sample allelic
effect size estimates (effect of heterozygous versus homozygous reference carriers for
the environmental states observed in the population) on BMI for the four GIANT
variants with G×E (FWER 5%). Estimated persistent genetic effects are shown
by the red bars and the green bars indicate the top and bottom 5% quantiles of
variation in effect sizes due to G×E. Clockwise from top left: box plots of the
genotype (x-axis) versus the phenotype (y-axis) for FTO, SEC16B, PARK2 and
MC4R, for individuals at the extremes of the risk spectrum (individuals in the
top and bottom 5% quantiles based on the estimated aggregate environments, or
equivalently those individuals that lie above and below the green bars in the violin
plot) and equivalently for all individuals in the population. The displayed P values
and mean estimated allelic effects (β) for different population strata are calculated
using LMM-Renv.
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comparisons, I also compared the out-of-sample predictions and in-sample estimates
of only the G×E component of the allelic effect for the test set of individuals. This
was achieved by subtracting the predicted persistent effect (added to generate the
per-individual allelic effects, see Section 3.2.3) and the in-sample estimate of the
variant effect using all testing individuals, respectively (Fig. 3.15d). Whilst, I note
that the estimated and predicted allelic effect sizes may be overestimated due to the
winner’s curse360, the consistency in the direction of effect between the estimates
and predictions suggests that I am able to identify individuals at the extreme ends
of the risk spectrum. The out-of-sample per-individual allelic effect predictions also
provide further evidence for a possible opposite direction of effect at PARK2.
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Fig. 3.15 Out of sample prediction of per-individual allelic effect sizes |
Assessment of per-individual allelic effects for 11 GIANT variants with evidence for
G×E (Benjamini-Hochberg adjustment, FDR < 0.05), considering a 50:50 split
of the cohort into training and test fractions. (a) Violin plot, displaying the
distributions of the in-sample estimated allelic effect sizes for the training fraction
(as in Fig. 3.14). Estimated persistent genetic effects are shown by the red bars and
the green bars indicate the top and bottom 5% quantiles of variation in effect sizes
due to G×E. P values denote the significance of genetic effects within the respective
strata, assessed using LMM-Renv. Nominally significant associations (P < 0.05)
are highlighted in red. (b) Analogous allelic effect size distributions as in a, for the
test fraction (out-of-sample predictions, using only the environmental states of test
individuals). Yellow crosses denote the mean predicted genetic effect within the top
and bottom 5% strata (considering strata with nominally significant associations in
the training fraction, i.e. P values that are highlighted in red in a). (c) Scatter plot
of allelic effect sizes, displaying out-of-sample predictions for the extreme strata
of test set individuals (yellow crosses in b, x-axis) versus in-sample estimates for
the extreme strata of test set individuals, obtained using LMM-Renv (using the
genotypes and phenotypes of the test set individuals in the strata). Different GIANT
variants are coded in colour. (d) Analogous scatter plot as in c, however displaying
the differences between genetic effects in the 5% strata and population estimates of
persistent effects (effect sizes due to G×E).
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Finally, I examined whether it is the same environmental profiles that put individuals
at increased and decreased trait risk across different loci, by calculating the squared
Spearman’s correlation between pairs of the 11 GIANT loci with significant G×E
effects (FDR 5%, Benjamini-Hochberg adjused86; Fig. 3.16). This analysis suggests
that there is some shared environmental burden across loci due to G×E effects, in
particular if individuals carry the risk increasing alleles at both MC4R and FTO
or at both TLR4 and TOMM40 and again suggests that the interaction effect at
PARK2 is driven by different environmental exposures to those driving the G×E
effect at FTO, MC4R and SEC16B.
Fig. 3.16 Rank correlation of per-individual genetic effect sizes across loci
for UK Biobank data | Shown are squared Spearman correlation coefficients of
per-individual allelic effects estimates for 11 GIANT variants with evidence for G×E
(Benjamini-Hochberg adjustment, FDR < 0.05).
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3.5 Summary and discussion
In this chapter, I have shown the practical utility of StructLMM to identify variants
with a G×E component that alter BMI risk, using 64 lifestyle based environmental
variables and 252,188 individuals from UK Biobank.
Initially, I focussed on testing for interactions at the 97 loci identified by the GIANT
consortium316, confirming previous findings of a G×E effect at FTO 195–206,213,214,324
and in addition replicating a G×E effect at MC4R, which was previously found
to interact with physical activity in women aged 20 − 40 in a cohort of Nordic
individuals196. This analysis also revealed a further seven loci with significant G×E
effects (FDR 5%, Benjamini-Hochberg adjusted86; see Supplementary Table 3 in
Moore et al.245). I also considered a genome-wide G×E analysis, where 17,606
significantly associated BMI variants (P < 5 × 10−8, LMM-Renv) were tested for
G×E, yielding 23 loci with significant interaction effects (FDR 5%, Benjamini-
Hochberg adjusted86; see Supplementary Table 3 in Moore et al.245).
I then applied the StructLMM joint association test, which identified 23 loci (P <
5×10−8, see Supplementary Table 4 in Moore et al.245) with G×E contributions that
were not identified by conventional association tests (Fig. 3.9 and 3.10). Fourteen
of these loci remain exclusively detected by StructLMM (using a distance threshold
of +/ − 500 kb), even when the sample size is ≈ 2.7 times as large (considering
the recent study conducted by Yengo et al.317, which used 681,275 individuals,
including 456,426 UK Biobank individuals) as that considered for the analyses
presented in this chapter. I note that StructLMM is not intended as a replacement
for conventional association tests, as it will be less powered at loci where there is
virtually no environmental dependency (Fig. 3.10), since StructLMM is penalised
for grid searching. Instead, it should be regarded as a tool to identify additional loci
that are subject to G×E effects.
Whilst this work demonstrates the benefits of using StructLMM to identify variants
in the presence of G×E effects, the identification of novel loci with strong G×E
(large values of ρ) using the StructLMM joint association test not identified by
standard linear models, suggests that current methods which select variants for
interaction testing based on association results obtained from standard linear models
are not optimal. In the next chapter, I describe an improved strategy that enables
genome-wide interaction scans with sufficient power to detect G×E after multiple
testing correction. Testing for interaction effects at all genome-wide variants has
the added benefit of relaxing the assumption that the lead association and lead
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interaction variants are in high LD with one another.
A further increase in the number of significant loci may be achieved through using
a greater number of the available UK Biobank individuals. Currently, I remove
individuals with any missing environmental data but a possible extension to the
existing StructLMM framework would be to incorporate environment imputation
methods that leverage the correlation between the considered variables361, for
example using multivariate normal models362. Such imputation methods will become
increasingly important as the number of environments considered for analyses
increases and thus the number of individuals removed due to missing data increases.
Finally, I showed that further exploration of loci identified by StructLMM is also
possible using the methods implemented within StructLMM, as described in Section
3.2. Exploration of the environments driving the observed G×E effects at four loci
with significant interactions (FWER 5%) using Bayes factors, provides evidence
that multiple environments contribute to the interaction effects and that these
environments vary across the loci (Fig. 3.12 and 3.13).
Given that these interactions are likely poly-environment in nature, it is perhaps
more pertinent to explore the aggregate environment effects that lead to increased
or decreased trait risk. This analysis suggested that the interaction effect at PARK2
can both increase and decrease trait risk (i. e. there is no risk increasing allele per
se but that the risk increasing allele is dependent on the aggregate environmental
exposure). Determining whether observed interaction effects are truly due to
interactions with the environment or if instead the environments are acting as proxy
for potentially multiple genetic variants, such that the identified interaction effect
is actually an epistatic effect is particularly important for the interpretation and
utility of interactions that display opposite directions of effect. Whilst identification
of epistatic effects may reveal functional mechanisms such as genetic regulation or
physical interaction between the genetic products (proteins), interactions truly due
to the environment suggest that environmental changes based on the genotypes
carried at such loci may be particularly influential for trait risk.
I finally assessed the correlation of the estimated aggregate environment across
the 11 G×E loci (FDR 5%, Benjamini-Hochberg adjused86), thereby exploring the
impact of environmental exposures in the context of genetic risk scores. Whilst
there is evidence of strong correlation at some loci, such that BMI risk is strongly
exacerbated if an individual carries risk increasing alleles at multiple loci (e. g. at
both MC4R and FTO or at both TLR4 and TOMM40 ) and lies at the extreme of
the environmental risk distribution, this is not the case for the majority of loci
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(Fig. 3.16). This suggests that set test based approaches that aggregate G×E
effects across environments as is done in StructLMM are more appropriate than
set test methods that aggregate G×E effects across variants considering a single
environmental variable (as described in Sections 2.1 and 2.2.7). Furthermore, this
suggests that effective lifestyle based intervention should be individually tailored
based on the genetic risk variants that an individuals carries, rather than ubiquitous
across the population (that is not to say that everybody won’t benefit from a healthy
lifestyle). This can be thought of as a realisation of personal medicine.
Since the characterisation of loci is performed using the same dataset as for discovery,
these results should be interpreted with caution and validation with an independent
data set is ultimately required. However, ascertainment of a suitable dataset where
the same or very similar sets of environmental data is collated, will be difficult,
in particular, due the fact that environmental exposures vary with geographical
location.
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Chapter 4
Exploring genotype-environment
interaction effects across different
phenotypes
4.1 Introduction
The idea of phenome-wide association studies (PHEWAS) is not new151,154,363–366;
however, due to the lack of suitable data the first proof of concept study was not
conducted until 2010154. Whilst GWAS focus on a phenotype of interest, testing
for associations at all available genetic variants, PHEWAS are a complementary
hypothesis generating approach that is variant focussed, systematically testing a
large number of phenotypes for associations151,155,367.
PHEWAS can be classified as comprehensive or targeted; comprehensive approaches
test for associations at all available phenotypes, whilst targeted studies consider
a limited number of traits and diseases151. The first conducted phenome-wide
analysis is an example of a comprehensive study that focussed on five variants with
previous disease associations, testing for associations with 733 phenotypes, using
6,005 European-American individuals (a subset of the individuals available from
the electronic medical records and genomics (eMERGE) network)151,154,368. This
analysis was later expanded to test for associations between 3,144 SNPs (listed in
the GWAS catalog152) and 1,358 EMR-derived phenotypes in 13,835 individuals of
European ancestry, revealing 63 potentially pleiotropic (when a locus affects multiple
traits; see Section 1.2.4 for further details) associations (FDR < 0.1)151,369. A recent
study, examined associations comprehensively for both genotypes and phenotypes,
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considering a set of 635,525 genotyped SNPs and 541 binary ICD-9 codes and
25 continuous clinical laboratory measurements using 38,622 unrelated samples of
European American ancestry from the DiscovEHR study (a collaboration between
Geisinger and Regeneron Genetics Center)158. However, analysis at this scale did
require the use of a cloud computing platform158. Examples of targeted PHEWAS,
include testing for associations with different cancer types370–377 and autoimmune
diseases151,378.
As well as the identification of possible pleiotropic effects, revealing potentially
shared biological mechanisms and thus advancing our understanding of complex
traits and diseases8,139,140,156, PHEWAS can be used to aid the drug discovery
process151. There is evidence to suggest that genetic associations with a disease
predict potential drug targets155; for example a study conducted by Sanseau et
al. found that as of February 2011 15.6% of genes identified through GWAS are
existing drug targets compared with just 5.7% of genes when considering the whole
genome155,379. Therefore, PHEWAS may reveal opportunities for drug repurposing,
whereby existing drugs may be used to treat other diseases; this can be achieved
by focussing on loci which are known drug targets and testing whether these loci
are associated with other traits155,367,380,381. Alternatively, if opposite directions
of variant effects across different traits are observed, then this may be suggestive
of adverse drug reactions, such that a locus may be discounted as a viable drug
target381. Finally, PHEWAS can be used to identify novel drug targets that are
potentially highly profitable through the identification of loci that affect multiple
phenotypes with minimal evidence of opposite directions of effect381.
Tools and software that facilitate easy running of such phenome-wide association
scans are starting to be developed151. In particular, automated data harmonisation
tools that encompass QC procedures to deal with diverse phenotypic data, including
the presence of both binary and continuous phenotypes, are emerging151,382.
PHEASANT is one such recently developed tool, designed to perform automated
phenome scans in UK Biobank382. In addition databases are emerging, including
PhenoScanner (http://www.phenoscanner.medschl.cam.ac.uk) that collates
results irrespective of P value significance from large scale association scans, enabling
rapid phenome-wide scans383 and the PHEWAS catalog (https://phewascatalog.
org)369 that stores nominally significant results (P < 0.05) from phenome-wide
studies that exceed a given threshold, developed in a similar vein to the GWAS
catalog152.
However, despite these developments, the significance threshold for PHEWAS is
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not well established. Bonferroni multiple testing is likely too stringent due to the
correlation between phenotypes367 (see Section 1.1.6). Whilst PC based methods to
calculate the effective number of traits (described in Section 1.1.6) can be applied
if the considered genetic variants are independent of one another, calculation of the
effective number of tests is not straightforward when many variants are considered
due to the potential correlations between both the phenotypes and the variants384.
Furthermore, a proportion of the tests represent already known genotype-phenotype
associations and can therefore be considered as positive controls rather than
experimental tests of association384. Differences in the power to detect associations
across different traits due to differing sample sizes, in particular for binary phenotypes
where the number of cases can vary substantially, is a further complication that is
yet to be addressed158. Current standard practice is to therefore, consider both a
lenient 10% FDR threshold369,381,385 (or less frequently a Bonferroni multiple testing
correction based on the effective number of tests as described in Section 1.1.6), e. g.
Verma et al.158) applied to all variant-phenotype associations tested for and a 5%
Bonferroni or FDR threshold for each analysed variant (i. e. applying a multiple
testing correction only across considered phenotypes)158,369,386.
It is well known that complex traits and diseases are influenced not only by genetic
factors, but in addition by environmental exposures and interaction effects between
genetic factors and the environment. However, all phenome-wide studies to date,
except for one, do not consider interaction effects. The exception is a pilot phenome-
wide epistasis scan (which the authors refer to as a phenome-wide interaction study,
PHEWIS for short), that considers 26 phenotypes obtained from 2,547 treatment-
naive AIDS patients387. Epistatic interactions were tested for at 1,773 variants that
replicated in marginal association studies and lie in functionally active regions based
on chromatin state annotations, such that in total 40,842,828 interaction tests were
conducted387. 12,146 significant SNP-SNP interactions (FDR adjusted P < 0.01)
across only two of the phenotypes were identified (details of the overlap between the
two traits were not provided)387.
PHEWIS may substantially increase our knowledge of the contribution of interaction
effects to complex traits and diseases. They may reveal that interaction factors are
trait or locus specific, or reveal a greater overlap in the loci that impact different
traits than that observed when considering only persistent genetic effects.
Furthermore, PHEWIS can be used to explore the relative importance of G×E
effects compared to persistent genetic effects across different traits by evaluating
the amount of phenotypic variation explained by persistent and G×E effects (see
Section 3.2.1) at different loci or in aggregate across multiple loci. The importance
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of different factors for explaining phenotypic variability is a fundamental question
in the field44,388.
Typically, phenotypic variation is partitioned into genetic and non-genetic
components, with the fraction of phenotypic variation explained by genetic factors
referred to as heritability44,45. Heritability, is a population based measure, since by
definition it is dependent on the importance of non-genetic factors which can vary
across samples44,388.
There are two commonly used definitions of heritability, narrow and broad sense
heritability. Narrow sense heritability is the amount of phenotypic variation that is
explained by additive persistent genetic effects (such that the non-genetic component
described above does in fact contain non-additive genetic effects) whilst broad sense
heritability is the amount of phenotypic variation explained by genetics, including
dominant and interaction effects389.
Twin and adoption studies are classic designs for heritability studies, that provide
broad sense heritability estimates on the assumption that the amount of shared
environmental exposures can be accounted for389,390. By comparison, for the classical
family-based design or more recent population based heritability studies, differences
in environmental exposures across individuals cannot be controlled and thus these
analyses estimate narrow sense heritability389.
Initial, population based heritability estimates were calculated using variants that
were deemed significant based on GWAS, resulting in very low heritability
estimates389. There has since been a shift to estimating heritability based on all
measured genetic variants, increasing population based heritability estimates389.
Despite this increase, classic heritability estimates tend to be higher than population
based heritability estimates, with the difference described as ‘missing
heritability’389,391. There is a consensus that some of this difference is attributable
to epistasis and G×E88,389–391, although inclusion of these additional phenotypic
partitions and subsequent estimation of phenotypic variation explained by interaction
effects is not typical.
There are two studies which are notable exceptions that attempt to estimate the
amount of phenotypic variation explained by interaction effects. The first was a
small-scale (820 individuals) family-based study that examined the contribution of
G×E effects for four type 2 diabetes related traits, for each of 15 dietary and lifestyle
environmental factors392. The phenotypic variation explained by G×E effects was
estimated using SNPs genome-wide, identifying zero, four, two and five environments
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for fasting glucose, fasting insulin, HOMA-IR and HOMA-B that explain more
phenotypic variation than persistent genetic effects392. However, the family-based
design is a key weakness of this study, leading to possible overestimation of both
persistent and G×E contributions and bias in the variance explained due to greater
sharing of environments within than between families392. Furthermore,
environmental contributions were estimated separately for each exposure such that
the summed phenotypic variation explained by G×E across all environments was
greater than 100% due to correlation between the environments392. The second
study primarily used phenotypic variation analyses to determine the presence of
interaction effects on BMI for age and eight other dietary and lifestyle based factors
(using 97,510 individuals from UK Biobank), concluding that the majority of
genotype-environment interactions explain very little phenotypic variation, with the
exception of age and smoking which are estimated to explain 8.1% and 4.0%388.
In this work, I perform an initial exploration of interaction effects across different
phenotypes in a similar manner to existing targeted PHEWAS and examine the
contribution of G×E effects jointly at multiple environments across different
phenotypes, relative to persistent genetic effects. Hypothesising that variants with
largely persistent genetic effects for one trait might also influence other traits (in
particular those that are correlated with the primary trait) in combination with
environmental exposures, I use StructLMM to test for interaction effects between
64 lifestyle based factors and variants that are significantly associated with basal
metabolic rate (BMR) on nine additional phenotypes, body fat percentage (body
fat %), weight, BMI, diastolic blood pressure (DBP), systolic blood pressure (SBP),
hip circumference (HC), waist circumference (WC), standing height (height) and
peak expiratory flow (PEF). BMR is the amount of energy a body needs at rest
for maintenance, and in UK Biobank participants it was calculated based on body
composition through the use of bioelectrical impedance analysis.
To address the potentially large number of variants significantly associated with
BMR that are to be taken forward for G×E testing, combined with the relatively low
power of interaction tests, I employ the use of a conditional FDR (cFDR) multiple
testing correction393,394. The cFDR was originally developed for application to two
independent association scans, leveraging genetic pleiotropy between the traits394.
Application of this method to identify variants associated with schizophrenia
conditional on bipolar disorder increased the number of loci (LD, r2 < 0.2) from six
using a uniform 5% FDR to 58 using a conditional 5% FDR394. This work was later
extended, such that the correction could be applied to experimental designs with
common controls, in which the two association scans are not completely independent
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of one another393.
The key concept of this multiple testing correction, is that the prior probability of a
test being false is not uniform across all hypotheses tested and as a result the use of
a uniform FDR is not optimal for maximising the number of discoveries for a given
number of expected false discoveries395. This prior probability is described through
the use of a covariate, which for the aforementioned studies are the association P
values obtained from conducting an association scan for one trait that can be used
as prior information on the likelihood that a variant is associated with the second
trait. Similar methods are also available that use other covariates, such as functional
annotations that pre-determine categories of variants, with some categories of
variants more likely to be enriched for associations. In these categorical settings,
the FDR is applied separately to each category, known as the stratified FDR396,397
or the independent hypothesis weighting method395. Since the cFDR, effectively
assigns each variant to its own category, it can be thought of as a continuous version
of these stratification based methods85.
In this chapter, I show that it is possible to condition the interaction results obtained
using StructLMM on the association results obtained from marginal association
analyses using LMMs. In this setting, the cFDR can be interpreted as bridging two
analysis designs. The first that is commonly used, filters variants for interaction
testing based on marginal association results175,177,180,193,219–231, thereby only
enabling detection of interaction effects at variants with strong marginal priors.
The second is a genome-wide interaction scan that tests all available variants, which
thus suffers from a high multiple testing burden. Explicitly, in Section 4.2, I provide
mathematical details of the cFDR and the conditions that need to be satisfied and in
Section 4.3.4, I demonstrate its potential to identify loci with significant interaction
effects.
4.2 Methods
In this section, I will describe methods that I use throughout this chapter. I will start
by describing the data pre-processing steps that were applied to the UK Biobank
data. Whilst very similar to the data pre-processing steps described in Section 3.3.1,
a major difference in this work is the construction of a pipeline that minimises the
per phenotype QC, similar to the advantages of previous automated pipelines such
as PHEASANT382. This will be particularly important in future work when a
greater number of phenotypes are considered. This will be followed by details of
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the calibration assessment methods and the method used to identify independent
loci. I will then describe the cFDR multiple testing correction and finally, the
method used to estimate the amount of phenotypic variation explained by different
components.
4.2.1 UK Biobank data preprocessing
The analyses in this chapter have been conducted using the full release of UK
Biobank (Application 41672)215,271.
Phenotype and environment pre-processing
First, I identify individuals that are to be excluded from all analyses. These are poor
quality samples flagged by UK Biobank using the field ‘het.missing.outliers’ (based
on heterozygosity and the amount of missing data), individuals with more than ten
3rd degree relatives using the field ‘excess.relatives’ in the released ‘Sample-QC’ file
and those that withdrew consent (104 in total). I then kept only those individuals
that were genetically ‘White British’ based on the field ‘in.white.British.ancestry.
subset’ and finally removed any remaining individuals that were listed in field ‘ID1’
using the released ‘Relatedness’ file such that there were no relatives (3rd degree or
closer) included in the analysis. This left a total of 335,587 individuals.
BMR, body fat %, weight, BMI, DBP, SBP, HC, WC, standing height and PEF
phenotype data are all based on ‘Instance 0’ of UK Biobank fields ‘23105’, ‘23099’,
‘21002’, ‘21001’, ‘4079’, ‘4080’, ‘49’, ‘48’, ‘50’ and ‘3064’, respectively (see http:
//biobank.ctsu.ox.ac.uk/crystal/ for details).
The same set of lifestyle based factors used in Chapter 3 (see Section 3.3.1) were
selected. Namely, 20 environmental variables: 9 ordinal dietary variables (‘Oily
fish intake’, ‘Non-oily fish intake’, ‘Processed meat intake’, ‘Poultry intake’, ‘Beef
intake’, ‘Lamb/mutton intake, ‘Pork intake’, ‘Cheese intake’ and ‘Salt added to
food’), three continuous dietary variables (‘Cooked vegetable intake’, ‘Bread intake’,
‘Tea intake’), three physical activity variables (‘Number of days/week walked 10+
minutes’, ‘Number of days/week of moderate physical activity 10+ minutes’,
‘Number of days/week of vigorous physical activity 10+ minutes’), ‘Alcohol intake
frequency’, ‘Sleep duration’, ‘Townsend deprivation index’, ‘Smoking status’ and
‘Time spent watching television’, using the data from ‘Instance 0’ (see http://
biobank.ctsu.ox.ac.uk/crystal/ for details), were selected. Again following
137
the pre-processing steps conducted in Chapter 3 (see Section 3.3.1), for the three
continuous dietary variables, I set values exceeding the 99th percentile (based on
the 335,587 individuals) to missing. For ‘Sleep duration’, I set the top and bottom
percentiles (based on the 335,587 individuals) to missing and for each individual
calculated the squared deviations from the mean sleep duration, creating an
additional environmental variable, ‘Squared sleep duration res.’ (21st environmental
variable). For ‘Time spent watching television’, less than 0.5 hours of was encoded
as 0.5 and I set values in the upper and lower percentile (based on the 335,587
individuals) to missing. A total of 251,720 individuals have no missing environmental
data.
Individuals with data missing for any of the environmental variables or the phenotype
under study were removed as part of the testing procedure, such that a data set for
each considered phenotype after removing individuals with any missing data does
not require storage. A total of 248,015 (BMR), 247,904 (body fat %), 251,261
(weight), 251,205 (BMI), 235,626 (DBP), 235,623 (SBP), 251,441 (HC), 251,443
(WC), 251,390 (height) and 231,211 (PEF) individuals were included in the analyses.
A rank-based inverse normal transformation (commonly used for genetic analyses,
see Pain et. al 398) was then applied to the phenotype under study.
Generation of principle components
Genetic principle components (PCs) were generated using FlashPCA version 2.0339,
based on the set of 147,604 SNPs flagged by the field ‘used.in.pca.calculation’ in
the released ‘Sample-QC’ file and the 335,587 individuals that passed the sample
QC procedures and did not have any missing environmental data (described above).
Ten PCs were used to control for population structure.
Variant selection
Variants selected for exploration across different phenotypes, were those that
exceeded the genome-wide significance threshold of 5 × 10−8 based on publicly
available summary statistics (available for download from http://www.nealelab.
is/blog/2017/9/11/details-and-considerations-of-the-uk-biobank-gwas,
downloaded on March 1st 2018)399 from an association scan of BMR.
This previously conducted GWAS was based on 337,199 samples and 10,894,597
variants, including ten PCs and sex as covariates in a linear regression analysis.
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Briefly, sample QC involved keeping only unrelated individuals of ‘White British’
ancestry and variants based on the HRC panel with an INFO score > 0.8, MAF
> 0.1% and HWE P > 1× 10−10 (see http://www.nealelab.is/blog/2017/9/11/
details-and-considerations-of-the-uk-biobank-gwas for further details).
Environment covariance, Σ, and model covariates
The environmental covariance matrix was generated identically to that described in
Chapter 3 (see Section 3.3.1 for details) for the set of individuals included in each
phenotype analysis. The covariates included in the analyses were also identical to
those described in Chapter 3 (see Section 3.3.1 for details).
4.2.2 Calibration
Calibration was assessed by permuting the 173,297 variants (over the individuals
included for each phenotype) on chromosome 20 such that any true association and
interaction signals should be destroyed. The resulting 173,297 P values from the
StructLMM interaction test (StructLMM-int) or association test (LMM-Renv) were
used to generate QQ plots of the expected negative log P values (x-axis) versus the
observed negative log P values (y-axis) and inflation parameters, λGC =
log10(m)
log10(0.5)
,
where m is the median P value of the 173,297 variants tested, were calculated.
4.2.3 Defining loci
Independent loci were defined based on the variants significantly associated (P <
5×10−8) with BMR using the publicly available summary statistics (see Section 4.2.1
for further details) by iteratively (i) selecting the most significant variant and (ii)
clumping all variants in LD, r2 ≥ 0.1 (calculating LD using 10,000 UK Biobank
individuals randomly selected from the 251,720 individuals that passed sample QC
and had no missing environmental data) within +/ − 1 Mb, until no variant was
left. This resulted in 1,104 loci and these defined loci (and the variants assigned to
each locus) are kept constant throughout all analyses.
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4.2.4 cFDR
The cFDR adjusted P values are calculated as follows. Let pPm and p
C
m be the P
values of the mth variant for the principal trait of interest and the second trait which
is to be used as the covariate conditioned on, respectively. Then the P values for
the principal trait at all M tested variants are given by {pP1 , pP2 , ..., pPM} and the P
values at all M tested variants for the second trait (to be conditioned on) are given
by {pC1 , pC2 , ..., pCM}. Then the cFDR adjusted P value for the mth variant, is given
by:
pPmadj =
pPm
Number pairs (pPi , p
C
i ) with p
P
i ≤ pPm and pCi ≤ pCm
× (Number pCi ≤ pCm).
(4.1)
The mth variant is declared to be significantly associated with the principal trait of
interest if pPmadj < α (often α = 0.05).
A conventional hard filtering approach tests only variants with pC < global threshold
(e. g. global threshold = 5× 10−8) for association at a second trait, with a uniform
FDR applied to all selected variants. In comparison, from Eq. 4.1, it can be seen that
with the cFDR approach the threshold for selecting variants is successively relaxed
until all variants are tested for association at a second trait, requiring increasing
evidence of association with the second trait, for a significant effect to be declared.
As a result the cFDR can be viewed as a ‘soft’ thresholding approach, yielding a
greater number of identified true associations if associations are shared across the
two traits393.
Conditions for the cFDR to hold are that the principal and covariate tests are
independent of one another and that both tests are calibrated under the null.
In this work, I define the interaction P values obtained from the StructLMM
interaction test as those coming from the principal trait and the association P
values obtained from LMM-Renv as the covariate to condition on. Dai et. al 229
provide a formal proof that test statistics (using the LRT and score test) based
on any two nested models are independent, which without loss of generality holds
for the StructLMM interaction test and LMM-Renv. Explicitly, the tested term in
StructLMM interaction test, x  βG×E (see Eq. 2.9) is the only term not included
in LMM-Renv model (see Eq. 2.121), meaning that the models are nested and as
a result the test statistics corresponding to the marginal genetic and interaction
effects are independent of one another. I also show that the StructLMM interaction
and the LMM-Renv association test are calibrated for all considered phenotypes in
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Section 4.3.2.
Analogous to the aforementioned application to independent association scans, this
conditional multiple testing correction in the interaction test setting will increase the
number of true interactions identified, if interaction signals are enriched for amongst
the association signals (here association signals means evidence for associations and
does not require associations to be deemed significant).
4.2.5 Estimation of phenotypic variance explained
For each locus (see Section 4.2.3 for definition) I select the lead variant per phenotype
for both the association test (smallest P value obtained using LMM-Renv) and the
interaction test (smallest cFDR adjusted P values obtained using StructLMM-int).
For each selected variant (in total, 2×1, 104×9 = 19, 872), I estimate the fraction of
the phenotypic variance explained by marginal genetic (G) and interaction (G×E)
effects as described in Section 3.2.1. I then sum the marginal genetic contributions
based on the lead association variants and the G×E contributions based on the lead
interaction variants over the loci, to give an aggregate estimate of the phenotypic
variation explained by marginal genetic and interaction effects at the defined 1,104
loci (see Section 4.2.3). This approach is analogous to that used to estimate the
heritability explained by significantly associated genetic loci obtained from
GWAS389,400. An estimate of the total phenotypic variation explained by both
persistent and interaction effects at the considered set of 1,104 loci and 64
environments can be obtained by summing the respective aggregate estimates.
4.3 Results
In this section, I first outline the rationale for selecting variants associated with
BMR to take forward for further analysis. I then show calibration results for the
ten phenotypes considered in this analysis. This is followed by the results from
association and interaction testing at the selected variants for the ten phenotypes
considered in this work. Finally, I explore the relative importance of G×E effects
compared to persistent genetic effects for the considered phenotypes.
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4.3.1 Basal metabolic rate significantly associated variants
Working under the hypothesis that variants significantly associated with one trait
might also influence other traits (in particular those correlated with the primary
trait) in combination with environmental exposures and that traits with a relatively
high estimated heritability will be good candidates to identify many such variants, I
initially focus on basal metabolic rate (BMR). BMR has an estimated heritability of
28.64%, which is higher than other cardiometabolic traits, including weight (26.66%),
BMI (24.63%), HC (22.30%,), body fat % (22.02%,), WC (20.36%), DBP (14.37%)
and SBP (13.36%; all heritability estimates are based on the partitioned heritability
estimates provided at https://nealelab.github.io/UKBB_ldsc/h2_browser.
urlhtml). I also consider height (estimated heritability, 46.23%) and PEF (estimated
heritability, 9.35%) for which I don’t expect to see interaction effects between the
selected 64 lifestyle based environments and variants that are associated with BMR
and thus these traits act as negative controls.
There are 57,328 variants significantly associated (P < 5×10−8) with BMR (Fig. 4.1;
see Section 4.2.1 for further details). These significant variants were used to define
1,104 loci (+/ − 1 Mb, LD r2 < 0.1; see Section 4.2.3 for details) used throughout
the subsequent analyses for ease of comparison.
Fig. 4.1 Manhattan plot of genome-wide association results for BMR
| Manhattan plot of negative log P values (y-axis) against chromosome and
position (x-axis) based on publicly available summary statistics from a genome-wide
association scan of BMR using UK Biobank data (see Section 4.2.1 for details). The
genome-wide significance threshold of 5× 10−8 is represented by the red dashed line
and variants that exceed this threshold are coloured in yellow.
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4.3.2 Calibration assessment
To check that the data was pre-processed appropriately and in addition to check that
the data was appropriately calibrated satisfying one of the conditions required for
application of the cFDR (see Section 4.2.4), I assessed the empirical calibration of
LMM-Renv and the StructLMM interaction (StructLMM-int) tests (see Section 2.3
for model details) for the ten considered phenotypes. Both methods were sufficiently
calibrated across all phenotypes (Fig. 4.2).
BMR
StructLMM-int LMM-Renv
Body fat % Weight BMI DBP
SBP HC WC Height PEF
Fig. 4.2 Calibration of interaction and association tests on UK
Biobank data | QQ plots of negative log P values from StructLMM interaction
(StructLMM-int) test (green) and LMM-Renv association test (yellow) applied to
UK Biobank phenotype data based on permuted genetic variants (chromosome
20). From left to right and top to bottom: basal metabolic rate (BMR), body fat
percentage (body fat %), weight, body mass index (BMI), diastolic blood pressure
(DBP), systolic blood pressure (SBP), hip circumference (HC), waist circumference
(WC), standing height (height) and peak expiratory flow (PEF).
4.3.3 Association of variants with the considered phenotypes
Considering, now only the 57,328 variants that were significantly associated with
BMR (as described in Section 4.3.1), I test for associations using LMM-Renv (see
Section 2.3 for model details) with each of the ten phenotypes. Using the same
genome-wide significance threshold (5 × 10−8) and loci defined based on the BMR
summary statistics (see Sections 4.2.3 and 4.3.1), I examine the number of the 1,104
loci that are significant associations with each of the considered traits (Fig. 4.3).
The percentage of loci that are associations with other traits ranges from 2.99% for
SBP to 59.15% for height.
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1104 (100%)
148 (13.41%)
624 (56.52%)
243 (22.01%)
47 (4.26%)
33 (2.99%)
373 (33.79%)
214 (19.38%)
653 (59.15%)
39 (3.53%)
Fig. 4.3 Association results with the considered phenotypes | Top:
Manhattan plot of negative log P values (y-axis; using LMM-Renv) against
chromosome and position (x-axis) for the 57,328 variants significantly associated
(P < 5 × 10−8) with BMR for ten phenotypes using UK Biobank data. Variants
that exceed the genome-wide significance threshold (P < 5 × 10−8) are coloured
according to the phenotypes that they are associated with, with non significant
results represented by grey dots. Bottom: Indicator plot with phenotypes (y-axis)
against chromosome and position (x-axis), where each dot represents a variant that
is significantly associated (P < 5 × 10−8) with the phenotype. The number of loci
(out of a total of 1,104) that are significantly associated with each phenotype are
displayed down the right hand side with the corresponding percentage displayed in
brackets. Significantly associated BMR, body fat %, weight, BMI, DBP, SBP, HC,
WC, height and PEF variants are represented by yellow, light green, orange, purple,
magenta, teal, dark green, red, cyan and blue coloured dots, respectively.
144
4.3.4 Interaction of variants for different considered
phenotypes
I test for interaction effects between each of the 57,328 variants that were significantly
associated with BMR (as described in Section 4.3.1) and 64 lifestyle based
environments using the StructLMM interaction test (see Section 4.2.1 for details).
Since interaction tests are often underpowered (see Section 1.3.2), I combine the
StructLMM interaction test with a cFDR multiple testing correction (see Section
4.2.4 for a description of this method) in an attempt to increase the number of
true interaction variants identified, whilst maintaining the expected number of false
discoveries. I will first show the potential of this multiple testing correction method,
followed by the interaction results for the different considered phenotypes.
Application of the cFDR for identification of G×E effects
To demonstrate the potential of the cFDR in the interaction test setting, I apply
the method to genome-wide interaction results (7,515,856 SNPs as described in
Section 3.3.1). As outlined in Section 1.1.6, QQ plots can be used to visualise
departure of the test statistics from the null distribution, with departure in the tail,
evidence that associations are present. In this setting, where I condition interaction
results based on association results, I can determine if using association results
as a covariate is informative by plotting stratified QQ plots. A leftward shift of
the QQ plots for increasingly stringent association P value thresholds indicates an
enrichment of interaction signals amongst variants that display evidence of
association394. Whilst the stratified QQ plots for BMI indicate that this is the case
(Fig. 4.4a), the corresponding plot for height displays no enrichment (Fig. 4.4b).
The lack of enrichment when considering height also indicates that false interaction
signals are not induced via this conditioning mechanism, further confirming that the
association test LMM-Renv and the StructLMM interaction test are independent of
one another, a condition required for the validity of this multiple testing correction
method.
The number of significant interaction variants for BMI increases from 119 using a 5%
FDR (Fig. 4.4c) to 1,088 using a 5% cFDR (Fig. 4.4d), corresponding to eight and 60
loci (+/−1 Mb, r2 < 0.1). Note that the cFDR multiple testing correction identifies
a superset of the variants identified using the FDR multiple testing correction, such
that the cFDR does not restrict the identification of interaction variants to those
with evidence of association. However, many additional variants that display some
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Fig. 4.4 Application of the cFDR to genome-wide interaction results
| (a-b) QQ plots of negative log P values from the StructLMM interaction test
stratified according to the association test result obtained using LMM-Renv based
on genome-wide scans for (a) BMI and (b) height. The interaction results for
all variants genome-wide are shown in blue, whilst those with an association
P < 5 × 10−3, P < 5 × 10−5 and P < 5 × 10−8 are displayed in orange,
green and red, respectively. (c-d) Scatter plots of negative log P values from
StructLMM interaction test (y-axis) against negative log P values from the
LMM-Renv association test (x-axis), with non-significant interaction variants shown
in grey and significant interaction variants coloured according to the corresponding
association P value bin using (c) a 5% FDR threshold (no variants with significant
interaction effects have association P values in the range 5× 10−8 to 5× 10−3) and
(d) a 5% cFDR threshold.
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evidence of association are identified, in agreement with the theory that the presence
of variants that influence trait risk may be masked by interaction effects177,188.
Interaction results
Testing for interaction effects at the 57,328 variants (corresponding to 1,104 loci)
that were significantly associated with BMR combined with a cFDR multiple testing
correction reveals that as expected, the two phenotypes height and PEF, chosen as
negative controls, are flat in the interaction space (with the exception of one variant
and correspondingly one locus associated with height; Fig. 4.5).
In addition, as hypothesised with the exception of SBP, the number of loci with
significant interaction effects is higher for other cardiometabolic traits than BMR,
with only eight loci significant for BMR compared to a range of 14 - 36 loci for the
other six cardiometabolic traits considered (Fig. 4.5). A total of 74 distinct loci with
interaction effects are identified (see Table B1, Appendix B for a table containing
results for these 74 loci). 32.43% of these loci are shared across at least three
phenotypes, with the set of shared phenotypes varying across the loci (see Table B2,
Appendix B for a summary of the number of loci shared for different combinations
of traits). It is also worth noting, that many of the identified loci with significant
interaction effects (P cFDR-adjusted < 0.05) were not significant associations (P <
5× 10−8) for the same trait, again highlighting that the cFDR adjustment does not
lead to the identification of interaction effects only at well established association
loci. Explicitly, ten of 36 (HC), four of 27 (WC), six of 14 (DBP), three of 30 (BMI)
and eight of 22 (body fat %) loci identified (P cFDR-adjusted < 0.05) were not
associated with the same trait, such that as many as 42.86% of the loci identified
through interaction testing were not significant associations under the assumption
of a persistent genetic effect across all individuals for DBP.
One locus with significant interaction effects lies in the IGF1R gene and is associated
with BMR (P = 5.12 × 10−23), weight (P = 5.03 × 10−10) and height (P = 3.47 ×
10−68) and is found to interact with significant effects on weight (P cFDR-adjusted =
0.0113), WC (P cFDR-adjusted = 0.0462) and HC (P cFDR-adjusted = 0.00640)
with rs116222218 being the lead interaction variant for all three traits (see Table B1,
Appendix B, locus number 56). In addition to its well known association with
height401,402, IGF1R is also associated with fasting plasma glucose403. Evidence
from animal studies also shows that IGF1R plays a role in metabolism404 and in
particular, that IGF1R gene knockout mice display evidence of altered fat mass,
which in some cases was observed to be age, sex and diet dependent405–409, supporting
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Fig. 4.5 Interaction results with the considered phenotypes | Top:
Manhattan plot of negative log cFDR adjusted interaction P values (y-axis;
using StructLMM-int) against chromosome and position (x-axis) for the 57,328
variants significantly associated (P < 5 × 10−8) with BMR for ten phenotypes
using UK Biobank data. Variants that exceed the genome-wide significance
threshold (P cFDR-adjusted < 0.05) are coloured according to the phenotypes
that they are interactions for, with non significant results represented by grey dots.
Bottom: Indicator plot with phenotypes (y-axis) against chromosome and position
(x-axis), where each dot represents a variant that has a significant G×E effect
(P cFDR-adjusted < 0.05) on a phenotype. The number of loci (out of a total
of 1,104) that have significant interaction effects with each phenotype, based on the
64 lifestyle based environments considered, are displayed down the right hand side
with the corresponding percentage displayed in brackets. Variants with significant
interaction effects on BMR, body fat %, weight, BMI, DBP, SBP, HC, WC, height
and PEF are represented by yellow, light green, orange, purple, magenta, teal, dark
green, red, cyan and blue coloured dots, respectively.
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the presence of G×E effects at this locus.
A second interesting locus lies in the AS3MT gene which is significantly associated
with height (P = 7.06×10−10), SBP (P = 1.20×10−14) and BMR (P = 4.44×10−9)
and found to have a significant interaction effect for DBP (P cFDR-adjusted =
0.0426; rs72841270 is the lead interaction variant; see Table B1, Appendix B, locus
number 41). Interestingly, two studies have found strong significant associations
for SBP (the variant reported by Simino et al. lies only 7,757 bp from the lead
interaction variant found in this analysis), whilst no significant associations were
reported for DBP410,411. These previous studies are consistent with the results for
this analysis using the UK Biobank data for which a strong association with SBP is
observed (P = 1.20× 10−14), whilst the corresponding P value for association with
DBP was not genome-wide significant (P = 3.25 × 10−7). These results suggests
that the same locus influences DBP and SBP, two traits that have a phenotypic
correlation of 0.671 (based on 235,623 UK Biobank individuals with phenotypic
measurements for both traits) but that the effect on DBP is masked by the presence
of interaction effects.
A further interesting locus lies within the DOT1L gene which is significantly
associated with HC (P = 1.19 × 10−10), height (P = 1.78 × 10−58), weight (P =
2.46 × 10−10) and BMR (P = 3.67 × 10−18), again with a significant interaction
effect for DBP (P cFDR-adjusted = 0.0445; rs12981806 is the lead interaction
variant; see Table B1, Appendix B, locus number 71). Variants 21,104 bp and
26,553 bp from this lead interaction variant have been reported as associations
for pulse pressure (the difference between DBP and SBP) and 94,139 bp away for
myocardial infarction412–414. These previous findings together with evidence for
an association with DBP (P = 3.90 × 10−7, marginally below the genome-wide
significance threshold) based on UK Biobank data, suggest that this locus has an
affect on DBP, which is again masked by the presence of G×E effects.
4.3.5 Distribution of ρ across different traits
As well as the identification of interaction variants across multiple phenotypes, I
can also explore the relative importance of the G×E effects across the different
phenotypes. This can be achieved via the estimation of ρ (defined as the fraction of
the genetic variance explained by G×E effects at a given variant; see Section 3.2.1
for method details) per significant locus-trait pair at the lead interaction variant
(smallest cFDR-adjusted P value < 0.05). This analysis reveals that for the single
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locus with a significant interaction effect on height and the majority of BMR loci
identified with significant G×E effects, the variants largely have the same effect
across all individuals, with only a small component that is environmentally
dependent (Fig. 4.6a and h). In comparison, loci identified with significant
interaction effects for other traits have a larger component of the genetic variance
explained by interaction effects (Fig. 4.6). This is particularly true of DBP, where
for nine of the 14 loci, G×E effects explain more of the genetic variance than
persistent genetic effects (ρ > 0.5; Fig. 4.6e). These results indicate that the
relative importance of G×E effects compared to persistent genetic effects varies
across different traits, with G×E effects relatively unimportant for height and BMR
but that they are particularly important for DBP.
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Fig. 4.6 Distribution of ρ for the considered phenotypes | Distribution of
ρ at the lead interaction variant per locus-trait pair with an identified significant
interaction effect (P cFDR-adjusted < 0.05) for (a) BMR, (b) body fat %, (c)
weight, (d) BMI, (e) DBP, (f) HC, (g) WC and (h) height (SBP and PEF are not
included since there were no loci with significant G×E effects). ρ = 0 means that
the effect of a variant is the same across all individuals (i. e. no G×E effects present),
whilst ρ = 1 means that a variant only exerts its effect through interactions with
the environment.
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4.3.6 Relative importance of G×E effects compared to
persistent genetic effects
In addition to focusing on the relative importance of G×E effects at individual
loci (see Section 4.3.5), I can also consider a more global picture by estimating the
aggregate G×E effect for the 64 considered environments across the selected 1,104
loci and compare this to the aggregate persistent genetic effect at the same set
of loci (see Section 4.2.5 for method details). This approach again confirms that
G×E effects on height and BMR are small compared to persistent genetic effects
(Fig. 4.7a and i); G×E effects explain only 0.0122 (height) and 0.0142 (BMR) of
the phenotypic variation whilst persistent genetic effects explain 0.1236 (height)
and 0.0721 (BMR) of the phenotypic variation, such that G×E effects explain
only 0.0901 (height) and 0.1645 (BMR) of the total explained phenotypic variation
(these fractions can be thought of as global estimates of ρ). A larger proportion
of the estimated explained phenotypic variation is accounted for by G×E effects
for weight (0.2209), HC (0.2843), BMI (0.3546), WC (0.3801), body fat % (0.4403)
and SBP (0.4504), with G×E effects accounting for more of the total phenotypic
variation explained than persistent genetic effects for DBP at the considered 1,104
loci (Fig. 4.7). Explicitly, G×E effects explain 0.0328 of DBP phenotypic variation
whilst persistent genetic effects only explain 0.0242 of the phenotypic variation, such
that G×E effects explain 0.5751 of the total estimated phenotypic variation that is
explained by both persistent genetic and G×E effects.
With the approach taken here, it can be seen that the absolute fraction of phenotypic
variation explained by persistent genetic effects is marginally lower for BMR (0.0721)
than for HC (0.0858) and weight (0.0928), which could be viewed as contradicting
the publicly available heritability estimates based on UK Biobank data referenced
in Section 4.3.1. However, there are several plausible explanations to explain this
discrepancy.
One possibility is a differing definition of phenotypic variation explained as used in
this work to the publicly available heritability estimates. For the latter estimates,
some covariates are regressed from the phenotype such that the phenotypic variation
does not include the effect of these covariates, whilst I assume that covariates
explain some phenotypic variation. The amount of phenotypic variation explained
by covariates can vary across traits, which can result in some reordering of the
amount of phenotypic variation explained by persistent genetic effects. The primary
reason for not pre removing the effect of covariates in this analysis is that there is
some subjectivity surrounding what constitutes a covariate versus an environment,
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Fig. 4.7 Estimated fraction of phenotypic variation explained by
persistent genetic and G×E effects | Bars display the estimated absolute
fraction of the phenotypic variation explained by persistent genetic (G) in blue
and G×E effects in orange based on lead variants across 1,104 loci and for 64
environments, with the summed total of these two absolute fractions, an estimate of
the total phenotypic variation explained. The pie charts display the relative fraction
of this estimated explained phenotypic variation due to persistent genetic (G) in blue
and G×E effects in orange for (a) BMR, (b) body fat %, (c) weight, (d) BMI, (e)
DBP, (f) SBP, (g) HC, (h) WC, (i) height and (j) PEF.
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e. g. age. It should be noted that taking the effect of covariates into account has
no bearing on the estimates of the fraction of the estimated explained phenotypic
variation due to G×E effects.
A second reason is that these estimates are based on a fraction of the genome (57,328
variants), whilst the previous heritability estimates are genome-wide estimates.
The use of lead variants per loci (using stringent criteria to define loci) could
further compound this effect as I am not accounting for any secondary effects
and underestimation of the phenotypic variation explained at loci can occur if
the selected lead variant is tagging the causal variant. This effect may be further
exacerbated since the loci are defined based on the BMR association results. Thus
these estimates provide a lower bound on the amount of phenotypic variation
explained by both the persistent and G×E components. If the amount of
underestimated heritability varies substantially between the persistent genetic and
G×E components, this may effect the proportion of genetic variance explained by
G×E. As a result further work is still needed to confirm the estimates provided in
this section.
4.4 Summary and discussion
In this chapter, I have applied the StructLMM interaction test to identify interaction
effects across multiple traits at variants that are significantly associated with BMR
(P < 5×10−8), considering a set of 64 lifestyle based environments. This analysis was
combined with a cFDR multiple testing correction, which has not been previously
applied to the interaction test setting. To the best of my knowledge, this is the first
analysis to explore loci with G×E effects across different phenotypes and to estimate
the amount of phenotypic variation explained by G×E effects jointly accounting for
multiple environmental variables.
I first demonstrate that application of the cFDR multiple testing correction (at a
5% threshold) to genome-wide results for BMI can dramatically increase the number
of loci (from eight to 60) identified with significant interaction effects compared to
using the widely employed FDR multiple testing correction (also at a 5% threshold;
Fig. 4.4c and d). I note that use of the cFDR still enables the detection of strong
interaction effects at variants which display little to no evidence of persistent
association effects, whilst also identifying many additional variants that have weak to
strong evidence for associations. This approach would also alleviate the observation
in Chapter 3 that additional loci (with strong G×E effects) to those detected
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using standard LMMs were detected using the StructLMM joint association test,
suggesting that existing methods that select variants for interaction testing based
on association P values from previous studies or an association scan in the same
dataset are not optimal.
I then test for interaction effects at 57,328 variants with 64 lifestyle based factors
on ten phenotypes, including two traits, height and PEF, which act as negative
controls since I do not expect to find interactions effects on these traits for the
considered set of variants and environments. Appropriate multiple testing correction
for phenome-wide studies is not well established, with the majority of previous
studies considering both a relaxed global 10% FDR across all tested variant-trait
pairs and a per variant 5% Bonferroni or FDR correction across all tested traits.
Application of the cFDR to all variant-trait pairs tested, is likely to result in greater
biases than that already noted in PHEWAS that apply a uniform FDR to all tested
associations158. This is likely to arise due to differences in the strength of associations
and enrichment of interaction effects amongst association signals across different
traits. I therefore use a more stringent (than the usual 10% FDR) 5% cFDR per
trait, noting that the traits included in this analysis are not independent of one
another, such that a further Bonferroni correction for the number of traits would
be too stringent. As this work is not predominantly variant focussed but rather an
initial exploration of the interaction landscape across different phenotypes, I do not
consider a per variant correction in this work. I note that application of the cFDR
per variant is not valid as there are too few data points to empirically learn the
dependence of interaction effects on association effects at each variant.
The interaction analysis for the ten considered traits reveals 74 unique interaction
loci (two phenotypes, SBP and PEF have no significant interaction loci and height
has only one significant interaction locus). 32.43% of these identified interaction loci
are shared across at least three phenotypes although this set of shared phenotypes
does vary at different loci, suggesting that the presence of interaction hotspots that
do not solely occur due to trait correlation. Additionally, there are differences in
the relative importance of G×E effects compared to persistent genetic effects across
the different traits, both when examining individual loci and when examining the
1,104 loci in aggregation.
In particular, there exist multiple lines of evidence, suggesting that G×E effects are
particularly important compared to persistent genetic effects for DBP. Explicitly,
42.86% of the identified DBP loci with significant interaction effects are not
significant associations for this trait. Furthermore, the minimum estimated value
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of ρ across the significant identified loci with interaction effects is 0.361, with
G×E effects explaining more of the genetic variance than persistent genetic effects
(ρ > 0.5) at nine of the 14 identified loci. Similarly, the aggregate G×E effect across
the 1,104 loci examined in this analysis, based on the lead variants, explain more
phenotypic variation than persistent genetic effects. Furthermore, early GWAS,
including the WTCCC, conducted on diastolic blood pressure and hypertension
were underpowered to find significantly associated variants, compared to other
traits57,415–418. Together these results suggest that many variants that affect DBP
are masked during association analyses that assume the effect of a variant is identical
across all individuals, due the presence of moderate to strong G×E effects. As a
result, in order to identify the variants that influence DBP, either very large sample
sizes are required for persistent effect association analyses or G×E effects need to
be accounted for. Interestingly, there is evidence from previous studies examining
different populations to suggest that DBP and BMR are correlated independently
of body size419–421. In UK Biobank, the phenotypic correlation between BMR and
DBP based on 330,198 individuals with measurements available for both traits is
0.2313; yet only 4.26% of loci that are significantly associated (P < 5× 10−8) with
BMR are significant associations (P < 5× 10−8) for DBP (Fig. 4.3). This suggests
that there may be shared environmental risk factors that have quite a large impact
on both traits and/or that genetic variants that impact one of the two traits impact
the second trait once environmental exposures are accounted for. The analysis
conducted in this chapter does provide some evidence for the latter; the difference
in the amount of phenotypic variation explained by persistent genetic effects for
BMR and DBP based on the 1,104 loci that are associated (P < 5 × 10−8) with
BMR is 4.79%, with this difference in explained phenotypic variation reducing to
2.93% when G×E effects at the 1,104 loci are also accounted for.
Whilst, it is exciting to observe traits for which G×E effects are more important than
persistent genetic effects, it is important to note that these are preliminary results
that warrant further investigation. In particular, these results are based on the lead
variant at each locus and therefore provide lower bound estimates on the amount
of phenotypic variation explained by persistent and G×E effects. These estimates
are likely to increase if all variants at these loci are considered due to secondary
effects and improved tagging of the causal variant. It will also be interesting to
see if the patterns observed in this analysis hold when all variants genome-wide are
considered.
Methods to estimate the phenotypic variation explained based on all variants that
account for LD between the variants do exist, namely GCTA, LDAK and
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LDSC68,303,422. Due to the large sample size of UK Biobank, LDSC68 which utilises
summary statistics would be the most appropriate. Whilst currently designed
to estimate the phenotypic variation explained by persistent genetic effects, the
implemented partitioned LDSC423 that estimates the amount of phenotypic variation
explained by different functional SNP classes could be readily adapted such that one
partition accounts for the persistent genetic effects and the other for the G×E effects.
However, a major caveat of using this method is that it relies on a precomputed
LD reference panel; correlation between variants multiplied by the environmental
exposure can be quite different to correlation between the variants. One potential
possibility is to precompute a correlation reference panel under the prior assumption
that all environments are equally likely to interact with the genetic variants, the
same prior assumption made in the interaction test i. e. Corr(xi ×
∑L
l=1 el,xj ×∑L
l=1 el), where xi and xj are dosage vectors of two genetic variants and el is the
lth environmental exposure vector. I note that this method can be less accurate
than methods that use raw data, in particular when the number of SNPs on which
the estimates are based is small, with a recommendation that at least 600,000 SNPs
are used (this recommendation can be found at https://github.com/bulik/ldsc/
wiki/FAQ).
Therefore, whilst this LDSC based approach may work if applied to SNPs genome-
wide, it is unlikely to be appropriate for the 57,318 variants considered here. To
overcome this I could consider using LDAK, which also has functionalities to include
multiple partitions, although I will likely need to consider a small subset of individuals
(in the range of 10, 000 − 30, 000 individuals) for computational reasons. This
relatively small sample size may not be sufficient to obtain stable estimates of the
phenotypic variance explained by G×E424. Additionally, to estimate the amount of
phenotypic variation explained by this approach, it may be necessary to consider
further partitions of the variants with different variance components, due to possible
differences in the architecture of the G×E landscape compared to the persistent
genetic landscape. Incorporation of the adaptive MultiBLUP method, which
automatically identifies classes of SNPs with different effect sizes, may be appropriate
to achieve this425.
A more challenging problem that would be interesting to explore is the correlation
between traits in the G×E domain analogous to existing genetic correlation
approaches, or alternatively genetic correlation when accounting for both persistent
and G×E effects426. This calculation with existing methods such as LDSC requires a
signed summary statistic per variant which corresponds to the persistent SNP effect
direction (or alternatively can also be thought of as the average direction of the
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variant effect across all individuals). However, for G×E analysis using StructLMM
we have a variant effect per individual such that the correlation calculation is now
a 3D problem rather than a 2D problem, as is the case when considering persistent
genetic effects.
Further avenues of exploration include increasing the set of traits analysed; in
particular, inclusion of type 2 diabetes would be an interesting addition. Finally,
in many cases, I observe that the lead association and lead interaction variants
are not at the same chromosomal position and that the genetic variance due to
persistent effects attenuates at a slower rate than the genetic variance explained
by G×E effects. It would be interesting to explore why this might be the case.
Two possible hypotheses that spring to mind are (i) the correlation across variants
multiplied by environmental exposures have a shorter range than the correlation
based only on variant dosages, perhaps enabling G×E tests to act as a fine mapping
tool and/or (ii) that identified persistent genetic effects are tagging multiple G×E
effects. Alternatively, this may be due to artefacts such as the strength of the
association or interaction effect.
Together, these results provide a first insight of the G×E landscape across different
phenotypes and demonstrate that G×E effects can have a relatively large impact on
trait outcomes, highlighting the potential importance of studying such interaction
effects.
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Chapter 5
Concluding remarks
This thesis focusses on method development and application, to test for G×E effects
that may be driven by multiple environments. Despite knowledge of interaction
effects existing for more than a century427 and the commonly held belief that
interaction effects will explain additional phenotypic variation88,389–391, far fewer
G×E effects have been identified than persistent genetic effects. As discussed in
Section 1.3.2, G×E studies are underpowered compared to association analyses
of identical sample size, predominantly due to inherent difficulties in ascertaining
environmental data compared to variant information. This includes a lack of well-
defined standards and an unbounded ‘global’ environmental domain (both in space
and time).
It is likely that these shortcomings and the subsequent perceived ‘lack of success’
has fuelled less interest in conducting interaction studies compared to association
studies, despite their potential utility in improving understanding of the mechanisms
underlying complex traits and diseases. This may partially explain the low number
of reported significant interaction effects.
Whilst there is further progress to be made, there have been recent efforts to
improve the quality of the environmental information collected for large cohorts
of individuals. This is not limited to UK Biobank which was used throughout
this thesis; large population based biobanks exist in other countries, for example,
deCODE in Iceland (https://www.decode.com), Kaiser Permanante Research Bank
in the USA (https://researchbank.kaiserpermanente.org) and the Estonian
Biobank (https://www.geenivaramu.ee/en/access-biobank). Therefore
methods that deal and take advantage of this wealth of data are now required.
In Chapter 2, I describe a new method, StructLMM, that tests for interaction
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effects at multiple environments or association effects in the presence of multiple
environmental exposures. I demonstrate that unlike other multi-environment
interaction and association tests, StructLMM is calibrated across a wide range of
settings. In addition, I exhibit the power gains of this method over existing tests
that consider a single environmental variable. This is most extreme when multiple
environments contribute to the interaction effect and G×E effects at a given variant
are moderate to strong. Further advantages of this method compared to testing
for effects at multiple environments one by one, are a reduced multiple testing
burden and improved interpretation of the identified interactions. In particular,
as highlighted in Chapter 3, the multiple environments used for interaction testing
may be acting as an improved proxy for the causal environmental variable (which
may be a composite of environmental factors and/or unmeasured factors) driving the
observed interaction effects. Therefore, exploration of the individual environments
driving an observed interaction effect is perhaps less pertinent than the identification
of environmental states and thus individuals within the population that are at
increased trait risk if they carry the risk increasing alleles. A future methodological
improvement specific to StructLMM is the integration of methods that impute
missing environmental data to increase sample size and thus power, particularly
advantageous when many environmental variables are included in the analysis (as
discussed in Section 3.5). Furthermore, the method could be extended and
generalised, such that it can be applied to binary traits (see Section 2.5).
Initial application of StructLMM in Chapter 3, accounting for 64 lifestyle based
environments, revealed a number of novel interaction and association effects on
BMI using the UK Biobank data. One interesting result that perhaps warrants
further exploration is the possible opposite direction of effect observed at PARK2.
It was initially found to be associated with BMI by the GIANT consortium and
later linked to BMI change during a 10 year follow up study316,331. Little is known
about the precise functional properties of the PARK2 gene, which encodes the
Ubiquitin E3 ligase Parkin428. However there is a growing body of evidence that
PARK2 plays a critical role in mitochondrial homeostasis429–434. Of greater interest,
a PARK2 knock out mouse study found no difference in body weight or adiposity
between wild type and knockout mice on a regular chow-fed diet but observed
that knockout mice were resistant to weight gain on a high fat diet434,435; it is
thought that this is due to reduced intestinal lipid absorption in PARK2 knock
out mice434,435. Exploration of the environments driving this observed interaction
effect using Bayes factors in Chapter 3, suggests that tea intake is the most relevant
environmental factor. Upon closer examination of the association landscape for
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tea intake using publicly available data (https://biobankengine.stanford.edu/
coding/INI1488)399, I note a number of variants are strongly associated with this
environment. It is therefore plausible that the observed opposite direction of effect
is capturing an instance of epistasis. Identification of epistatic effects may be
functionally informative; for example it may increase knowledge of how PARK2
gene expression is regulated or which other gene products (proteins) the PARK2
gene product interacts with. Alternatively, if epistatic interactions can be ruled out
then the observed environmentally dependent opposite direction of effect at PARK2
(see Fig. 3.14) may be of clinical importance; specifically lifestyle changes based on
the genotype that an individual carries may have a relatively large impact on BMI
risk.
A second interesting result from Chapter 3, is that across the vast majority of
identified interaction loci, the same individuals are not at the extremes of the
trait risk spectrum. This suggests, that the environmental exposures driving the
interaction effects differ across the loci and subsequently, lifestyle modifications with
the greatest impact should be tailored to the individual based on the genetic risk
variants that they carry, somewhat a realisation of personalised medicine. That is
not to say that all individuals within a population will not benefit from following a
healthy lifestyle. This also implies that existing G×E burden based approaches (see
Section 2.2.7), including the use of GRS are likely underpowered and in general not
appropriate.
I demonstrate in Chapter 4 that the StructLMM interaction test can be combined
with a cFDR multiple testing correction, boosting the number of identified interaction
effects for a given expected false discovery rate. Specifically, the number of loci
(+/−1 Mb, LD r2 < 0.1) identified with significant G×E effects on BMI when testing
7,515,856 SNPs genome-wide (using the StructLMM interaction test) increased from
8 to 60 using 5% FDR (Benjamini-Hochberg) and 5% conditional FDR multiple
testing adustments, respectively. Whilst originally developed for application to
two independent association scans, its application in this setting, conditioning on
association results is novel. I note that this method is not only applicable to use
in combination with StructLMM but can be applied to existing interaction tests
that consider a single environmental variable. This method can be viewed as a soft
thresholding version of existing methods that select variants to take forward for
interaction testing based on marginal association results using a defined threshold.
An alternative, that was not considered in this work but could be a future direction
for exploration is to consider a cFDR approach that conditions on variance
heterogeneity results, analogous to current variance heterogeneity hard thresholding
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approaches e. g. the recently developed method by Young et al.436. However, unless
conditioning on variance heterogeneity rather than marginal genetic effects, yields
substantial increases in power, the approach currently considered has greater
practicality since association scans are usually performed as a default first analysis
and no further work is required to use these results as covariates.
Application of the StructLMM interaction test to a broader range of phenotypes, in
Chapter 4, enabled initial exploration of the gene-environment interaction landscape
across different traits. Whilst it was not necessarily surprising to see that G×E
effects explain additional phenotypic variance, comparison with the phenotypic
variance explained by persistent genetic effects highlights the potential importance
of interaction effects, such that they deserve greater attention in the future.
The work described in Chapter 4 is preliminary, with further work required to
confirm the reported findings. In particular, adaptation and development of existing
methods such as LDAK424 is required to take into account the effect of all variants
at the 1,104 considered loci to confirm or refute the amount of phenotypic variation
explained by persistent and G×E effects. Having said this, estimation of the fraction
of genetic variance explained by G×E effects (ρ) at individual significant interaction
loci does suggest that these results are likely to hold true. It would also be interesting
to examine if the observations in Chapter 4 based on the BMR associated variants
(P < 5× 10−8) are consistent when considering all variants genome-wide.
Future directions related to this phenome-wide interaction analysis are to explore
G×E overlap, similar to definitions of genetic correlation426. In addition, further
exploration of why lead persistent and interaction genetic variants at a locus differ
would be interesting; explicitly, determining whether the observed effects are tagging
the same signal or if association effects are tagging multiple interaction signals would
be of value to the field.
Whilst throughout this thesis, I only apply these methods to the analysis of G×E
effects, these approaches could equally be applied to explore epistasis or other
burgeoning areas, such as viral-host or microbiota-host genetics, both of which have
the potential to yield insightful and interesting findings.
The work in this thesis addresses some of the existing problems related to interaction
tests, namely dealing with the depth of environmental data available and the use of
multiple testing methods that increase the number of identified interaction loci at
a given FDR. However, there are still problems that exist that are not specific to
StructLMM and/or the cFDR multiple testing correction methods.
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The first is the scope of the environmental data collected. In particular global
standards and definitions need to be agreed and environmental data needs to be
collected more densely in time and over lifespans. An advantage of continual
environmental data collection is that behavioural changes due to perceived
‘monitoring’ will not be an issue, reducing the noise of interaction tests. However,
even if these problems are overcome, the collection of this data will take decades.
A further, more feasible avenue of interaction method development is improved
specification of the null model. Specifically, this would encompass inclusion of
non-linear additive environmental terms within the null model, perhaps through
the use of machine learning methods such as the random forest approach437.
Overall, the work in this thesis demonstrates the necessity and advantages of jointly
modelling G×E effects at multiple environments, providing a robust computationally
efficient novel method StructLMM to do so. Such methods combined with the
increasing availability of large scale biobanks have the potential to further advance
our understanding of complex traits and diseases.
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Large population cohorts that combine genetic profiling with deep phenotype and environmental data, including diet, physi-cal activity and other lifestyle covariates, have fostered interest 
to study G× E. Already, such analyses have identified G× E for differ-
ent traits in humans, including disease risk1,2 and molecular traits3,4.
Established G× E methods test for interactions between a single 
environmental variable and individual genetic variants5. Recent 
extensions enable assessment of G× E across sets of genetic variants, 
either using genetic risk scores6 or variance component tests7–9. 
Although there is evidence that multiple environments can interact 
with a single genetic locus to influence phenotypes (for example, a 
number of environments have been shown to alter the effect of FTO 
on body mass index (BMI), including physical activity10–13, diet12–15  
and smoking12), there are no robust methods for the joint G× E 
analysis of multiple environmental variables. Multivariate G× E tests 
can have power advantages, in particular to identify interactions 
that are simultaneously driven by multiple environments or because 
combinations of multiple environmental variables act as proxy for 
unobserved drivers of G× E. Additionally, joint tests reduce the 
multiple testing burden. Thus, as increasingly high-dimensional 
environmental data are available in population cohorts and given 
the desire to fully understand the impact of multiple environments 
in complex traits and diseases, there is a growing need for multi-
environment G× E tests. Here, we present StructLMM, a variance 
component test to identify and characterize G× E interactions with 
multiple environments. Our model can handle hundreds of envi-
ronmental variables, and it can be applied to large cohorts of hun-
dreds of thousands of individuals.
Results
Conventional linear mixed models (LMMs) are used to test for 
associations with constant genetic effect sizes across individuals in 
the population, also called persistent genetic effects. Covariates and 
additional random effect components are included to account for 
population structure, environment, or other additive (confounding) 
effects. StructLMM extends the LMM framework by modeling het-
erogeneity in effect sizes due to G× E
  ⏟⏟ ⏟
β ψβ= + + ⊙ +
⏟
+ .×
×
y Xb x x e
(1)covariates
G
persistent G
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Here, βG denotes the effect size of a conventional persistent 
genetic effect component, and β β β= …× × ×[ , , ]NG E G E1 G E T is a vec-
tor of per-individual effect sizes to account for heterogeneous 
genetic effects, which follows a multivariate normal distribution, 
β σ Σ∼× ×N 0( , )G E G E
2 . Depending on the functional form of the 
environmental covariance Σ, this model can account for different 
types of G× E, for example, hierarchies of discrete environmental 
groups, or as considered here, G× E effects based on a set of con-
tinuous and discrete environmental covariates (Fig. 1b,c). The same 
environmental covariance is also used to account for additive envi-
ronmental effects, e ~ N(0, Σ). StructLMM is technically related to 
existing variance component tests for rare variants16 and epistasis17 
(comparison to alternative methods in Supplementary Note).
Using the multi-environment model defined above (equation (1)), 
we propose a score test to identify loci with significant G× E interac-
tion effects. Additionally, the same framework can be used to define 
a joint association test that accounts for the possibility of hetero-
geneous effect sizes due to G× E, which generalizes previous two 
degrees of freedom single-environment association tests5,18. Both 
tests are computationally efficient, enabling genome-wide analyses 
using hundreds of environmental variables on cohorts of hundreds 
of thousands of individuals. The model facilitates different analyses 
to characterize G× E effects at individual loci, including estimation 
of the fraction of genetic variance explained by G× E (ρ, Methods) 
and estimating per-individual allelic effects based on environmen-
tal profiles in the population (Fig. 1d), thus identifying individuals 
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at increased or decreased trait risk. Finally, StructLMM can be 
used to explore which environments are most relevant for G× E by 
comparing models that contain all environmental factors and mod-
els with environmental variables removed (Fig. 1e; full derivation 
in Methods).
Model validation using simulated data. Initially, we considered 
simulated data using genotypes from the 1000 Genomes project19 
to assess the statistical calibration and power of StructLMM. To 
mimic environmental distributions as observed in real settings, 
we simulated G× E based on 60 environmental covariates from UK 
Biobank, including physical activity, diet, and other lifestyle factors 
(Methods). We varied the sample size of the simulated population, 
the magnitude of G× E effects, the number of driving environments 
for G× E, and other parameters (Supplementary Table 1).
First, we confirmed the statistical calibration of the StructLMM 
interaction test (referred to as StructLMM-int), either consider-
ing phenotypes simulated without any genetic effects (Fig. 2a and 
Supplementary Figure 1a,b) or simulating from a persistent effect 
model without interactions (the null model of StructLMM-int; 
Supplementary Figure 1a,b).
Next, we simulated phenotypes with variable fractions of the 
genetic variance explained by G× E (ρ, Methods) and assessed the 
power of StructLMM-int. For comparison, we also considered a sin-
gle-environment one degree of freedom fixed effect test (SingleEnv-
Renv-int, Supplementary Table 2; as described in Gauderman et al.18, 
Bonferroni adjusted for the number of environments, Methods), 
using the same random effect component (as for StructLMM) to 
account for additive environmental effects under the null.
The power of both tests increases as the fraction of the genetic 
effect explained by G× E (ρ) increases, noting that StructLMM-int 
is substantially better powered than the SingleEnv-Renv-int test 
(Fig. 2b and Supplementary Fig. 2a). As a second parameter, we 
varied the number of active environments that contribute to G× E 
but used all 60 environmental variables during testing. The results 
of this analysis show that StructLMM-int increasingly outperforms 
the corresponding SingleEnv-Renv-int G× E test as the number of 
active environments increases (Fig. 2c and Supplementary Fig. 2b).
We considered a number of additional settings, including vary-
ing the total number of observed environments, the fraction of 
phenotypic variance explained by additive environmental effects 
and simulating interaction effects using environments that are not 
included at the testing stage, with the latter corresponding to G× E 
effects driven by environments for which there are no measure-
ments available, a scenario that is likely to occur in practice. We 
also considered settings where the environments were themselves 
heritable, varied the extent of distributional skew and considered 
binary environments with different frequencies. Across all settings, 
StructLMM-int had consistent power advantages over alternative 
methods and remained calibrated (Supplementary Figs. 2–4).
For the same settings, we also considered the StructLMM joint 
association test, which accounts for the possibility of heterogeneous 
effect sizes due to G× E, and compared it to a two degrees of free-
dom single-environment test using fixed effects (as described in 
Kraft et al.5; Bonferroni adjusted for the number of environments, 
Methods; Supplementary Table 2), as well as to conventional asso-
ciation tests that only model persistent effects (Supplementary 
Table 2). In these experiments (Supplementary Figs. 2–4), the 
StructLMM joint association test yielded similar power advantages 
as StructLMM-int when testing for interactions, indicating that 
StructLMM can be useful to discover additional associations, in 
particular for variants with strong G× E (Supplementary Fig. 2a).
Finally, we considered alternative implementations of interaction 
and association tests (Supplementary Table 2), using fixed effects 
to account for additive environment instead of a random effect 
component, which yielded near-identical results (Supplementary 
Figure 2). We also note that multi-environment G× E tests can 
in principle be implemented based on fixed effect tests with as 
many degrees of freedoms as environments (Supplementary 
Table 2). However, we observed that such tests were not always 
calibrated (Supplementary Figure 1b), in particular for large num-
bers of environments, and in addition had lower performance 
(Supplementary Fig. 1c,d).
Taken together, these results show increased power and robust-
ness of StructLMM compared with existing methods, in particular 
when large numbers of environments drive G× E interaction effects, 
as might be expected to occur for the majority of complex traits 
and diseases.
Application to data from UK Biobank. Initially, we applied 
StructLMM-int to test for G× E interactions at 97 variants (corre-
sponding genes as annotated by GIANT20) that have previously been 
linked to BMI using independent data20. We considered 252,188 
unrelated individuals of European ancestry, for which BMI and 64 
lifestyle covariates, similar to those used in Young et al.13 (12 diet-
related factors, three factors linked to physical activity and six lifestyle 
factors, modeled as gender adjusted and age adjusted; Methods and 
Supplementary Figures 5 and 6), were available in the full release of 
UK Biobank21. StructLMM-int identified four significant G× E effects 
(α < 0.05, Bonferroni adjusted), whereas a single-environment one 
degree of freedom fixed-effect test (SingleEnv-Renv-int), identified 
only two of these interactions (Fig. 3a, Supplementary Fig. 7 and 
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NAtuRe GeNetICS | www.nature.com/naturegenetics
Technical RepoRTNATUrE GENETicS
Supplementary Table 3). Among the loci identified by StructLMM-
int was the FTO locus (rs1558902, ρ = 0.14; Supplementary Fig. 8a), 
which has previously been implicated in G× E for multiple environ-
ments10,12–14; MC4R (Fig. 3b), for which an interaction with physical 
activity in females aged 20–40 years has been suggested previously 
(P adj = 0.025, reported in ref. 12); SEC16B (Supplementary Fig. 8b), 
for which secondary analyses provided some evidence for an inter-
action (P = 0.025) with physical activity in Europeans11 and in a 
separate study in Hispanics22; and PARK2 (Supplementary Fig. 8c), 
a gene that has been linked to time-dependent variation in BMI23. 
StructLMM also enhanced the significance of interactions identi-
fied by both tests (P StructLMM-int = 4.23 × 10–16 versus P adj 
SingleEnv-Renv-int = 6.76 × 10–6 and P StructLMM-int = 1.15 × 10–4 
versus P adj SingleEnv-Renv-int = 4.48 × 10–4 for FTO and SEC16B, 
respectively). Larger differences in the number of discoveries were 
observed at more lenient thresholds, for example, 11 versus six loci 
with G× E at false discovery rate (FDR) < 5% (Benjamini–Hochberg 
adjustment; Supplementary Table 3).
We also considered additional fixed effect interaction tests, 
including multi-environment G× E tests based on fixed effects, 
which identified fewer interactions than StructLMM-int (N = 2 ver-
sus N = 4; α < 0.05), as well as alternative implementations of the sin-
gle-environment interaction test, which consistent with the results 
on simulations, yielded near-identical results to SingleEnv-Renv-int 
(Supplementary Figs. 9 and 10 and Supplementary Table 3).
Finally, as an alternative filtering strategy, we applied the 
same interaction tests to 17,606 variants with significant persis-
tent associations with BMI in UK Biobank (P < 5 × 10–8; LMM-
Renv). StructLMM-int identified 23 loci with G× E interactions 
(FDR < 5%; Benjamini–Hochberg adjusted, ± 500 kb, r2 > 0.1), 
including SEC16B, MC4R and FTO, compared with, at most, 11 
loci identified by alternative methods (Supplementary Fig. 11 and 
Supplementary Table 3).
The StructLMM framework can also be used to test for associa-
tions while accounting for the possibility of effect size heterogeneity 
due to G× E. To explore this option, we applied the StructLMM joint 
association test to BMI, using low-frequency and common variants 
(imputed variants, minor allele frequency (MAF) > 1%, 7,515,856 
variants in total) and the same set of 64 lifestyle covariates as consid-
ered in the interaction analysis. For comparison, we also considered 
an LMM using the same random effect component to account for 
additive environmental effects, as in StructLMM (LMM-Renv), and 
a linear model without accounting for additive environment (LM). 
Although the choice of null model can have a large impact on loci 
discovery (P < 5 × 10–8, ± 500 kb, r2 > 0.1; LMM-Renv: 327 loci, of 
which 14.37% were not detected by the LM; LM, 379 loci, of which 
25.59% were not detected by LMM-Renv; Supplementary Table 4 
and Supplementary Fig. 12), StructLMM identified 23 loci that were 
not detected by other methods (351 unique loci in total; Fig. 3c, 
Supplementary Table 4 and Supplementary Figs. 13–16), indicating 
that the StructLMM joint association test can be used to identify 
additional loci with a strong G× E component. One such locus lies 
in the ADAMTSL3 gene (rs4842838, P StructLMM = 9.35 × 10–10, 
P LMM = 3.83 × 10–7, P LM = 2.37 × 10–5), which codes for a glyco-
protein24. Other variants within this gene have been linked to BMI-
related traits, including lean body mass25, waist circumference26 and 
hip circumference adjusted for BMI27.
Once G× E loci have been identified, StructLMM can be used for 
the interpretation of these effects, and in particular to estimate per-
individual allelic effects based on environmental profiles to iden-
tify individuals with increased or decreased trait risk (Fig. 4a). We 
confirmed the robustness of these estimates using hold-out valida-
tion, providing further evidence for possible opposite directions of 
effect at PARK2 (Supplementary Fig. 17). To explore which envi-
ronmental variables are most relevant for individual G× E signals, 
we calculated Bayes factors (BF) between the full model and models 
with individual environmental exposures removed (Supplementary 
Fig. 18), identifying between 20 and 25 environments with putative 
G× E effects (Bayes factors > 0). Because the environments are not 
independent of one another, we used backward elimination based 
on Bayes factors between the full model and models with increas-
ing numbers of environments removed. These analyses identified 
physical activity measures for females (no evidence for males) as 
contributing to G× E at MC4R, in agreement with findings in ref. 12, 
but also yielded a number of additional environments (Fig. 4b and 
Supplementary Fig. 18). For all loci, we consistently observed that 
multiple environments contribute to G× E, but there is evidence of 
differences in the G× E architecture, with FTO being associated with 
the largest number of environments and SEC16B and PARK2 being 
associated with a smaller number of environments (Supplementary 
Fig. 18). Differences in the environments that contribute to G× E 
effects were also apparent when correlating per-individual allelic 
effect size estimates across loci (Supplementary Fig. 19).
Identification of eQTL interactions with cellular state. As a 
second application, we considered a gene expression dataset28 to 
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illustrate how StructLMM can be used to identify context-depen-
dent regulatory effects on gene expression, for example due to exter-
nal stimuli4 or differences in cell type composition29, using hundreds 
of environment covariates. Insights into context-dependent genetic 
regulation of gene expression are important to identify disease-rele-
vant cell types and molecular pathways30–32.
We reanalyzed a large whole-blood expression dataset com-
prising 2,040 genotyped individuals profiled with RNA-seq28 
(Methods) and applied StructLMM-int to test for cell-context inter-
actions at cis expression quantitative trait loci (eQTL). Following 
Zhernakova et al.28, we considered gene expression levels both as 
phenotypes and as proxy (environmental) variables, which can tag 
variation in blood cell composition and other factors across indi-
viduals. Specifically, we considered a set of 443 highly variable genes 
as environmental variables in our analysis (Methods).
Initially, we applied a linear model to identify lead cis eQTL 
variants for 23,506 expressed genes (within ± 250 kb from the cen-
ter of the gene, Methods). Next, we applied StructLMM-int to test 
for cell-context interactions at lead variants for each of these genes. 
The model produced calibrated P values despite the large number of 
environments (Supplementary Fig. 20), identifying 3,483 eQTL with 
a cell-context interaction (FDR < 5%, termed interaction eQTL; 
Supplementary Table 5). Although globally interactions with cell 
context tended to explain small fractions of the cis genetic variance 
on gene expression (ρ < 0.2, for 68.0% of interaction eQTL; 
Fig. 5a), G× E explained more variance than persistent genetic effects 
for 532 genes (ρ > 0.5, for 15.3% of interaction eQTL). We also com-
pared StructLMM-int to alternative multi-environment interac-
tion tests based on fixed effects, which were markedly less robust 
and identified fewer interaction eQTL (Supplementary Fig. 20). 
Similarly, we compared the discovered interaction eQTL to results 
from a stepwise procedure that was used to identify interac-
tion eQTL in the primary analysis of the same data28 (details in 
Supplementary Note), which yielded markedly fewer interactions 
(3,372 versus 1,841 interaction eQTL, considering StructLMM and 
the approach in ref. 28; FDR < 5%; Supplementary Fig. 20; consider-
ing 17,952 genes assessed in both studies). Finally, we considered 
alternative approaches to normalize the expression data (Methods), 
thereby assessing potential biases due to gene-exposure correlations 
and distributional skew of counts-based gene expression profiles. 
These results indicated that StructLMM is robust to both potential 
sources of bias (Supplementary Fig. 21).
Next, we overlapped the interaction eQTL with risk variants from 
the NHGRI-EBI GWAS catalog V1.0.1 (ref. 33), identifying 64 puta-
tive colocalization events (r2 > 0.8 between lead eQTL and GWAS 
variants; Supplementary Fig. 22 and Methods), including GWAS 
variants for autoimmune diseases, infectious diseases and blood cell 
traits (Supplementary Table 6 and Supplementary Datasets 1 and 2). 
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Notably, 46 of these interaction eQTL were not reported in the pri-
mary analysis28. One example is an interaction eQTL for CTSW 
expression (Fig. 5b–d, P StructLMM-int = 2.2 × 10–15, ρ = 0.12), which 
is in linkage disequilibrium (LD) with a risk variant for Crohn’s disease 
rs568617 (r2 = 0.98, Supplementary Fig. 23). To investigate the molec-
ular pathways that are associated with this interaction, we stratified 
the population into strata with the smallest and largest allelic effects, 
as estimated using StructLMM (Fig. 5b,c), and tested for pathways that 
were enriched among differentially expressed genes between these 
groups (Methods). This identified T cell selection (GO: 0045058), 
positive T cell selection (GO: 0046632) and positive regulation of inter-
leukin-17 secretion (GO: 0032740) as the top three processes for this 
interaction eQTL (Fisher exact test; genome-wide enrichment results 
in Supplementary Table 6), GO terms that are consistent with known 
roles of IL-17–producing CD4+ T cells in the pathogenesis of inflam-
matory bowel disease, including Crohn’s disease34.
Taken together, results from this analysis demonstrate the broad 
applicability of StructLMM, including in settings with large num-
bers of environmental factors.
Discussion
We propose a method based on variance component tests to iden-
tify G× E interactions using multiple environments. Conceptually, 
our approach is related to set tests for groups of variants, but 
instead of aggregating across multiple genetic variants, StructLMM 
jointly models multiple environmental variables to identify G× E 
interactions. Compared with conventional single and multiple 
degrees of freedom fixed-effect G× E tests, this approach enjoys 
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power advantages (Fig. 2 and Supplementary Figs. 1–4) and yields 
increased robustness, in particular when analyzing large numbers of 
environmental variables (Supplementary Figs. 1 and 20).
We applied StructLMM to data from UK Biobank to assess G× E 
at 97 GIANT variants associated with BMI, confirming established 
G× E effects at FTO, and we identified, for the first time, three 
additional G× E signals at stringent thresholds (Family Wise Error 
Rate (FWER) < 5%; Fig. 3a), some of which confirm prior evi-
dence11,12,14,15,22,23. More-lenient FDR-based significance thresholds, 
as frequently employed for G× E analyses6,12, yielded 11 GIANT 
variants with evidence for G× E (FDR < 5%; Benjamini‒Hochberg 
adjusted; Supplementary Table 3), and a genome-wide analysis based 
on all variants that are associated with BMI identified 23 loci with 
significant G× E effects (Supplementary Fig. 11 and Supplementary 
Table 3). We also show that the same framework can be used to test 
for associations, demonstrating that accounting for heterogeneity 
in effect sizes can identify additional loci, similarly to previously 
reported benefits of two degrees of freedom fixed-effect tests5.
In addition to offering power advantages, StructLMM yields 
per-individual allelic effect size estimates that reflect G× E. We have 
shown that this allows for different downstream analyses, includ-
ing the identification of individuals with increased or decreased 
genetic risk. This would be of particular interest in the complex 
disease field, as it may provide further explanation as to why indi-
viduals who share the same set of risk variants may have different 
outcomes in longitudinal follow-up. In particular, identifying sets 
of environments that may decrease disease risk for individuals car-
rying the same genetic burden may provide useful avenues for tar-
geted disease prevention. We also explore which environments are 
putative drivers of the observed G× E effects. However, such down-
stream analyses, when using the same dataset for discovery, should 
be interpreted with caution. Ultimately, independent validation 
cohorts will be required to confirm such findings.
As a second-use case, we applied StructLMM to test for cell-
context interactions in a large blood eQTL study, where the same 
modeling principles enabled the identification of context-specific 
eQTL. Several of these interaction eQTL colocalized with GWAS 
variants, and the marker genes of the cellular environments that 
underlie these interaction effects could be connected to plausible 
molecular pathways (Supplementary Table 6).
Although we found that StructLMM is a robust and powerful 
alternative to conventional linear interaction tests, our approach is 
not free of limitations. First, there are general challenges when ana-
lyzing G× E that although not specific to our model need to be taken 
into consideration. One such challenge is environmental variables 
that are themselves heritable. Accounting for heritable covariates in 
association tests can lead to spurious associations due to collider 
bias35. Our results indicate that interaction tests are more robust to 
such correlations (Supplementary Fig. 3). However, gene exposure 
associations alter the interpretation of interactions, reflecting epi-
static relationships between genetic factors. A second generic chal-
lenge is the selection of candidate variants for G× E tests. To reduce 
the multiple testing burden, we selected variants that have persistent 
effects on the phenotype. However, the fact that our association test 
identifies novel loci with strong G× E (ρ) if applied genome-wide 
indicates that this filter is not optimal.
Among more specific limitations and areas of future work for 
StructLMM, we note the computational requirements of the model 
are more demanding than conventional LMMs, despite scaling lin-
early with the number of individuals. A second potential limita-
tion is that StructLMM does not currently enable accounting for 
relatedness. Although the model has an additive random effect 
component, it is currently used to model additive environmental 
effects. Generalizations to simultaneously account for a relatedness 
could be considered, for example, using suitable low-rank approxi-
mations36 or other speed-ups to retain scalability to large sample 
sizes. Finally, although StructLMM can in principle be used in con-
junction with any environmental covariance, we have limited our 
attention to linear covariances. The model could be extended to 
account for non-linear interactions, for example, using polynomial 
covariance functions. Future developments in this direction will 
be increasingly valuable as larger cohort sizes enable detection of 
higher-order interaction effects.
URLs. Haplotype Reference panel, http://www.haplotype-refer-
ence-consortium.org/site; Phase 3 1000 Genomes reference panel, 
http://grch37.rest.ensembl.org.
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Methods
The structured linear model. A conventional LMM to test for associations can be 
cast as:
ψβ= + + +y Xb x u
where β is the focal variant effect size, X is the fixed-effect design matrix of K 
covariates, and b is the corresponding effect size. The variable u denotes additive 
(confounding) factors, and ψ denotes i.i.d. noise. The random effect component  
u and the noise vector ψ follow multivariate normal distributions, σ Σ∼u N 0( , )ue2  
and ψ σ∼ IN 0( , )n2 , where the covariance matrix Σu reflects the covariance of 
population structure, environment or other (confounding) factors. Association 
tests for non-zero effects of the focal variant correspond to alternative  
hypothesis β ≠ 0.
StructLMM generalizes the conventional LMM for association testing by 
introducing per-individual effect sizes due to G× E
β ψβ= + + ⊙ + +×y Xb x x u (2)G E
where βG×E is a per-individual allelic effects vector that follows a multivariate 
normal distribution with environment covariance Σ:
β σ Σ∼× ×N 0( , ) (3)G EG E
2
The covariance Σ captures heterogeneity in allelic effects in the population 
and is estimated using a linear covariance function based on a set of observed 
environmental variables, where we assume Σ Σ=u . If collider bias35 is a 
concern, non-heritable environmental variables should be selected. Non-linear 
environmental effects can be modeled by combining observed environmental 
variables (for example, effects from environments × age or environments × gender; 
Supplementary Note).
Statistical testing. Based on equation (1), we define an interaction test (σ >× 0G E2 )  
where persistent genetic and additive environment effects are accounted for in 
the null model and an association test (σ >× 0G E2  and β ≠ 0), which jointly tests 
for associations while accounting for the possibility of heterogeneous genetic 
effects due to G× E. Both tests are implemented as efficient score tests, similar to 
the approach in SKAT and SKAT-O37,38, with linear complexity in the number of 
individuals (Supplementary Note).
Estimation of ρ. Estimates of the fraction of the genetic variance explained by G× E 
(ρ) can be obtained from maximum likelihood estimates of the model in equation (4).
ρ=
+
×
×
Var
Var Var
(4)
G E
G G E
with VarG denoting the fraction of the variance explained by persistent effects and 
VarG×E denoting variance due to G× E.
Exploring the most relevant environments for G×E. Bayes factors between the 
full model and models with individual environments or sets of environments 
removed from the environmental covariance Σ (Supplementary Note) can be used 
to assess the relevance of environments.
Estimation of per-individual allelic effects. Per-individual (for each environment 
state) allelic effects can be estimated using BLUP39.
Additionally, the model yields posterior estimates of the realization of  
the unobserved environmental state that explains the G× E effect  
(Supplementary Note).
Simulations. Simulation procedure overview. Simulations were based on 
genotypes of European individuals from the 1000 Genomes project19 (phase 1, 
1,092 individuals, 379 Europeans), considering 103,527 variants on chromosome 
21 (minor allele frequency ≥ 2%). Following refs 40,41, we generated synthetic 
genotypes of unrelated individuals for different sample sizes while preserving 
the population structure of the seed population (as in ref. 9). We considered 33 
environmental exposures using empirical environmental covariates from 70,282 
UK Biobank individuals (based on the Interim release), augmented using element-
wise interactions with gender and age, resulting in 100 environmental variables. 
These environmental variables were preprocessed as in the UK Biobank analysis 
(discussed below) and randomly assigned to synthetic genotypes (details in 
Supplementary Note).
Assessment of statistical calibration. Statistical calibration of different tests was 
assessed using phenotypes simulated from an empirical null model, considering (i) 
no genetic effect (Fig. 2a and Supplementary Fig. 1a,b) and (ii) simulated persistent 
genetic effects (100 persistent genetic effect variants, no G× E interactions; 
Supplementary Fig. 1a,b). Calibration was assessed using QQ plots and genomic 
control (λ = .
log m
logGC
( )
(0 5)
10
10
; m is the median P value), based on P values from 
chromosome 21 pooled across 100 repeat experiments.
Power simulations. Phenotypes with G× E interactions were simulated, varying 
the fraction of variance explained by G× E, the number of active environments 
and other parameters (Supplementary Table 1 and Supplementary Note). We 
also studied the effect of gene-exposure correlations (Supplementary Fig. 3 and 
Supplementary Note) and considered synthetic environments to assess the effect of 
(rare) binary environmental variables (Supplementary Fig. 4 and Supplementary 
Note). We considered 1,000 repeat experiments for each setting, randomly 
selecting a segment of approximately 2 Mb from chromosome 21 and simulating 
G× E effects from one causal variant. Power at 1% FWER (Bonferroni adjusted 
across variants) was assessed considering variants in linkage disequilibrium with 
selected true causal variants (r2 ≥ 0.8) as true positives, reporting average power 
across repeat experiments (individual experiments return 1 or 0).
Comparison methods. We compared StructLMM to alternative single- and multi-
environment models, as well as standard genetic association tests. For interaction 
tests, we considered alternative single-environment G× E interaction tests  
(i) using random effect (SingleEnv-Renv-int) or (ii) fixed-effect (SingleEnv-Fenv-int) 
components to account for additive environmental effects due to all environments, 
and finally (iii) an additive single-environment fixed effect term based on the 
specific environment considered in the G× E test only (SingleEnv-Senv-int). 
The same models were considered to test for associations, using a two degrees 
of freedom (df) statistical test5 (SingleEnv-Renv, SingleEnv-Fenv, SingleEnv-
Senv, respectively). Additionally, for association tests, we considered linear 
association tests, again either using a multi-environment random effect for additive 
environment (LMM-Renv) or a multi-environment fixed effect  
(LM-Fenv) component to account for additive environmental effects, as well 
a linear model with no additive environment effect term (LM). All tests were 
implemented using LRT, considering Bonferroni-adjusted minimum P value per 
variant across environments for single-environment models. Finally, we assessed 
the performance of fixed-effect multi-environment interaction and association 
tests, again considering either random or fixed additive environment components 
based on all observed environments, considering either an LRT or score test. 
Performance of these multi-environment tests was assessed using the average area 
under the curve (AUC) across repeat experiments (using true positive definitions 
as for power), computed in the range FPR < 0.10 and normalized to the 0‒1 range, 
such that 0 corresponds to chance performance and 1 is the performance of an 
ideal model (Supplementary Fig. 1c,d). An overview of all methods compared is 
provided in Supplementary Table 2 and details in Supplementary Note.
Analysis of BMI in UK Biobank. This research was conducted using the full 
release of the UK Biobank Resource (Application 14069)21. The UK Biobank  
study has approval from the North West Multi-Centre Research Ethics Committee 
and all participants included in the analyses provided informed consent to  
UK Biobank.
Data pre-processing. BMI phenotype data are ‘Instance 0’ of UK Biobank data field 
21001. Individuals with missing BMI data were discarded from the analysis and 
BMI log transformed13,42. Following ref. 13, we considered 21 lifestyle covariates 
as environments, discarding individuals with outlying or missing environmental 
variables (Supplementary Note). We further discarded individuals of non-British 
ancestry and related individuals. After filtering and QC on the BMI phenotype, 
genotype and the environmental variables, we obtained a set of 252,188 individuals 
for analysis. Principal components for population structure adjustment were 
calculated using flashpca version 2.0 (ref. 43) using 147,604 variants, as indicated by 
the field ‘in_PCA’ from the released marker QC file.
Genotype data. We used genotypes that were imputed with the HRC panel (build 
GRCh37). We performed QC of the imputed variants on the fly, using a fast 
bgen reader, implemented as part of StructLMM, treating genotype-sample pairs 
with low imputation accuracy (max. probability < 0.5) as missing and discarding 
variants with missingness > 5%, MAF < 1%, HWE P < 1 × 10‒6 and INFO score 
r2 < 0.4 (based on the UK Biobank imputation MAF and info file). Genotype 
dosages of remaining variants were calculated using available probabilities 
(including genotype-sample pairs with low imputation accuracy) and mean 
imputation used for any genotype-sample pairs with missing data. 7,515,856 
variants passed these filters.
Environmental covariance and covariates. To generate the environment matrix E, we 
augmented all 21 environmental variables described above (excluding age) by gender 
and age by multiplying the continuous age vector, the binary male indicator vector 
and the binary female indicator vector with each of the 21 environment variables, 
which resulted in 63 covariates. The environmental covariance was estimated 
based on standardized environmental variables (not including zero values due to 
augmentation when mean adjusting) followed by per-individual standardization 
(Supplementary Figs. 5 and 6; full details in Supplementary Note). In all analyses,  
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a mean vector, genotype chip, gender, age2, age3, gender × age, gender × age2,  
gender × age3, 10 genetic principal components were included as covariates.
Calibration of interaction and association tests. To validate the tested methods and 
QC procedures, we assessed the empirical calibration using permuted genotype 
variants (173,297 variants) on chromosome 20 (Supplementary Fig. 7).
Interaction testing. We considered 97 GIANT variants previously associated with 
BMI20 to test for G× E interactions using StructLMM-int and single-environment 
fixed-effect interaction tests (SingleEnv-Renv-int and SingleEnv-Senv-int, 1 df, 
Supplementary Note) and a multi-environment fixed-effect-based interaction 
test (64 df, MultiEnv-Renv-LRT-int, Supplementary Note). Variants with 
significant G× E were reported at FWER 5% (P < 0.05/97), and alternatively 
using a more lenient threshold at FDR < 5% (Benjamini–Hochberg adjustment44; 
Supplementary Table 3).
We also selected the 17,606 variants with LMM-Renv P values < 5 × 10–8 and 
compared results using StructLMM-int to those from single-environment fixed-
effect interaction tests (SingleEnv-Renv-int, Supplementary Note) and a multi-
environment fixed-effect-based interaction test (64 df, MultiEnv-Renv-LRT-int, 
Supplementary Note). This filter is valid, as LMM-Renv corresponds to the null 
model of both StructLMM-int and SingleEnv-Renv-int. Variants with significant 
G× E were reported at FDR < 5% (Benjamini–Hochberg44 adjustment), followed 
by LD clumping to define independent loci: we iteratively (i) selected the most 
significant variant (using the FDR-adjusted P values) and (ii) removed all variants 
in LD (r2 > 0.1) within ± 500 kb, until no variant was left, resulting in 23, 11 and  
9 clumps (loci), respectively (Supplementary Table 3).
Association testing. We used StructLMM, LMM-Renv and LM for genome-wide 
association analyses, reporting significant associations at P < 5 × 10–8, for which 
ρ was estimated using StructLMM (Fig. 3c and Supplementary Table 4). LD 
clumping was used to define independent loci identified by each of the three 
methods; we iteratively (i) selected the most significant variant and (ii) removed all 
variants in LD (r2 > 0.1) within ± 500 kb, until no variant was left, resulting in 351, 
327 and 379 loci, respectively. We compared the methods pairwise, identifying loci 
found by only one method, by calculating the LD (r2) between significant variants 
within a clump identified by one method and significant variants from the other 
method that lie within ± 500 kb, resulting in 32 and 16 loci (StructLMM and LMM-
Renv), 65 and 98 loci (StructLMM and LM) and 47 and 97 loci (LMM-Renv and 
LM). We also compared the genome-wide results of StructLMM to those from a 
multiple degrees of freedom (65 df) fixed-effect association test MultiEnv-Renv-
LRT, again using genome-wide significance thresholds of 5 × 10–8 and estimating  
ρ for all significant variants (Supplementary Fig. 9).
Per-individual allelic effect estimation. We performed in-sample estimation of the 
allelic effect (discussed above) for each of 252,188 individuals at each of the four 
interaction loci (FWER 5%; Fig. 4a). Allelic effects were assessed out of sample 
by randomly splitting the cohort into training and test fractions, to assess out-of-
sample predictions (Supplementary Fig. 17 and Supplementary Note). To assess 
whether the same set of individuals are at the extreme ends of the effect size 
spectrum across multiple interaction variants (5% FDR-adjusted), we computed 
the squared Spearman’s correlation coefficient and then used Ward hierarchical 
clustering (Supplementary Fig. 19).
Explorative analysis of driving environments. We explored which environments 
had putative effects on G× E by comparing the log marginal likelihood of the full 
model to models with individual or sets of environments excluded. We initially 
assessed the relevance of individual environments based on the log(Bayes factor) of 
removing single environments (Supplementary Fig. 18). To account for correlations 
between environments, we also used a backwards elimination procedure 
(Supplementary Note), greedily removing environments until there was evidence 
that we selected a full set of environments that can drive the observed G× E effect 
(Fig. 4b and Supplementary Fig. 18).
Analysis of cell-context eQTL in a large blood cohort. Genotype data pre-
processing. We used freeze one from the BIOS consortium (EGA; accession 
EGAS00001001077) and analyzed 2,040 samples for which genotypes and QC-
passing RNA-seq data were available. Processed genotype and expression data were 
taken from the primary analysis28. Imputed genotypes (from the four biobanks 
CODAM, LifeLines, the Leiden Longevity Study and the Rotterdam Study) were 
merged to perform a mega-analysis, as opposed to the meta-analysis in the original 
paper. After merging, we performed joint QC of the genetic variants, retaining 
variants that met the following conditions: MACH-R2 > 0.5, call rate > 0.95, 
HWE > 1 × 10–4 and MAF > 5%, resulting in 5,683,643 variants for analysis.
Ethical approval. The ethical approval for this study lies with the individual 
participating cohorts (CODAM, LLD, LLS and RS)45–48.
Expression data. The expression data were taken from the original quantifications 
(after TMM normalization), and we selected features that were identified in at least 
10% of the samples, resulting in 23,506 expressed genes for analysis. Expression 
values were quantile normalized, and we used ENSEMBL 71 as gene annotation.
Environmental covariance. We used gene expression levels to build the StructLMM 
covariance, capturing cell-type composition and other sources of cell-context 
heterogeneity. Specifically, we considered a set of highly variable proxy genes, 
identified through a two-step procedure: (i) we selected the top 25% most variable 
genes based on the interquartile range of non-quantile normalized data, (ii) we 
pruned this set, ranking the genes by variability and removing genes with r2 ≥ 0.2 
with a higher-ranked feature. This method resulted in a set of 443 proxy genes, 
which we used to build a linear covariance for StructLMM based on quantile-
normalized expression levels.
cis-eQTL map. We identified cis-eQTL using a linear association test, considering 
genetic variants within 250 kb from the center of the gene body. After the primary 
analysis28, we considered the following 53 factors as covariates: the first 25 principal 
components calculated from the full gene expression profiles, the leading ten MDS 
components on the genotypes (computed using PLINK v1.90b3.32); cell counts 
of neutrophils, eosinophils, basophils, lymphocytes and monocytes; age; gender; 
dataset batch; and the first eight principal components derived from SAMtools 
flagstat and Picard tools (Supplementary Note).
Interaction eQTL analysis. For each of the 23,506 genes, we tested for interactions 
at the lead variant from the cis-eQTL map using StructLMM-int. For comparison, 
we also considered a multivariate fixed effect test, MultiEnv-Renv-LRT-int 
(Supplementary Note) either using the same environmental variables as in 
StructLMM or based on a reduced representation using the leading twenty 
principal components (Supplementary Note). Significant interactions were 
reported at FDR < 5% (Storey’s procedure49). Calibration of all methods was 
assessed by repeating the analysis with permuted genotypes. We considered 
analogous analyses using residual gene expression levels as environments, 
regressing out the cis genetic variant tested from all environments (Supplementary 
Fig. 21a–c), to rule out potential spurious effects due to strong gene-exposure 
correlations. As an additional control, we considered an alternative normalization 
of the expression data using boxcox normalization followed by removal of outliers 
(2.5 standard deviations, Supplementary Fig. 21d–f).
Overlap with GWAS hits and pathways analysis. We overlapped our set of 
interaction eQTL with GWAS variants that are part of the NHGRI-EBI GWAS 
catalog33 that pass the genome-wide significance threshold (P < 5 × 10–8). We 
defined a colocalization event based on (i) eQTL and GWAS variants are within 
10 kb and (ii) high linkage disequilibrium between variants (r2 ≥ 0.8, estimated 
from Phase 3 1000 Genomes reference panel). For the pathway enrichment 
analysis, we used the following procedure for each analyzed interaction eQTL:  
(i) we used StructLMM to predict per-individual allelic effects (described above); 
(ii) we defined the groups of samples with the highest or lowest predicted allelic 
effect, each containing 10% of the total number of samples (N = 204); (iii) we 
computed rank-based correlation of genome-wide expression levels and the 
vector of group binary indicators (based on N = 408 samples); (iv) we defined the 
100 genes with the highest positive correlation as differentially expressed; (v) we 
performed enrichment analysis of GO biological processes in the differentially 
expressed test using topGO50 (standard Fisher’s exact test, algorithm = classic, 
nodeSize = 5). In Supplementary Table 6, we report both the top-enriched  
broad biological process and the three top-enriched narrow processes  
(broad/narrow terms are defined as those with more/less than 100 annotated  
genes in the background set). In the CTSW example in Fig. 5, the aggregate 
interacting environment was estimated as described above.
Further statistical details and derivates are provided in Supplementary Note.
Reporting Summary. Further information on research design is available in the 
Nature Research Reporting Summary linked to this article.
Code availability. StructLMM is available from https://github.com/limix/struct-
lmm and is supported within the LIMIX framework51 at https://github.com/limix/
limix. For tutorials and illustrations on how to use the model, see http://struct-
lmm.readthedocs.io.
Data availability
The BIOS RNA data can be obtained from the European Genome-phenome 
Archive (EGA; accession EGAS00001001077). Genotype data are available from 
the respective biobanks.
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Supplementary tables 
  
 
Supplementary Table 1 | Parameters used for the simulation experiments. Shown are 
the default parameter values and ranges as considered in the calibration and power 
experiments. Specifically, simulation experiments shown in (Fig. 1,2, Supp. Fig. 2) are based 
on empirical environments from UK Biobank, varying the sample size (𝑁), the number of 
environments (𝐿), the percentage of environments that contribute to GxE (𝜋), sample variance 
explained by the total genetic effect (G+GxE effect, 𝑣௚), fraction of the genetic variance due to 
GxE (𝜌) and the variance explained by additive environmental effects (𝑣௘), population structure 
(𝑣௣௢௣), residual noise (𝑣௡) and number of unobserved environments contributing to GxE 
(𝐿୳୬୭ୠୱ). Default parameter values are shown in bold and are left constant when varying other 
parameters. In additional simulations based on synthetic environments (Supp. Fig. 3,4), we 
vary LD between variants that affect environments and variants with G or GxE effects (𝑟ଶ), the 
average fraction of variance explained by the variant across environments (𝑣௫, heritability). 
For simulated skewed environments, we vary the shape parameter of the gamma distribution 
(𝑎) and finally, for binary environments, we vary both the fraction of environments that are 
binary (𝑓஻) and the event frequency (𝜈). All remaining genetic parameters were set to default 
parameters. 
 
Supplementary Table 2 | Tabular overview of considered methods. Shown is the name of 
the method (column 1; name of the association method displayed and ‘-int’ appended to the 
single- and multi-environment test names for the corresponding interaction tests), whether a 
random or fixed effect term is used to model GxE under the alternative hypothesis (column 2), 
whether a random or fixed effect term is used to model the additive environment (column 3), 
the statistical test used to assess the alternative hypothesis (column 4), how many parameters 
are used to model the additive environment (column 5), the number of additional parameters 
used to model the alternative hypothesis versus the null hypothesis for interaction and 
association tests (columns 6 and 7 respectively). The number of model parameters in the final 
three columns assume that 60 environmental variables are used in the test (default simulation 
setting; see Supp. Table 1). The tests are grouped into multi-environment tests, single-
environment tests, and linear association tests. Representative methods that are considered 
in main text results are highlighted in bold. 
 
Supplementary Table 3 | Interactions identified by StructLMM for BMI in UK Biobank. 
Provided as supplementary data file Supplementary_table_3.xlsx. 
 
Supplementary Table 4 | Associations identified by StructLMM and LMM in the 
association analysis of BMI using data from UK Biobank. Provided as supplementary data 
file Supplementary_table_4.xlsx. 
 
Supplementary Table 5 | Summary table of interaction eQTL analysis in blood cohort. 
Provided as supplementary data file Supplementary_table_5.xlsx. 
 
Supplementary Table 6 | Pathway enrichment analysis for interactions eQTL that are in 
linkage with GWAS loci. Provided as supplementary data file Supplementary_table_6.xlsx. 
 
Supplementary Dataset 1 | eQTL Manhattan plots for interaction eQTL that colocalise 
with disease variants. Manhattan plots provided as supplementary data file 
Supplementary_data_1.zip. 
 
Supplementary Dataset 2 | Interaction eQTL colocalising with disease variants.  Figures 
analogous to Fig. 5b-d for 64 interaction eQTL with putative colocalisation with disease 
variants, provided as supplementary data file Supplementary_data_2.zip. 
Supplementary figures 
 
 
Supplementary Figure 1 | Calibration of StructLMM and comparison with alternative 
multi-environment tests. (a) QQ plots of negative log P values from StructLMM-int (green) 
and StructLMM (blue) for 103,527 variants on chromosome 21, either simulating no genetic 
effects (no G, no GxE, 𝑣௚ ൌ 0) or simulating persistent genetic effects (no GxE, 𝜌 ൌ 0; only 
StructLMM-int). Simulations are based on 100 environments (𝐿 ൌ 100, 𝜋 ൌ 100%). From top 
to bottom: increasing sample sizes of a synthetic population based on the European 
population from the 1000 Genomes project: 1,000 individuals, 2,000 individuals and 5,000 
individuals.  Default parameters were used for all other simulation settings; see Supp. Table 
1. 
(b) Genomic inflation factor 𝜆ୋେ of P values from StructLMM and alternative multi-environment 
tests based on fixed effects (Supp. Table 2), for different numbers of environmental variables 
(𝐿, 𝜋 ൌ 100%; x-axis) and for increasing sample size (𝑁, top to bottom). Shown are results 
from StructLMM-int and multi-environment fixed effect interaction tests (column 1), and 
equivalent association tests (column 2) when no genetic effects are simulated (𝑣௚ ൌ 0). 
Column 3 depicts results from StructLMM-int and multi-environment fixed effect interaction 
tests for simulated persistent genetic effects (𝜌 ൌ 0). Multi-environment fixed effect models 
using LR tests yielded inflated test statistics (inflation factors GC>1) for large numbers of 
environmental factors in relation to the sample size, whilst score tests yielded deflated 
statistics (inflation factors GC<1) for the corresponding settings. StructLMM was calibrated in 
all settings. (c,d) Performance assessment of alternative methods for detecting interactions 
(top panels) and associations (bottom panels) based on simulated data, using the settings as 
in Fig. 2b,c and Supp. Fig. 2a,b for two sample sizes: 𝑁 ൌ 2,000 (c) and 𝑁 ൌ 5,000 (d). 
Compared were StructLMM-int and alternative multi-environment interaction tests based on 
fixed effects (Supp. Table 2, top panels), StructLMM and additional multi-environment 
association tests (Supp. Table 2, bottom panels). As the fixed effect tests are not always 
calibrated (see panel b), shown are model performance values as assessed by the area under 
the curve (relative AUC, in the range 0<FPR<0.10, normalised such that 0 corresponds to 
chance performance and 1 to an ideal model).   
 
 
 
 
 
 
 
Supplementary Figure 2 | Assessment of power using simulated data. Power comparison 
of alternative methods for detecting interactions (top panels) and associations (bottom panels) 
based on simulated data, extending the results as shown in Fig. 2, varying (a) the fraction of 
the genetic variance explained by GxE (𝜌), (b) the number of environments with non-zero GxE 
effects (𝜋ሻ, (c) the total number of environments (𝐿, 50% contributing to GxE effects), (d) the 
fraction of variance explained by additive environment effects (𝑣௘) and (e) the number of 
environments that contribute to GxE but are not used (observed, 𝐿୳୬୭ୠୱ) for the respective 
tests. Considered were top panels: the StructLMM interaction test (StructLMM-int) and 
alternative implementations of single-environment interaction tests (Supp. Table 2); bottom 
panels: StructLMM association test and alternative implementations of 2-df fixed effect tests 
that jointly tests for persistent associations and interactions with a single environment (Supp. 
Table 2), as well as alternative implementations of linear (mixed) models to test for persistent 
effects (Supp. Table 2). Methods were assessed in terms of power (at FWER<1%) for 
detecting simulated causal variants (Methods). Stars denote default values of genetic 
parameters, which were retained when varying other parameters (see Supp. Table 1 & 
Methods for details on the simulation strategy). A synthetic European population of 5,000 
individuals based on 1000 Genomes Project genotypes was used for all experiments 
(Methods). 
 
 
 
Supplementary Figure 3 | Assessment of power and calibration in the presence of 
heritable exposures. Power comparison of alternative methods for detecting interactions (top 
panels) and associations (bottom panels) with simulated genetic effects both on environmental 
variables and phenotypes. Considered were (a) increasing the LD (r2) between causal variants 
associated with the environment and those with additive G and GxE effects on the phenotype 
and (b) the average fraction of the exposures variance explained by genetic effects. Stars 
denote the default value that was retained when varying the other parameter (see Supp. Table 
1). Top panel: power to detect interactions, considering the StructLMM interaction test 
(StructLMM-int) and the default implementation of the single-environment interaction tests 
(SingleEnv-Renv-int, Supp. Table 2). Bottom panel: power to detect association, considering  
StructLMM, the default 2-df fixed effect test that jointly tests for persistent associations and 
interactions with a single environment (SingleEnv-Renv, Supp. Table 2), and linear models to 
test for persistent effects (LM, LMM-Renv, Supp. Table 2). Models were assessed in terms of 
power (FWER<1%) for detecting simulated causal variants (Methods). (c) QQ plot of negative 
log P values obtained from StructLMM-int (green) and StructLMM (blue) for pronounced gene-
exposure correlations (𝑣௫ ൌ 0.2), when no genetic effects are simulated (𝑣௚ ൌ 0) for 103,527 
variants on chromosome 21. (d) QQ plot of negative log P values obtained from StructLMM-
int (green) when persistent genetic effects were simulated (𝜌 ൌ 0), assuming strong LD 
between gene-exposure effects and variants associated with phenotype (𝑣௫ ൌ 0.2, r2 ൌ 1) for 
103,527 variants on chromosome 21. Stars denote default values of genetic parameters, 
which were retained when varying other parameters (see Supp. Table 1 & Methods for details 
on the simulation strategy). A synthetic European population of 5,000 individuals based on 
1000 Genomes Project genotypes was used for all experiments (Methods). 
 
 
 
Supplementary Figure 4 | Assessment of power and calibration using simulated data 
for skewed and binary environments. (a-c) Power comparison and calibration when 
simulating skewed environments drawn from a Gamma distribution. (a) Power comparison for 
varying shape of the gamma distribution (low values correspond to skewed environments, 
shape 100 correspond to approximately Gaussian distributed environments). (b,c) QQ plots 
of negative log P values obtained from StructLMM and StructLMM-int on data with skewed 
environments for 103,527 variants on chromosome 21, when simulating no genetic effect 
(𝑣௚ ൌ 0) (b) or when simulating persistent genetic effects (c, StructLMM-int only, 𝜌 ൌ 0). (d-g) 
Power comparison and calibration for simulated binary environments. (d) Power comparison 
when varying the fraction of binary environments 𝑓஻ (for constant event frequency 𝜈). (e) Power 
comparison when varying the event frequency of binary environments. Stars denote the 
default value that was retained when varying the other parameter (see Supp. Table 1). (f,g) 
QQ plots of negative log P values obtained from StructLMM and StructLMM-int for rare binary 
environments for 103,527 variants on chromosome 21, either simulating no genetic effect 
(𝑣௚ ൌ 0) (f) or for simulated persistent genetic effects (g, StructLMM-int only, 𝜌 ൌ 0). Fixed 
parameter settings are indicated in the top left corner of the corresponding panels.  A synthetic 
European population of 5,000 individuals based on 1000 Genomes Project genotypes was 
used for all experiments (Methods). 
 
 
 
 
 
Supplementary Figure 5 | Covariance structure of UK Biobank individuals based on 64 
environmental variables. Sample covariance matrix for 5,000 randomly selected individuals, 
calculated based on 64 environmental variables considered for UK Biobank analyses: 12 diet-
related factors, three factors linked to physical activity and a six lifestyle factors, modelled as 
gender-adjusted and age-adjusted (Methods). Dark red denotes pairs of individuals with 
stronger environmental similarity, whilst blue corresponds to negative covariance of 
environmental similarity (anti correlation). Blocks of strong correlation/anti correlation, 
correspond to groups of individuals of the same gender. 
 
Supplementary Figure 6 | Structure of 64 environmental variables considered for UK 
Biobank analyses. Shown are correlation coefficients between pairs of environmental 
variables, considering 12 diet-related factors, three factors linked to physical activity and a six 
lifestyle factors, modelled as gender-adjusted and age-adjusted (Methods). Environments are 
ordered using hierarchical clustering. 
 
 
  
 
Supplementary Figure 7 | Calibration of interaction and association tests on UK 
Biobank data. QQ plots of negative log P values from different interaction and association 
tests applied to UK Biobank BMI phenotype data (n = 252,188 unrelated individuals of 
European ancestry) based on permuted genetic variants (chromosome 20, 173,297 variants). 
(a) QQ plots of negative log P values for StructLMM-int (green), StructLMM (blue), LM (light 
grey) and LMM-Renv (yellow). (b) QQ plots of negative log P values for SingleEnv-Renv-int, 
for each of 64 considered environmental variables. LM, LMM-Renv and StructLMM tests were 
calibrated, whereas the fixed effect interaction tests show variable levels of statistical 
calibration. See Supp. Table 2 for an overview of considered methods. 
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Supplementary Figure 8 | Supplementary results for interactions identified by 
StructLMM. (a-c) Local Manhattan plots of interactions identified by StructLMM at FTO, 
SEC16B and PARK2 respectively. From top to bottom: LMM-Renv association test, 
StructLMM interaction test, SingleEnv-Renv interaction test for the environment with the most 
significant GxE effect at the respective GIANT variant, local gene models. The red vertical line 
indicates the position of the GIANT variant as in Fig. 3a.  
 
 
 
 
Supplementary Figure 9 | Comparison of multi-environment GxE tests based on fixed 
effects on UK biobank data. (a) QQ plots of negative log P values from a multi-environment 
fixed effect model to test for associations while accounting for heterogeneity in effect sizes 
due to GxE (MultiEnv-Renv-LRT) and an interaction test (MultiEnv-Renv-LRT-int) applied to 
UK Biobank BMI phenotype data and permuted genetic variants (chromosome 20, 173,297 
variants), which are calibrated for this sample size (n = 252,188). (b) Scatter plot of negative 
log P values from GxE interaction tests at 97 GIANT variants (Locke et al., 2015), considering 
the MultiEnv-Renv-LRT-int interaction test (x-axis) versus the StructLMM-int test (y-axis). 
Dashed lines correspond to α<0.05, Bonferroni adjusted for the number of tested GIANT 
variants and colour denotes the estimated fraction of genetic variance due to GxE (fitted 
parameter 𝜌).  StructLMM-int and MultiEnv-Renv-LRT-int identified four and two significant 
loci respectively. (c) Scatter plot of negative log P values from the MultiEnv-Renv-LRT 
association test (x-axis) versus the StructLMM association test (y-axis). Dashed lines indicate 
genome-wide significance at P<5x10-8 and colour denotes the estimated fraction of genetic 
variance due to GxE (fitted parameter 𝜌), with (d) displaying a zoom-in view of variants close 
to genome-wide significance. StructLMM and MultiEnv-Renv-LRT identify 17,630 and 2,037 
significant variants respectively. All displayed results are generated using 252,188 unrelated 
individuals of European ancestry. 
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Supplementary Figure 10 | Comparison of different single and multi-environment 
interaction test based on fixed effects on UK Biobank data. Compared are two alternative 
single-environment tests (SingleEnv-Renv-int, SingleEnv-Senv-int), as well as a multi-
environment test (MultiEnv-Renv-LRT-int) based on fixed effects and StructLMM-int at 97 
GIANT variants (Locke et al., 2015). Scatter plot of negative log P values of (a) fixed effect 
tests, either accounting for additive environment effects of all environments (SingleEnv-Renv-
int, using random effects, x-axis) or of the single environment that is tested (SingleEnv-Senv-
int, using fixed effects, y-axis), (b) fixed effect tests, that account for additive environmental 
effects of the single environment tested (SingleEnv-Senv-int, x-axis) versus StructLMM-int (y-
axis), (c) single-environment fixed effect interaction test with an additive environmental 
random effect component (SingleEnv-Renv-int, x-axis) versus the multi-environment fixed 
effect interaction test (MultiEnv-Renv-LRT-int, y-axis) and (d) single-environment fixed effect 
interaction test with a fixed effect additive environment term accounting for the single 
environment that is tested for GxE effects under the alternative (SingleEnv-Senv-int, x-axis) 
versus the multi-environment fixed effect interaction test (MultiEnv-Renv-LRT-int, y-axis). 
Dashed lines correspond to α<0.05 and colour denotes the estimated fraction of genetic 
variance due to GxE (fitted parameter 𝜌).  For single-environment models (SingleEnv-Renv-
int, SingleEnv-Senv-int), shown is the Bonferroni adjusted minimum P value across the set of 
tested environments (P-adj). SingleEnv-Renv-int and SingleEnv-Senv-int identify the same 
significant loci, but different significant loci to those identified by MultiEnv-Renv-LRT-int. All 
displayed results are generated using 252,188 unrelated individuals of European ancestry. 
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Supplementary Figure 11 | Comparison of interaction test results for genome-wide 
variants associated with BMI on UK Biobank data. Comparison of the StructLMM 
interaction test (StructLMM-int), a single-environment interaction test (SingleEnv-Renv-int) as 
well as multi-environment fixed effect interaction test (MultiEnv-Renv-LRT-int), at 17,606 
variants that were significantly associated with BMI based on an LMM (LMM-Renv, P<5x10-
8). Scatter plots of negative log Benjamini-Hochberg adjusted P values (P-adj) between (a) 
SingleEnv-Renv-int (x-axis) versus StructLMM-int (y-axis), (b) MultiEnv-Renv-LRT-int (x-axis) 
versus StructLMM-int (y-axis) and (c) SingleEnv-Renv-int (x-axis) versus MultiEnv-Renv-LRT-
int (y-axis). Dashed lines correspond to P-adj<0.05 and colour denotes the estimated fraction 
of genetic variance due to GxE (fitted parameter 𝜌 based on StructLMM). For the single-
environment test (SingleEnv-Renv-int), shown is the Bonferroni adjusted minimum P value 
across the tested environments (P-adj). StructLMM-int identified 23 loci with GxE, followed by 
SingleEnv-Renv-int (11 loci) and MultiEnv-Renv-LRT-int (9 loci; FDR<5%, Benjamini-
Hochberg adjusted, LD clumped loci, r2<0.1 within 500kb, Methods; see Supp. Table 3 for 
full results). All displayed results are generated using 252,188 unrelated individuals of 
European ancestry. 
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Supplementary Figure 12 | Comparison of LMM and LM results on UK Biobank data. 
Scatter plot of genome-wide negative log P values from the LM association test, without 
accounting for additive environmental effects (x-axis), versus an LMM association test that 
accounts for additive environmental effects using the same random effect component as used 
in StructLMM (LMM-Renv, y-axis). Dashed lines indicate genome-wide significance at 
P<5x10-8. All displayed results are generated using 252,188 unrelated individuals of European 
ancestry. 
 
 
Supplementary Figure 13 | Distribution of the estimated extent of GxE for significant 
loci identified by the StructLMM association test and LMM-Renv on UK Biobank data. 
Cumulative number of significant associations (P<5x10-8, LD clumped loci, r2<0.1 within 
500kb, Methods) identified by LMM-Renv (yellow, N=327 loci) and StructLMM (blue, N=351 
loci) in decreasing (a) and increasing (b) order of the estimated extent of GxE (fitted parameter 
𝜌). (c) Estimated density of the fraction of genetic variance due to GxE (𝜌) for loci identified 
by LMM-Renv (yellow) and StructLMM (blue). (d) Histogram of the fraction of genetic variance 
due to GxE (𝜌), considering the subset of loci exclusively identified by either approach 
(Methods): LMM-Renv (yellow, total 16), StructLMM (blue, total 32). Loci identified by 
StructLMM tended to have a greater extent of GxE, whereas loci that were LMM-Renv 
specific tended to have no or little evidence for effect size heterogeneity due to GxE.  
The latter can be explained by the fact that StructLMM will be slightly less powered than the 
LMM-Renv when no or very little GxE is present since StructLMM is penalised for testing 
multiple values 𝜌 (see also Supp. Fig. 2). 
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Supplementary Figure 14 | Results from association tests applied to UK Biobank data. 
Manhattan plots, showing negative log P values obtained from (a) LMM-Renv and (b) the 
StructLMM association test. Additional loci identified by StructLMM (P<5x10-8) as in Supp. 
Table 4 are highlighted with a blue cross. The dashed red line denotes the genome-wide 
significance threshold (P<5x10-8). All displayed results are generated using 252,188 unrelated 
individuals of European ancestry. 
 
 
 
 
 
 
  
 
Supplementary Figure 15 | Local Manhattan plots for additional association loci 
identified by StructLMM versus LMM-Renv on UK Biobank data. Shown are additional 
associations as in Supp. Table 4, with the red vertical line indicating the position of the 
StructLMM lead variant. From top to bottom: Manhattan plot of negative log P values from 
StructLMM, LMM-Renv and the local gene models for (a-s) RP11-147C23.1, FAM150B, 
PLCL1, CCNL1, PCDH7, ANTXR2, NR2F1, HACE1, RGS17, ZNF596, NEK6, NRP1, 
rs9537309 (no gene within +/-500 kb), rs2875131 (no gene within +/-500 kb), rs9540493 (no 
gene within +/-500 kb), ONECUT1, ADAMTSL3 and ASXL3 respectively. Associations were 
assigned to genes based on the nearest protein coding gene within +/-500 kb respectively. 
The maximum LD (r2) between significant StructLMM variants in the loci exclusive to 
StructLMM under consideration and significant LMM-Renv variants in other loci within the +/-
500 kb region is 0.052, 0.00049 for panels (b and d) respectively. All displayed results are 
generated using 252,188 unrelated individuals of European ancestry. 
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Supplementary Figure 16 | Local Manhattan plots for additional association loci 
identified by StructLMM versus LMM-Renv on UK Biobank data. Shown are additional 
associations as in Supp. Table 4, with the red vertical line indicating the position of the 
StructLMM lead variant. From top to bottom: Manhattan plot of negative log P values from 
StructLMM, LMM-Renv and the local gene models. (a-n) PHC2, MAD1L1, BTRC, RP11-
73M18.2, PPCDC, AXIN1, RIT2, NANP, FAM182B, SMPD3, TERF2, PEPD, ZNF790 and 
MAPK1 respectively.  Loci were assigned to genes based on the nearest protein coding gene 
within +/-500 kb respectively. The maximum LD (r2) between significant StructLMM variants in 
the loci exclusive to StructLMM under consideration and significant LMM variants in other loci 
within the +/-500 kb region is 0.054 for panel (h). All displayed results are generated using 
252,188 unrelated individuals of European ancestry. 
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Supplementary Figure 17 | Out of sample prediction of per-individual allelic effect sizes. 
Assessment of per-individual allelic effects for 11 GIANT variants with evidence for GxE 
(lenient Benjamini-Hochberg adjustment, FDR<0.05, Supp. Table. 3), considering a 50:50 
split of the cohort into training and test fractions. (a) Violin plots, displaying the estimated 
density of individuals in the training fraction (n = 126,094) that exert an allelic effect of a 
particular size given the distribution of the environmental factors within the population (in 
sample estimates as in Fig. 4a; see Methods). Mean and the top and bottom 5% strata of the 
effect size distribution are indicated by the red and green bars, respectively. P values denote 
the significance of genetic effects assessed using LMM-Renv (not accounting for GxE) using 
individuals within the respective strata. Nominally significant associations (P<0.05, two-sided 
LR test) highlighted in red. (b) Analogous allelic effect size distribution as in a, displaying 
predictions in the test fraction (out-of-sample predictions, based on environmental states of 
individuals in the test fraction (n = 126,094) but without using BMI phenotypes; Methods). 
Yellow crosses denote the mean predicted genetic effect within the top and bottom 5% strata 
(considering strata with nominally significant associations in training fractions, i.e. P values 
that are highlighted in red in a). (c) Scatter plot of allelic effect sizes, predicted out of sample 
P = 0.0048
P = 0.010
P = 0.038
P = 0.00010
P = 0.53
P = 0.12 P = 0.016
P = 4.55x10-7
P = 0.27
P = 0.022
P = 0.0012
P = 2.54x10-18
P = 0.83
P = 1.15x10-12
P = 0.0022
P = 0.85
P = 0.67
P = 0.0013
P = 0.84
P = 0.00020P = 2.90x10-7
a
b
P = 0.0016
Es
tim
ate
d a
llel
ic e
ffe
ct
for test set individuals (yellow crosses in b, x-axis) versus within-sample estimates obtained 
from LMM-Renv based on test set individuals in the top and bottom 5% strata (not accounting 
for GxE, using the genotypes and phenotypes of the test set individuals in the strata). Different 
GIANT variants are coded in colour. (d) Analogous scatter plot as in c, however displaying the 
differences between genetic effects in the 5% strata and population estimates of persistent 
effects (effect sizes due to GxE).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplementary Figure 18 | Exploration of putative driving environments at the identified 
GxE interaction effects UK Biobank data. Relevance of individual environmental variable 
for GxE effects at four loci, showing Bayes factors (BF) between models containing all 64 
environments and models with a single environmental variable removed. Shown are results 
for (a) FTO, (b) SEC16B, (c) PARK2 and (d) MC4R, ordered by Bayes factor, with positive 
evidence above the dashed lines whilst those with negative evidence lie below. (e-g) 
Cumulative evidence of individual environmental variables contributing to GxE at FTO, 
SEC16B and PARK2, showing Bayes factors between the full model and models with 
increasing numbers of environmental variables removed using (greedy) backward elimination 
(Methods). For comparison, shown is the total evidence of all environmental variables. The 
additional environment that is removed at each elimination step is labelled on the y-axis with 
the total number of environmental variables removed in considered models shown in brackets. 
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Supplementary Figure 19 | Rank correlation of per-individual genetic effect sizes across 
loci for UK Biobank data. Shown are squared Spearman correlation coefficients of per-
individual (n = 252,188) allelic effects estimates for 11 GIANT variants with evidence for GxE 
(more lenient Benjamini-Hochberg adjustment, FDR<0.05, Supp. Table 3). 
 
 
 
 
Supplementary Figure 20 | Statistical calibration and power of alternative interaction 
tests applied to the blood eQTL dataset. Compared were the StructLMM interaction test 
(StructLMM-int) and multi-environment fixed effect tests with as many degrees of freedom as 
environmental variables (MultiEnv-Renv-LRT-int, labelled MultiEnv-int in the figure), as well 
as a multi-environment fixed effect test based on 20 principal components of the 
environmental variables (MultiEnv-20PC-Renv-LRT-int, labelled MultiEnv-20PC-int). Shown 
are results from applying all methods to test for cell-context interactions at 23,506 lead eQTL 
variants (n = 2,040; Methods). (a) QQ plot of negative log P values obtained on permuted 
genotype data. Whereas P values from StructLMM-int and MultiEnv-20PC-Renv-LRT-int were 
calibrated, MultiEnv-Renv-LRT-int yielded inflated P values, most likely owing to the large 
number of degrees of the freedom, and hence this model was not considered further. (b) 
Number of interaction eQTL discovered by StructLMM-int and MultiEnv-20PC-Renv-LRT-int 
as a function of the FDR threshold (Benjamini-Hochberg adjustment). (c,d) Scatter plot of 
negative log P values from StructLMM-int versus MultiEnv-20PC-Renv-LRT-int with a zoom 
in-view shown in panel d. Dashed orange lines correspond to the 5% FDR thresholds. (e,f) 
Overlap of the sets of interaction eQTL identified by StructLMM-int and MultiEnv-20PC-Renv-
LRT-int (e, FDR<5%; considering all 23,506 tested variants) and interaction eQTL identified 
in the primary analysis of the data (f, Zhernakova et al., FDR<5%; considering 17,952 shared 
lead eQTL between studies). 
 
 
 
 
 
Supplementary Figure 21 | Assessment of the robustness of interaction effects on the 
blood eQTL data to data pre-processing. Compared are the StructLMM-int results from the 
primary analysis and analogous results obtained using alternative data processing strategies 
(n = 2,040). First, to assess the potential of spurious associations due to strong gene-exposure 
associations, we considered a GxE analysis where for each analysed gene, the additive effect 
of the lead genetic variant was regressed out from all proxy genes used as environments prior 
to interaction testing (environments were rank-inverse transformed a second time; Methods). 
(a) Scatter plot of the negative log P values from the original (x-axis) and the analysis with 
environments that were adjusted for cis genetic effects (cis corr, y-axis). (b) Zoom-in view and 
(c) venn diagram of significant interaction effects (FDR<5%). (d-f) Analogous results 
considering boxcox normalisation followed by removal of outlying samples (gene expression 
levels that exceeded 2.5 standard deviations) as an alternative pre-processing strategy. (d-f) 
Analogous scatter plots and analysis of overlap as shown in a-c. Both control analyses 
recovered a large fraction of the primary interaction eQTL (98.8% and 75.2% respectively), 
indicating that the interactions identified are sufficiently robust.  
 
 
 
 
 
 
 
Supplementary Figure 22 | Distribution of estimated per-individual allelic effect sizes at 
interaction eQTL that colocalise with GWAS variants. (a) Upper panel: estimated fraction 
of genetic variance due to GxE effects (𝜌). Bottom panel: violin plots displaying the distribution 
of allelic effects for each locus across the environmental profiles in the population (n = 2,040). 
Blue lines in the violin plots show the median values of the distribution. (b) Zoom-in of a, 
depicting data from the eleven associations with the largest fraction of genetic variance 
attributable to GxE effects. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 23 | eQTL association for CTSW. Manhattan plot of negative log P 
values obtained from cis eQTL mapping of CTSW (n = 2,040). The red star indicates the lead 
eQTL variant, annotated with the identifier of the colocalising GWAS variant (rs568617, 
r2=1.00 associated to Crohn's disease); Manhattan plots for other putative colocalisation 
events are provided in Supp. Dataset 1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Note
Contents
1. The StructLMM model 3
1.1. Model definition . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3
1.2. Definition of the environment covariance . . . . . . . . . . . . . . . . . . 4
1.3. Derivation as marginalised linear G× E interaction model . . . . . . . . 5
1.4. Interaction and joint association tests . . . . . . . . . . . . . . . . . . . 5
1.4.1. Interaction test . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.4.2. Association test . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7
1.4.3. Computational complexity . . . . . . . . . . . . . . . . . . . . . . 9
1.5. Characterisation of G×E loci . . . . . . . . . . . . . . . . . . . . . . . . 9
1.5.1. Estimation of variance components and the fraction of genetic
variance explained by GxE . . . . . . . . . . . . . . . . . . . . . 9
1.5.2. Exploring the environments that drive the observed interaction
effects . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
1.5.3. Estimation of per-individual allelic effect sizes due to G× E . . . 11
1.5.4. Computational Complexity . . . . . . . . . . . . . . . . . . . . . 13
2. Relationship with prior work and comparison methods 13
2.1. Relationship to other G×E tests . . . . . . . . . . . . . . . . . . . . . . 13
2.2. Relationship to other LMM implementations . . . . . . . . . . . . . . . 15
3. Comparison methods 16
3.1. Single environment models . . . . . . . . . . . . . . . . . . . . . . . . . . 16
3.2. Association tests . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
3.2.1. Alternative multivariate G×E tests based on fixed effects . . . . 18
3.3. Original analysis of blood eQTL data . . . . . . . . . . . . . . . . . . . . 19
4. Simulations 20
4.1. Environment covariates . . . . . . . . . . . . . . . . . . . . . . . . . . . 20
4.2. Phenotype simulation strategy . . . . . . . . . . . . . . . . . . . . . . . 21
4.3. Gene-exposure correlations . . . . . . . . . . . . . . . . . . . . . . . . . 21
4.4. Skewed and binary environments . . . . . . . . . . . . . . . . . . . . . . 22
1
5. Analysis of BMI in UK Biobank 22
5.1. Hold-out validation of per-individual genetic effect sizes . . . . . . . . . 22
6. Analysis of cell-context eQTLs in a large blood cohort 23
6.1. Generation of principal components from SAMtools flagstat and Picard
tools . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
A. Proof for form of Q 23
2
1. The StructLMM model
1.1. Model definition
A conventional linear mixed model used for association testing can be cast as
y = Xb+ xβG︸︷︷︸
G
+u+ψ, (1)
where y denotes the N × 1 phenotype vector for N individuals, x denotes the N × 1
genotype vector of the focal variant, X ∈ RN×K the fixed effect design matrix of K
covariates and b ∈ RK×1 their effect sizes. The variable u is a random effect and
can be used to account for additional additive effects, such as population structure,
environment or other additive (confounding) factors and ψ denotes iid noise. The
random effect component u and the noise vector ψ are assumed to follow multivariate
normal distributions
u ∼ N (0, σ2eΣu) (2)
ψ ∼ N (0, σ2nIN) , (3)
where the covariance matrix Σu ∈ RN×N is the covariance sample structure of the
random effect. Under this conventional linear model, the focal variant x is assumed
to have a persistent genetic effect on all samples included in the analysis.
StructLMM extends the conventional linear mixed model by including an additional
per-individual effect term that accounts for G×E, which can be represented as an N×1
vector, βG×E. The model can be cast as
y = Xb+ xβG︸︷︷︸
G
+x βG×E︸ ︷︷ ︸
G×E
+ u︸︷︷︸
E
+ψ, (4)
where  denotes the element-wise (Hadamard) product. The per-individual effect size
vector βG×E is modelled as random effect, following the multivariate normal distribu-
tion
βG×E ∼ N
(
0 , σ2G×EΣ
)
, (5)
where the covariance matrix Σ ∈ RN×N parameterises how per-individual effects co-
vary across individuals and is calculated as a function of observed environmental vari-
ables Σ ≡ Σ (E) ∈ RN×N , where E is the N ×L matrix of L observed environments.
Note that for the special case σ2G×E = 0, this model reduces to a standard linear
mixed model for genetic association testing. In StructLMM, the random effect compo-
nent u is used to account for additive environmental effects. While in general different
covariance functions could be considered for additive environmental effects and in-
teractions, we assume Σu ≡ Σ for simplicity. Specific choices for the environmental
covariance Σ(E) are discussed in Section 1.2.
3
Marginal Likelihood For parameter inference, we consider the marginalised form of
the model in Eq (4), which is obtained by integrating over the G×E effects βG×E and
the random effect component u
y ∼ N
Xb+ xβG︸︷︷︸
G
, σ2G×Ediag(x)Σdiag(x)︸ ︷︷ ︸
G×E
+σ2eΣ︸︷︷︸
E
+ σ2nI︸︷︷︸
noise
 . (6)
Here, we used the identity xβG×E = diag(x)βG×E in Eq (4), with diag(x) denoting
the N ×N diagonal matrix whose diagonal is x.
1.2. Definition of the environment covariance
In principle, StructLMM can be applied with any valid covariance function [1] of the
observed environments. In this work, we only consider linear covariance functions, de-
fined on a potentially large number of continuous and discrete environmental variables
Σ (E) = EET . (7)
The use of a linear covariance function was primarily motivated by two appealing prop-
erties. First, as the number of samples typically exceeds the number of environments
in larger cohorts (L << N), the linear covariance will be low-rank, enabling parame-
ter inference with a computational complexity that scales linearly with the cohort size
(Section 1.4.3). Second, a linear covariance is directly interpretable as there is a one-
to-one correspondence between StructLMM and multivariate linear regression using L
covariates to account for the interaction term (see Section 1.3). Note that, depending
on the choice of E, the linear covariance can be used to (i) model group-specific effects,
which correspond to the setting where Σ is a block diagonal matrix with blocks cor-
responding to the different groups, or per-individual effect sizes (see Fig. 1b-c) and
(ii) account for non-linear relationships between the observed environmental variables
by combining simple observed environments to create more complex ones (similar to
the use of basis functions; see below for more details).
Normalisation of environmental variables A standard strategy to normalise the vari-
ables for defining a linear covariance is to consider standardised features rescaled by
1√
L
. This normalisation ensures that the resulting random effect has sample mean 0
and sample variance 1 [2]. Other normalisation procedures, including row standard-
isation, such that the resulting random effect has per-individual variance 1 or is a
correlation matrix, are also valid [1]. Different normalisation procedures correspond
to slightly different assumptions regarding the variance explained by different environ-
ments within the interaction and additive environment term, similar to building linear
covariances using genetic factors [3].
Accounting for non-linear relationships between environmental variables Non-
linear effects can be accounted for by introducing additional transformed environmen-
tal variables, similar to using basis functions for non-linear regression. For example,
4
to model possible dependencies of G×E and additive environmental effects of L envi-
ronments e1, . . . , eL with a categorical variable c ∈ {0, 1}N×1 (e.g. gender), one can
define Σ using the extended set of environments E = [c⊗ e1, . . . , c⊗ eL, (1N − c)⊗
e1, . . . , (1N − c) ⊗ eL] ∈ RN×2L. This approach is used to define a gender-adjusted
and age-adjusted environmental covariance.
1.3. Derivation as marginalised linear G× E interaction model
When using a linear environmental covariance, StructLMM can be interpreted as a
random-effect implementation of the multi-environment linear interaction model where
persistent genetic and G×E effects are modelled as fixed effects. This relationship is
similar to the well-known equivalence between multivariate Bayesian linear regression
and a linear mixed model (e.g. [4]). Briefly, denoting with e1, . . . , eL the set of observed
N × 1 vectors for L environmental variables, the linear model underlying StructLMM
can be cast as
y = Xb+ xβG︸︷︷︸
G
+
L∑
l=1
(x el)βl︸ ︷︷ ︸
G×E
+
L∑
l=1
elαl︸ ︷︷ ︸
E
+ψ, (8)
where ψ ∼ N (0, σ2nIN). Defining prior variances on G×E and additive environmental
effects
βl ∼ N (0, σ2G×E), (9)
αl ∼ N (0, σ2e), (10)
and marginalising over βl and αl results in the marginalised StructLMM model in
Eq. (6). It is of note that both the association and interaction tests in StructLMM can
also be directly implemented in the fixed effect framework, without marginalization.
These alternative tests are considered in Supp. Fig. 1b, where we observe that
fixed effect tests are not always calibrated and are underpowered in some settings. See
Section 3.2.1 for full details on the implementation of alternative methods that are
compared to StructLMM.
1.4. Interaction and joint association tests
We define two variance component score tests based on the StructLMM model, (i) an
interaction test to identify loci with G×E and (ii) an association test that accounts
for heterogeneity in genetic effect sizes due to G× E (jointly testing the G and G×E
effects).
1.4.1. Interaction test
Using the marginalised model in Eq. 6, a test for G×E interactions corresponds to the
alternative hypothesis σ2G×E > 0. We define an efficient score-based test that enables
the calculation of P values with a complexity that scales linearly in the number of
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individuals, provided that the environment covariance Σ is low rank. We note that
the null of the interaction test reduces to a standard linear mixed model with a low-
rank covariance matrix for additive random effects, for which existing efficient inference
strategies can be reused [5].
Score test for interaction test In the model in Eq (4-5), the score-test statistics can
be computed analogously to the procedure described in [6]
Q =
1
2
yTPK1Py
=
1
2
yTP (diag(x)Σdiag(x))Py
=
1
2
yTP
[
diag(x)E
]︸ ︷︷ ︸
W
[
diag(x)E
]T
Py
=
1
2
∥∥W TPy∥∥2 . (11)
where we have defined
K1 = diag(x)Σdiag(x),
W = diag(x)E,
P = H−10 −H−10 [X,x]
(
[X,x]TH−10 [X,x]
)−1
[X,x]TH−10 . (12)
The matrix H0 denotes the total covariance matrix estimated under the null model
H0 = σˆ
2
eΣ + σˆ
2
nI, (13)
where σˆ2e and σˆ
2
n correspond to the (null model) maximum likelihood estimates (MLE)
of σ2e and σ
2
n. It can be shown that Q follows a mixture of χ
2 distributions [6, 7]
Q ∼
∑
k
akχ
2
1, (14)
where the vector of the coefficients a = [ak]k can be computed as the eigenvalues of
P
T
2K1P
1
2
a = eigh
(
P
T
2K1P
1
2
)
(15)
= eigh
(
W TPW
)
. (16)
As the distribution of the score test statistics is a mixture of χ2, following the proce-
dure in SKAT [6], P values are computed using Davies method [8] (an exact method
which directly inverts the characteristic function), switching to the Liu method [9] (an
approximation method based on moment matching) when the Davies method fails to
converge (see [10] for full details).
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1.4.2. Association test
To define a joint association test that accounts for the possibility of effect size het-
erogeneity, we consider a fully marginalised form of the model described in Eq. 4,
where both the G×E and the persistent effect effect sizes, following distributions
βG×E ∼ N
(
0 , σ2G×EΣ
)
and βG ∼ N
(
0 , σ2G
)
, respectively, are integrated out. This
fully marginalised model can be cast as
y ∼ N
Xb , σ2GtotKρ︸ ︷︷ ︸
G+G×E
+σ2eΣ︸︷︷︸
E
+ σ2nI︸︷︷︸
noise
 (17)
where σ2Gtot = σ
2
G + σ
2
G×E denotes the total variance of the genetic effect (including
both persistent and G×E components). Additionally, we have introduced
Kρ = (1− ρ) xxT︸ ︷︷ ︸
G
+ ρdiag(x)Σdiag(x)︸ ︷︷ ︸
G×E
, (18)
where the parameter ρ is defined as the fraction of the total genetic variance explained
by G×E effects, ρ = σ2G×E/σ2Gtot . We note that this fully marginalised form of the
model can also be derived from the linear model
y = Xb+ x β + u+ψ, (19)
by marginalizing over β, assuming the following multivariate normal prior
β ∼ N
0 , σ2Gtot
(1− ρ)11T︸ ︷︷ ︸
G
+ ρΣ︸︷︷︸
GxE
 . (20)
Note that in this representation β accounts for G and G×E effects, with the first
covariance term corresponding to a persistent genetic effect (G, full correlation of the
genetic effect sizes across individuals) whereas the second covariance term accounts
for heterogeneity of genetic effect sizes due to G×E.
In the marginalised form of the model given by Eq (17-18), an association test corre-
sponds to assessing the alternative hypothesis σ2Gtot > 0. The form of both the model
and the test allow us to implement an efficient optimal score test procedure, building
on the work in [11]. This score-based test again has complexity that scales linear in
the number of individuals, provided that the environment covariance Σ is low rank.
Below we present details of how the test is implemented, first considering the case of
known ρ followed by general case of unknown ρ.
Score test for given ρ. The score test for given ρ is analogous to the one described in
Section 1.4.1 but with K1 replaced by Kρ =
(
(1− ρ) xxT + ρdiag(x)Σdiag(x)) such
that W =
[√
1− ρx √ρdiag(x)E] and [X,x] replaced by X.
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Score test for unknown ρ. As in the test σ2Gtot > 0 in the marginalised model in
Eq (17-18), the fraction of genetic variance due to G×E (ρ) is in general unknown,
one would like to select ρ to maximise detection power. Following [11], we define the
optimal score test as follows:
1. Define a grid of R values ρ1 < ρ2 < · · · < ρR for ρr (by default, we consider
[0, 0.5, 0.75, 0.84, 0.91, 0.96, 0.99, 1]);
2. For each value ρr, compute the score test statistic Qρr using Eq (11) and
corresponding P values pρr using the modified Liu method (an approximation
method);
3. Compute a P value for the test statistic T = min {pρ1 , . . . , pρR}.
By definition, this P value can be computed from Qρ1 , . . . , QρR and T as
PT = p(t < T ) = 1− P (Qρ1 < qρ1(T ), Qρ2 < qρ1(T ), ..., Qρν < qρ1(T )) (21)
where qρr (T ) denotes the (1− T )th percentile of Qρr . It can be shown that Qρ can be
written as follows (see derivation in Appendix A)
Qρ =
1
2
ρκ+
1
2
τρη0, (22)
where
κ =
m∑
k=1
λkηk + ξ (23)
λ = eigh (Λ) (24)
Λ = Λ0 − 1
c
ααT (25)
Var (ξ) =
4
c
αTΛ0α− 4
c2
(
αTα
)2
(26)
τρ = c(1− ρ) + ρ
c
αTα (27)
ηk
iid∼ χ21 (28)
Λ0 = E
Tdiag(x)Pdiag(x)E (29)
α = ETdiag(x)Px (30)
c = xPxT . (31)
Replacing Eq (22) in Eq (21) results in
PT = p(t < T ) = 1− E
[
P (κ < min { (2qρr (T )− τρrη0) /ρr| η0}Rr=1
]
, (32)
This P value can computed using one-dimensional numerical integration in the same
manner as for the interaction test; using Davies method [8] (an exact method which
directly inverts the characteristic function), switching to the Liu method [9] (an ap-
proximation method based on moment matching) when convergence fails (see [11, 10]
for details).
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1.4.3. Computational complexity
To evaluate the interaction and joint association tests, we need to first fit the null model
and then compute the corresponding score test statistics. A naive implementation of
both of these operations would result in computations that scale cubically with the
number of individuals, i.e. O(N3). To reduce the complexity of both operations,
we exploit that, when considering a linear covariance of L environments, the total
covariance matrix is
σ2eEE
T + σ2nI, (33)
where the first term is low rank (L << N). In this setting, the null model can be fit
with computational complexity O(NR2 +R3), where R is the rank of the first covari-
ance term term (in Eq (33), in this case, R = L). We refer to [7, 12] for further details.
Concerning the computation of the score test statistics for interaction test, Q can be
calculated with computational complexity O(NL2 +NK2 +NLK +L2K +K3 +L3)
where K corresponds to the number of covariates, while the coefficient a of the χ21-
mixture (eigenvalues of W TPW , see Eq (16)), can be computed in O(NL2 +NK2 +
NLK +L2K +K3 +L3). The computation of P values either using the Davies or Liu
method does not depend on the number of individuals.
For the association test for unknown ρ, the standard score-based procedure is re-
peated multiple times, corresponding to the number of values in the grid search over
ρ. The additional variables that need to be computed (see Eqs 23-31) have linear com-
putational complexity with the number of individuals. Finally, the one-dimensional
numerical integration step (using Davies or Liu method) has a computational com-
plexity that is independent of the number of individuals.
1.5. Characterisation of G×E loci
The StructLMM framework facilitates different analyses for characterising G×E ef-
fects. Although all the computations of these analyses remain linear in the number of
individuals, the underlying computations are less efficient than those required for score
tests, as maximum likelihood model parameters need to be determined explicitly for
each variant that is considered. For this reason, we recommend using these analyses
exclusively at the suggestive loci identified by StructLMM association and interaction
tests.
1.5.1. Estimation of variance components and the fraction of genetic variance
explained by GxE
StructLMM allows for decomposing the phenotypic variance into genetic (G), G×E
and additive environment (E) variance components. Based on the marginalised model
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in Eq (6), the three variance components can be estimated as
var(G) = varS
(
xβˆG
)
= βˆ2GvarS (x) , (34)
var(G×E) = varM
(
σˆ2G×E(xE)(xE)T
)
, (35)
var(E) = varM
(
σˆ2EEE
T
)
. (36)
Here, varS denotes the sample variance and varM(K) denotes the expected value of
the sample variance of z with z ∼ N ( 0 , K ). We also use the following two identities
for terms that involve the linear covariance matrix, Σ = EET , diag(x)Σdiag(x) =
(x E)(x E)T ∗ and denote the MLE estimates of βG, σ2G×E and σ2E as βˆG, σˆ2G×E
and σˆ2E, respectively.
Using varM(K) =
1
N−1 tr(PK), where P = I − 1dim(K)11T [2, 13], we obtain
var(G×E) =
1
N − 1 σˆ
2
G×E ‖P (xE)‖2 (37)
var(E) =
1
N − 1 σˆ
2
E ‖PE‖2 . (38)
Finally, the estimated fraction of genetic variance explained by G×E effects (ρ) follows
as
ρˆ =
var(G×E)
var(G) + var(G×E)
. (39)
It can be seen that this is equivalent to ρ described in Section 1.4.2 (optimal score test
procedure), such that var(G×E) ≡ σ2G×E and var(G) + var(G×E) ≡ σ2tot
Note that the estimate ρˆ is based on a MLE whilst the estimate obtained from the opti-
mal score test procedure corresponds to the minimum P value obtained from searching
over a grid of predefined values, which has a different objective.
1.5.2. Exploring the environments that drive the observed interaction effects
The evidence of individual environmental variables or sets of environments for driving
the observed G×E effects can be assessed by comparing the log marginal likelihood
of models with and without these environments included. The resulting Bayes fac-
tors from such comparisons are directly calibrated because the number of parameters
fit using maximum likelihood is independent of the number of environmental variables.
Given a variant and a set of L environments E = {e1, . . . , eL}, the evidence for a
subset of environments, Ei ⊆ E , Li < L driving the observed G×E effect can be
estimated as
log(Bayes factor)(Ei) = LML(ME)− LML(ME\Ei) (40)
∗We use the  operator between vectors and matrices to denote the matrix obtained by the
element-wise multiplication of matrix columns by the input vector.
10
where LML(ME) and LML(ME\Ei) denotes the marginal log-likelihood of the model
in Eq (6), either considering the full or reduced sets of environments to define the
G×E environment covariance respectively. Specifically, while in ME all environments
are used in the G×E covariance, in ME\Ei only the environments not in Ei are consid-
ered (the operation \ denotes the set difference). Note that the additive environment
covariance remains the same in both models and is always estimated using all envi-
ronments. To identify a putative causal set of driving environments, we use a greedy
backward elimination procedure. Initially, we calculate the log(Bayes factor) for each
environmental variable, to identify the marginal environment with the most evidence:
imax = argmaxi (log(Bayes factor)(Ei)). Subsequently, this environment is removed
and the process iterated, stopping when there is positive evidence based on the log
Kass and Raftery scale [14] that we have selected a full set of environments that can
drive the observed G×E effect (i.e. when the delta log(Bayes Factor) between the
model under consideration and the model that removes all environmental variables is
<1).
1.5.3. Estimation of per-individual allelic effect sizes due to G× E
StructLMM allows for estimating per-individual allelic effect sizes of selected variants
based on the distribution of environmental profiles attained in a population. For a
given locus, the effect size of the non-reference allele in environment profile e? can be
estimated using a procedure based on the best linear unbiased predictor (BLUP, [15]):
1. Estimate the G + G×E effect for a homozygous reference individual in environ-
mental profile e? using BLUP and the model in Eq (6)
ref(e?) = xrβˆG︸ ︷︷ ︸
G
+ σˆ2G×Exre
?T (xE)T Hˆ−1
(
y −Xbˆ− xβˆG
)
︸ ︷︷ ︸
G×E
. (41)
Here, Hˆ, βˆ and bˆ are MLE of the total covariance matrix, the genetic effect size
β and the covariate effect sizes b in the model in Eq (6), while xr is the value
corresponding to the encoding of the homozygous reference genotype.
2. Compute the BLUP of the G + G× E for a heterozygous individual in environ-
mental profile e? using the same model
alt(e?) = xaβˆG︸ ︷︷ ︸
G
+ σˆ2G×Exae
?T (xE)T Hˆ−1
(
y −Xbˆ− xβˆG
)
︸ ︷︷ ︸
G×E
, (42)
where xa corresponds to the encoding of the heterozygous genotype.
3. The allelic effect in environment profile e? is then defined as the difference be-
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tween alt(e?) and ref(e?)
β(tot)(e?) = alt(e?)− ref(e?) (43)
= (xa − xr)
 βˆG︸︷︷︸
G
+ σˆ2G×Ee
?T (xE)T Hˆ−1
(
y −Xbˆ− xβˆG
)
︸ ︷︷ ︸
G×E
(44)
= (xa − xr)
 βˆG︸︷︷︸
G
+βG×E(e?)︸ ︷︷ ︸
G×E
 (45)
In order to compute allelic effects for N? different environmental profiles {e?1, . . . , e?N?},
we use Eq (44) in vectorial form as
β(tot)(E?) = (xa − xr)
1N βˆG︸ ︷︷ ︸
G
+ σˆ2G×EE
?(xE)T Hˆ−1
(
y −Xbˆ− xβˆG
)
︸ ︷︷ ︸
G×E
 , (46)
where β(tot) is N? × 1 vector of genetic effects in the corresponding N? profiles and
E? is the N? × L environment matrix
E? =
e?1. . .
e?N
 . (47)
This formula can be applied for the whole set of N observed environmental profiles
(E? = E) (in-sample estimations), for environmental profiles from test/validation
samples (out-of-sample predictions).
Finally, we note that if the genetic vector x is standardised, then xr =
−2p√
2p(1−p) and
xa =
1−2p√
2p(1−p) , where p is the observed minor allele frequency (MAF). It follows that
xa − xr = 1√
2p(1−p) .
Aggregate environment driving G×E. StructLMM can also be used to estimate the
aggregate environment to explain G×E at single loci, which can be interpreted as the
MAP posterior estimate of βG×E. An estimate can be derived based form the linear
model equivalence underlying StructLMM in Eq (8) (see Section 1.3), which we use to
rewrite the G×E term as
L∑
l=1
(x el)βl = x
(
L∑
l=1
elβl
)
= x (Eβ′G×E), (48)
where β′G×E = [β1, β2, ..., βL]
T and Eβ′G×E denotes the aggregate environment driving
G×E. Using the StructLMM model in Eq (6), a maximum a posteriori estimate of the
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aggregate environment is Eβˆ′G×E, where
βˆ′G×E = σˆ
2
G×E(xE)T Hˆ−1
(
y −Xbˆ− xβˆG
)
. (49)
1.5.4. Computational Complexity
The post-processing analyses for characterising G×E effects build on the marginal
model in Eq. (6), which is amenable to fast inference schemes. Specifically, introducing
Z = [σG×Ediag(x)E, σEE], the model in Eq (6) can be written as
y ∼ N
([
X x
] [b
β
]
, ZZT + σ2nI
)
. (50)
Note, that this model has the same form as the null model, where the first covariance
term has rank 2L. Maximum likelihood can thus be achieved with computational
complexity O(N(2L)2 + (2L)3) (see [7, 12] for details).
2. Relationship with prior work and comparison methods
In this section, we review existing methods for G×E and we describe LMMs that
are otherwise related to StructLMM. In Section 2.1 we review related existing G×E
testing strategies; in Section 2.2 we discuss technical similarities between StructLMM
and existing LMM-based approaches. Finally, in Section 3 we describe alternative
methods that are compared with StructLMM.
2.1. Relationship to other G×E tests
Single-environment G×E tests A standard linear model to test for G×E using quan-
titative traits and a single environmental variable can be cast as
y = Xb+ xβG + (x e)βG×E + eβE +ψ, (51)
where y is a N × 1 vector of quantitative trait measurements for N individuals, X is
the N ×K fixed effect design matrix for K covariates, b is the K × 1 vector of their
effect sizes, x is an N × 1 genotype vector for the variant under consideration, βG the
corresponding persistent genetic effect, e an N × 1 environment vector for the studied
environment, βG×E the genotype-environment interaction effect and ψ a noise term,
typically assumed to be iid normal ψ
iid∼ N ( 0 , σ2n ) [16]. The model in Eq (51) can
be used both for testing G×E (βG×E 6= 0) or to test for association while accounting
for G×E ([βG, βG×E] 6= 0) [17, 18].
G×E variant-set tests The model in Eq (51) can be extended to aggregate effects
across multiple variants, enabling G×E variant-set tests for single environments. For
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a set of R genetic variants {g1, . . . gR}, a variant-set model can be cast as
y = Xb+
R∑
s=1
gsβ
G
s +
R∑
s=1
(gs  e)βG×Es + eβE +ψ. (52)
Tukey’s one degree-of-freedom (df) is one of the first G×E variant-set tests [19], which
assumes proportionality between interaction and marginal genetic effect sizes (i.e.,
βG×Es = θβ
G
s , s = 1, . . . , R). This assumption can be restrictive, but comes with
the advantage that variant-sets can be tested via θ 6= 0 (1 df). Other strategies to
re-weight the interaction effects and limit the number of testing parameters have been
proposed (for example, Jiao et al [20] proposed using gene-environment correlations).
Another reweighting scheme that is commonly used for G×E analysis is known as the
genetic risk score (GRS), where one assumes βGs = wsβ
G and βG×Es = wsβ
G×E . In
GRS analyses, the SNP weight ws is either i) set to ws = 1 for all s (unweighted GRS,
[21]) or ii) to ws = β
P
s , where β
P
s is the effect size of variant s identified from a previous
study that tested only for main genetic effects (weighted GRS, [22]). GRS analyses
have been used in G×E interaction analyses of BMI in UK Biobank data [22, 23] using
a weighted score based on the effect sizes estimated from the 2015 GIANT association
analysis for BMI [24].
A class of G×E variant-set tests that is technically related to StructLMM is based on
random effects for βG×E , which build on linear mixed models, similarly to StructLMM.
In the following we describe the interaction sequence kernel association test (GESAT) [25],
as representative of a family of related methods [25, 26, 27, 28]. Starting from equation
Eq (52), GESAT can be derived by defining a multivariate normal prior on the genetic
effect sizes, βG×E ∼ N (0, τIR), where interactions can be tested by assessing τ 6= 0
using a score test (see Section 1.4). GESAT models the additive genetic effects in the
null model using fixed effects, estimated using ridge regression to mitigate the large
number of covariates in the test [29]. The score-based test statistics of the interaction
test is
Q = (y − µˆ)>SS>(y − µˆ), (53)
where S = [g1  e, . . . , gR  e] and µˆ is the optimised mean under the null model. Q
follows a mixture of χ2 distributions with 1 df [6] (see Section 1.4). Among the gener-
alisations of GESAT are methods tailored towards rare variants (iSKAT, [26]), with a
prior on βG×E that accounts both for scenarios where the G×E effects have consistent
effect directions or have independent effects (βG×E ∼ N (0, τ(pi1R1TR + (1− pi)IR)).
An optimal score-test is considered to assess statistical significance (see Section 1.4).
The testing procedure in iSKAT is related to the association test in StructLMM, but
there are important differences. First, the prior used in iSKAT is designed to empower
the detection of interaction effects between multiple rare variants and a single envi-
ronmental variable. Conversely, StructLMM considers a prior on the effect of a single
variants due to G×E with multiple environments. Additionally, a technical difference
is in how the two methods deal with the high number of covariates: while StructLMM
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uses a random effect, iSKAT uses ridge regression. Finally, StructLMM can also be
used to efficiently fit the full model with G+E+G×E effects, which is critical to enable
for the characterisation of selected G×E loci (see Section 1.5).
StructLMM is also related to a recently proposed random effect set test, iSet [30],
which builds on a framework for multi-trait set tests [12]. Critically, the model is lim-
ited to analyses of moderately sized cohorts (at most tens of thousands of samples),
it only considers categorical environments and it cannot be used for the analysis of
multiple environments.
Existing multi-environment G×E anlayses The only multivariate G×E analysis with
multiple environments we are aware of has been proposed in [31], in which the authors
study G×E effects on BMI at the FTO locus. Briefly, the authors employ a two-
step approach, first selecting relevant environmental variables based on their additive
effect on the phenotype (using a cross validation scheme), and then assess G×E effects
using a z-score test statistics using a multivariate fixed effect model (as in Eq. (8)).
Thus, the method is similar to the fixed effect model we implement for comparison
(Section 1.5.2). At present, there is no software that implements this procedure [31],
which also does not scale to genome-wide applications due to the costly cross-validation
step.
2.2. Relationship to other LMM implementations
Although the models follow different aims, StructLMM is technically related to the
optimal score-based test originally implemented in SKAT-O [11], a rare variant asso-
ciation test. The SKAT-O model can be cast as
y = Xb+GβG +ψ, (54)
where where G = [g1, . . . gR] denote the N × R genetic design matrix for R rare
variants and βG is set to follow the multivariate normal distribution
βG ∼ N (0, τ(pi1R1TR + (1− pi)IR) . (55)
This formulation interpolates between fully correlated genetic effects (1R1
T
R) and in-
dependent genetic effects (IR). The relation to StructLMM becomes apparent from
Eqs (19-20), considering that x  β = diag(x)β. In essence, SKAT-O interpolates
between models that consider different correlation structures of genetic effects across
variants, whereas StructLMM interpolates between different covariance models for per-
individual genetic effects.
A second related model is an LMM-based method for gene-gene (G×G) interaction
test introduced in [32], between a single variant and multiple others. While concep-
tually related, the proposed tests scales quadratically with the number of samples
(StructLMM is linear), and hence this method cannot be applied to larger datasets.
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Additionally, the method does not consider a joint association test but instead is lim-
ited to testing for interactions at this point.
Finally, we note that the approaches we employ for efficient fitting of the null and
alternative models in StructLMM borrows ideas from previous efficient implementa-
tions of linear mixed models using low-rank random effect, including [5, 33, 7, 12, 30].
3. Comparison methods
We compare StructLMM to alternative implementations of single and multi environ-
ments GxE models. Additionally, for association tests, we present comparisons to
alternative implementations of linear persistent effect tests. Here we provide full de-
tails on the models these tests build on. For a compact tabular summary, we refer to
Supp. Table 2 with the methods (SingleEnv-Renv, LMM-Renv and MultiEnv-Renv-
LRT) that are used in the main text results displayed in bold. These methods were
chosen as the default comparison partners as they use the same random effect term
to model the additive environment under the null as StructLMM and hence are most
directly comparable.
3.1. Single environment models
Single Environment model with Single environment additive effect (SingleEnv-
Senv). Standard interaction tests and joint association tests consider the following
model [16, 17] for each environment el in isolation:
y ∼ N
Xb+ xβG︸︷︷︸
G
+ (x el)βG×E︸ ︷︷ ︸
G×E
+ (el)γ︸ ︷︷ ︸
E
, σ2nI︸︷︷︸
noise
 , (56)
where y is an N × 1 phenotype vector for N individuals, X is the N ×K fixed effect
design matrix for K covariates, b is the K×1 vector of their effect sizes, x is an N ×1
genotype vector for the variant being tested, βG the corresponding genetic effect and
ψ the residuals. This model can be used to assess the presence of G×E interaction
with environment el by testing βG×E 6= 0 (1 df). A joint P value that corresponds to
the alternative hypothesis that at least one of L environments is participating in G×E
effects, can then be constructed by performing L tests followed by appropriate adjust-
ment for multiple testing (we consider Bonferroni). Similarly, a joint association test
that accounts for G×E effects due to single environments el can be derived by testing
[βG, βG×E] 6= 0 (2 df), where again multiple environments and their corresponding
tests can be combined using Bonferroni adjustment.
Single Environment model with multi-environment additive effect as Fixed effect
(SingleEnv-Fenv). One can extend the standard approach presented above by mod-
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elling additive environment effects from multiple environments:
y ∼ N
Xb+ xβG︸︷︷︸
G
+ (x el)βG×E︸ ︷︷ ︸
G×E
+
L∑
l=1
(el)γl︸ ︷︷ ︸
E
, σ2nI︸︷︷︸
noise
 . (57)
Again, the presence of interaction and association can be assessed by testing βG×E 6= 0
and [βG, βG×E] 6= 0 for each environment respectively, where again multiple environ-
ments can be combined using Bonferroni adjustment. This model provides a more
accurate null model for both tests, modelling additive effects of other relevant envi-
ronments.
Single Environment model with multi-environment additive effect as Random effect
(SingleEnv-Renv). Alternatively, one can use a random effect to model multivari-
ate additive environments, which is analogous to the approach taken in StructLMM.
Specifically, one can define an environmental covariance Σ based on the observed en-
vironments as described in Section 1.2 and consider the model
y ∼ N
Xb+ xβG︸︷︷︸
G
+ (x el)βl︸ ︷︷ ︸
G×E
, σ2eΣ︸︷︷︸
E
+ σ2nI︸︷︷︸
noise
 , (58)
where again interaction and association tests can be implemented as described above.
In the main paper, we consider this model as it has the same background model as
StructLMM but perform comparisons with alternative implementations in Supp. Fig.
2.
3.2. Association tests
Linear model (LM). For comparison, we consider a conventional linear model (LM),
assuming genetic effect sizes that are constant in the population
y ∼ N
Xb+ xβG︸︷︷︸
G
, σ2nI︸︷︷︸
noise
 . (59)
Association with genetic variant x can be assessed through the 1dof test βG 6= 0.
Linear model with multivariate additive environment effects. In a linear model,
multivariate additive effects from environment can be accounted for by the means of
a fixed effect term, which results in the model (LM-Fenv):
y ∼ N
Xb+ xβG︸︷︷︸
G
+
L∑
l=1
(el)γl︸ ︷︷ ︸
E
, σ2nI︸︷︷︸
noise
 . (60)
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Alternatively, similarly to StructLMM, one can use a random effect with environment
covariance Σ, obtaining the following linear mixed model (LMM-Renv)
y ∼ N
Xb+ xβG︸︷︷︸
G
, σ2eΣ︸︷︷︸
E
+ σ2nI︸︷︷︸
noise
 . (61)
In the main paper, we consider the random-effect model as it has the same background
model as StructLMM but perform comparisons with alternative implementations in
Supp. Fig. 2.
3.2.1. Alternative multivariate G×E tests based on fixed effects
Multi Environment model with multi-environment additive effect as Fixed effect
(MultiEnv-Fenv). Whilst we implement StructLMM using a random effect term to
model GxE, an alternative implementation using multiple fixed effects can be consid-
ered. Explicitly, denoting with e1, . . . , eL the N × 1 vectors for L environments, a
fixed-effect-based multi-environment model can be cast as
y ∼ N
Xb+ xβG︸︷︷︸
G
+
L∑
l=1
(x el)βl︸ ︷︷ ︸
G×E
+
L∑
l=1
(el)γl︸ ︷︷ ︸
E
, σ2nI︸︷︷︸
noise
 , (62)
where both interactions due to L environmental variables and their additive effects are
modelled as fixed effects. Within this model, the presence of interactions and associ-
ations can be assessed by testing [β1, . . . , βL] 6= 0 (L df test) and [β, β1, . . . , βL] 6= 0
(L+ 1 df test), respectively.
We consider both an LR-based and a score-based implementations of the tests (in
Supp. Fig. 1b), which we respectively refer to as MultiEnv-Fenv-LRT and MultiEnv-
Fenv-Score. Briefly, for the score test, we employ the Rao’s score test statistic [34]
RS = UT0 I
−1
0 U0, (63)
where U0 and I0 are respectively the gradient and the Fisher Information matrix
(FIM) with respect to the tested parameters, computed use MLE under the null†.
Rao’s score test statistic has an asymptotic chi-square distribution with the number
†Specifically, for the test β 6= 0 in the Gaussian model
y ∼ N (Fα+Wβ,H), (64)
we have
U(β) = (y − Fα0)TH−10 W , (65)
I(β) = W TH−10 W , (66)
where α0 and H0 are MLE of α and H under the null model.
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of tested parameters as degrees of freedom.
Whilst the LR test is inflated, the score test is deflated when the number of envi-
ronments is large relative to the sample size and again highlighting the benefits of the
StructLMM tests that have constant number of parameters independent of the number
of environments.
Multi Environment model with multi-environment additive effect as Random ef-
fect (MultiEnv-Renv). As with the single environment and linear model tests, the
multivariate additive environment effect can be modelled as a random effect with envi-
ronment covariance Σ, analogous to the StructLMM model, resulting in the following
model
y ∼ N
Xb+ xβG︸︷︷︸
G
+
L∑
l=1
(x el)βl︸ ︷︷ ︸
G×E
, σ2eΣ︸︷︷︸
E
+ σ2nI︸︷︷︸
noise
 , (67)
where again interaction and association tests can be performed as described above.
Again as described above both LR tests (MultiEnv-Renv-LRT) and score tests (MultiEnv-
Renv-Score) can be employed.
PC-based fixed effect G×E test Motivated by the observation that multi-environment
fixed effect models for G×E are in general not calibrated, in particular when analysing
larger numbers of environments (Supp. Fig. 1b), one can in principle considered
PCA to reduce the effect number of environmental variables in the test. The model is
identical to the approach described in Eq (67), but is based on the leading M principal
components calculated based on the full set of L environments, where M < L. We con-
sider this approach when analysing the eQTL data, where the proxy for environment
is high-dimensional Supp. Fig. 20.
3.3. Original analysis of blood eQTL data
We here provide a brief description of the method used in [35] to identify expression
quantitative trait loci whose effect depends on cellular context, Briefly, the authors
considered the single-environment model in Eq (51) where y is the gene expression
of the analysed eQTL gene, g its cis eQTL and e the environment-gene. Then the
following procedure was considered:
• Fit model for each eQTL gene as outcome (y) and each genome-wide gene as
environment (e);
• Compute the test statistic ζl =
∑
i z
2
il for each environment-gene l, where zil is
the z-score of the interaction G×E term from the model with gene eQTL i as
outcome (y) and gene l as environment (e);
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• Define the environment-gene with maximal test statistic as proxy gene and
regress out its expression from all gene expression levels.
This procedure was repeated ten times, which led to the identification of ten proxy
genes. Each proxy gene was then linked to a specific cell type or molecular pathway
called module through various analyses (see [35] for more details). Once the proxy
genes and the corresponding modules had been identified, Zhernakova et al. considered
again the single-environment model in Eq (51) to test for interactions with specific
modules at individual eQTL (each eQTL gene as outcome and each proxy gene as
environment). The significance threshold for this second stage was assessed through
permutations and results reported at 5% FDR.
4. Simulations
4.1. Environment covariates
In order to mimic realistic distributions in the real data analysis, we considered en-
vironmental exposures from UK Biobank data. Specifically, we extracted 33 environ-
mental factors, which include 9 ordinal dietary variables (’Oily fish intake’, ’Non-oily
fish intake’, ’Processed meat intake’, ’Poultry intake’, ’Beef intake’, ’Lamb/mutton in-
take, ’Pork intake’, ’Cheese intake’ and ’Salt added to food’), three continuous dietary
variables (’Cooked vegetable intake’, ’Bread intake’, ’Tea intake’), three physical ac-
tivity variables (’Number of days/week walked 10+ minutes’, ’Number of days/week of
moderate physical activity 10+ minutes’, ’Number of days/week of vigorous physical
activity 10+ minutes’), ’Alcohol intake frequency’, ’Sleep duration’, ’Sleep duration
residuals squared’, ’Townsend deprivation index’, ’Smoking status’, ’Time spent watch-
ing television’, ’Usual walking pace’, ’Frequency of friend/family visits’, ’Time spend
outdoors in summer’, ’Time spent outdoors in winter’, ’Time spent using computer’,
’Nap during day’, ’Overall health rating’, ’Nitrogen dioxide air pollution 2010’, ’Nitro-
gen oxides air pollution 2010’, ’Traffic intensity on the nearest major road’, ’Average
daytime sound level of noise pollution’, ’Average evening sound level of noise pollu-
tion’‡. For the three continuous dietary and five pollutant variables, we removed values
exceeding the 99th percentile. For ‘Sleep duration’, we removed the top and bottom
percentiles and for each individual, calculated the squared deviations from the mean
sleep duration, creating environmental variable, ‘Squared sleep duration res.’ (33rd en-
vironmental variable). For the four variables (‘Time spent watching television’ , ‘Time
spent using computer’, ‘Time spend outdoors in summer’, ‘Time spent outdoors in
winter’), less than 0.5 hours of was encoded as 0.5 and we excluded individuals in the
upper and lower percentile. These variables were further augmented by element wise
interactions with gender and age (and the inclusion of age itself), resulting in a total of
L = 100 environmental variables. We randomly assigned environmental profiles from
the 70,282 individuals for which all environmental factors were available (based on the
‡Environments in blue were also considered in the BMI analysis and were preprocessed as described
in the corresponding section.
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Interim release) to the genotypes. The environmental covariance was built as a linear
covariance from standardised values.
4.2. Phenotype simulation strategy
Phenotype data were generated as the sum of a persistent genetic effect from a genetic
variant (g), additive environment effects from a set of E environments (e), G×E effects
from a subset of L1 ≤ L environments (i), a contribution from population structure
(u) and iid gaussian noise (ψ)
y = g + e+ i+ u+ψ. (68)
The individual contributions from each term as in Eq (68) were simulated as follows:
• Persistent genetic effect from a randomly selected genetic variant is rescaled
to have sample variance (1− ρ) · vg;
• Additive environment effects are generated as e = EEβE, where EE is the
N × L design matrix for L environments in N individuals and βE is generated
as βE
iid∼ N (0, 1). Subsequently, e is rescaled to have sample variance ve;
• G×E effects are generated as i = (EG×EβG×E)⊗x, where EG×E is the N×L1
design matrix for L1 < L environments in N individuals and βG×E is generated
as βG×E
iid∼ {+1,−1}. Subsequently, i is rescaled to have sample variance ρ · vg;
• Population structure is simulated as u = Fβpop, where F is the N×10 matrix
of the leading 10 principal components from the realised relatedness matrix and
βpop is generated as βpop
iid∼ N (0, 1). Subsequently, u is rescaled to have sample
variance vpop;
• Noise is generated as iid Gaussian and rescaled to have sample variance vn =
1− vg − ve − vpop.
In a first set of simulation experiments, we vary the sample size (N), the number of
environments (L), the percentage of them with G×E effects (pi = L1L ), the variance
explained by the total genetic effect (G+G×E effect, vg), the proportion of the genetic
variance due to G×E effects (ρ) and the variance explained by additive environmental
effects (ve) while we fix the variance explained by population structure (vpop = 40%).
The specific parameter settings and the considered ranges of settings are provided
in Supp. Table 1. Additionally to these extensive simulations, we also simulated
scenarios with gene-exposure correlation, skewed and binary environments. Full details
on these additional simulations are given in the next sections.
4.3. Gene-exposure correlations
We simulated environments that are subject to a genetic effect from a variant in LD
with the variant affecting the phenotype. Specifically, we generated new environments
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as
vec (E) ∼ N (0,C ⊗R) , (69)
where C is the covariance between environments and R is the covariance between
individuals. We set C = Cˆ and R = vxxex
T
e + (1− vx)Rˆ, where Cˆ and Rˆ are column
and row covariances estimated from environments in real data repectively, xe the geno-
type of the variant correlated with the environments and vx the variance explained
by this variant on environments. After generation, the environments were standard-
ised and then the phenotype simulation procedure described in Section 4.2 was applied.
In our simulations we varied (i) the LD between the variant correlated with the envi-
ronments and the one associated with the phenotype and (ii) the average heritability
of environments (vx) when the phenotype and environments are affected by the the
same variant. Calibration was assessed in the extreme scenario of same variant and
vx = 0.20%.
4.4. Skewed and binary environments
First, we generated environments as
vec (E) ∼ N
(
0, Cˆ ⊗ Rˆ
)
, (70)
where Cˆ and Rˆ are environment and individuals covariances estimated from envi-
ronments in real data. After generation, the environments were transformed to have
non-Gaussian distributions and then the phenotype simulation procedure described
in Section 4.2 was applied. To generate skewed distributions, we rank-inverse trans-
formed the generated environments to a Gamma distribution with shape a and scale 1.
We varied the shape a of all simulated environments. Calibration was assessed in the
extreme scenario a = 0.1. For binary environment scenarios, we binarised a fraction
fB of the generated environments to have a specific sample frequency ν. We varied
the fraction fB of binary environments (fixing ν = 2%) and the frequency ν (fixing
fB=1). Calibration was assessed in the extreme scenario fB = 1 and ν = 0.5%.
5. Analysis of BMI in UK Biobank
5.1. Hold-out validation of per-individual genetic effect sizes
For out-of-sample assessment of the allelic predictions, we randomly split the 252,188
individuals into training and testing groups (126,094 individuals). We used the training
group to fit the model and estimated allelic effects at the 11 interaction loci (5%
FDR-adjusted) within sample, similar to the approach taken on the full dataset. We
then identified the 5% (6,305) of individuals with the highest and lowest estimated
allelic effects. For these strata of individuals, we use their genotype and phenotype
information and test for associations using the LMM-Renv from which we identify
a subset of strata that have nominally significant P values (P < 0.05, Supp. Fig.
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17a). Next, we predicted allelic effects in the test set (Supp. Fig. 17b) based on all
data in the training fraction and the environmental profiles in the test fraction, again
identifying the 5% strata of individuals with the highest and lowest estimated allelic
effects. We averaged over the predicted allelic effects of test individuals in the 5%
strata (only for significant strata in the training set estimations (Supp. Fig. 17a))
to produce a mean predicted allelic effect (yellow crosses, Supp. Fig. 17b). We then
used the genotypes and phenotypes of test individuals in in the top and bottom strata
to estimate the genetic effect based on their phenotype data (using LMM-Renv). We
compared mean predicted allelic effect with the estimated genetic effect (Supp. Fig.
17c) and we compared the mean predicted and estimated effects when considering the
GxE component only. For the latter comparison, we subtracted the persistent SNP
effect (using the estimate from the StructLMM fit on the training fraction) from the
predicted mean effect of the strata. For the LMM-Renv estimated effect, this was
achieved by the subtracting the variant effect identified from the LMM-Renv using all
individuals in the testing set from the variant effect identified from the LMM-Renv
using only individuals in the top and bottom 5% strata (Supp. Fig. 17d).
6. Analysis of cell-context eQTLs in a large blood cohort
6.1. Generation of principal components from SAMtools flagstat
and Picard tools
The first eight principal components derived from SAMtools flagstat and Picard tools
were calculated from the following fields: GC, Bam.genome total, Bam.exon total,
Counts.number detected genes, PF BASES, PF ALIGNED BASES, CODING BASES,
UTR BASES, INTRONIC BASES, INTERGENIC BASES, PCT CODING BASES,
PCT UTR BASES, PCT INTRONIC BASES, PCT INTERGENIC BASES, PCT
MRNA BASES, PCT USABLE BASES, MEDIAN CV COVERAGE, MEDIAN 5PRIME
BIAS, MEDIAN 3PRIME BIAS, MEDIAN 5PRIME TO 3PRIME BIAS.
A. Proof for form of Q
First, let us rewrite Qρ
Qρ =
1
2
yTKρy (71)
=
1
2
(1− ρ)yTPdiag(x)11Tdiag(x)Py + 1
2
ρyTPdiag(x)EETdiag(x)Py(72)
=
1
2
c(1− ρ)vTMv + 1
2
ρvTZEETZTv (73)
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where
v = P
T
2 y (74)
Z = P
T
2 diag(x) (75)
M =
1
c
Z11TZT (76)
c = 1TZTZ1 (77)
Eq (73) can be equivalently written as
Qρ =
1
2
ρκ+
1
2
τρη0 (78)
where
κ = φ+ ξ (79)
φ = vT (I −M)ZEETZT (I −M)v (80)
ξ = 2vT (I −M)ZEETZTMv (81)
τρ = c(1− ρ) + ρ
c
1TZTZEETZTZ1 (82)
η0 = v
TMv (83)
Indeed, replacing Eqs (83) in (78)
Qρ =
1
2
ρvT (I −M)ZEETZT (I −M)v + (84)
ρvT (I −M)ZEETZTMv + (85)(
c(1− ρ) + ρ
c
1TZTZEETZTZ1
)
vTMv (86)
=
1
2
ρvTZEETZTv − ρvTZEETZTMv + 1
2
ρvTMZEETZTMv + (87)
+ρvTZEETZTMv − ρvTMZEETZTMv + (88)
1
2
c(1− ρ)vTMv + 1
2c
ρ1TZTZEETZTZ1vT
1
c
Z11TZT︸ ︷︷ ︸
M
v (89)
=
1
2
c(1− ρ)vTMv + 1
2
ρvTZEETZTv + (90)
−1
2
ρvTMZEETZTMv +
1
2
ρvT
1
c
Z11TZT︸ ︷︷ ︸
M
ZEETZT
1
c
Z11TZT︸ ︷︷ ︸
M
v(91)
=
1
2
c(1− ρ)vTMv + 1
2
ρvTZEETZTv (92)
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Denoting with C a symmetric matrix, withA andB two general matrices and suppose
v ∼ N ( 0 , I ), then we have
vTCv ∼
∑
k
wkχ
2
1, where w = eigh (C) (93)
and
E
(
vTAv
)
= tr (A) (94)
Cov
(
vTAv,vTBv
)
= tr
(
A(B +BT )
)
(95)
where we used E
(
vTAvvTBv
)
= tr
(
A(B +BT )
)
+ tr (A) tr (B) from the matrix
cookbook section 8.2.4. Using these properties and that MM = M §, we have
• φ ∼∑mk=1 λkχ21 where λ = eigh (Λ)
• Λ = ETZT (I−M)ZE
• E (ξ) = 2tr ((I −M)ZEETZTM) = 0
• Var (ξ) = 4tr ((I −M)ZEETZTMZEETZT )
• Cov (ξ, η0) = 4tr
(
(I −M)ZEETZTM) = 0
• Cov (ξ, φ) = 4tr ((I −M)ZEETZTM(I −M)ZEETZT (I −M)) = 0
• Cov (φ, η0) = 4tr
(
(I −M)ZEETZT (I −M)M) = 0
• η0 = vTMv =
(
zˆTv
)T (
zˆTv
) ∼ χ21, as zˆ = Z1‖Z1‖ is a direction.
Using Eqs (74-77) and introducing
Λ0 = E
Tdiag(x)Pdiag(x)E (96)
α = ETdiag(x)Px (97)
c = xPxT (98)
we can rewrite Λ, Var (ξ) and τρ as
Λ = Λ0 − 1
c
ααT (99)
Var (ξ) =
4
c
αTΛ0α− 4
c2
(
αTα
)2
(100)
τρ = c(1− ρ) + ρ
c
αTα (101)
§from which follows (I −M)(I −M) = (I −M) and M(I −M) = 0
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Appendix B: Summary of results
from StructLMM interaction test
described in Chapter 4 for the
different considered phenotypes
Table B1 Loci containing significant interaction effects when examining
ten phenotypes | Table of the 74 loci (the locus numbers referred to in Chapter 4
are displayed in column 1) that contain significant interaction effects (cFDR adjusted
P < 0.05, as described in Section 4.3.4), summarising the interaction and association
results for all ten considered phenotypes. Shown are the chromosome (column 2),
position (column 3), reference allele (column 4), alternate allele (column 5) and the
considered trait (column 6), corresponding to the lead interaction variant (based on
the cFDR adjusted P values) at the locus. The cFDR adjusted P value (column 7)
and the association P value (column 8) for this lead interaction variant, as well as
the lead association P value for this trait at the considered locus (column 9) with
the corresponding position, reference allele and alternate allele (column 10) are
also shown. Finally the estimated values of ρ (which describes the fraction of the
genetic variance attributable to G×E effects) for significant interaction trait-locus
pairs (cFDR adjusted P < 0.05) are displayed in column 11. Significant interaction
trait-locus pairs (cFDR adjusted P < 0.05) are highlighted in yellow, significant
association trait-variant pairs (P < 5×10−8 considering the lead interaction variant)
are highlighted in green and significant association trait-locus pairs (P < 5 × 10−8
considering the lead association variant) are highlighted in red.
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Locus # Chrom Pos A1 A2 Trait Lead cFDR P Assoc P Lead assoc P Lead assoc (pos_a1_a2) 𝞀
1 1 78623626 C T BMR 0.485115095 9.89E-41 1.50E-53 78450517_C_A N/A
1 1 78450517 C A Body fat % 0.047694988 1.86E-13 1.71E-14 77967507_T_A 0.280916404
1 1 78450517 C A Weight 0.122702537 7.04E-49 7.04E-49 78450517_C_A N/A
1 1 77804242 A G BMI 0.314752288 2.4745E-07 6.40E-21 78450517_C_A N/A
1 1 78623626 C T DBP 0.101809306 0.000858182 0.000858182 78623626_C_T N/A
1 1 79053963 G A SBP 0.890856086 0.550761 0.0444988 78515616_T_C N/A
1 1 77967507 T A HC 0.2052569 1.30E-28 2.41E-31 78450517_C_A N/A
1 1 77804242 A G WC 0.235242678 9.10281E-09 2.36E-19 77967507_T_A N/A
1 1 77989923 T C Height 0.512716214 1.88E-03 2.94E-37 78450517_C_A N/A
1 1 78603463 T C PEF 0.80376406 0.922341 5.58218E-05 77958837_A_C N/A
2 1 177889480 A G BMR 0.029553417 3.66E-49 3.66E-49 177889480_A_G 0.092713702
2 1 177889025 A C Body fat % 0.001653532 7.41E-33 7.41E-33 177889025_A_C 0.14595585
2 1 177889025 A C Weight 7.36785E-05 1.81E-59 9.70E-60 177889480_A_G 0.133170654
2 1 177889480 A G BMI 0.000243557 9.15E-58 6.64E-58 177889025_A_C 0.122221004
2 1 177889025 A C DBP 0.165634694 0.279346 0.144081 177769090_A_G N/A
2 1 177902753 G C SBP 0.879627989 7.12E-03 0.00556686 177901713_T_C N/A
2 1 177889025 A C HC 1.64901E-05 1.62E-50 1.59E-50 177889480_A_G 0.163157748
2 1 177889025 A C WC 0.003604642 1.35E-40 1.35E-40 177889025_A_C 0.130233486
2 1 177904428 T C Height 0.977110719 2.68E-05 7.08E-06 177864554_G_A N/A
2 1 177784137 C T PEF 0.926158188 0.936254 1.67E-02 177940341_C_T N/A
3 1 32129041 A G BMR 0.489739316 1.69E-11 1.69E-11 32129041_A_G N/A
3 1 32129041 A G Body fat % 0.13770815 3.65E-03 3.65E-03 32129041_A_G N/A
3 1 32129041 A G Weight 0.033055662 1.22E-09 1.22E-09 32129041_A_G 0.474532888
3 1 32129041 A G BMI 0.033303101 4.84E-05 4.84E-05 32129041_A_G 0.692052692
3 1 32093167 G C DBP 0.663586177 0.0028325 0.000348579 32135022_T_A N/A
3 1 32068843 G A SBP 0.934568754 0.0284506 0.00807843 32132063_C_T N/A
3 1 32129041 A G HC 0.02452063 3.03E-06 1.51E-07 32147673_C_T 0.618713941
3 1 32129041 A G WC 0.020793065 5.80E-06 5.66602E-06 32131163_C_G 0.668326792
3 1 32135022 T A Height 0.969035374 7.32211E-08 1.52E-10 32135773_A_G N/A
3 1 32134763 C T PEF 0.869709873 0.000121185 1.14548E-06 32093167_G_C N/A
4 1 209517898 G A BMR 0.61189081 9.91E-09 3.85E-09 209547268_T_C N/A
4 1 209541991 T A Body fat % 0.048494308 2.60E-06 1.24E-06 209520450_T_C 0.626154327
4 1 209543560 T G Weight 0.167028228 1.80E-08 8.99E-10 209517989_A_G N/A
4 1 209519772 G C BMI 0.344742013 4.95E-09 9.15825E-10 209520450_T_C N/A
4 1 209517898 G A DBP 0.326251649 0.00400114 0.000571677 209547268_T_C N/A
4 1 209541832 A T SBP 0.938691084 0.0269913 0.00652523 209435733_T_C N/A
4 1 209519772 G C HC 0.212481146 1.42E-09 1.42E-09 209519772_G_C N/A
4 1 209543560 T G WC 0.321064547 1.53E-09 1.54279E-10 209439141_T_C N/A
4 1 209437172 T A Height 0.601509791 5.82E-01 2.89E-01 209547268_T_C N/A
4 1 209517898 G A PEF 0.960817432 0.635425 0.321481 209547268_T_C N/A
5 1 177841895 G A BMR 0.667325375 4.78E-09 4.78E-09 177841895_G_A N/A
5 1 177841895 G A Body fat % 0.451031978 4.80E-04 4.80E-04 177841895_G_A N/A
5 1 177841895 G A Weight 0.236817639 2.22E-09 2.22E-09 177841895_G_A N/A
5 1 177841895 G A BMI 0.407072933 4.02E-06 4.02E-06 177841895_G_A N/A
5 1 177841895 G A DBP 0.828133625 0.0629333 0.0629333 177841895_G_A N/A
5 1 177841895 G A SBP 1 0.911727 0.911727 177841895_G_A N/A
5 1 177841895 G A HC 0.041989446 1.73E-07 1.73E-07 177841895_G_A 0.556811929
5 1 177841895 G A WC 0.113713105 1.11E-04 1.11E-04 177841895_G_A N/A
5 1 177841895 G A Height 0.947969629 1.35E-04 1.35E-04 177841895_G_A N/A
5 1 177841895 G A PEF 0.961987137 0.713037 0.713037 177841895_G_A N/A
6 2 636017 C T BMR 0.206172621 2.80E-60 6.86E-61 615627_C_T N/A
6 2 628749 C T Body fat % 0.049673689 2.27E-25 2.27E-25 628749_C_T 0.088949109
6 2 636017 C T Weight 0.036935355 2.64E-62 2.16E-62 636790_T_C 0.048659565
6 2 637597 C T BMI 0.067251227 9.33026E-58 5.76808E-58 628504_A_G N/A
6 2 615658 A G DBP 0.398428505 3.56E-03 5.32206E-08 651407_T_C N/A
6 2 603883 G T SBP 0.833461782 2.79012E-05 3.35937E-08 651407_T_C N/A
6 2 651430 T C HC 0.348093557 1.07E-49 1.07E-49 651430_T_C N/A
6 2 651430 T C WC 0.005475278 7.32413E-42 7.32413E-42 651430_T_C 0.098096406
6 2 630034 A T Height 0.976959777 2.90E-04 7.29E-05 600575_G_T N/A
6 2 621954 T C PEF 0.865597041 0.00571869 8.46E-04 620297_A_G N/A
7 2 422144 T C BMR 0.285740488 3.24E-55 1.64E-56 417167_T_C N/A
7 2 417167 T C Body fat % 0.077745921 3.10E-30 3.10E-30 417167_T_C N/A
7 2 417167 T C Weight 0.012488514 2.47E-62 2.47E-62 417167_T_C 0.056226875
7 2 554731 T C BMI 0.035924077 4.86E-09 3.93E-59 417167_T_C 0.326819518
Locus # Chrom Pos A1 A2 Trait Lead cFDR P Assoc P Lead assoc P Lead assoc (pos_a1_a2) 𝞀
7 2 409112 A G DBP 0.704699245 0.181109 0.000153779 430975_C_T N/A
7 2 409112 A G SBP 0.886962052 0.353992 0.00730148 450234_G_A N/A
7 2 417167 T C HC 0.030189074 3.02E-47 3.02E-47 417167_T_C 0.06680839
7 2 417167 T C WC 0.039946183 5.43E-42 5.43E-42 417167_T_C 0.064012608
7 2 554731 T C Height 0.869953554 3.46E-02 2.99E-04 466003_G_A N/A
7 2 407713 A C PEF 0.83342247 0.00689385 0.00689385 407713_A_C N/A
8 2 181436641 C T BMR 0.66692424 1.20E-08 9.88E-10 181570507_A_G N/A
8 2 181436641 C T Body fat % 0.173257094 3.97E-10 9.35E-11 181568007_A_G N/A
8 2 181436641 C T Weight 0.158451389 4.31E-12 2.48E-13 181570507_A_G N/A
8 2 181436641 C T BMI 0.019256633 6.19699E-12 8.71E-13 181570507_A_G 0.437541334
8 2 181436641 C T DBP 0.465213155 0.0309296 0.0309296 181436641_C_T N/A
8 2 181607676 A C SBP 0.957429638 0.026061 0.0096148 181517642_T_C N/A
8 2 181436641 C T HC 0.013059068 1.86E-10 3.82E-12 181517642_T_C 0.515004806
8 2 181561742 T C WC 0.085039056 1.02E-13 2.09E-14 181567556_T_A N/A
8 2 181561742 T C Height 0.984961919 2.43E-01 1.47E-02 181605907_A_G N/A
8 2 181599070 C A PEF 0.96306362 0.916364 0.159004 181528663_T_C N/A
9 3 49936910 T A BMR 0.340018606 5.79E-23 1.80E-23 49920571_T_C N/A
9 3 50041313 C T Body fat % 0.165763781 1.37446E-20 1.66E-22 49920571_T_C N/A
9 3 49938227 C G Weight 0.09232712 5.7149E-31 4.00E-32 49920571_T_C N/A
9 3 49941436 G A BMI 0.025648863 1.5507E-36 9.35E-40 49920571_T_C 0.222685097
9 3 49860854 T C DBP 0.048316304 1.41405E-06 2.38187E-11 49881134_A_T 0.512688295
9 3 49860854 T C SBP 0.820360422 0.000008811 0.000008811 49860854_T_C N/A
9 3 49941436 G A HC 0.068382623 4.08753E-15 1.60E-17 49920571_T_C N/A
9 3 50210289 C G WC 0.129612367 8.68969E-16 2.68E-22 49920571_T_C N/A
9 3 50198537 A G Height 0.8622064 8.52E-01 0.000227307 50071965_C_T N/A
9 3 49843723 T C PEF 0.832789753 0.00042064 0.00042064 49843723_T_C N/A
10 4 106263450 T G BMR 0.108332326 1.23E-19 9.18E-24 106211443_A_G N/A
10 4 106230708 T C Body fat % 0.41634082 0.182115 6.58E-04 106181573_G_A N/A
10 4 106293180 G A Weight 0.041020046 4.29134E-06 1.02E-10 106216667_A_G 0.616611037
10 4 106293180 G A BMI 0.274934427 0.99075 0.00155541 106044276_C_A N/A
10 4 106181573 G A DBP 0.123488293 0.055048 0.0539094 106189614_G_T N/A
10 4 106263450 T G SBP 0.795080238 2.40696E-06 4.77067E-07 106259572_T_C N/A
10 4 106293180 G A HC 0.060676364 0.00129835 4.40E-06 106044276_C_A N/A
10 4 106044283 T A WC 0.327194132 1.45E-02 0.00027627 106081636_T_C N/A
10 4 106181570 G A Height 0.680839511 7.88672E-23 1.86E-50 106216367_T_C N/A
10 4 106257007 A C PEF 0.771439027 9.22E-04 6.68413E-07 106082120_G_A N/A
11 4 102708997 C A BMR 0.488783312 2.42E-09 2.42E-09 102708997_C_A N/A
11 4 102708997 C A Body fat % 0.159552043 1.07E-11 1.07E-11 102708997_C_A N/A
11 4 102708997 C A Weight 0.093691207 6.98E-13 6.98E-13 102708997_C_A N/A
11 4 102708997 C A BMI 0.019585217 1.40E-19 1.40E-19 102708997_C_A 0.247258419
11 4 102709308 T C DBP 0.904262715 0.0266914 0.0266914 102709308_T_C N/A
11 4 102708997 C A SBP 0.950617421 0.202831 0.0397945 102709308_T_C N/A
11 4 102708997 C A HC 0.504370621 3.50E-12 3.50E-12 102708997_C_A N/A
11 4 102708997 C A WC 0.15748701 4.15E-11 4.15E-11 102708997_C_A N/A
11 4 102708997 C A Height 0.986225006 1.37E-03 1.37E-03 102708997_C_A N/A
11 4 102709308 T C PEF 0.973562014 0.708587 0.708587 102709308_T_C N/A
12 5 87497612 T C BMR 0.515889613 4.95E-09 6.75E-18 87682877_C_G N/A
12 5 87497612 T C Body fat % 0.194829457 3.19726E-05 1.32E-10 87682877_C_G N/A
12 5 87497612 T C Weight 0.043407349 3.07E-09 8.10E-20 87682877_C_G 0.621358715
12 5 87840688 G A BMI 0.082757387 7.67395E-10 7.96E-18 87682877_C_G N/A
12 5 88248730 A C DBP 0.075404794 0.00767108 5.0774E-06 87301956_G_C N/A
12 5 87512532 G A SBP 0.857420733 0.000984105 5.59374E-05 87393746_A_G N/A
12 5 87497612 T C HC 0.149863675 8.52E-06 4.56E-12 87682877_C_G N/A
12 5 87497612 T C WC 0.046965639 1.391E-07 5.55E-17 87682877_C_G 0.619896312
12 5 87997279 A G Height 0.982744622 8.06E-01 1.52E-03 87469449_C_A N/A
12 5 87795525 G A PEF 0.88067218 0.00408832 1.50E-03 87328066_C_T N/A
13 5 6712834 T C BMR 0.847309613 4.53E-08 8.75E-09 6754402_T_C N/A
13 5 6739039 T G Body fat % 0.011994174 1.16E-04 5.28E-05 6754402_T_C 0.846513595
13 5 6739039 T G Weight 0.255630492 3.50E-09 1.04E-09 6754402_T_C N/A
13 5 6737571 A G BMI 0.126467521 0.00149388 6.33E-04 6754402_T_C N/A
13 5 6711630 C T DBP 0.794477911 0.0652209 0.0378624 6754402_T_C N/A
13 5 6712834 T C SBP 0.991428861 0.572664 0.358811 6745571_A_T N/A
13 5 6739039 T G HC 0.437364134 5.54E-06 1.77E-06 6745571_A_T N/A
13 5 6712834 T C WC 0.210424144 5.17E-05 1.23E-05 6754402_T_C N/A
Locus # Chrom Pos A1 A2 Trait Lead cFDR P Assoc P Lead assoc P Lead assoc (pos_a1_a2) 𝞀
13 5 6748659 T C Height 0.961025417 6.96E-10 3.27E-11 6712044_C_G N/A
13 5 6718563 A G PEF 0.994713978 0.150894 0.130009 6749085_T_G N/A
14 6 34717578 C T BMR 0.045232701 2.43E-68 1.58E-72 34589632_C_T 0.099028865
14 6 35238183 T G Body fat % 0.077080633 3.94127E-08 1.7804E-25 34735883_T_C N/A
14 6 35238183 T G Weight 0.063112733 1.45E-21 4.58E-68 34552736_G_A N/A
14 6 34769765 C T BMI 0.177891935 6.71429E-24 1.58689E-29 34644261_G_A N/A
14 6 34545999 A C DBP 0.400660371 0.0674444 9.90266E-05 34796084_C_T N/A
14 6 34478514 C T SBP 0.872543695 0.48834 0.000123508 35044456_A_C N/A
14 6 35163949 T A HC 0.159657368 2.41E-19 4.47E-57 34552736_G_A N/A
14 6 35099094 C T WC 0.031996066 5.40519E-16 1.11E-28 34552736_G_A 0.354652517
14 6 34692585 A G Height 0.942464965 3.36E-17 1.27E-82 34623905_C_T N/A
14 6 34506397 T C PEF 0.727350582 0.000142915 3.25943E-05 35386872_C_T N/A
15 6 130378833 T C BMR 0.210928502 8.14E-53 8.24E-56 130374461_T_A N/A
15 6 130350294 G A Body fat % 0.313762326 8.53E-02 1.28E-02 130440798_G_A N/A
15 6 130350294 G A Weight 0.095798826 8.98E-33 3.62E-33 130384187_C_T N/A
15 6 130350294 G A BMI 0.370933604 8.31392E-06 4.97E-06 130384187_C_T N/A
15 6 130445031 G A DBP 0.490453734 0.924806 0.0312236 130335109_C_T N/A
15 6 130335109 C T SBP 0.855806143 9.27E-04 9.27E-04 130335109_C_T N/A
15 6 130350294 G A HC 0.034810144 6.28E-18 7.90E-19 130384187_C_T 0.258647546
15 6 130349119 C T WC 0.319902097 6.24E-04 1.83E-04 130384187_C_T N/A
15 6 130377843 C T Height 0.949991683 3.71E-70 9.57E-78 130374461_T_A N/A
15 6 130420941 C T PEF 0.79027379 0.000597738 1.03087E-05 130345835_G_A N/A
16 6 31597700 C T BMR 0.023965939 1.84E-38 4.58E-47 31840021_T_A 0.203315122
16 6 31244789 A T Body fat % 0.06490973 0.340236 1.35456E-10 32071637_T_C N/A
16 6 31323416 G C Weight 0.000774273 6.22E-18 3.59E-32 31613739_T_C 0.387742637
16 6 31346621 G C BMI 0.014350677 8.36205E-05 1.41953E-17 31613739_T_C 0.79177428
16 6 31319478 A G DBP 0.011875155 7.52007E-14 5.52164E-19 31242089_A_T 0.360641786
16 6 31178465 A C SBP 0.109435311 0.000129852 2.8755E-15 31610686_A_G N/A
16 6 31316526 T C HC 0.001723726 1.84E-13 3.45603E-27 31613739_T_C 0.389986122
16 6 31236854 T C WC 0.005669761 0.56865 5.59033E-11 31613739_T_C 0.971235159
16 6 32623223 A C Height 0.306589401 1.38448E-29 2.22E-80 31327895_G_A N/A
16 6 32107851 G A PEF 0.723450255 0.000576952 3.28001E-11 31147476_G_A N/A
17 6 126964675 G A BMR 0.110429772 1.37E-31 1.17E-38 126704795_C_T N/A
17 6 126760994 T C Body fat % 0.06057023 1.9727E-11 3.32E-12 127048230_C_T N/A
17 6 126964675 G A Weight 0.038994932 1.73E-07 4.49E-11 126704795_C_T 0.383873185
17 6 126972883 A G BMI 0.091025464 0.000192213 9.01251E-07 127048609_T_A N/A
17 6 126717064 A G DBP 0.125990236 0.00511951 4.10E-10 126938446_C_T N/A
17 6 127183470 A G SBP 0.800604023 3.35084E-06 4.98322E-09 126938446_C_T N/A
17 6 126975115 A G HC 0.37336374 0.0284294 1.62E-07 126604298_G_A N/A
17 6 127118646 G A WC 0.49437224 0.0217578 5.58E-04 127048230_C_T N/A
17 6 127149538 C T Height 0.363609625 1.40E-17 2.30E-98 126851160_C_T N/A
17 6 126802598 A G PEF 0.858070471 1.75E-04 8.61235E-05 126717064_A_G N/A
18 6 108983527 C T BMR 0.190879657 6.77E-31 1.69E-33 108876002_G_A N/A
18 6 108998953 C T Body fat % 0.32412585 5.54646E-06 7.9093E-10 108865663_T_G N/A
18 6 108983527 C T Weight 0.123876819 1.80E-23 4.28E-28 108876002_G_A N/A
18 6 109020634 T C BMI 0.023087066 0.00450541 3.399E-12 108888593_C_G 0.922163258
18 6 109009194 A G DBP 0.837929337 0.40067 0.00686157 109009646_C_T N/A
18 6 108994161 A G SBP 0.844286939 0.000782267 2.19841E-05 109009646_C_T N/A
18 6 108865663 T G HC 0.105530283 2.30E-13 1.26E-16 108888593_C_G N/A
18 6 109005588 A G WC 0.064037441 4.65E-12 8.86E-18 108888593_C_G N/A
18 6 109020634 T C Height 0.885430683 2.99E-10 6.54E-24 108983527_C_T N/A
18 6 109019721 G A PEF 0.884334209 6.53028E-05 9.47401E-08 108974098_C_T N/A
19 6 35420923 C T BMR 0.531798593 4.07E-24 6.96E-28 35416039_C_A N/A
19 6 35448189 T C Body fat % 0.198488973 6.02E-03 2.69E-03 35424188_A_G N/A
19 6 35420628 A C Weight 0.181329177 6.89E-17 5.19E-19 35448189_T_C N/A
19 6 35448189 T C BMI 0.275373558 1.28302E-06 1.28302E-06 35448189_T_C N/A
19 6 35120374 C A DBP 0.030374146 2.46E-05 3.49E-06 35389031_T_C 0.62344561
19 6 35404354 T C SBP 0.800461854 3.70241E-06 1.00941E-07 35388758_C_T N/A
19 6 35420628 A C HC 0.163488335 1.18E-11 4.51E-13 35448189_T_C N/A
19 6 35420923 C T WC 0.194985535 1.10E-07 7.74E-09 35424188_A_G N/A
19 6 35439932 T C Height 0.882397333 3.78E-25 7.76E-59 35395010_C_T N/A
19 6 35291638 T C PEF 0.787027347 1.20E-03 7.07186E-10 35033854_G_A N/A
20 6 28758828 G C BMR 0.366931394 2.33E-19 1.24E-25 29355148_C_A N/A
20 6 28679945 A C Body fat % 0.168892074 7.45E-04 6.45985E-09 29915061_T_C N/A
Locus # Chrom Pos A1 A2 Trait Lead cFDR P Assoc P Lead assoc P Lead assoc (pos_a1_a2) 𝞀
20 6 29730185 G A Weight 0.088324303 1.20E-09 8.58E-23 29355148_C_A N/A
20 6 28890800 G C BMI 0.044005465 3.21143E-05 1.18735E-06 28736484_C_T 0.760982378
20 6 29354799 A G DBP 0.185169245 9.89E-05 1.28483E-07 29730185_G_A N/A
20 6 29181314 G A SBP 0.844210072 0.00111708 0.00111708 29181314_G_A N/A
20 6 29516242 A C HC 0.079355862 2.13631E-08 2.64E-17 29355148_C_A N/A
20 6 28890800 G C WC 0.106376755 5.06217E-05 5.85E-07 29355148_C_A N/A
20 6 29396874 T C Height 0.698566591 6.50E-27 3.07E-40 28908612_A_G N/A
20 6 28682763 T C PEF 0.863122697 0.000856195 3.77856E-10 29730185_G_A N/A
21 6 31373260 G C BMR 0.262411855 1.09E-15 4.66E-22 31213413_T_G N/A
21 6 31243767 G C Body fat % 0.151592573 0.0125029 0.000751218 31164224_C_G N/A
21 6 31240692 G A Weight 0.087015973 2.75E-12 2.33E-14 31213413_T_G N/A
21 6 31243767 G C BMI 0.148286866 0.15347 6.56859E-07 31183907_A_G N/A
21 6 31411321 A C DBP 0.113932783 0.0524721 3.86624E-09 31353639_C_T N/A
21 6 31170066 A G SBP 0.869176808 0.454701 0.00304827 31266085_C_G N/A
21 6 31373260 G C HC 0.076815582 5.74E-06 8.19E-10 31274582_G_A N/A
21 6 31243767 G C WC 0.015729489 0.181094 1.0536E-05 31136575_T_C 0.99198901
21 6 31114335 A G Height 0.518795604 4.51E-09 1.03E-62 31331500_C_G N/A
21 6 31239407 G T PEF 0.847194449 0.00303719 2.13951E-08 31022266_G_C N/A
22 6 32206465 G A BMR 0.238218058 1.78E-17 9.93E-22 32451888_A_G N/A
22 6 32554197 T G Body fat % 0.191055512 0.0104197 3.07E-05 32190390_T_G N/A
22 6 32554197 T G Weight 0.066600585 1.03E-08 3.18059E-17 32623371_C_T N/A
22 6 32554197 T G BMI 0.111898074 6.18548E-07 2.35877E-08 32644553_C_T N/A
22 6 32206539 C T DBP 0.025690663 7.3314E-07 4.56939E-14 32844103_A_G 0.552141895
22 6 32722754 G A SBP 0.885863373 0.352655 1.45418E-07 31800868_G_C N/A
22 6 31742067 A G HC 0.118217725 1.06895E-05 7.80542E-13 32644553_C_T N/A
22 6 31722780 C T WC 0.159642205 0.410621 1.93502E-06 32644553_C_T N/A
22 6 32634318 C A Height 0.437590146 9.72E-26 2.66E-33 32652620_G_A N/A
22 6 32754091 C T PEF 0.814638209 0.000414469 6.87804E-09 32627934_G_A N/A
23 6 31101674 C T BMR 0.506229064 1.71E-14 9.65E-19 31117075_C_A N/A
23 6 31098134 A T Body fat % 0.171479518 4.88E-01 0.000280281 31248886_C_T N/A
23 6 31101674 C T Weight 0.064955614 1.48E-10 5.41E-13 31113214_C_A N/A
23 6 31243008 G T BMI 0.154508909 0.125087 2.53456E-05 31248886_C_T N/A
23 6 31242762 C T DBP 0.149548279 3.67297E-05 4.55333E-08 31117075_C_A N/A
23 6 31136666 A G SBP 0.817042645 0.000916325 1.07217E-05 31141836_C_T N/A
23 6 31101674 C T HC 0.094927732 5.56E-07 4.41E-12 31113214_C_A N/A
23 6 31101674 C T WC 0.016024078 1.02E-01 4.87E-04 31113214_C_A 0.96679765
23 6 31286247 G A Height 0.964707584 3.46E-09 3.41E-27 31117075_C_A N/A
23 6 31130502 T C PEF 0.87751256 0.00712665 6.53E-05 31299899_T_C N/A
24 6 31382717 A T BMR 0.092644371 9.42E-10 1.32E-18 30914843_C_T N/A
24 6 29924831 T C Body fat % 0.02388548 1.07306E-06 1.07306E-06 29924831_T_C 0.620235603
24 6 30726939 A C Weight 0.004871038 2.07243E-12 1.35E-16 30914843_C_T 0.56825856
24 6 29939854 C T BMI 0.042059826 6.9938E-07 6.9938E-07 29939854_C_T 0.7523845
24 6 30792117 G C DBP 0.012497354 2.02411E-09 2.36904E-12 30342753_G_A 0.478461664
24 6 30888161 T C SBP 0.853944211 0.000573371 0.000264558 31363026_G_T N/A
24 6 31330015 C G HC 0.004140969 2.73E-07 1.14968E-11 29939854_C_T 0.560855903
24 6 30726939 A C WC 0.002287469 0.042813 0.00476112 31329386_A_G 0.990512423
24 6 31382717 A T Height 0.53011149 5.4219E-22 4.77E-26 30811265_G_C N/A
24 6 31363026 G T PEF 0.856748437 0.00265285 2.62904E-12 30285312_G_C N/A
25 6 40369081 C T BMR 0.369344655 1.24E-15 1.24E-15 40369081_C_T N/A
25 6 40368860 T G Body fat % 0.185842807 4.24E-12 9.25E-19 40362023_C_T N/A
25 6 40369081 C T Weight 0.074770749 1.06E-20 1.06E-20 40369081_C_T N/A
25 6 40369081 C T BMI 0.012430743 1.72E-24 7.59E-25 40362751_G_A 0.268451621
25 6 40360755 G A DBP 0.215090965 0.0325912 0.00834341 40409243_T_C N/A
25 6 40362525 C T SBP 0.939545451 0.00918073 0.00918073 40362525_C_T N/A
25 6 40369081 C T HC 0.012246303 7.03E-17 1.01E-18 40409243_T_C 0.36645827
25 6 40369081 C T WC 0.000443226 6.30E-23 6.30E-23 40369081_C_T 0.341530569
25 6 40369159 A G Height 0.987785052 4.22E-01 4.74E-02 40362751_G_A N/A
25 6 40409243 T C PEF 0.93261618 0.573655 0.186134 40362751_G_A N/A
26 6 31380449 C T BMR 0.517486079 3.88E-13 9.62E-15 31046494_G_A N/A
26 6 31242174 G A Body fat % 0.25316997 3.01E-01 8.89E-04 31242509_C_T N/A
26 6 31242174 G A Weight 0.051791262 3.23E-06 1.16E-09 31316079_A_C N/A
26 6 31242174 G A BMI 0.164608554 0.520013 3.70E-05 31327064_T_C N/A
26 6 31242174 G A DBP 0.132763883 9.88915E-06 4.21451E-07 31379817_T_C N/A
26 6 31270084 A G SBP 0.848005549 4.65632E-06 1.31848E-06 31270176_T_C N/A
Locus # Chrom Pos A1 A2 Trait Lead cFDR P Assoc P Lead assoc P Lead assoc (pos_a1_a2) 𝞀
26 6 31242174 G A HC 0.027600954 1.58E-03 2.53E-10 31242509_C_T 0.748569529
26 6 31242174 G A WC 0.025474695 1.82E-01 5.43E-04 31084639_C_T 0.994967675
26 6 31234602 T C Height 0.960625411 1.08E-09 8.49E-43 31380449_C_T N/A
26 6 31234602 T C PEF 0.870747881 0.00468511 1.89524E-06 31172332_C_A N/A
27 6 28453102 G C BMR 0.428237182 3.37E-10 6.89E-13 28227145_G_C N/A
27 6 28514583 T C Body fat % 0.287559533 3.46E-03 2.41387E-07 28280137_T_C N/A
27 6 28453102 G C Weight 0.050827235 1.56E-10 1.38E-13 28227145_G_C N/A
27 6 28465355 C T BMI 0.163563889 0.0141103 0.000258903 28103473_G_A N/A
27 6 28029378 C G DBP 0.304910591 1.02375E-07 3.27959E-09 28323968_G_A N/A
27 6 28495240 T G SBP 0.878614784 0.00165133 0.0011838 28447519_T_G N/A
27 6 28453102 G C HC 0.021501267 6.50E-11 6.01E-14 28227145_G_C 0.45715365
27 6 28450437 G A WC 0.136838222 0.00412506 0.000442475 28182896_C_G N/A
27 6 28451144 G T Height 0.967576509 4.28E-12 5.53E-21 28465355_C_T N/A
27 6 28575172 T A PEF 0.946066096 4.76E-02 0.00551043 28514583_T_C N/A
28 6 29849687 G C BMR 0.035385433 4.77E-09 2.82E-11 29906313_A_C 0.666752006
28 6 29849657 T C Body fat % 0.006765242 2.74E-05 2.74E-05 29849657_T_C 0.723972591
28 6 29849657 T C Weight 0.004296876 3.65E-10 2.79E-11 29906313_A_C 0.574739348
28 6 29849657 T C BMI 0.027264995 4.19459E-08 4.19459E-08 29849657_T_C 0.615616353
28 6 29849657 T C DBP 0.056244164 9.75669E-05 2.62267E-06 30073847_C_T N/A
28 6 29906978 G A SBP 0.915890656 0.00453372 0.00394459 29906313_A_C N/A
28 6 29842444 G A HC 0.001162084 4.86E-05 7.30E-11 29849657_T_C 0.773088523
28 6 29849657 T C WC 0.000282912 2.62E-03 1.55E-04 29924159_C_G 0.9515344
28 6 30065319 G A Height 0.963089921 4.91E-11 3.78E-21 30073847_C_T N/A
28 6 30073847 C T PEF 0.937658413 0.670551 5.82844E-10 29849657_T_C N/A
29 6 29546799 G A BMR 0.472286604 4.83E-08 2.29E-10 29488249_A_G N/A
29 6 29546799 G A Body fat % 0.166876846 7.00E-04 6.31E-04 29548089_G_A N/A
29 6 29548089 G A Weight 0.014199202 1.35E-09 5.44E-10 29537224_A_G 0.725397337
29 6 29548089 G A BMI 0.10675527 1.76E-04 1.76E-04 29548089_G_A N/A
29 6 29559238 T C DBP 0.01403405 4.7084E-10 8.48396E-11 29752808_A_G 0.451037419
29 6 29548089 G A SBP 0.865152649 0.505975 0.393688 29752808_A_G N/A
29 6 29548089 G A HC 0.158266856 1.22E-07 9.56E-08 29752808_A_G N/A
29 6 29548089 G A WC 0.0046656 8.93E-02 8.93E-02 29548089_G_A 0.999670769
29 6 29559238 T C Height 0.979359506 3.32E-10 1.23E-16 29488249_A_G N/A
29 6 29488249 A G PEF 0.952316331 0.622958 7.14268E-11 29607101_T_C N/A
30 6 154392675 T C BMR 0.374434111 1.15E-09 2.95E-10 154336892_T_C N/A
30 6 154333183 T C Body fat % 0.07685939 2.8525E-07 1.03525E-07 154319449_G_T N/A
30 6 154392675 T C Weight 0.046737778 2.74E-10 7.28E-13 154336892_T_C 0.463803923
30 6 154403818 C T BMI 0.044223838 3.23995E-09 1.93E-12 154336892_T_C 0.476470073
30 6 154336892 T C DBP 0.683932488 0.802297 0.179087 154333183_T_C N/A
30 6 154382367 C T SBP 0.898095547 0.684383 0.681579 154388306_T_G N/A
30 6 154333183 T C HC 0.028927172 6.03355E-12 1.14E-12 154336892_T_C 0.359303048
30 6 154363387 C T WC 0.158115035 2.73173E-08 8.80E-10 154336892_T_C N/A
30 6 154336892 T C Height 0.995767726 2.14E-01 4.90E-02 154405730_A_T N/A
30 6 154362254 A G PEF 0.963148326 0.679429 0.47093 154290321_G_A N/A
31 6 28578286 A G BMR 0.710367858 4.93E-09 3.54E-10 28191057_C_T N/A
31 6 28578286 A G Body fat % 0.104914536 6.51E-13 6.51E-13 28578286_A_G N/A
31 6 28578286 A G Weight 0.091510394 2.87E-15 2.87E-15 28578286_A_G N/A
31 6 28578286 A G BMI 0.18031361 3.33941E-14 3.33941E-14 28578286_A_G N/A
31 6 28578286 A G DBP 0.031492001 6.05656E-06 1.70014E-09 28191057_C_T 0.657198915
31 6 28599105 G A SBP 0.892903738 0.683005 0.346436 28228342_A_G N/A
31 6 28578286 A G HC 0.433892653 1.55E-13 1.55E-13 28578286_A_G N/A
31 6 28578286 A G WC 0.016655446 1.61E-06 1.61E-06 28578286_A_G 0.830685889
31 6 28168343 C T Height 0.96911031 1.36E-06 4.22E-07 28203300_A_G N/A
31 6 28207200 C T PEF 0.871909334 0.000137277 1.93223E-15 28578286_A_G N/A
32 6 31440014 C A BMR 0.564518084 2.34E-09 6.23E-10 31351572_G_T N/A
32 6 31440014 C A Body fat % 0.072886958 1.96E-02 1.96E-02 31440014_C_A N/A
32 6 31440014 C A Weight 0.042123263 1.30E-08 1.30E-08 31440014_C_A 0.490767893
32 6 31440014 C A BMI 0.121497246 0.000112735 0.000112735 31440014_C_A N/A
32 6 31351572 G T DBP 0.394826063 0.000830002 0.00019397 31208591_G_T N/A
32 6 31351572 G T SBP 0.869880608 0.00138061 0.00115922 31220752_C_T N/A
32 6 31440014 C A HC 0.034388632 3.11E-06 3.11E-06 31440014_C_A 0.512832757
32 6 31440014 C A WC 0.062811542 4.46E-03 4.46E-03 31440014_C_A N/A
32 6 31221396 A G Height 1 6.18E-24 1.77E-25 31351572_G_T N/A
32 6 31220752 C T PEF 0.973905495 0.854468 0.425266 31351572_G_T N/A
Locus # Chrom Pos A1 A2 Trait Lead cFDR P Assoc P Lead assoc P Lead assoc (pos_a1_a2) 𝞀
33 6 29842451 A G BMR 0.451164348 8.32E-09 8.32E-09 29842451_A_G N/A
33 6 29818726 A G Body fat % 0.029978553 3.63089E-07 3.63089E-07 29818726_A_G 0.512682676
33 6 29842451 A G Weight 0.007591409 1.80E-11 1.80E-11 29842451_A_G 0.597074492
33 6 29842451 A G BMI 0.055933008 5.73E-07 5.73E-07 29842451_A_G N/A
33 6 29907961 G C DBP 0.023999641 5.57889E-07 4.19E-07 29818568_T_C 0.461974752
33 6 29834472 C T SBP 0.977640435 0.311611 0.0129255 30800068_G_A N/A
33 6 29821937 C T HC 0.016166886 2.98E-11 5.07E-12 29818726_A_G 0.491553622
33 6 29842451 A G WC 0.002260426 2.97E-03 2.97E-03 29842451_A_G 0.959382266
33 6 29821937 C T Height 0.831377943 2.85E-04 6.26E-16 30800577_C_T N/A
33 6 30800577 C T PEF 1 4.52E-11 6.77262E-12 29818726_A_G N/A
34 7 92327026 A G BMR 0.019834678 6.95E-51 1.65E-55 92250140_T_G 0.117735009
34 7 92277030 T C Body fat % 0.216422699 0.0293858 1.02E-02 92253972_G_A N/A
34 7 92327026 A G Weight 0.017180925 3.40E-29 4.36E-33 92253972_G_A 0.208187367
34 7 92327026 A G BMI 0.061219812 0.0973123 0.022842 92279363_T_C N/A
34 7 92223957 T C DBP 0.076620722 0.00346198 0.00146737 92237396_A_T N/A
34 7 92215430 G A SBP 0.737655006 1.79784E-09 2.84715E-15 92253972_G_A N/A
34 7 92327026 A G HC 0.095783184 5.30E-19 7.81E-20 92253972_G_A N/A
34 7 92327026 A G WC 0.30562912 4.83E-08 9.63E-09 92253972_G_A N/A
34 7 92253972 G A Height 0.845623833 3.16E-111 5.37E-115 92250140_T_G N/A
34 7 92243719 C T PEF 0.845008254 0.0011117 0.00062571 92237426_G_A N/A
35 7 2887195 C T BMR 0.112324753 7.57E-35 5.22E-40 2859847_G_A N/A
35 7 2864706 C A Body fat % 0.056146988 3.28E-08 1.8973E-09 2912928_T_C N/A
35 7 2890774 C T Weight 0.030382729 3.56803E-30 1.98E-34 2862542_C_A 0.165510044
35 7 2758158 G A BMI 0.169158844 0.46547 0.00358741 2912928_T_C N/A
35 7 2830498 C T DBP 0.071489207 0.00459333 0.00402076 2832973_G_A N/A
35 7 2799686 G T SBP 0.888337698 0.323813 0.0101224 2751285_T_G N/A
35 7 2772431 A C HC 0.00392662 2.27E-22 1.14E-26 2862542_C_A 0.186535382
35 7 2772431 A C WC 0.021629074 2.46E-09 6.60E-12 2862542_C_A 0.431995909
35 7 2913736 G T Height 0.77515197 3.41E-26 1.00E-119 2802522_T_C N/A
35 7 2811543 T C PEF 0.923377795 0.974676 2.83E-02 2758158_G_A N/A
36 8 95359638 T G BMR 0.616264278 7.90E-11 1.91E-11 95594720_C_A N/A
36 8 95595162 G A Body fat % 0.229526936 0.00035829 8.02305E-05 95631555_G_A N/A
36 8 95595162 G A Weight 0.320495945 1.24E-07 3.37E-11 95359638_T_G N/A
36 8 95595162 G A BMI 0.030810207 1.22747E-11 1.22747E-11 95595162_G_A 0.462104964
36 8 95354366 C G DBP 0.846217449 0.331449 0.0136669 95595162_G_A N/A
36 8 95615216 A G SBP 0.905307133 0.00455471 0.00341518 95605260_G_A N/A
36 8 95595162 G A HC 0.141421179 1.36E-07 6.09E-11 95359638_T_G N/A
36 8 95359638 T G WC 0.225497233 2.00E-08 2.00E-08 95359638_T_G N/A
36 8 95530969 G A Height 0.548682018 2.93E-01 7.77E-03 95595162_G_A N/A
36 8 95489281 T C PEF 0.943209077 0.0414984 0.0147959 95369109_T_C N/A
37 8 10939273 G T BMR 0.65593528 1.89E-09 8.90E-10 10665444_C_A N/A
37 8 11281273 A G Body fat % 0.05687746 0.00880797 3.63E-07 10665444_C_A N/A
37 8 11281273 A G Weight 0.056437267 1.92E-07 1.54E-11 10665444_C_A N/A
37 8 11281273 A G BMI 0.019184584 3.48932E-13 6.18E-19 10665444_C_A 0.336736787
37 8 10761585 G A DBP 0.068478224 1.50991E-14 1.43712E-14 10788875_C_T N/A
37 8 11024663 C A SBP 0.759257952 2.502E-09 9.09793E-14 10604164_T_C N/A
37 8 11281273 A G HC 0.049539799 1.40E-06 2.39E-10 10665444_C_A 0.621762467
37 8 11281273 A G WC 0.258655469 0.028632 2.30993E-05 10580550_G_C N/A
37 8 10580550 G C Height 0.92353557 3.53E-01 4.07E-07 10810451_A_G N/A
37 8 10665444 C A PEF 0.851073929 0.000466217 2.85067E-07 10957243_A_G N/A
38 9 98316094 G A BMR 0.01042101 2.44E-19 1.55E-21 98256235_T_G 0.268381152
38 9 98209594 G A Body fat % 0.219618083 4.29E-03 4.29E-03 98209594_G_A N/A
38 9 98316094 G A Weight 0.024649646 3.76E-08 5.38E-09 98380222_G_A 0.377428447
38 9 98316331 G C BMI 0.251353475 7.23E-01 0.0160085 98316094_G_A N/A
38 9 98142657 G A DBP 0.606178952 0.00442128 0.00442128 98142657_G_A N/A
38 9 98181368 C G SBP 0.885579129 0.355509 0.00215635 98239190_G_C N/A
38 9 98316094 G A HC 0.054065489 1.19E-04 8.11E-06 98185205_G_A N/A
38 9 98316094 G A WC 0.390401484 4.54E-02 1.08E-03 98205443_C_A N/A
38 9 98185205 G A Height 0.990567218 2.50E-29 2.08E-70 98316094_G_A N/A
38 9 98256235 T G PEF 0.906585566 0.00580355 0.00580355 98256235_T_G N/A
39 9 129464827 C T BMR 0.677874862 1.05E-08 1.85E-09 129464856_A_G N/A
39 9 129464827 C T Body fat % 0.029297828 1.44E-03 6.14E-04 129460914_A_G 0.779322664
39 9 129464827 C T Weight 0.201782771 1.61E-07 2.95E-08 129460914_A_G N/A
39 9 129464827 C T BMI 0.026155868 5.19806E-08 1.62E-08 129464856_A_G 0.553340265
Locus # Chrom Pos A1 A2 Trait Lead cFDR P Assoc P Lead assoc P Lead assoc (pos_a1_a2) 𝞀
39 9 129467340 C T DBP 0.428446291 0.0263767 0.00964725 129460914_A_G N/A
39 9 129460914 A G SBP 0.959764006 0.0202954 0.0202954 129460914_A_G N/A
39 9 129464856 A G HC 0.103478686 2.02E-07 2.02E-07 129464856_A_G N/A
39 9 129464827 C T WC 0.229674155 4.70E-05 2.10E-05 129464856_A_G N/A
39 9 129462901 T C Height 0.98574984 4.91E-01 3.76E-01 129460914_A_G N/A
39 9 129467340 C T PEF 0.95791195 0.0679593 0.0679593 129467340_C_T N/A
40 10 104749725 A G BMR 0.544786197 1.93E-12 5.52E-14 104610926_G_T N/A
40 10 104635103 G A Body fat % 0.115229232 0.000180365 0.000180365 104635103_G_A N/A
40 10 104635103 G A Weight 0.13162895 3.44E-10 2.19E-12 104610926_G_T N/A
40 10 104635103 G A BMI 0.062096308 1.19503E-08 1.19503E-08 104635103_G_A N/A
40 10 104680137 T A DBP 0.012540984 1.57286E-13 9.48086E-17 104906211_T_C 0.440687101
40 10 104616663 T C SBP 0.621354519 6.35E-23 1.41954E-28 104906211_T_C N/A
40 10 104635103 G A HC 0.237288673 2.02666E-09 9.54E-10 104635344_G_C N/A
40 10 104635103 G A WC 0.161909217 4.7412E-06 2.33E-06 104610926_G_T N/A
40 10 104601565 A T Height 0.410629583 2.16E-10 3.00E-33 104278601_T_C N/A
40 10 104844872 T C PEF 0.760525531 8.44E-05 6.01661E-07 104487871_T_C N/A
41 10 104636655 G C BMR 0.724148907 2.80E-08 4.44E-09 104642237_T_G N/A
41 10 104636655 G C Body fat % 0.366038989 7.60E-01 7.60E-01 104636655_G_C N/A
41 10 104636655 G C Weight 0.421937773 8.75E-05 1.44E-05 104642237_T_G N/A
41 10 104636655 G C BMI 0.710162539 0.0790437 5.70E-02 104642237_T_G N/A
41 10 104642237 T G DBP 0.042609177 3.24891E-07 3.24891E-07 104642237_T_G 0.602419518
41 10 104636655 G C SBP 1 1.77583E-13 1.20007E-14 104642237_T_G N/A
41 10 104636655 G C HC 0.702816992 9.96E-03 2.72E-03 104642237_T_G N/A
41 10 104636655 G C WC 0.621756064 2.76E-02 1.73E-02 104642237_T_G N/A
41 10 104636655 G C Height 0.973443626 3.24E-08 7.06E-10 104642237_T_G N/A
41 10 104642237 T G PEF 0.766975994 0.00277521 0.00277521 104642237_T_G N/A
42 11 27583129 T C BMR 0.24430835 6.09E-23 1.06E-28 27728102_G_A N/A
42 11 27456488 T C Body fat % 0.006009166 6.67355E-12 1.92E-24 27709630_C_G 0.315200356
42 11 27714884 T C Weight 0.0175533 4.11E-35 3.43E-37 27728102_G_A 0.142367245
42 11 27456488 T C BMI 0.004652358 3.78748E-17 4.37534E-37 27702383_G_T 0.233369246
42 11 27677586 G T DBP 0.277462267 0.144367 0.000984586 27734420_T_C N/A
42 11 27640223 T G SBP 0.874169219 0.428339 0.00327971 27728102_G_A N/A
42 11 27516785 C G HC 0.000976009 4.33E-24 1.38E-33 27728102_G_A 0.280512372
42 11 27456059 C T WC 0.000713111 1.6275E-17 1.28E-31 27709630_C_G 0.304525847
42 11 27523186 G T Height 0.831709132 6.49E-02 9.52E-03 27703480_T_A N/A
42 11 27636576 C T PEF 0.935301846 0.729971 0.114782 27736207_C_T N/A
43 11 65245829 T A BMR 0.483117431 2.65E-11 2.65E-11 65245829_T_A N/A
43 11 65294799 C T Body fat % 0.091254854 2.28686E-08 2.28686E-08 65294799_C_T N/A
43 11 65314830 A T Weight 0.078517471 6.96E-11 1.26E-11 65245829_T_A N/A
43 11 65314830 A T BMI 0.029576301 2.78708E-09 2.03141E-09 65294799_C_T 0.635310979
43 11 65220206 G A DBP 0.899826144 0.560974 0.382412 65245829_T_A N/A
43 11 65256164 G A SBP 0.866152737 0.00182183 0.00182183 65256164_G_A N/A
43 11 65314830 A T HC 0.56480224 4.41E-04 1.42E-04 65245829_T_A N/A
43 11 65294799 C T WC 0.005247311 2.03555E-10 2.03555E-10 65294799_C_T 0.602600835
43 11 65228278 C T Height 0.98162151 8.20E-04 2.47E-04 65229828_G_T N/A
43 11 65229828 G T PEF 0.964042442 0.146818 0.103457 65232345_T_C N/A
44 11 843461 T C BMR 0.669967471 6.86E-09 6.81E-09 838842_C_G N/A
44 11 840363 C T Body fat % 0.554900968 7.89E-04 7.89E-04 840363_C_T N/A
44 11 843461 T C Weight 0.351861718 1.07E-07 1.85E-08 840363_C_T N/A
44 11 843461 T C BMI 0.406564968 2.95396E-07 1.77981E-09 840363_C_T N/A
44 11 840363 C T DBP 0.041649087 0.522426 0.213946 843461_T_C 0.998655082
44 11 843461 T C SBP 1 0.0316425 0.0316425 843461_T_C N/A
44 11 840363 C T HC 0.424805639 1.45E-08 1.45E-08 840363_C_T N/A
44 11 843461 T C WC 0.547655072 3.65E-04 3.09E-05 840363_C_T N/A
44 11 840363 C T Height 1 7.49E-01 3.03E-01 843461_T_C N/A
44 11 843461 T C PEF 0.954575722 0.0338666 0.03314 840363_C_T N/A
45 12 50263148 G A BMR 0.549161549 9.77E-30 9.77E-30 50263148_G_A N/A
45 12 50285780 T G Body fat % 0.056898308 1.07E-11 1.13E-22 50256063_C_T N/A
45 12 50285780 T G Weight 0.078693615 7.13E-23 1.36E-36 50263148_G_A N/A
45 12 50285780 T G BMI 0.016558793 2.52354E-19 8.27E-31 50263148_G_A 0.317830331
45 12 50205712 G A DBP 0.335066507 0.000494527 0.000494527 50205712_G_A N/A
45 12 50208343 A G SBP 0.84973948 0.00141202 0.00129234 50213076_C_T N/A
45 12 50199316 G C HC 0.017825321 3.58998E-13 1.00E-23 50263148_G_A 0.512580375
45 12 50285780 T G WC 0.061724656 1.11E-13 2.08E-22 50256063_C_T N/A
Locus # Chrom Pos A1 A2 Trait Lead cFDR P Assoc P Lead assoc P Lead assoc (pos_a1_a2) 𝞀
45 12 50278561 T C Height 0.986003085 1.23E-01 5.53E-04 50263148_G_A N/A
45 12 50213254 C T PEF 0.959950122 0.653213 0.0254209 50264802_G_A N/A
46 12 111833788 G A BMR 0.104791879 5.23E-18 3.28E-20 112059557_C_T N/A
46 12 112871372 A G Body fat % 0.283852457 2.01E-01 0.00157225 112801608_A_G N/A
46 12 112486818 A G Weight 0.042175981 2.09E-10 1.21E-12 112200150_T_C 0.508460892
46 12 112486818 A G BMI 0.354728719 2.23E-05 2.9842E-06 112200150_T_C N/A
46 12 111973358 A G DBP 0.113939055 1.71155E-54 1.71155E-54 111973358_A_G N/A
46 12 112007756 C T SBP 0.185649087 1.16087E-17 2.53624E-18 111884608_T_C N/A
46 12 112486818 A G HC 0.024506181 3.49E-11 2.00E-13 112200150_T_C 0.441977223
46 12 111715197 C T WC 0.226516061 3.97E-02 7.56852E-05 112245170_A_C N/A
46 12 112849899 G A Height 0.80359742 1.04E-05 1.39E-10 111884608_T_C N/A
46 12 112146964 C T PEF 0.917147783 0.926677 0.0494916 112179471_T_C N/A
47 12 120867798 A G BMR 0.285753083 5.77E-19 5.77E-19 120867798_A_G N/A
47 12 120907309 T A Body fat % 0.119557449 2.56E-13 2.56E-13 120907309_T_A N/A
47 12 120907309 T A Weight 0.047244877 1.92E-22 1.81E-22 120867798_A_G 0.347775438
47 12 120907309 T A BMI 0.090251461 6.4172E-09 6.4172E-09 120907309_T_A N/A
47 12 120846213 G A DBP 0.621447863 0.0147006 0.000507037 120559928_C_T N/A
47 12 121089313 A G SBP 0.891304736 0.415667 0.0606656 120752247_C_T N/A
47 12 120907309 T A HC 0.162153375 1.94E-16 6.63E-17 120867798_A_G N/A
47 12 120541599 G A WC 0.186730402 1.94E-08 1.04E-14 120867798_A_G N/A
47 12 120384155 G T Height 0.975998883 8.91E-12 6.93E-23 120867798_A_G N/A
47 12 120559928 C T PEF 0.953717148 0.0790798 0.0488547 120503552_G_A N/A
48 12 1035708 T C BMR 0.402900513 4.87E-12 5.43E-16 991306_G_A N/A
48 12 975276 T G Body fat % 0.155412844 3.83E-04 4.14E-09 991306_G_A N/A
48 12 1032472 G A Weight 0.026535476 1.10E-09 4.30E-17 991306_G_A 0.548662027
48 12 998365 G T BMI 0.046468981 2.25E-07 5.09E-16 991306_G_A 0.600075911
48 12 975276 T G DBP 0.885996812 0.728694 0.242116 893613_T_C N/A
48 12 1028526 C T SBP 0.909970413 0.311729 0.00734641 1035708_T_C N/A
48 12 1032472 G A HC 0.021804978 8.00E-06 4.11E-13 991306_G_A 0.703971003
48 12 1022679 A G WC 0.029660796 1.43E-05 1.01E-11 991306_G_A 0.712558336
48 12 1034186 G A Height 0.560605758 1.71E-04 3.08E-05 1001807_G_A N/A
48 12 997833 G A PEF 0.967204481 0.583582 0.29548 1033183_C_A N/A
49 12 103761501 G A BMR 0.648086367 6.70E-09 2.97E-10 103724090_G_A N/A
49 12 103761501 G A Body fat % 0.179021954 4.30E-07 7.87E-08 103755097_A_G N/A
49 12 103761501 G A Weight 0.21789763 2.20E-11 1.85E-12 103724090_G_A N/A
49 12 103761501 G A BMI 0.042837503 2.65004E-13 1.05E-14 103724090_G_A 0.440924686
49 12 103663536 T A DBP 0.801871119 0.00587393 0.00203174 103661104_A_G N/A
49 12 103661104 A G SBP 0.988220397 0.320641 0.308398 103658925_C_G N/A
49 12 103761501 G A HC 0.434114554 3.16E-09 1.21E-11 103706754_C_G N/A
49 12 103761501 G A WC 0.397991334 1.64E-09 9.44E-10 103724090_G_A N/A
49 12 103720658 C A Height 0.983543573 5.42E-01 1.90E-01 103662895_T_C N/A
49 12 103767871 G A PEF 0.960334866 0.943187 0.510004 103724090_G_A N/A
50 13 97081460 T G BMR 0.259589692 1.74E-08 3.17E-10 96922449_G_A N/A
50 13 97060551 T C Body fat % 0.187595285 1.31E-04 1.74E-06 97047020_G_A N/A
50 13 97081460 T G Weight 0.022310831 7.32E-09 5.29E-12 97047020_G_A 0.727548773
50 13 97020705 C G BMI 0.192015542 1.05E-11 4.14621E-12 97047020_G_A N/A
50 13 96922449 G A DBP 0.757796417 0.0569201 0.0409497 97034410_G_A N/A
50 13 97201221 C T SBP 0.891388356 0.306014 0.000100702 97034410_G_A N/A
50 13 97121087 G A HC 0.034404021 8.98032E-07 6.06E-10 97047020_G_A 0.876383291
50 13 97121087 G A WC 0.050803063 1.17404E-06 9.98E-10 97047020_G_A N/A
50 13 97085948 A G Height 0.480990376 1.23E-04 6.71E-05 97081460_T_G N/A
50 13 96928767 T C PEF 0.959152035 0.747903 0.496629 96922191_T_C N/A
51 14 25948867 C T BMR 0.422238944 1.14E-19 2.46E-20 25927832_A_G N/A
51 14 25965098 T C Body fat % 0.642811501 0.0122699 1.34E-05 25930988_C_A N/A
51 14 25948867 C T Weight 0.201666622 5.74E-16 2.34E-17 25927832_A_G N/A
51 14 25949019 T G BMI 0.279176293 2.45711E-15 2.44854E-16 25930988_C_A N/A
51 14 25946258 C T DBP 0.859336424 0.675854 0.337258 25925165_T_A N/A
51 14 25956292 G A SBP 0.993952059 0.599028 0.434895 25946258_C_T N/A
51 14 25950864 C T HC 0.125594231 2.04E-08 5.36E-13 25932585_A_G N/A
51 14 25933965 G T WC 0.049518435 1.51E-09 4.79E-10 25935161_G_A 0.461125426
51 14 25944306 C A Height 0.985915985 9.54E-02 3.53E-02 25925165_T_A N/A
51 14 25946258 C T PEF 0.94139405 0.800435 0.328555 25925403_C_T N/A
52 14 103380403 G T BMR 0.599178619 3.76E-09 3.70E-11 103246470_A_G N/A
52 14 103380403 G T Body fat % 0.254222707 1.19E-10 8.42E-12 103246470_A_G N/A
Locus # Chrom Pos A1 A2 Trait Lead cFDR P Assoc P Lead assoc P Lead assoc (pos_a1_a2) 𝞀
52 14 103380403 G T Weight 0.18022383 4.15E-13 2.13E-15 103246470_A_G N/A
52 14 103380403 G T BMI 0.20101626 3.697E-14 3.08E-16 103246470_A_G N/A
52 14 103326780 T C DBP 0.832835359 0.00827298 0.000257937 103249127_G_C N/A
52 14 103326780 T C SBP 0.883413862 0.480493 0.260119 103387971_C_G N/A
52 14 103360000 A G HC 0.316829079 2.74E-09 5.12E-12 103246470_A_G N/A
52 14 103380403 G T WC 0.015919514 6.28E-13 2.75E-13 103246470_A_G 0.430738993
52 14 103256961 A G Height 0.978779168 9.46E-01 6.68E-01 103246470_A_G N/A
52 14 103256199 C G PEF 0.960776136 0.683238 1.16E-01 103269755_C_A N/A
53 14 29681294 G A BMR 0.54623277 5.59E-11 4.39E-11 29681138_G_C N/A
53 14 29681138 G C Body fat % 0.034814319 2.13E-11 2.13E-11 29681138_G_C 0.461999574
53 14 29677727 T C Weight 0.18720059 1.77E-12 3.64E-14 29680331_G_A N/A
53 14 29677727 T C BMI 0.175350161 4.85969E-11 3.27E-13 29681138_G_C N/A
53 14 29702590 T G DBP 0.852609282 0.645917 0.311985 29726942_C_A N/A
53 14 29684521 T C SBP 0.883575821 0.441895 0.196457 29681138_G_C N/A
53 14 29677727 T C HC 0.32167856 1.08E-12 1.29E-13 29681138_G_C N/A
53 14 29677727 T C WC 0.072406231 8.24E-11 7.21E-12 29680331_G_A N/A
53 14 29729003 G A Height 0.985584671 3.81E-01 3.61E-02 29681294_G_A N/A
53 14 29677727 T C PEF 0.955460135 0.941756 0.477354 29727517_G_A N/A
54 14 94028197 C T BMR 0.505340789 8.26E-09 4.82E-11 94073093_A_G N/A
54 14 94073093 A G Body fat % 0.016176104 3.97E-08 1.13E-12 94023972_G_A 0.47162039
54 14 94028197 C T Weight 0.030449004 7.10E-14 1.72E-15 94023972_G_A 0.390102385
54 14 94028197 C T BMI 0.043712251 6.60677E-19 6.48E-20 94023972_G_A 0.231960483
54 14 94023972 G A DBP 0.754385345 0.311833 0.0665612 93820274_C_T N/A
54 14 94135104 T C SBP 0.901885167 2.73E-01 0.0335752 93702672_T_A N/A
54 14 94054707 T C HC 0.028061688 4.22776E-13 3.60E-16 94023972_G_A 0.293969388
54 14 94007075 C T WC 0.01439818 1.80566E-14 5.77E-15 94023972_G_A 0.284131562
54 14 94135104 T C Height 0.891895665 9.57E-01 1.99E-02 93912668_C_A N/A
54 14 94031914 A G PEF 0.89855997 0.0578662 0.0285052 93715988_C_G N/A
55 14 101531854 A G BMR 0.602876133 7.03E-09 7.03E-09 101531854_A_G N/A
55 14 101531854 A G Body fat % 0.024541258 8.90E-05 8.90E-05 101531854_A_G 0.603207328
55 14 101531854 A G Weight 0.061451862 5.70E-09 5.70E-09 101531854_A_G N/A
55 14 101531854 A G BMI 0.041214793 2.80E-09 2.80E-09 101531854_A_G 0.422554231
55 14 101531854 A G DBP 0.909186686 0.346215 0.346215 101531854_A_G N/A
55 14 101531854 A G SBP 0.989274841 0.145421 0.145421 101531854_A_G N/A
55 14 101531854 A G HC 0.201996842 5.59E-08 5.59E-08 101531854_A_G N/A
55 14 101531854 A G WC 0.17713209 8.54E-09 8.54E-09 101531854_A_G N/A
55 14 101531854 A G Height 1 6.97E-01 6.97E-01 101531854_A_G N/A
55 14 101531854 A G PEF 0.97669192 0.663229 0.663229 101531854_A_G N/A
56 15 99196678 C T BMR 0.197501081 1.11E-09 5.13E-23 99186488_G_C N/A
56 15 99196678 C T Body fat % 0.246151041 5.54E-03 0.00104698 99210597_G_C N/A
56 15 99196678 C T Weight 0.011276677 2.50E-03 5.03E-10 99186488_G_C 0.847938607
56 15 99196678 C T BMI 0.111544338 0.021358 0.00680232 99210597_G_C N/A
56 15 99196678 C T DBP 0.392499969 0.0226466 0.00662338 99180380_A_C N/A
56 15 99186250 G A SBP 0.895496174 0.645121 0.00468427 99192535_C_T N/A
56 15 99196678 C T HC 0.00639994 2.94E-01 6.14E-07 99183876_T_C 0.994218607
56 15 99196678 C T WC 0.046206465 4.01E-01 0.150711 99210597_G_C 0.987916732
56 15 99193276 A C Height 0.359673902 2.74E-26 3.47E-68 99194896_C_G N/A
56 15 99183876 T C PEF 0.891342914 8.96793E-05 9.69802E-06 99190601_G_A N/A
57 16 53802494 C T BMR 2.26683E-08 7.97E-138 7.97E-138 53802494_C_T 0.162900473
57 16 53802494 C T Body fat % 2.37807E-08 3.10E-96 3.10E-96 53802494_C_T 0.201104781
57 16 53802494 C T Weight 7.52776E-15 7.69E-170 7.69E-170 53802494_C_T 0.170159273
57 16 53802494 C T BMI 8.09319E-13 6.39E-192 6.39E-192 53802494_C_T 0.126505341
57 16 53834607 T C DBP 0.210525155 0.0762335 0.00233064 53798523_G_A N/A
57 16 53800387 A G SBP 0.635892508 0.0056188 7.58945E-06 53807764_A_G N/A
57 16 53806453 A G HC 9.8432E-11 5.27E-137 5.27E-137 53806453_A_G 0.159912361
57 16 53802494 C T WC 1.07784E-14 1.41E-145 1.41E-145 53802494_C_T 0.176452164
57 16 53798622 G T Height 0.677591436 5.59E-01 1.54E-02 53806145_T_C N/A
57 16 53824226 A G PEF 0.928217585 0.706211 0.0304904 53755146_A_G N/A
58 16 30125840 G C BMR 0.215356118 7.61E-32 7.43E-52 30045789_C_G N/A
58 16 30097630 C T Body fat % 0.020196953 1.22E-07 2.37E-16 29926552_T_C 0.529981164
58 16 30134656 T C Weight 0.036965928 1.02E-33 4.85E-48 29994922_C_T 0.193610163
58 16 30376691 G A BMI 0.033676911 3.11311E-08 1.68359E-33 29954654_T_G 0.594208542
58 16 29885698 A G DBP 0.6770583 4.96E-03 0.00192427 29958216_G_A N/A
58 16 29885698 A G SBP 0.881645336 0.000463528 0.000422663 29958216_G_A N/A
Locus # Chrom Pos A1 A2 Trait Lead cFDR P Assoc P Lead assoc P Lead assoc (pos_a1_a2) 𝞀
58 16 30139900 T G HC 0.022090769 2.41E-20 2.09647E-34 29954654_T_G 0.299605154
58 16 29994922 C T WC 0.025559914 2.09E-38 2.09E-38 29994922_C_T 0.112894578
58 16 29932691 T C Height 0.956757922 5.58E-10 7.36E-22 30048553_C_T N/A
58 16 30068469 T G PEF 0.914695284 0.0257903 1.38E-02 29963812_C_T N/A
59 16 4014282 C G BMR 0.121676437 1.29E-30 1.29E-30 4014282_C_G N/A
59 16 4017392 T A Body fat % 0.001749538 5.71E-14 6.80E-18 4015729_C_T 0.419140003
59 16 4015729 C T Weight 0.001488005 4.97E-33 4.97E-33 4015729_C_T 0.219634964
59 16 4015729 C T BMI 0.001533762 4.93097E-25 4.93097E-25 4015729_C_T 0.238978631
59 16 4003974 T C DBP 0.255114235 0.00278263 2.68972E-08 4014282_C_G N/A
59 16 4006163 A T SBP 0.312048617 0.0250987 0.00293857 4014282_C_G N/A
59 16 4015729 C T HC 0.001174165 1.34E-27 1.34E-27 4015729_C_T 0.235748409
59 16 4015729 C T WC 0.002117565 3.13E-21 3.13E-21 4015729_C_T 0.297050615
59 16 4035068 A G Height 0.758227765 0.00152439 1.40E-15 4015313_A_G N/A
59 16 4002320 C G PEF 0.921040088 0.0201169 0.0186105 4003974_T_C N/A
60 16 28944396 C G BMR 0.423262324 2.81E-17 7.68E-21 28649651_C_A N/A
60 16 28542172 T C Body fat % 0.007313628 4.06454E-20 3.37E-35 28868962_C_G 0.292462563
60 16 28542172 T C Weight 0.018458164 5.79E-21 2.48E-35 28504181_G_A 0.259414603
60 16 28347140 A C BMI 0.027930549 1.86E-26 1.71E-27 28649651_C_A 0.192820833
60 16 28336882 T C DBP 0.631459876 0.0423541 0.000550524 28532188_T_G N/A
60 16 28582849 A G SBP 0.857376802 0.00147017 0.00147017 28582849_A_G N/A
60 16 28542172 T C HC 0.014381264 1.18289E-22 2.09E-39 28868962_C_G 0.242955409
60 16 28542172 T C WC 0.008803196 6.23685E-19 9.09927E-34 28832382_C_T 0.23950203
60 16 28871191 C G Height 0.695370818 2.98E-06 2.82E-07 28718755_A_G N/A
60 16 28977020 G A PEF 0.725401282 0.134479 0.0792737 28937259_T_C N/A
61 16 31165795 G A BMR 0.436878028 1.07E-09 9.23E-15 31025641_C_T N/A
61 16 30820866 T C Body fat % 0.122022139 5.43993E-13 3.34E-17 31025641_C_T N/A
61 16 31054040 G C Weight 0.149451607 4.12E-21 2.12E-22 31025641_C_T N/A
61 16 31336719 G A BMI 0.14410213 3.38234E-12 7.25E-25 31025641_C_T N/A
61 16 31105554 A C DBP 0.329825172 2.91E-07 4.84E-11 30585535_T_C N/A
61 16 30833246 C T SBP 0.575195383 0.00293246 0.000309817 31118024_C_A N/A
61 16 31011821 T G HC 0.253313906 3.44E-27 3.14E-27 31011183_A_G N/A
61 16 31014179 C T WC 0.007330149 1.10E-21 3.37E-22 31025641_C_T 0.254077401
61 16 31185882 G A Height 0.982463146 0.730283 1.24E-03 30823047_G_T N/A
61 16 31229022 G A PEF 0.923495006 0.8663 0.0683319 31363788_C_T N/A
62 17 76665365 A G BMR 0.613588923 1.52E-10 4.52E-13 76746325_G_A N/A
62 17 76746325 G A Body fat % 0.249544411 6.48E-04 1.51E-04 76799795_G_A N/A
62 17 76685106 A G Weight 0.293406541 8.94E-09 1.02E-11 76739141_G_A N/A
62 17 76831800 T C BMI 0.378863158 0.00307636 0.000152207 76739141_G_A N/A
62 17 76739850 C T DBP 0.015867251 3.9583E-08 2.10035E-08 76696986_G_A 0.621427804
62 17 76661528 G A SBP 0.758837738 6.29093E-09 1.80563E-10 76798362_C_T N/A
62 17 76684970 G A HC 0.405281407 1.80E-04 9.16E-07 76739141_G_A N/A
62 17 76828154 A G WC 0.331472537 0.000951906 1.07E-05 76739141_G_A N/A
62 17 76789991 A T Height 0.670607018 6.64E-14 1.33E-14 76790279_C_T N/A
62 17 76685106 A G PEF 0.88288213 0.00754951 0.00488715 76718842_C_T N/A
63 17 1820080 G A BMR 0.669898802 6.81E-09 1.03E-10 1844519_G_A N/A
63 17 1849662 G A Body fat % 0.2624483 1.88E-10 7.52E-20 1835482_C_T N/A
63 17 1820080 G A Weight 0.299185608 5.93E-15 1.35E-17 1835482_C_T N/A
63 17 1835482 C T BMI 0.286485295 7.49E-19 7.49E-19 1835482_C_T N/A
63 17 1866892 G T DBP 0.337285986 0.0161086 5.95805E-05 1849663_C_A N/A
63 17 1849662 G A SBP 0.844473214 0.000290258 0.000289966 1849663_C_A N/A
63 17 1820080 G A HC 0.376156244 3.23E-15 8.31E-17 1824305_C_A N/A
63 17 1820080 G A WC 0.045633399 1.52E-14 3.11E-17 1835482_C_T 0.478951977
63 17 1846831 C A Height 0.992620753 7.82E-01 2.89E-01 1866892_G_T N/A
63 17 1830836 C T PEF 0.827120094 0.00059473 1.49325E-05 1853400_G_C N/A
64 17 65800140 G A BMR 0.460479953 1.19E-08 2.38E-09 65832016_T_C N/A
64 17 65828371 T A Body fat % 0.013819782 3.84E-22 3.58E-23 65836001_A_C 0.351807448
64 17 66004689 T G Weight 0.048111668 2.30E-14 4.37E-19 65837235_A_G 0.30366108
64 17 65828371 T A BMI 0.192974953 1.23E-10 8.05E-12 65832016_T_C N/A
64 17 65892343 G T DBP 0.630045246 3.57E-01 0.136709 65800140_G_A N/A
64 17 65892064 T A SBP 0.877069112 0.424261 0.0393061 65960854_T_C N/A
64 17 65885911 C T HC 0.149247527 1.12E-10 4.69E-15 65837235_A_G N/A
64 17 65892507 G C WC 0.033720933 1.21224E-17 2.20E-20 65836001_A_C 0.282283182
64 17 65968003 A G Height 0.957257245 3.31E-08 9.82E-09 65892343_G_T N/A
64 17 65977053 C T PEF 0.936492097 0.655713 0.204969 66007279_T_C N/A
Locus # Chrom Pos A1 A2 Trait Lead cFDR P Assoc P Lead assoc P Lead assoc (pos_a1_a2) 𝞀
65 18 57829135 T C BMR 0.002912981 7.12E-131 7.12E-131 57829135_T_C 0.046781485
65 18 57829135 T C Body fat % 1.33628E-06 1.90E-25 1.13E-25 57850422_G_T 0.33974902
65 18 57829135 T C Weight 1.36714E-06 7.15E-114 7.15E-114 57829135_T_C 0.091566496
65 18 57829135 T C BMI 6.60627E-07 2.54E-75 1.54964E-75 57848651_A_G 0.14602229
65 18 58053203 C G DBP 0.517341605 0.0145459 0.000271105 57869750_C_T N/A
65 18 57846077 C T SBP 0.88516826 0.517474 0.0107927 58022740_G_C N/A
65 18 57802714 G A HC 2.74094E-07 1.04E-56 1.35E-68 57829135_T_C 0.214206749
65 18 57829135 T C WC 1.22375E-07 1.86E-65 1.45E-65 57848651_A_G 0.167059809
65 18 57802714 G A Height 0.298231216 1.54E-26 6.85E-30 57829135_T_C N/A
65 18 57890756 G T PEF 0.901203295 0.0301395 0.00160984 58030066_T_A N/A
66 18 57955945 T G BMR 0.300054428 1.07E-33 1.03E-38 57958244_C_T N/A
66 18 57997729 C T Body fat % 0.024651119 5.66E-17 2.57E-19 57961249_C_T 0.250035583
66 18 57967655 A C Weight 0.007034753 2.64E-19 5.81E-43 57961249_C_T 0.258213459
66 18 57967655 A C BMI 0.017810572 3.47868E-17 3.39E-38 57961249_C_T 0.236602448
66 18 57985366 T C DBP 0.389048539 0.00375156 0.000436143 57981916_C_A N/A
66 18 57981916 C A SBP 0.94111167 0.00908446 0.00908446 57981916_C_A N/A
66 18 57967655 A C HC 0.022238492 4.00E-16 1.18E-26 57961249_C_T 0.272323883
66 18 57967655 A C WC 0.000114937 1.13759E-15 1.60E-31 57961249_C_T 0.382552715
66 18 57948098 T C Height 0.563062706 0.295555 4.97E-05 57958244_C_T N/A
66 18 57921433 A T PEF 0.898239598 1.25E-02 0.00990152 57934238_T_C N/A
67 18 21137442 A G BMR 0.55817787 3.29E-13 1.66E-21 21109466_G_T N/A
67 18 21137442 A G Body fat % 0.036357684 7.5203E-12 4.42091E-16 21080859_C_A 0.611122101
67 18 21137442 A G Weight 0.056487593 1.23E-16 1.32E-23 21109466_G_T N/A
67 18 21137442 A G BMI 0.284076644 1.70808E-10 2.67458E-14 21090023_A_G N/A
67 18 21003267 C G DBP 0.131369497 0.00440781 7.30293E-05 20897797_C_G N/A
67 18 21133937 G A SBP 0.892748676 3.42E-01 0.0732569 21109466_G_T N/A
67 18 21137442 A G HC 0.093462043 1.97548E-14 1.36E-18 21126952_C_T N/A
67 18 21137442 A G WC 0.095982894 1.27677E-12 1.58E-19 21109466_G_T N/A
67 18 21074922 G A Height 0.947142117 2.85E-06 1.96E-20 20890718_G_T N/A
67 18 21074922 G A PEF 0.922434386 0.663676 0.0505057 21069137_G_T N/A
68 18 57913703 T C BMR 0.436448949 2.34E-18 2.34E-18 57913703_T_C N/A
68 18 57805566 G A Body fat % 0.576550027 5.81E-04 6.28E-05 57913703_T_C N/A
68 18 57913703 T C Weight 0.056229522 1.35E-17 1.35E-17 57913703_T_C N/A
68 18 57913703 T C BMI 0.093372719 6.08E-13 6.08E-13 57913703_T_C N/A
68 18 57913703 T C DBP 0.543306852 0.0583561 0.0583561 57913703_T_C N/A
68 18 57902986 T C SBP 0.888743541 0.571271 0.414622 57913703_T_C N/A
68 18 57913703 T C HC 0.262508484 2.86E-10 2.86E-10 57913703_T_C N/A
68 18 57913703 T C WC 0.013694334 1.08E-12 1.08E-12 57913703_T_C 0.411437602
68 18 57948257 T C Height 0.984357831 8.08E-04 2.05E-05 57863787_A_G N/A
68 18 57948257 T C PEF 0.928728335 0.0287188 0.0277088 57965832_G_A N/A
69 18 57809744 C T BMR 0.821673947 1.16E-17 1.16E-17 57809744_C_T N/A
69 18 57809744 C T Body fat % 0.117718759 1.10E-05 1.10E-05 57809744_C_T N/A
69 18 57809744 C T Weight 0.300871343 7.89E-16 7.89E-16 57809744_C_T N/A
69 18 57809744 C T BMI 0.17004344 7.11E-13 7.11E-13 57809744_C_T N/A
69 18 57809744 C T DBP 0.944323754 0.496845 0.496845 57809744_C_T N/A
69 18 57809744 C T SBP 1 0.964222 0.964222 57809744_C_T N/A
69 18 57809744 C T HC 0.399705353 8.33E-11 8.33E-11 57809744_C_T N/A
69 18 57809744 C T WC 0.038868995 4.71E-12 4.71E-12 57809744_C_T 0.391633563
69 18 57809744 C T Height 1 1.80E-02 1.80E-02 57809744_C_T N/A
69 18 57809744 C T PEF 0.979981602 0.963139 0.963139 57809744_C_T N/A
70 19 30266706 G A BMR 0.332909589 3.84E-20 7.17E-22 30290357_G_C N/A
70 19 30265235 G A Body fat % 0.052192771 1.88E-12 1.66E-13 30294991_G_T N/A
70 19 30265235 G A Weight 0.009380638 1.38E-21 1.28E-23 30290357_G_C 0.273402478
70 19 30266706 G A BMI 0.00785281 4.83268E-15 7.72E-16 30290357_G_C 0.415999842
70 19 30255090 G A DBP 0.113670143 9.33278E-11 4.7535E-19 30288177_G_A N/A
70 19 30249397 C G SBP 0.804252296 0.000777643 5.8359E-05 30305684_G_A N/A
70 19 30265235 G A HC 0.027412606 1.78E-13 4.19E-14 30305684_G_A 0.334001762
70 19 30265235 G A WC 0.029727296 2.33E-16 1.24E-17 30290357_G_C 0.367318415
70 19 30343667 G C Height 0.966632317 1.17E-07 6.15E-09 30305684_G_A N/A
70 19 30313603 C G PEF 0.884406614 0.00333688 0.00197873 30300841_G_A N/A
71 19 2176403 G A BMR 0.675924313 3.67E-18 3.67E-18 2176403_G_A N/A
71 19 2198619 C T Body fat % 0.723076299 0.732931 0.015334 2192015_C_T N/A
71 19 2192634 G A Weight 0.382675737 2.58E-08 2.46E-10 2186757_T_C N/A
71 19 2195065 G T BMI 0.660003125 0.942624 0.0206876 2186757_T_C N/A
Locus # Chrom Pos A1 A2 Trait Lead cFDR P Assoc P Lead assoc P Lead assoc (pos_a1_a2) 𝞀
71 19 2205668 C G DBP 0.044505536 1.22053E-06 3.90E-07 2198619_C_T 0.731396717
71 19 2207041 A G SBP 0.882039416 0.487541 9.68827E-05 2197734_G_A N/A
71 19 2192634 G A HC 0.45031647 5.25E-08 1.19E-10 2186757_T_C N/A
71 19 2145450 T C WC 0.538633526 0.793858 4.87E-02 2186757_T_C N/A
71 19 2199351 T C Height 0.338975574 3.31438E-26 1.78E-58 2155042_G_A N/A
71 19 2191980 T C PEF 0.945213812 0.574725 0.0821891 2156954_T_C N/A
72 20 33954913 C A BMR 0.159097391 5.80E-75 2.31E-111 34025756_A_G N/A
72 20 33213196 A C Body fat % 0.345747346 0.899691 0.000185875 34145773_C_T N/A
72 20 34158394 A G Weight 0.185064208 5.2484E-19 1.93E-53 34025756_A_G N/A
72 20 34154425 T C BMI 0.331483984 0.0517891 1.80E-04 33844938_A_C N/A
72 20 33744323 G C DBP 0.250582369 0.811229 7.43361E-05 34712310_T_C N/A
72 20 33750479 T C SBP 0.804006775 0.000936799 0.000152688 33880363_A_T N/A
72 20 33280836 C T HC 0.123609821 1.64598E-07 1.60E-30 34025756_A_G N/A
72 20 34030606 G A WC 0.154091691 3.68592E-06 6.03983E-07 34375497_G_A N/A
72 20 34025756 A G Height 0.042109879 8.85E-292 8.85E-292 34025756_A_G 0.019327587
72 20 34185161 G T PEF 0.78172655 0.000101738 2.04414E-19 34025756_A_G N/A
73 20 32077925 C T BMR 0.426049364 3.18E-09 4.14E-31 32300634_A_C N/A
73 20 32026350 C G Body fat % 0.022910021 0.239543 0.00508457 32019417_T_C 0.972627687
73 20 32254831 G T Weight 0.032128724 5.04E-04 5.31E-19 32289763_A_G 0.453201617
73 20 32245869 C G BMI 0.198466659 0.950966 9.81E-05 32505658_G_C N/A
73 20 32365469 T C DBP 0.582007581 0.00599631 9.63135E-06 32298286_C_T N/A
73 20 32325270 G A SBP 0.891924552 0.602071 0.058945 32327399_T_C N/A
73 20 32245869 C G HC 0.135723084 1.15E-02 1.49E-14 32333181_G_T N/A
73 20 32026350 C G WC 0.118464709 0.260485 5.35E-05 32505658_G_C N/A
73 20 32199872 G A Height 0.35112472 6.25E-15 6.49E-54 32304653_C_G N/A
73 20 32358788 C T PEF 0.861774352 0.000288037 7.30457E-05 32188142_C_T N/A
74 22 42038786 C T BMR 0.646371909 1.16E-10 2.31E-19 42070374_A_C N/A
74 22 42038786 C T Body fat % 0.467272287 5.59E-01 1.11E-06 41884954_A_G N/A
74 22 42287203 C G Weight 0.651812058 1.60E-05 6.50E-13 42070374_A_C N/A
74 22 42287203 C G BMI 0.613620123 3.50E-03 3.17682E-08 41804716_G_A N/A
74 22 42248860 G A DBP 0.048818986 2.14856E-05 2.14856E-05 42248860_G_A 0.601719508
74 22 42339525 G A SBP 0.939131496 0.485512 0.0166884 42269628_C_T N/A
74 22 42287203 C G HC 0.739308528 3.92E-02 2.40E-06 41884954_A_G N/A
74 22 41804716 G A WC 0.570642786 1.04E-06 1.04E-06 41804716_G_A N/A
74 22 42339525 G A Height 0.974556542 1.27E-10 2.69E-16 42184143_C_T N/A
74 22 42287203 C G PEF 0.859508417 0.000317339 1.05325E-05 42070374_A_C N/A
Table B2 Overlap of loci containing significant interaction effects for the
ten considered phenotypes | Tables summarising the number of the 74 loci
(column 2) with significant interaction effects (cFDR adjusted P < 0.05, as described
in Section 4.3.4) that are unique to any given trait (column 1; single trait loci),
shared across at least two, three, four, five and six traits (column 1, no loci are
shared amongst more than six traits).
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Trait Number of loci Traits Number of loci
DBP 8 Weight, BMI, HC, WC 16
WC 8 Body fat %, Weight, HC, WC 12
Body fat % 5 Body fat %, Weight, BMI, HC 11
BMI 5 Body fat %, Weight, BMI, WC 11
Weight 3 Body fat %, BMI, HC, WC 11
HC 3 BMR, Weight, BMI, HC 5
Height 1 BMR, Weight, BMI, WC 5
BMR 0 BMR, Weight, HC, WC 5
BMR, BMI, HC, WC 5
BMR, Body fat %, Weight, BMI 4
Traits Number of loci BMR, Body fat %, Weight, HC 4
Weight, HC 23 BMR, Body fat %, Weight, WC 4
Weight, WC 23 BMR, Body fat %, BMI, HC 4
BMI, HC 21 BMR, Body fat %, BMI, WC 4
HC, WC 21 BMR, Body fat %, HC, WC 4
BMI, WC 18 Weight, DBP, HC, WC 3
Weight, BMI 17 Body fat %, Weight, DBP, HC 2
Body fat %, Weight 15 Body fat %, Weight, DBP, WC 2
Body fat %, WC 14 Body fat %, DBP, HC, WC 2
Body fat %, BMI 13 Weight, BMI, DBP, HC 2
Body fat %, HC 12 Weight, BMI, DBP, WC 2
BMR, Weight 7 BMI, DBP, HC, WC 2
BMR, WC 6 BMR, Weight, BMI, DBP 1
BMR, BMI 5 BMR, Weight, DBP, HC 1
BMR, HC 5 BMR, Weight, DBP, WC 1
DBP, WC 5 BMR, BMI, DBP, HC 1
BMR, Body fat % 4 BMR, BMI, DBP, WC 1
Weight, DBP 4 BMR, DBP, HC, WC 1
BMI, DBP 3 Body fat %, Weight, BMI, DBP 1
DBP, HC 3 Body fat %, BMI, DBP, HC 1
Body fat %, DBP 2 Body fat %, BMI, DBP, WC 1
BMR, DBP 1
Traits Number of loci
Traits Number of loci Body fat %, Weight, BMI, HC, WC 11
Weight, HC, WC 19 BMR, Weight, BMI, HC, WC 5
Weight, BMI, HC 17 BMR, Body fat %, Weight, BMI, HC 4
BMI, HC, WC 17 BMR, Body fat %, Weight, BMI, WC 4
Weight, BMI, WC 16 BMR, Body fat %, Weight, HC, WC 4
Body fat %, Weight, WC 14 BMR, Body fat %, BMI, HC, WC 4
Body fat %, Weight, HC 12 Body fat %, Weight, DBP, HC, WC 2
Body fat %, HC, WC 12 Weight, BMI, DBP, HC, WC 2
Body fat %, Weight, BMI 11 BMR, Weight, BMI, DBP, HC 1
Body fat %, BMI, HC 11 BMR, Weight, BMI, DBP, WC 1
Body fat %, BMI, WC 11 BMR, Weight, DBP, HC, WC 1
BMR, Weight, BMI 5 BMR, BMI, DBP, HC, WC 1
BMR, Weight, HC 5 Body fat %, Weight, BMI, DBP, HC 1
BMR, Weight, WC 5 Body fat %, Weight, BMI, DBP, WC 1
BMR, BMI, HC 5 Body fat %, BMI, DBP, HC, WC 1
BMR, BMI, WC 5
BMR, HC, WC 5
BMR, Body fat %, Weight 4 Traits Number of loci
BMR, Body fat %, BMI 4 BMR, Body fat %, Weight, BMI, HC, WC 4
BMR, Body fat %, HC 4 BMR, Weight, BMI, DBP, HC, WC 1
Single trait loci
Loci shared across at least two traits
Loci shared across at least three traits
Loci shared across at least four traits
Loci shared across at least five traits
Loci shared across at least six traits
Traits Number of loci Traits Number of loci
BMR, Body fat %, WC 4 Body fat %, Weight, BMI, DBP, HC, WC 1
Weight, DBP, WC 4
Weight, DBP, HC 3
DBP, HC, WC 3
Body fat %, Weight, DBP 2
Body fat %, DBP, HC 2
Body fat %, DBP, WC 2
Weight, BMI, DBP 2
BMI, DBP, HC 2
BMI, DBP, WC 2
BMR, Weight, DBP 1
BMR, BMI, DBP 1
BMR, DBP, HC 1
BMR, DBP, WC 1
Body fat %, BMI, DBP 1

